{"data": [{"Element": "<div class=\"WordSection1\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">ANNEX I</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"TitleA\"><span lang=\"EN-GB\">SUMMARY OF PRODUCT CHARACTERISTICS</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE\nMEDICINAL PRODUCT</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Hepsera\n10\u00a0mg tablets</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE AND\nQUANTITATIVE COMPOSITION</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Each tablet\ncontains 10\u00a0mg adefovir dipivoxil.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"left\" class=\"EMEAEnBodyText\" style=\"margin:0in;text-align:left;\npage-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Excipient(s)\nwith known effect:</span></u></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Each tablet\ncontains 113\u00a0mg lactose monohydrate.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">For the full\nlist of excipients, see section\u00a06.1.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL <span style=\"text-transform:uppercase\">form</span></span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tablet.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">White to off\u2011white,\nround, flat\u2011faced, bevelled\u2011edge tablets, 7\u00a0mm in diameter,\ndebossed with \u201cGILEAD\u201d and \u201c10\u201d on one side and a stylised shape of a liver on\nthe other side.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Clinical\nparticulars</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic\nindications</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Hepsera is\nindicated for the treatment of chronic hepatitis\u00a0B in adults with:</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">compensated liver disease with evidence of\nactive viral replication, persistently elevated serum alanine aminotransferase\n(ALT) levels and histological evidence of active liver inflammation and\nfibrosis. \u00a0Initiation of Hepsera treatment should only be considered when the\nuse of an alternative antiviral agent with a higher genetic barrier to\nresistance is not available or appropriate (see section\u00a05.1).</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">decompensated liver disease in combination with\na second agent without cross-resistance to Hepsera.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.2\u00a0\u00a0\u00a0\u00a0 Posology and method\nof administration</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Therapy should\nbe initiated by a physician experienced in the management of chronic\nhepatitis\u00a0B.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Posology</span></u></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Adults:</span></i><span lang=\"EN-GB\"> The recommended dose of Hepsera is 10\u00a0mg (one tablet) once\ndaily taken orally with or without food.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Higher doses\nmust not be administered.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The optimum\nduration of treatment is unknown.\u00a0 The relationship between treatment response\nand long\u2011term outcomes such as hepatocellular carcinoma or decompensated\ncirrhosis is not known.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In patients with\ndecompensated liver disease, adefovir should always be used in combination with\na second agent, without cross-resistance to adefovir, to reduce the risk of\nresistance and to achieve rapid viral suppression.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Patients should\nbe monitored every six months for hepatitis\u00a0B biochemical, virological and\nserological markers.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Treatment discontinuation may be considered as follows:</span></i></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 In HBeAg\u00a0positive patients without\ncirrhosis, treatment should be administered for at least 6\u201112\u00a0months\nafter HBe\u00a0seroconversion (HBeAg\u00a0loss and HBV\u00a0DNA loss with anti\u2011HBe\u00a0detection)\nis confirmed or until HBs\u00a0seroconversion or there is loss of efficacy\n(see\u00a0section\u00a04.4). \u00a0Serum ALT and HBV\u00a0DNA levels should be\nfollowed regularly after treatment discontinuation to detect any late\nvirological relapse.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 In HBeAg\u00a0negative patients without\ncirrhosis, treatment should be administered at least until\nHBs\u00a0seroconversion or there is evidence of loss of efficacy. \u00a0With\nprolonged treatment for more than 2\u00a0years, regular reassessment is\nrecommended to confirm that continuing the selected therapy remains appropriate\nfor the patient.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In patients with\ndecompensated liver disease or cirrhosis, treatment cessation is not\nrecommended (see\u00a0section\u00a04.4).</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Special populations</span></u></i></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Elderly:</span></i><span lang=\"EN-GB\"> No data are available to support a dose recommendation for patients\nover the age of 65\u00a0years (see\u00a0section\u00a04.4).</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Renal impairment:</span></i><span lang=\"EN-GB\"> Adefovir is eliminated by renal excretion and adjustments of the\ndosing interval are required in patients with a creatinine clearance\n&lt;\u00a050\u00a0ml/min or on dialysis.\u00a0 The recommended dosing frequency\naccording to renal function must not be exceeded (see\u00a0sections\u00a04.4\nand 5.2).\u00a0 The proposed dose interval modification is based on extrapolation of\nlimited data in patients with end stage renal disease (ESRD) and may not be\noptimal.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Patients with creatinine clearance between 30 and 49\u00a0ml/min:</span></i></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">It is\nrecommended to administer adefovir dipivoxil (one 10\u00a0mg tablet) every 48\u00a0hours\nin these patients. \u00a0There are only limited data on the safety and efficacy of\nthis dosing interval adjustment guideline.\u00a0 </span><span lang=\"EN-GB\">Therefore,\nclinical response to treatment and renal function should be closely monitored\nin these patients (see\u00a0section\u00a04.4).</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Patients with creatinine clearance &lt;\u00a030\u00a0ml/min and\ndialysis patients:</span></i></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">There are no\nsafety and efficacy data to support the use of adefovir dipivoxil in patients\nwith a creatinine clearance &lt;\u00a030\u00a0ml/min or on dialysis.\u00a0\nTherefore, use of adefovir dipivoxil is not recommended in these patients and\nshould only be considered if the potential benefits outweigh the potential\nrisks. \u00a0In that case, the limited data available suggest that for patients with\ncreatinine clearance between 10 and 29\u00a0ml/min, adefovir dipivoxil (one\n10\u00a0mg tablet) may be administered every 72\u00a0hours; for haemodialysis\npatients, adefovir dipivoxil (one 10\u00a0mg tablet) may be administered every\n7\u00a0days following 12\u00a0hours continuous dialysis (or 3\u00a0dialysis\nsessions, each of 4\u00a0hours duration). \u00a0These patients should be closely\nmonitored for possible adverse reactions and to ensure efficacy is maintained\n(see\u00a0sections\u00a04.4 and 4.8).</span><span lang=\"EN-GB\">\u00a0 </span><span lang=\"EN-GB\">No dosing interval recommendations are available for other dialysis\npatients (e.g. ambulatory peritoneal dialysis patients) or non\u2011haemodialysed\npatients with creatinine clearance less than 10\u00a0ml/min.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Hepatic\nimpairment:</span></i><span lang=\"EN-GB\"> No dose adjustment is required in\npatients with hepatic impairment (see\u00a0section\u00a05.2).</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Clinical\nresistance:</span></i><span lang=\"EN-GB\"> Lamivudine\u2011refractory patients\nand patients harbouring HBV with evidence of resistance to lamivudine\n(mutations at rtL180M, rtA181T and/or rtM204I/V) should not be treated with\nadefovir dipivoxil monotherapy in order to reduce the risk of resistance to\nadefovir. \u00a0Adefovir may be used in combination with lamivudine in lamivudine\u2011refractory\npatients and in patients harbouring HBV with mutations at rtL180M and/or\nrtM204I/V. \u00a0However, for patients harbouring HBV that contains the rtA181T\nmutation, consideration should be given to alternative treatment regimens due\nto the risk of reduced susceptibility to adefovir (see\u00a0section\u00a05.1).</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In order to\nreduce the risk of resistance in patients receiving adefovir dipivoxil\nmonotherapy, a modification of treatment should be considered if serum\nHBV\u00a0DNA remains above 1,000\u00a0copies/ml at or beyond 1\u00a0year of\ntreatment.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Paediatric\npopulation:</span></i><span lang=\"EN-GB\"> Hepsera is not recommended for use in\nchildren below the age of 18\u00a0years due to limitations of the available\ndata on safety and efficacy (see section\u00a05.1).</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Method of administration</span></u></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Hepsera tablets\nshould be taken once daily, orally with or without food.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.3\u00a0\u00a0\u00a0\u00a0 Contraindications</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Hypersensitivity to the active substance or to\nany of the excipients listed in section\u00a06.1.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.4\u00a0\u00a0\u00a0\u00a0 Special warnings and precautions for use</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">General:</span></i><span lang=\"EN-GB\"> Patients should be advised that therapy with adefovir dipivoxil has\nnot been proven to reduce the risk of transmission of hepatitis\u00a0B virus to\nothers and therefore appropriate precautions should still be taken.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Renal\nfunction:</span></i><span lang=\"EN-GB\"> Adefovir is excreted renally, by a\ncombination of glomerular filtration and active tubular secretion.\u00a0 Treatment\nwith adefovir dipivoxil may result in renal impairment.\u00a0 Long\u2011term\ntreatment with adefovir dipivoxil may increase the risk of renal impairment.\u00a0 While\nthe overall risk of renal impairment in patients with adequate renal function\nis low, this is of special importance in patients both at risk of or having\nunderlying renal dysfunction, and also in patients <span style=\"layout-grid-mode:\nline\">receiving medicinal products that may affect renal function.</span></span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">It is recommended that creatinine\nclearance is calculated in all patients prior to initiating therapy with\nadefovir dipivoxil </span><span lang=\"EN-GB\">and that renal function (creatinine\nclearance and serum phosphate) be monitored every four weeks during the first\nyear and then every three months thereafter.\u00a0 In patients at risk for renal\nimpairment, consideration should be given to more frequent monitoring of renal\nfunction.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In patients who\ndevelop renal insufficiency and have advanced liver disease or cirrhosis,\ndosing interval adjustment of adefovir or switch to an alternative therapy for\nhepatitis\u00a0B infection should be considered.\u00a0 Treatment cessation for\nchronic hepatitis\u00a0B in these patients is not recommended.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Patients with creatinine clearance between 30 and\u00a049\u00a0ml/min:</span></i></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The dosing\ninterval of adefovir dipivoxil should be adjusted in these patients (see\u00a0section\u00a04.2).\n\u00a0In addition, renal function should be closely monitored with a frequency\ntailored to the individual patient\u2019s medical condition.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Patients with creatinine clearance &lt;\u00a030\u00a0ml/min and\ndialysis patients:</span></i></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adefovir\ndipivoxil is not recommended in patients with a creatinine clearance of\n&lt;\u00a030\u00a0ml/min or on dialysis. \u00a0Administration of adefovir dipivoxil\nin these patients should only be considered if the potential benefits outweigh\nthe potential risks. \u00a0If treatment with adefovir dipivoxil is considered\nessential, then the dosing interval should be adjusted (see\u00a0section\u00a04.2).\u00a0\nThese patients should be closely monitored for possible adverse reactions and\nto ensure efficacy is maintained.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Patients receiving medicinal products that may affect renal\nfunction:</span></i></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adefovir\ndipivoxil should not be administered concurrently with tenofovir disoproxil\nfumarate (Viread).</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Caution is\nadvised in patients receiving other medicinal products that may affect renal\nfunction or are excreted renally (e.g. cyclosporin and tacrolimus, intravenous\naminoglycosides, amphotericin\u00a0B, foscarnet, pentamidine, vancomycin, or\nmedicinal products which are secreted by the same renal transporter, human\nOrganic Anion Transporter\u00a01 (hOAT1), such as cidofovir). \u00a0Co\u2011administration\nof 10\u00a0mg adefovir dipivoxil with medicinal products in these patients may\nlead to an increase in serum concentrations of either adefovir or a co\u2011administered\nmedicinal product. \u00a0The renal function of these patients should be closely\nmonitored with a frequency tailored to the individual patient\u2019s medical\ncondition.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">For renal safety\nin patients pre\u2011 and post\u2011transplantation with lamivudine-resistant\u00a0HBV,\nsee\u00a0</span><span lang=\"EN-GB\">section\u00a04.8.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Hepatic\nfunction:</span></i><span lang=\"EN-GB\"> Spontaneous exacerbations in chronic\nhepatitis\u00a0B are relatively common and are characterised by transient\nincreases in serum ALT.\u00a0 After initiating antiviral therapy, serum ALT may\nincrease in some patients as serum HBV\u00a0DNA levels decline.\u00a0 In patients\nwith compensated liver disease, these increases in serum ALT are generally not\naccompanied by an increase in serum bilirubin concentrations or hepatic\ndecompensation (see\u00a0section\u00a04.8).</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Patients with\nadvanced liver disease or cirrhosis may be at a higher risk for hepatic\ndecompensation following hepatitis exacerbation which may be fatal.\u00a0 In these\npatients, including patients with decompensated liver disease, treatment\ncessation is not recommended and these patients should be monitored closely\nduring therapy.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoEndnoteText\"><span lang=\"EN-GB\">In the event of these patients\ndeveloping renal insufficiency, see above <i>Renal function</i>.</span></p>\n<p class=\"MsoEndnoteText\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If treatment\ncessation is necessary, patients should be closely monitored for several months\nafter stopping treatment as exacerbations of hepatitis have occurred after\ndiscontinuation of 10\u00a0mg adefovir dipivoxil.\u00a0 These exacerbations occurred\nin the absence of HBeAg seroconversion and presented as serum ALT elevations\nand increases in serum HBV\u00a0DNA.\u00a0 Elevations in serum ALT that occurred in\npatients with compensated liver function treated with 10\u00a0mg adefovir\ndipivoxil were not accompanied by clinical and laboratory changes associated\nwith liver decompensation.\u00a0 Patients should be closely monitored after stopping\ntreatment.\u00a0 Most post\u2011treatment exacerbations of hepatitis were seen\nwithin 12\u00a0weeks of discontinuation of 10\u00a0mg adefovir dipivoxil.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoEndnoteText\"><i><span lang=\"EN-GB\">Lactic acidosis and severe\nhepatomegaly with steatosis:</span></i><span lang=\"EN-GB\"> Occurrences of lactic\nacidosis (in the absence of hypoxaemia), sometimes fatal, usually associated\nwith severe hepatomegaly and hepatic steatosis, have been reported with the use\nof nucleoside analogues.\u00a0 As adefovir is structurally related to nucleoside\nanalogues, this risk cannot be excluded.\u00a0 Treatment with nucleoside analogues\nshould be discontinued when rapidly elevating aminotransferase levels,\nprogressive hepatomegaly or metabolic/lactic acidosis of unknown aetiology\noccur.\u00a0 Benign digestive symptoms, such as nausea, vomiting and abdominal pain,\nmight be indicative of lactic acidosis development.\u00a0 Severe cases, sometimes\nwith fatal outcome, were associated with pancreatitis, liver failure/hepatic\nsteatosis, renal failure and higher levels of serum lactate.\u00a0 Caution should be\nexercised when prescribing nucleoside analogues to any patient (particularly\nobese women) with hepatomegaly, hepatitis or other known risk factors for liver\ndisease.\u00a0 These patients should be followed closely.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">To differentiate\nbetween elevations in transaminases due to response to treatment and increases\npotentially related to lactic acidosis, physicians should ensure that changes\nin ALT are associated with improvements in other laboratory markers of chronic\nhepatitis\u00a0B.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Co\u2011infection\nwith hepatitis\u00a0C or D:</span></i><span lang=\"EN-GB\"> There are no data on\nthe efficacy of adefovir dipivoxil in patients co\u2011infected with\nhepatitis\u00a0C or hepatitis\u00a0D.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Co\u2011infection\nwith HIV:</span></i><span lang=\"EN-GB\"> Limited data are available on the safety\nand efficacy of 10\u00a0mg adefovir dipivoxil in patients with chronic\nhepatitis\u00a0B, co\u2011infected with HIV.\u00a0 To date there is no evidence\nthat daily dosing with 10\u00a0mg adefovir dipivoxil results in emergence of\nadefovir-associated resistance mutations in the HIV\u00a0reverse\ntranscriptase.\u00a0 Nonetheless, there is a potential risk of selection of\nHIV\u00a0strains resistant to adefovir with possible cross\u2011resistance to\nother antiviral medicinal products.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">As far as\npossible, treatment of hepatitis\u00a0B by adefovir dipivoxil in an HIV\u00a0co\u2011infected\npatient should be reserved for patients whose HIV\u00a0RNA is controlled.\u00a0\nTreatment with 10\u00a0mg adefovir dipivoxil has not been shown to be effective\nagainst HIV\u00a0replication and therefore should not be used to control\nHIV\u00a0infection.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Elderly:</span></i><span lang=\"EN-GB\"> The clinical experience in patients &gt;\u00a065\u00a0years of age\nis very limited.\u00a0 Caution should be exercised when prescribing adefovir\ndipivoxil to the elderly, keeping in mind the greater frequency of decreased\nrenal or cardiac function in these patients, and the increase in concomitant\ndiseases or concomitant use of other medicinal products in the elderly.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Resistance:</span></i><span lang=\"EN-GB\"> Resistance to adefovir dipivoxil (see\u00a0section\u00a05.1) can\nresult in viral load rebound which may result in exacerbation of\nhepatitis\u00a0B and, in the setting of diminished hepatic function, lead to\nliver decompensation and possible fatal outcome. \u00a0Virological response should\nbe closely monitored in patients treated with adefovir dipivoxil, with\nHBV\u00a0DNA measured every 3\u00a0months. \u00a0If viral rebound occurs, resistance\ntesting should be performed. \u00a0In case of emergence of resistance, treatment\nshould be modified.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Hepsera contains\nlactose monohydrate.\u00a0 Consequently, patients with rare hereditary problems of\ngalactose intolerance, the Lapp lactase deficiency, or glucose\u2011galactose\nmalabsorption should not take this medicinal product.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.5\u00a0\u00a0\u00a0\u00a0 Interaction with other medicinal products and other forms of\ninteraction</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Interaction\nstudies have only been performed in adults.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The potential\nfor CYP450 mediated interactions involving adefovir with other medicinal\nproducts is low, based on the results of <i>in\u00a0vitro</i> experiments in\nwhich adefovir did not influence any of the common CYP isoforms known to be\ninvolved in human drug metabolism and based on the known elimination pathway of\nadefovir.\u00a0 A clinical study in liver\u2011transplant patients has shown that\nno pharmacokinetic interaction occurs when adefovir dipivoxil 10\u00a0mg once\ndaily is administered concomitantly with tacrolimus, an immunosuppressant which\nis predominantly metabolised via the CYP450 system.\u00a0 A pharmacokinetic\ninteraction between adefovir and the immunosuppressant, cyclosporin, is also\nconsidered unlikely as cyclosporin shares the same metabolic pathway as\ntacrolimus.\u00a0 Nevertheless, given that tacrolimus and cyclosporin can affect\nrenal function, close monitoring is recommended when either of these agents is\ncoadministered with adefovir dipivoxil (see\u00a0section\u00a04.4).</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Concomitant\nadministration of 10\u00a0mg adefovir dipivoxil and 100\u00a0mg lamivudine did\nnot alter the pharmacokinetic profile of either medicinal product.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adefovir is\nexcreted renally, by a combination of glomerular filtration and active tubular\nsecretion.\u00a0 Co\u2011administration of 10\u00a0mg adefovir dipivoxil with other\nmedicinal products that are eliminated by tubular secretion or alter tubular\nfunction may increase serum concentrations of either adefovir or the co\u2011administered\nmedicinal product (see\u00a0section\u00a04.4).</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Due to the high\npharmacokinetic variability of pegylated interferon, no definitive conclusion\ncan be drawn regarding the effect of adefovir and pegylated interferon co\u2011administration\non the pharmacokinetic profile of either medicinal product.\u00a0 Even though a\npharmacokinetic interaction is unlikely given the two products are eliminated\nvia different pathways, caution is recommended if both products are co\u2011administered.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.6\u00a0\u00a0\u00a0\u00a0 Fertility, pregnancy\nand lactation</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The use of\nadefovir dipivoxil must be accompanied by the use of effective contraception.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Pregnancy</span></u></i></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">There are limited\ndata on the use of adefovir dipivoxil in pregnant women.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Studies in\nanimals administered adefovir intravenously have shown reproductive toxicity\n(see\u00a0section\u00a05.3).\u00a0 Studies in orally dosed animals do not indicate\nteratogenic or foetotoxic effects.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adefovir\ndipivoxil is not recommended during pregnancy and in women of childbearing\npotential not using contraception.\u00a0 Adefovir dipivoxil should be used during pregnancy\nonly if the potential benefit justifies the potential risk to the foetus.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">There are no\ndata on the effect of adefovir dipivoxil on transmission of HBV from mother to\ninfant.\u00a0 Therefore, the standard recommended procedures for immunisation of\ninfants should be followed to prevent neonatal acquisition of HBV.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Breast\u2011feeding</span></u></i></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">A risk to the\nnewborns/infants cannot be excluded.\u00a0 It is recommended that mothers being\ntreated with adefovir dipivoxil do not breast\u2011feed their infants.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Fertility</span></u></i></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">No human data on\nthe effect of adefovir dipivoxil on fertility are available.\u00a0 Animal studies do\nnot indicate harmful effects of adefovir dipivoxil on male and female\nfertility.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.7\u00a0\u00a0\u00a0\u00a0 Effects on ability to drive and use machines</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">No studies on\nthe effects on the ability to drive and use machines have been performed.\u00a0\nHowever, based on the safety profile and mechanism of action, adefovir\ndipivoxil is expected to have no or negligible influence on these abilities.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.8\u00a0\u00a0\u00a0\u00a0 Undesirable effects</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><i><span lang=\"EN-GB\">a. Summary of the safety profile</span></i></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In patients with\ncompensated liver disease, the most frequently reported adverse reactions\nduring 48\u00a0weeks of adefovir dipivoxil therapy were asthenia (13\u00a0%),\nheadache (9\u00a0%), abdominal pain (9\u00a0%) and nausea (5\u00a0%).</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In patients with\ndecompensated liver disease, the most frequently reported adverse reactions\nduring up to 203\u00a0weeks of adefovir dipivoxil therapy were increased\ncreatinine (7\u00a0%) and asthenia (5\u00a0%).</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><i><span lang=\"EN-GB\">b. Tabulated summary of adverse reactions</span></i></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Assessment of adverse reactions is based on experience from\npost-marketing surveillance and from three pivotal clinical studies in patients\nwith chronic hepatitis\u00a0B:</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">two placebo\u2011controlled studies in which\n522\u00a0patients with chronic hepatitis\u00a0B and compensated liver disease\nreceived double-blind treatment with 10\u00a0mg adefovir dipivoxil (n=294) or\nplacebo (n=228) for 48\u00a0weeks.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">an open-label study in which pre\u2011 (n=226)\nand post\u2011liver transplantation patients (n=241) with lamivudine-resistant\nHBV were treated with 10\u00a0mg adefovir dipivoxil once daily, for up to\n203\u00a0weeks (median 51 and 99\u00a0weeks, respectively).</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The adverse\nreactions considered at least possibly related to treatment are listed below,\nby body system organ class, and frequency (see Table\u00a01).\u00a0 Within each\nfrequency grouping, undesirable effects are presented in order of decreasing\nseriousness.\u00a0 Frequencies are defined as very common (\u2265\u00a01/10),\ncommon (\u2265\u00a01/100, &lt;\u00a01/10) or not known (identified through\npost-marketing safety surveillance and the frequency cannot be estimated from\nthe available data).</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><a name=\"OLE_LINK7\"></a><a name=\"OLE_LINK8\"><b><span lang=\"EN-GB\">Table\u00a01:\nTabulated summary of adverse reactions associated with adefovir dipivoxil based\non clinical study and post\u2011marketing experience</span></b></a></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:100.0%;border-collapse:collapse;border:none\" width=\"100%\">\n<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;padding:\n  0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Frequency</span></b></p>\n</td>\n<td style=\"width:80.52%;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Adefovir dipivoxil</span></b></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Nervous system disorders:</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:80.52%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Headache</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Gastrointestinal disorders:</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:80.52%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Diarrhoea, vomiting,\n  abdominal pain, dyspepsia, nausea, flatulence</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Not known:</span></p>\n</td>\n<td style=\"width:80.52%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Pancreatitis</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Skin and subcutaneous tissue disorders:</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:80.52%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Rash, pruritus</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Musculoskeletal and connective tissue\n  disorders:</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Not known:</span></p>\n</td>\n<td style=\"width:80.52%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Osteomalacia (manifested as bone pain and infrequently\n  contributing to fractures) and myopathy, both associated with proximal renal\n  tubulopathy</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Renal and urinary disorders:</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Very common:</span></p>\n</td>\n<td style=\"width:80.52%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Increases in\n  creatinine</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:80.52%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Renal failure, abnormal renal function, hypophosphatemia</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Not known:</span></p>\n</td>\n<td style=\"width:80.52%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Fanconi syndrome, proximal renal tubulopathy</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">General disorders and administration site\n  conditions:</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Very common:</span></p>\n</td>\n<td style=\"width:80.52%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Asthenia</span></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><i><span lang=\"EN-GB\">c. Description of selected adverse reactions</span></i></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Exacerbation of hepatitis:</span></i></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Clinical and\nlaboratory evidence of exacerbations of hepatitis have occurred after\ndiscontinuation of treatment with 10\u00a0mg adefovir dipivoxil\n(see\u00a0section\u00a04.4).</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Long\u2011term safety data in patients with compensated disease:</span></i></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In a long\u2011term\nsafety study of 125\u00a0HBeAg negative patients with compensated liver\ndisease, the adverse event profile was overall unchanged after a median\nexposure of 226\u00a0weeks.\u00a0 No clinically significant changes in renal\nfunction were observed.\u00a0 However, mild to moderate increases in serum\ncreatinine concentrations, hypophosphatemia and a decrease in carnitine concentrations\nwere reported in 3\u00a0%, 4\u00a0% and 6\u00a0% of patients, respectively, on\nextended treatment.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In a long\u2011term\nsafety study of 65\u00a0HBeAg positive patients with compensated liver disease\n(after a median exposure of 234\u00a0weeks), 6\u00a0patients (9\u00a0%) had\nconfirmed increases in serum creatinine of at least 0.5\u00a0mg/dl from\nbaseline with 2\u00a0patients discontinuing from the study due to the elevated\nserum creatinine concentration.\u00a0 Patients with a confirmed increase in\ncreatinine of \u2265\u00a00.3\u00a0mg/dl by week\u00a048 were at a\nstatistically significant higher risk of a subsequent confirmed increase in\ncreatinine of \u2265\u00a00.5\u00a0mg/dl.\u00a0 Hypophosphatemia and a decrease in\ncarnitine concentrations were reported each in 3\u00a0% of patients on extended\ntreatment.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Based on\npost-marketing data, long\u2011term treatment with adefovir dipivoxil may lead\nto progressive alteration of renal function resulting in renal impairment (see\nsection\u00a04.4).</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Safety in patients with decompensated disease:</span></i></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Renal toxicity\nis an important feature of the safety profile of adefovir dipivoxil in patients\nwith decompensated liver disease.\u00a0 In clinical studies of wait-listed and\npost-liver transplantation patients, four percent (19/467) of patients\ndiscontinued treatment with adefovir dipivoxil due to renal adverse events.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><i><span lang=\"EN-GB\">d. Paediatric population</span></i></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Because of\ninsufficient data on safety and efficacy, Hepsera should not be used in\nchildren under the age of 18\u00a0years (see Sections\u00a04.2 and 5.1).</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\nnone\"><u><span lang=\"EN-GB\">Reporting of suspected adverse reactions</span></u></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Reporting suspected adverse reactions after authorisation of the\nmedicinal product is important.\u00a0 It allows continued monitoring of the\nbenefit/risk balance of the medicinal product.\u00a0 Healthcare professionals are\nasked to report any suspected adverse reactions via <span style=\"color:black;\nbackground:#D9D9D9\">the national reporting system listed in </span></span><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\"><a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"color:black;text-decoration:none\">Appendix\u00a0V</span></a></span><span lang=\"EN-GB\">.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.9\u00a0\u00a0\u00a0\u00a0 Overdose</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Administration\nof 500\u00a0mg adefovir dipivoxil daily for 2\u00a0weeks and 250\u00a0mg daily\nfor 12\u00a0weeks has been associated with the gastrointestinal disorders\nlisted above and anorexia.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If overdose\noccurs, the patient must be monitored for evidence of toxicity, and standard\nsupportive treatment applied as necessary.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adefovir can be\nremoved by haemodialysis; the median haemodialysis clearance of adefovir is\n104\u00a0ml/min.\u00a0 The elimination of adefovir by peritoneal dialysis has not\nbeen studied.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL\nPROPERTIES</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.1\u00a0\u00a0\u00a0\u00a0 Pharmacodynamic\nproperties</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Pharmacotherapeutic\ngroup:</span></i><span lang=\"EN-GB\"> Nucleoside and nucleotide reverse\ntranscriptase inhibitors, ATC code: J05AF08.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><u><span lang=\"EN-GB\">Mechanism\nof action and pharmacodynamic effects:</span></u></i><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">Adefovir dipivoxil is an oral prodrug of adefovir, an acyclic\nnucleotide phosphonate analogue of adenosine monophosphate, which is actively\ntransported into mammalian cells where it is converted by host enzymes to\nadefovir diphosphate.\u00a0 Adefovir diphosphate inhibits viral polymerases by\ncompeting for direct binding with the natural substrate (deoxyadenosine\ntriphosphate) and, after incorporation into viral DNA, causes DNA chain\ntermination.\u00a0 Adefovir diphosphate selectively inhibits HBV\u00a0DNA\npolymerases at concentrations 12\u2011, 700\u2011, and 10\u2011fold lower\nthan those needed to inhibit human DNA polymerases \u03b1, \u03b2, and \u03b3,\nrespectively.\u00a0 Adefovir diphosphate has an intracellular half\u2011life of 12\nto 36\u00a0hours in activated and resting lymphocytes.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adefovir is\nactive against hepadnaviruses <i>in\u00a0vitro</i>, including all common forms\nof lamivudine-resistant HBV (rtL180M, rtM204I, rtM204V, rtL180M/rtM204V),\nfamciclovir-associated mutations (rtV173L, rtP177L, rtL180M, rtT184S or\nrtV207I) and hepatitis\u00a0B immunoglobulin escape mutations (rtT128N and\nrtW153Q), and in <i>in\u00a0vivo</i> animal models of hepadnavirus replication.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Clinical efficacy and safety:</span></u></i></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The demonstration of the benefit of adefovir dipivoxil is based on\nhistological, virological, biochemical, and serological responses in adults\nwith:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">HBeAg positive and HBeAg negative chronic\nhepatitis\u00a0B with compensated liver disease.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">lamivudine-resistant HBV with either compensated\nor decompensated liver disease, including patients pre\u2011 and post\u2011liver\ntransplantation or co\u2011infected with HIV.\u00a0 In the majority of these\nstudies adefovir dipivoxil 10\u00a0mg was added to ongoing lamivudine treatment\nin patients failing lamivudine therapy.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In these\nclinical studies patients had active viral replication (HBV\u00a0DNA \u2265\u00a0100,000\u00a0copies/ml)\nand elevated ALT levels (\u2265\u00a01.2\u00a0x Upper Limit of Normal (ULN)).</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Experience in\npatients with compensated liver disease:</span></i><span lang=\"EN-GB\"> In two\nplacebo-controlled studies (total n=522) in HBeAg positive or in HBeAg negative\nchronic hepatitis\u00a0B patients with compensated liver disease, significantly\nmore patients (p\u00a0&lt;\u00a00.001) in the 10\u00a0mg adefovir dipivoxil\ngroups (53 and 64\u00a0%, respectively) had histological improvement from\nbaseline at week\u00a048 than in the placebo groups (25 and 33\u00a0%).\u00a0\nImprovement was defined as a reduction from baseline of two points or more in\nthe Knodell necro-inflammatory score with no concurrent worsening in the\nKnodell fibrosis score.\u00a0 Histological improvement was seen regardless of\nbaseline demographic and hepatitis\u00a0B characteristics, including prior\ninterferon\u2011alpha therapy.\u00a0 High baseline ALT levels\n(\u2265\u00a02\u00a0x\u00a0ULN) and Knodell Histology Activity Index (HAI)\nscores (\u2265\u00a010) and low HBV\u00a0DNA (&lt;\u00a07.6\u00a0log<sub>10</sub>\u00a0copies/ml)\nwere associated with greater histological improvement.\u00a0 Blinded, ranked assessments\nof both necro-inflammatory activity and fibrosis at baseline and week\u00a048,\ndemonstrated that patients treated with 10\u00a0mg adefovir dipivoxil had\nimproved necro-inflammatory and fibrosis scores relative to placebo-treated\npatients.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Assessment of\nthe change in fibrosis after 48\u00a0weeks treatment using the Knodell scores\nconfirms that patients treated with adefovir dipivoxil 10\u00a0mg had more\nregression and less progression of fibrosis than patients treated with placebo.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In the two\nstudies mentioned above, treatment with 10\u00a0mg adefovir dipivoxil was\nassociated with significant reductions in serum HBV\u00a0DNA (3.52 and\n3.91\u00a0log<sub>10</sub>\u00a0copies/ml, respectively, <i>versus</i> 0.55 and\n1.35\u00a0log<sub>10</sub>\u00a0copies/ml), increased proportion of patients\nwith normalisation of ALT (48 and 72\u00a0% <i>versus</i> 16 and 29\u00a0%) or\nincreased proportion of patients with serum HBV\u00a0DNA below the limits of\nquantification (&lt;\u00a0400\u00a0copies/ml Roche Amplicor Monitor PCR assay)\n(21 and 51\u00a0% <i>versus</i> 0\u00a0%) when compared with placebo.\u00a0 In the\nstudy in HBeAg positive patients, HBeAg seroconversion (12\u00a0%) and HBeAg\nloss (24\u00a0%) was observed significantly more frequently in patients\nreceiving 10\u00a0mg adefovir dipivoxil than in patients receiving placebo\n(6\u00a0% and 11\u00a0%, respectively) after 48\u00a0weeks of treatment.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In the HBeAg\u00a0positive\nstudy, treatment beyond 48\u00a0weeks resulted in further reductions in serum\nHBV\u00a0DNA levels and increases in the proportion of patients with ALT\nnormalisation, HBeAg loss and seroconversion.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In the\nHBeAg\u00a0negative study patients on adefovir dipivoxil (0\u201148\u00a0weeks)\nwere re-randomised in a blinded-manner to continue on adefovir dipivoxil or\nreceive placebo for an additional 48\u00a0weeks.\u00a0 At week\u00a096, patients\ncontinuing on adefovir dipivoxil 10\u00a0mg had sustained suppression of serum\nHBV\u00a0with maintenance of the reduction seen at week\u00a048.\u00a0 In over two\nthirds of patients suppression of serum HBV\u00a0DNA was associated with\nnormalisation of ALT levels.\u00a0 In most patients who stopped treatment with\nadefovir dipivoxil, serum HBV\u00a0DNA and ALT levels returned towards\nbaseline.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Treatment with\nadefovir dipivoxil resulted in improvement in the liver fibrosis from baseline\nto 96\u00a0weeks therapy when analysed using the Ishak score (median change: \u0394=\u00a0\u20111).\u00a0\nNo differences in the median fibrosis score were seen between groups using the\nKnodell fibrosis score.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Patients who\ncompleted the first 96\u00a0weeks of the HBeAg\u00a0negative study and received\nadefovir dipivoxil treatment during weeks\u00a049 to 96, were offered the\nopportunity to receive open-label treatment with adefovir dipivoxil from study\nweek\u00a097 through to week\u00a0240.\u00a0 Serum HBV\u00a0DNA levels remained\nundetectable and ALT levels normalised in approximately two thirds of patients\nfollowing treatment with adefovir dipivoxil for up to 240\u00a0weeks.\u00a0\nClinically and statistically significant improvement in fibrosis was seen in\nthe changes in Ishak scores from the start of adefovir dipivoxil treatment to\nthe end of the study (week\u00a0240) (median change: \u0394=\u00a0\u20111).\u00a0\nBy the end of the study, 7 of 12\u00a0patients (58\u00a0%) with bridging\nfibrosis or cirrhosis at baseline, had an improved Ishak fibrosis score of\n\u2265\u00a02\u00a0points. \u00a0Five patients achieved and maintained HBsAg\nseroconversion (HBsAg\u00a0negative/HBsAb\u00a0positive).</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Experience in\npatients pre\u2011 and post\u2011liver transplantation with lamivudine\u2011resistant\nHBV:</span></i><span lang=\"EN-GB\"> In a clinical study in 394 chronic\nhepatitis\u00a0B patients with lamivudine-resistant HBV<span style=\"layout-grid-mode:\nline\"> </span>(pre\u2011liver transplantation (n=186) and post\u2011liver\ntransplantation (n=208)), treatment with 10\u00a0mg adefovir dipivoxil resulted\nin a median reduction in serum HBV\u00a0DNA of 4.1 and 4.2\u00a0log<sub>10</sub>\u00a0copies/ml,\nrespectively, at week\u00a048.\u00a0 In the pre\u2011liver transplantation and post\u2011liver\ntransplantation cohorts 77 of 109 (71\u00a0%) patients and 64 of 159\n(40\u00a0%) patients, respectively, achieved undetectable HBV\u00a0DNA levels\nat week\u00a048 (&lt;\u00a01,000\u00a0copies/ml Roche Amplicor Monitor PCR\nassay).\u00a0 Treatment with 10\u00a0mg adefovir dipivoxil showed similar efficacy\nregardless of the patterns of lamivudine-resistant HBV\u00a0DNA polymerase\nmutations at baseline.\u00a0 Improvements or stabilisation were seen in\nChild-Pugh-Turcotte score.\u00a0 Normalisation of ALT, albumin, bilirubin and\nprothrombin time was seen at week\u00a048 in 51\u201185\u00a0% of the\npatients.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In the pre\u2011liver\ntransplantation cohort, 25 of 33 (76\u00a0%) patients achieved undetectable\nHBV\u00a0DNA levels and 84\u00a0% of patients had ALT normalisation at\n96\u00a0weeks.\u00a0 In the post\u2011liver transplantation cohort, 61 of 94\n(65\u00a0%) and 35 of 45 (78\u00a0%) of patients achieved undetectable\nHBV\u00a0DNA levels at 96\u00a0and 144\u00a0weeks, respectively, and 70\u00a0%\nand 58\u00a0% of patients had ALT normalisation at these study visits.\u00a0 The\nclinical significance of these findings as they relate to histological\nimprovement is not known.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Experience in\npatients with compensated liver disease and lamivudine\u2011resistant HBV:</span></i><span lang=\"EN-GB\"> In a double\u2011blind comparative study in chronic\nhepatitis\u00a0B <span style=\"layout-grid-mode:line\">patients with </span>lamivudine\u2011resistant\nHBV<span style=\"layout-grid-mode:line\"> </span>(n=58),<span style=\"layout-grid-mode:\nline\"> there was no </span>median reduction in HBV\u00a0DNA from baseline<span style=\"layout-grid-mode:line\"> after </span>48\u00a0weeks of treatment with\nlamivudine.\u00a0 Forty-eight weeks of treatment with adefovir dipivoxil 10\u00a0mg\nalone or in combination with lamivudine resulted in a similar significant\ndecrease in median serum HBV\u00a0DNA levels from baseline (4.04\u00a0<span style=\"layout-grid-mode:line\">log<sub>10</sub>\u00a0copies/ml and 3.59\u00a0log<sub>10</sub>\u00a0copies/ml,\nrespectively).\u00a0 The clinical significance of these observed changes in\nHBV\u00a0DNA has </span>not been established.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Experience in\npatients with decompensated liver disease and lamivudine\u2011resistant HBV:</span></i><span lang=\"EN-GB\"> In 40 HBeAg positive or HBeAg negative patients with\nlamivudine-resistant HBV and decompensated liver disease receiving treatment\nwith 100\u00a0mg lamivudine, addition of 10\u00a0mg adefovir dipivoxil\ntreatment for 52\u00a0weeks resulted in a median reduction in HBV\u00a0DNA of\n4.6\u00a0log<sub>10</sub>\u00a0copies/ml.\u00a0 Improvement in liver function was\nalso seen after one year of therapy.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Experience in\npatients with HIV co\u2011infection and lamivudine\u2011resistant HBV:</span></i><span lang=\"EN-GB\"> In an open-label investigator study in 35 chronic hepatitis\u00a0B\npatients with lamivudine-resistant HBV and co\u2011infected with HIV,\ncontinued treatment with 10\u00a0mg adefovir dipivoxil resulted in progressive\nreductions in serum HBV\u00a0DNA levels and ALT levels throughout the course of\ntreatment up to 144\u00a0weeks.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In a second open\u2011label,\none\u2011arm study, 10\u00a0mg adefovir dipivoxil and pegylated interferon\nalpha\u20112a were added to ongoing lamivudine therapy in 18 HIV/HBV co\u2011infected\npatients with lamivudine\u2011resistant HBV.\u00a0 Patients were all HBeAg\u00a0positive\nand had median CD4 cell count of 441\u00a0cells/mm<sup>3</sup> (no patient had\nCD4 count &lt;\u00a0200\u00a0cells/mm<sup>3</sup>).\u00a0 During therapy, serum HBV\u00a0DNA\nlevels were significantly lower compared to baseline for up to 48\u00a0weeks of\ntreatment while ALT levels declined progressively from week\u00a012.\u00a0 However,\non\u2011treatment HBV\u00a0DNA response was not maintained off\u2011therapy\nsince all the patients had a rebound in HBV\u00a0DNA after adefovir dipivoxil\nand pegylated interferon alpha\u20112a discontinuation.\u00a0 No patients became\nHBsAg\u2011 or HBeAg\u2011negative during the study.\u00a0 Due to the small sample\nsize and the study design, in particular the lack of treatment arms with\npegylated interferon alpha\u20112a monotherapy and with adefovir monotherapy, it\nis not possible to draw formal conclusions on the best therapeutic management\nof HIV co\u2011infected patients with lamivudine\u2011resistant HBV.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:8.1pt;line-height:normal;text-autospace:\nnone\"><i><span lang=\"EN-GB\">Clinical resistance in patients receiving adefovir\ndipivoxil as monotherapy and in combination with lamivudine:</span></i><span lang=\"EN-GB\"> In several clinical studies (HBeAg\u00a0positive,\nHBeAg\u00a0negative, pre\u2011 and post-liver transplantation with\nlamivudine-resistant HBV and lamivudine-resistant HBV co\u2011infected with\nHIV patients), genotypic analyses were conducted on HBV isolates from 379 of a\ntotal of 629\u00a0patients, treated with adefovir dipivoxil for 48\u00a0weeks.\u00a0\nNo HBV\u00a0DNA polymerase mutations associated with resistance to adefovir\nwere identified when patients were genotyped at baseline and at week\u00a048.\u00a0\nAfter 96, 144, 192 and 240\u00a0weeks of treatment with adefovir dipivoxil,\nresistance surveillance was performed for 293, 221, 116 and 64\u00a0patients,\nrespectively.\u00a0 Two novel conserved site mutations were identified in the HBV\npolymerase gene (rtN236T and rtA181V), which conferred clinical resistance to\nadefovir dipivoxil.\u00a0 The cumulative probabilities of developing these\nadefovir-associated resistance mutations in all patients treated with adefovir\ndipivoxil were 0\u00a0% at 48\u00a0weeks and approximately 2\u00a0%, 7\u00a0%, 14\u00a0%\nand 25\u00a0% after 96, 144, 192 and 240\u00a0weeks, respectively.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:8.1pt;line-height:normal;text-autospace:\nnone\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:8.1pt;line-height:normal;text-autospace:\nnone\"><i><span lang=\"EN-GB\">Clinical resistance in monotherapy studies in\nnucleoside na\u00efve patients:</span></i><span lang=\"EN-GB\"> In patients receiving\nadefovir dipivoxil monotherapy (HBeAg\u00a0negative study) the cumulative\nprobability of developing adefovir\u2011associated resistance mutations was\n0\u00a0%, 3\u00a0%, 11\u00a0%, 18\u00a0% and 29\u00a0% at 48, 96, 144, 192 and\n240\u00a0weeks respectively.\u00a0 In addition, the long\u2011term (4 to\n5\u00a0years) development of resistance to adefovir dipivoxil was significantly\nlower in patients who had serum HBV\u00a0DNA below the limit of quantification\n(&lt;\u00a01,000\u00a0copies/ml) at week\u00a048 as compared to patients with\nserum HBV\u00a0DNA above 1,000\u00a0copies/ml at week\u00a048.\u00a0 In HBeAg\u00a0positive\npatients, the incidence of adefovir-associated resistance mutations was\n3\u00a0% (2/65), 17\u00a0% (11/65) and 20\u00a0% (13/65) after a median\nduration exposure of 135, 189 and 235\u00a0weeks respectively.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:8.1pt;line-height:normal;text-autospace:\nnone\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:8.1pt;line-height:normal;text-autospace:\nnone\"><i><span lang=\"EN-GB\">Clinical resistance in studies where adefovir\ndipivoxil was added to ongoing lamivudine in patients with\nlamivudine-resistance:</span></i><span lang=\"EN-GB\"> In an open-label study of\npre\u2011 and post\u2011liver transplantation patients with clinical evidence\nof lamivudine-resistant HBV, no adefovir-associated resistance mutations were\nobserved at week\u00a048.\u00a0 With up to 3\u00a0years of exposure, no patients\nreceiving both adefovir dipivoxil and lamivudine developed resistance to\nadefovir dipivoxil. \u00a0However, 4\u00a0patients who discontinued lamivudine\ntreatment developed the rtN236T mutation while receiving adefovir dipivoxil\nmonotherapy and all experienced serum HBV rebound.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:8.1pt;line-height:normal;text-autospace:\nnone\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:8.1pt;line-height:normal;text-autospace:\nnone\"><span lang=\"EN-GB\">The currently available data both <i>in\u00a0vitro</i>\nand in patients suggest that HBV expressing the adefovir-associated resistance\nmutation rtN236T is susceptible to lamivudine.\u00a0 Preliminary clinical data\nsuggest the adefovir-associated resistance mutation rtA181V may confer a\nreduced susceptibility to lamivudine, and the lamivudine\u2011associated\nmutation rtA181T may confer a reduced susceptibility to adefovir dipivoxil.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:8.1pt;line-height:normal;text-autospace:\nnone\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Paediatric population:</span></u></i></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The efficacy and\nsafety of a daily dose of 0.25\u00a0mg/kg to 10\u00a0mg adefovir dipivoxil in\nchildren (aged from 2 to\u00a0&lt;\u00a018\u00a0years) were examined in a\ndouble\u2011blind, randomised, placebo\u2011controlled study in 173\npaediatric patients (115 on adefovir dipivoxil, 58 on placebo) who had\nHBeAg\u00a0positive chronic hepatitis\u00a0B, serum ALT levels\n\u2265\u00a01.5\u00a0x upper limit of normal (ULN) and compensated liver\ndisease.\u00a0 At week\u00a048, in children aged 2 to 11\u00a0years old, no\nstatistically significant difference was observed in the proportions of\npatients that achieved the primary endpoint of serum HBV<span style=\"color:\nblack;background:white\">\u00a0</span>DNA<span style=\"color:black;background:\nwhite\"> </span>&lt;\u00a01,000\u00a0copies/ml and normal ALT levels between the\nplacebo arm and the adefovir dipivoxil arm.\u00a0 In the adolescent population\n(n=83) (aged from 12 to &lt;\u00a018\u00a0years), significantly more patients\ntreated with adefovir dipivoxil achieved the primary efficacy endpoint and\nobtained significant reductions in serum HBV<span style=\"color:black;\nbackground:white\">\u00a0</span>DNA<span style=\"color:black;background:white\"> </span>(23\u00a0%)\ncompared to placebo\u2011treated patients (0\u00a0%).\u00a0 However, the\nproportions of subjects who achieved HBeAg seroconversion at week\u00a048 were\nsimilar (11\u00a0%) between the placebo arm and the adefovir dipivoxil\n10\u00a0mg arm in adolescent patients.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Overall, the\nsafety profile of adefovir dipivoxil in children was consistent with the known\nsafety profile in adult patients.\u00a0 However, a signal towards a higher rate of\ndecreased appetite and/or food intake was observed in the adefovir arm as\ncompared to the placebo arm.\u00a0 At week\u00a048 and 96, mean changes from\nbaseline in weight and BMI\u00a0Z\u00a0scores tended to decrease in adefovir\ndipivoxil\u2011treated patients.\u00a0 \u00a0At week\u00a048, all placebo-treated\nsubjects who did not exhibit HBeAg or HBsAg seroconversion, plus all adefovir\ndipivoxil\u2011treated subjects, were offered the opportunity to receive\nopen-label adefovir dipivoxil from study week\u00a049 through to week\u00a0240.\u00a0\nA high rate (30%) of hepatic flares was reported following discontinuation of\nadefovir dipivoxil during the 3\u00a0years open\u2011label phase of the\nstudy.\u00a0 Furthermore, for the few patients who remained on drug at week\u00a0240\n(n=12) BMI\u00a0Z\u00a0score was lower than typical for their age and gender.\u00a0\nVery few patients developed adefovir-associated mutations up to 5\u00a0years;\nhowever, the number of patients who remained on drugs above week 96\u00a0was\nlimited.\u00a0 Due to their limitations, the clinical data available do not allow to\ndraw definitive conclusions on the benefit/risk ratio of the adefovir treatment\nin children with chronic hepatitis\u00a0B (see section\u00a04.2).</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic properties</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adefovir\ndipivoxil is a dipivaloyloxymethyl ester prodrug of the active substance\nadefovir, an acyclic nucleotide analogue which is actively transported into\ncells where it is converted by host enzymes to adefovir diphosphate.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Absorption:</span></i><span lang=\"EN-GB\"> The oral bioavailability of adefovir from 10\u00a0mg adefovir\ndipivoxil is 59\u00a0%.\u00a0 Following oral administration of a single dose of\n10\u00a0mg adefovir dipivoxil to chronic hepatitis\u00a0B patients, the median\n(range) peak serum concentration (C<sub>max</sub>) was achieved after\n1.75\u00a0h (0.58\u20114.0\u00a0h).\u00a0 Median C<sub>max</sub> and AUC<sub>0\u2011\u221e</sub>\nvalues were 16.70\u00a0(9.66\u201130.56)\u00a0ng/ml and 204.40\u00a0(109.75\u2011356.05)\u00a0ng<b>\u00b7</b>h/ml,\nrespectively.\u00a0 Systemic exposure to adefovir was not affected when 10\u00a0mg\nadefovir dipivoxil was taken with a high fat meal.\u00a0 The t<sub>max</sub> was\ndelayed by two hours.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Distribution:</span></i><span lang=\"EN-GB\"> Preclinical studies show that after oral administration of adefovir\ndipivoxil, adefovir is distributed to most tissues with the highest\nconcentrations occurring in kidney, liver and intestinal tissues.\u00a0 <i>In\u00a0vitro</i>\nbinding of adefovir to human plasma or human serum proteins is \u2264\u00a04\u00a0%,\nover the adefovir concentration range of 0.1 to 25\u00a0\u03bcg/ml.\u00a0 The volume\nof distribution at steady\u2011state following intravenous administration of\n1.0 or 3.0\u00a0mg/kg/day is 392\u00b175 and 352\u00b19\u00a0ml/kg, respectively.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Biotransformation:</span></i><span lang=\"EN-GB\"> Following oral administration, adefovir dipivoxil is rapidly\nconverted to adefovir.\u00a0 At concentrations substantially higher (&gt;\u00a04,000\u2011fold)\nthan those observed <i>in\u00a0vivo</i>, adefovir did not inhibit any of the\nfollowing human CYP450 isoforms, CYP1A2, CYP2D6, CYP2C9, CYP2C19, CYP3A4.\u00a0 Based\non the results of these <i>in\u00a0vitro</i> experiments and the known\nelimination pathway of adefovir, the potential for CYP450 mediated interactions\ninvolving adefovir with other medicinal products is low.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Elimination:</span></i><span lang=\"EN-GB\"> Adefovir is excreted renally by a combination of glomerular\nfiltration and active tubular secretion.\u00a0 The median (min\u2011max) renal\nclearance of adefovir in subjects with normal renal function (Cl<sub>cr</sub>\u00a0&gt;\u00a080\u00a0ml/min)\nis 211\u2002ml/min (172\u2011316\u00a0ml/min), approximately twice calculated\ncreatinine clearance (Cockroft\u2011Gault method).<u>\u00a0 </u>After repeated\nadministration of 10\u00a0mg adefovir dipivoxil, 45\u00a0% of the dose is\nrecovered as adefovir in the urine over 24\u00a0hours.\u00a0 Plasma adefovir\nconcentrations declined in a biexponential manner with a median terminal\nelimination half\u2011life of 7.22\u00a0h (4.72\u201110.70\u00a0h).</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Linearity/non\u2011linearity:</span></i><span lang=\"EN-GB\"> The pharmacokinetics of adefovir are proportional to dose when\ngiven as adefovir dipivoxil over the dose range of 10 to 60\u00a0mg.\u00a0 Repeated\ndosing of adefovir dipivoxil 10\u00a0mg daily did not influence the\npharmacokinetics of adefovir.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Gender, age\nand ethnicity:</span></i><span lang=\"EN-GB\"> The pharmacokinetics of adefovir\nwere similar in male and female patients.\u00a0 Pharmacokinetic studies have not\nbeen conducted in the elderly.\u00a0 Pharmacokinetic studies were principally\nconducted in Caucasian patients.\u00a0 The available data do not appear to indicate\nany difference in pharmacokinetics with regard to race.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Renal impairment:</span></i><span lang=\"EN-GB\"> The mean (\u00b1 SD)\npharmacokinetic parameters of adefovir following administration of a single\ndose of 10\u00a0mg adefovir dipivoxil to patients with varying degrees of renal\nimpairment are described in the table below:</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:.9pt;border-collapse:collapse\" width=\"639\">\n<tr style=\"page-break-inside:avoid;height:7.5pt\">\n<td style=\"width:117.9pt;border:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"157\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Renal Function\n  Group</span></b></p>\n</td>\n<td style=\"width:161.1pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"215\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Unimpaired</span></b></p>\n</td>\n<td style=\"width:72.8pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"97\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Mild</span></b></p>\n</td>\n<td style=\"width:63.8pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Moderate</span></b></p>\n</td>\n<td style=\"width:63.8pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Severe</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:7.5pt\">\n<td style=\"width:117.9pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"157\">\n<p class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Baseline Creatinine Clearance (ml/min)</span></b></p>\n</td>\n<td style=\"width:161.1pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"215\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">&gt;\u00a080</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">(n=7)</span></b></p>\n</td>\n<td style=\"width:72.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"97\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">50\u201180</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">(n=8)</span></b></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">30\u201149</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">(n=7)</span></b></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">10\u201129</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">(n=10)</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:7.5pt\">\n<td style=\"width:117.9pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"157\">\n<p class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:\n  avoid\"><span lang=\"EN-GB\">C<sub>max</sub> (ng/ml)</span></p>\n</td>\n<td style=\"width:161.1pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"215\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">17.8\u00b13.2</span></p>\n</td>\n<td style=\"width:72.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"97\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">22.4\u00b14.0</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">28.5\u00b18.6</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">51.6\u00b110.3</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:7.5pt\">\n<td style=\"width:117.9pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"157\">\n<p class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:\n  avoid\"><span lang=\"EN-GB\">AUC<sub>0\u2011\u221e</sub> (ng<b>\u00b7</b>h/ml)</span></p>\n</td>\n<td style=\"width:161.1pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"215\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">201\u00b140.8</span></p>\n</td>\n<td style=\"width:72.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"97\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">266\u00b155.7</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">455\u00b1176</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">1240\u00b1629</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:7.5pt\">\n<td style=\"width:117.9pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"157\">\n<p class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:\n  avoid\"><span lang=\"EN-GB\">CL/F (ml/min)</span></p>\n</td>\n<td style=\"width:161.1pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"215\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">469\u00b199.0</span></p>\n</td>\n<td style=\"width:72.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"97\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">356\u00b185.6</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">237\u00b1118</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">91.7\u00b151.3</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:7.5pt\">\n<td style=\"width:117.9pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"157\">\n<p class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal\"><span lang=\"EN-GB\">CL<sub>renal</sub> (ml/min)</span></p>\n</td>\n<td style=\"width:161.1pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"215\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">231\u00b148.9</span></p>\n</td>\n<td style=\"width:72.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"97\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">148\u00b139.3</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">83.9\u00b127.5</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">37.0\u00b118.4</span></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">A four-hour\nperiod of haemodialysis removed approximately 35\u00a0% of the adefovir dose.\u00a0\nThe effect of peritoneal dialysis on adefovir removal has not been evaluated.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">It is\nrecommended that the dosing interval of 10\u00a0mg adefovir dipivoxil is\nmodified in patients with creatinine clearance between 30 and\u00a049\u00a0ml/min.\n\u00a0Adefovir dipivoxil is not recommended in patients with creatinine clearance of\n&lt;\u00a030\u00a0ml/min or in patients on dialysis (see\u00a0section\u00a04.2\nand 4.4).</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Hepatic\nimpairment:</span></i><span lang=\"EN-GB\"> Pharmacokinetic properties were similar\nin patients with moderate and severe hepatic impairment compared to healthy\nvolunteers (see\u00a0section\u00a04.2).</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Paediatric\npopulation: </span></i><span lang=\"EN-GB\">The pharmacokinetics of adefovir\ndipivoxil were studied in an efficacy and safety study of a daily dose of\n0.25\u00a0mg/kg to 10\u00a0mg adefovir dipivoxil in children (aged 2 to\n&lt;\u00a018\u00a0years).\u00a0 Pharmacokinetic analysis revealed that adefovir\nexposure was comparable among 3 age groups, 2 to 6\u00a0years (0.3\u00a0mg/kg),\n7 to 11\u00a0years (0.25\u00a0mg/kg) and 12 to 17\u00a0years (10\u00a0mg) and\nall age groups achieved adefovir exposure in the target range (for efficacy\nresults see\u00a0section\u00a05.1), which was based on adefovir plasma\nconcentrations in adult patients with chronic hepatitis\u00a0B with established\nsafety and efficacy profiles.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.3\u00a0\u00a0\u00a0\u00a0 Preclinical safety\ndata</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The primary dose\u2011limiting\ntoxic effect associated with administration of adefovir dipivoxil in animals\n(mice, rats and monkeys) was renal tubular nephropathy characterised by\nhistological alterations and/or increases in blood urea nitrogen and serum\ncreatinine.\u00a0 Nephrotoxicity was observed in animals at systemic exposures at\nleast 3\u201110\u00a0times higher than those achieved in humans at the\nrecommended therapeutic dose of 10\u00a0mg/day.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">No effects on\nmale or female fertility, or reproductive performance, occurred in rats and\nthere was no embryotoxicity or teratogenicity in rats or rabbits administered\nadefovir dipivoxil orally.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">When adefovir\nwas administered intravenously to pregnant rats at doses associated with\nnotable maternal toxicity (systemic exposure 38\u00a0times that achieved in\nhumans at the therapeutic dose) embryotoxicity and an increased incidence of\nfoetal malformations (anasarca, depressed eye bulge, umbilical hernia and\nkinked tail) were observed.\u00a0 No adverse effects on development were seen at\nsystemic exposures approximately 12\u00a0times that achieved in humans at the\ntherapeutic dose.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adefovir\ndipivoxil was mutagenic in the <i>in\u00a0vitro</i> mouse lymphoma cell assay\n(with or without metabolic activation), but was not clastogenic in the <i>in\u00a0vivo</i>\nmouse micronucleus assay.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adefovir was not\nmutagenic in microbial mutagenicity assays involving <i>Salmonella typhimurium</i>\n(Ames) and <i>Escherichia coli</i> in the presence and absence of metabolic\nactivation.\u00a0 Adefovir induced chromosomal aberrations in the <i>in\u00a0vitro</i>\nhuman peripheral blood lymphocyte assay without metabolic activation.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In long\u2011term\ncarcinogenicity studies in rats and mice with adefovir dipivoxil, no\ntreatment-related increase in tumour incidence was found in mice or rats\n(systemic exposures approximately 10 and 4\u00a0times those achieved in humans\nat the therapeutic dose of 10\u00a0mg/day, respectively).</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL PARTICULARS</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.1\u00a0\u00a0\u00a0\u00a0 List of excipients</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Pregelatinised starch</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Croscarmellose sodium</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Lactose monohydrate</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Talc</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Magnesium\nstearate</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Not applicable.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.3\u00a0\u00a0\u00a0\u00a0 Shelf life</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">2\u00a0years.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.4\u00a0\u00a0\u00a0\u00a0 Special precautions\nfor storage</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Do not store\nabove 30\u00baC.\u00a0 Store in the original package in order to protect from moisture. \u00a0Keep\nthe bottle tightly closed.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.5\u00a0\u00a0\u00a0\u00a0 Nature and contents\nof container</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Hepsera is\nsupplied in high-density polyethylene (HDPE) bottles with a child\u2011resistant\nclosure.\u00a0 Each bottle contains 30\u00a0tablets, silica gel desiccant and fibre\npacking material.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The following\npack sizes are available: outer cartons containing 1\u00a0bottle of\n30\u00a0tablets and outer cartons containing 90\u00a0(3\u00a0bottles of\n30)\u00a0tablets. \u00a0Not all pack sizes may be marketed.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.6\u00a0\u00a0\u00a0\u00a0 Special precautions\nfor disposal</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Any unused medicinal\nproduct or waste material should be disposed of in accordance with local\nrequirements.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION HOLDER</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead Sciences\nIreland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Carrigtohill</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">County Cork, T45\nDP77</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Ireland</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION\nNUMBER(S)</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">EU/1/03/251/001</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EU/1/03/251/002</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF FIRST\nAUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Date of first authorisation: 06 March 2003</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Date of latest\nrenewal: 06 March 2008</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 DATE OF REVISION OF\nTHE TEXT</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">{MM/YYYY}</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Detailed information\non this medicinal product is available on the website of the European Medicines\nAgency http://www.ema.europa.eu</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">ANNEX II</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-28.35pt;line-height:\nnormal\"><b><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S) RESPONSIBLE FOR BATCH\nRELEASE</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-28.35pt;line-height:\nnormal\"><b><span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING SUPPLY\nAND USE</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-28.35pt;line-height:\nnormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-28.35pt;line-height:\nnormal\"><b><span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS OF THE\nMARKETING AUTHORISATION</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-28.35pt;line-height:\nnormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-28.35pt;line-height:\nnormal\"><b><span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS WITH REGARD TO\nTHE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:77.9pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>\n<p class=\"TitleB\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S)\nRESPONSIBLE FOR BATCH RELEASE</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Name and address of the manufacturer(s) responsible for batch\nrelease</span></u></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Gilead Sciences Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">IDA Business &amp; Technology Park</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Carrigtohill Co. Cork</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Ireland</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"TitleB\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS\nOR RESTRICTIONS REGARDING SUPPLY AND USE</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Medicinal\nproduct subject to restricted medical prescription (see Annex\u00a0I: Summary\nof Product Characteristics, section\u00a04.2).</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"TitleB\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nCONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Periodic Safety Update Reports</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:normal;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:normal\"><span lang=\"EN-GB\">The marketing authorisation holder shall submit periodic safety\nupdate reports for this product in accordance with the requirements set out in\nthe list of Union reference dates (EURD list) provided for under Article\n107c(7) of Directive 2001/83</span><span lang=\"EN-GB\">/EC</span><span lang=\"EN-GB\">\nand published on the European medicines web-portal.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"TitleB\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS\nOR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL\nPRODUCT</span></p>\n<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\npage-break-after:avoid;background:white\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Risk Management Plan (RMP)</span></b></p>\n<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\npage-break-after:avoid;background:white\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\nbackground:white\"><span lang=\"EN-GB\" style=\"color:black\">The MAH shall perform\nthe required pharmacovigilance activities and interventions detailed in the\nagreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any\nagreed subsequent updates of the RMP.</span></p>\n<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\nbackground:white\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:normal\"><span lang=\"EN-GB\">An updated RMP should be submitted:</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">At the request of the European Medicines Agency;</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Whenever the risk management system is modified,\nespecially as the result of new information being received that may lead to a\nsignificant change to the benefit/risk profile or as the result of an important\n(pharmacovigilance or risk minimisation) milestone being reached.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\nbackground:white\"><span lang=\"EN-GB\" style=\"color:black\">If the dates for\nsubmission of a PSUR and the update of a RMP coincide, they can be submitted at\nthe same time.</span></p>\n<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\nbackground:white\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"SPCList\" style=\"line-height:normal;page-break-after:avoid;background:\nwhite\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\" style=\"color:black\">Obligation to conduct\npost-authorisation measures</span></b></p>\n<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\npage-break-after:avoid;background:white\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\npage-break-after:avoid;background:white\"><span lang=\"EN-GB\" style=\"color:black\">The\nMAH shall complete, within the stated timeframe, the following measures:</span></p>\n<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\npage-break-after:avoid;background:white\"><span lang=\"EN-GB\">\u00a0</span></p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:388.15pt;border:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 1.4pt 5.4pt\" valign=\"top\" width=\"518\">\n<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\n  page-break-after:avoid;background:white\"><b><span lang=\"EN-GB\" style=\"color:black\">Description</span></b></p>\n</td>\n<td style=\"width:76.2pt;border:solid windowtext 1.0pt;\n  border-left:none;background:white;padding:0in 5.4pt 1.4pt 5.4pt\" valign=\"top\" width=\"102\">\n<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\n  page-break-after:avoid;background:white\"><b><span lang=\"EN-GB\" style=\"color:black\">Due date</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:388.15pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 1.4pt 5.4pt\" valign=\"top\" width=\"518\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">The MAH commits to ensure continuous assessment of\n  cross-resistance of adefovir to established and new nucleos(t)ide analogues,\n  and provide reviews of these assessments as new data becomes available. The\n  role of adefovir and add-on lamivudine+adefovir in HBV therapy strategy\n  should be regularly discussed in the light of emerging data.</span></p>\n</td>\n<td style=\"width:76.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 1.4pt 5.4pt\" valign=\"top\" width=\"102\">\n<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\n  page-break-after:avoid;background:white\"><span lang=\"EN-GB\" style=\"color:black\">As\n  data becomes available</span></p>\n</td>\n</tr>\n</table>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\" style=\"margin-right:28.3pt;line-height:normal;background:\nwhite\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">ANNEX III</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">LABELLING AND PACKAGE LEAFLET</span></b></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"TitleA\"><span lang=\"EN-GB\">A. LABELLING</span></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\" style=\"line-height:normal;background:white\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE\nPACKAGING</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;border:none;padding:0in\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">CARTON AND BOTTLE LABELLING</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Hepsera 10\u00a0mg tablets</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adefovir\ndipivoxil</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Each tablet\ncontains 10\u00a0mg adefovir dipivoxil.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Contains lactose\nmonohydrate, see package leaflet for further information.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">30\u00a0tablets.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">90 (3\u00a0bottles of 30)\u00a0tablets.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Oral use.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Read the package\nleaflet before use.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nWARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\nCHILDREN</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Keep out of the\nsight and reach of children.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EXP</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nSTORAGE CONDITIONS</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Do not store\nabove 30\u00baC.\u00a0 Store in the original package in order to protect from moisture.\u00a0\nKeep the bottle tightly closed.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL\nPRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\nDERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0 NAME\nAND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Gilead Sciences Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Carrigtohill</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">County Cork, T45 DP77</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Ireland</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">EU/1/03/251/001 <span style=\"color:black;background:#D9D9D9\">30\u00a0tablets</span></span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">EU/1/03/251/002 90 (3\u00a0bottles of 30)\u00a0tablets</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Lot</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL\nCLASSIFICATION FOR SUPPLY</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION\nIN BRAILLE</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Hepsera</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">[</span><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">outer packaging only</span><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">]</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:#CCCCCC\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:#CCCCCC\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">2D barcode carrying the unique identifier included.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PC: {number} </span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">SN: {number}</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">NN: {number}</span></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"TitleA\"><span lang=\"EN-GB\">B. PACKAGE LEAFLET</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Package leaflet: Information for the user</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Hepsera 10\u00a0mg tablets</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">Adefovir dipivoxil</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Read all of\nthis leaflet carefully before you start taking this medicine because it\ncontains important information for you.</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Keep this leaflet. \u00a0You may need to read it\nagain.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you have any further questions, ask your\ndoctor or pharmacist.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 This medicine has been prescribed for you\nonly.\u00a0 Do not pass it on to others.\u00a0 It may harm them, even if their signs of\nillness are the same as yours.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you get any side effects, talk to your\ndoctor or pharmacist.\u00a0 This includes any possible side effects not listed in\nthis leaflet. \u00a0See section\u00a04.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">What is in this leaflet</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Hepsera is and what it is used for</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to know before you take Hepsera</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to take Hepsera</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side effects</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store Hepsera</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the pack and other information</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Hepsera is and\nwhat it is used for</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">What Hepsera is</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Hepsera belongs\nto a group of medicines called antiviral medicines.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">What it is used for</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Hepsera is used\nto treat chronic hepatitis\u00a0B, an infection with hepatitis\u00a0B virus\n(HBV), in adults.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Infection with\nthe hepatitis\u00a0B virus leads to damage to the liver.\u00a0 Hepsera reduces the\namount of the virus in your body, and has been shown to reduce liver damage.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to\nknow before you take Hepsera</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Do not take Hepsera</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">If you are allergic</span></b><span lang=\"EN-GB\"> to adefovir, adefovir dipivoxil or any of the other ingredients of\nthis medicine (listed in section\u00a06).</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Tell your doctor at once </span></b><span lang=\"EN-GB\">if you could be allergic to adefovir, adefovir dipivoxil or any of\nthe other ingredients of Hepsera.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Warnings and precautions</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Talk to your doctor before using Hepsera.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Tell your doctor if you have had kidney\ndisease</span></b><span lang=\"EN-GB\">, or if tests have shown problems with your\nkidneys. \u00a0Hepsera can affect the way your kidneys work. \u00a0The risk of this\noccurring is increased with long-term use of Hepsera.\u00a0 Your doctor should run\ntests to check your kidneys and liver are working properly, before and during\nyour treatment.\u00a0 Depending on the results, your doctor may change how often you\ntake Hepsera.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">If you are over 65\u00a0years of age your doctor\nmay monitor your health more closely.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Don\u2019t stop taking Hepsera</span></b><span lang=\"EN-GB\"> without your doctor\u2019s advice.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">After stopping Hepsera tell your doctor\nimmediately</span></b><span lang=\"EN-GB\"> about any new, unusual or worsening\nsymptoms that you notice after stopping treatment.\u00a0 Some patients have had\nsymptoms or blood tests indicating that their hepatitis has worsened after\nstopping treatment with Hepsera.\u00a0 It\u2019s best for your doctor to monitor your\nhealth after stopping treatment with Hepsera.\u00a0 You may need blood tests for\nseveral months after treatment.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Once you start taking Hepsera:</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">look out for possible signs of lactic\nacidosis</span></b><span lang=\"EN-GB\"> \u2013 see\u00a0section\u00a04, Possible side\neffects.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">your doctor should order blood tests every\nthree months</span></b><span lang=\"EN-GB\"> to check your medicine is keeping your\nchronic hepatitis\u00a0B infection under control.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Take care not to infect other people.</span></b><span lang=\"EN-GB\"> \u00a0Hepsera does not reduce the risk of passing on HBV to others\nthrough sexual contact or blood contamination. \u00a0You must continue to take precautions\nto avoid this.\u00a0 A vaccine is available to protect those at risk from becoming\ninfected with HBV.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">If you are HIV\u00a0positive this medicine will\nnot control your HIV\u00a0infection.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Children and adolescents</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Do not use Hepsera in children</span></b><span lang=\"EN-GB\"> or adolescents under 18\u00a0years of age.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Other medicines and Hepsera</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Do not take Hepsera if you are taking any\nmedicines containing tenofovir.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Tell your doctor or pharmacist</span></b><span lang=\"EN-GB\"> if you are taking, have recently taken or might take any other medicines,\nincluding medicines and herbal products obtained without a prescription.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">It is especially important to tell your\ndoctor</span></b><span lang=\"EN-GB\"> if you are taking or have recently taken any\nof the following medicines which may damage your kidneys, or interact with\nHepsera:</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">vancomycin and aminoglycosides, used for\nbacterial infections</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">amphotericin\u00a0B, for fungal infections</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">foscarnet, cidofovir or tenofovir disoproxil\nfumarate, for viral infections</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\nmargin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">pentamidine, for other types of infection.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Hepsera with food and drink</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Hepsera can be taken with or without food.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Pregnancy and breast-feeding</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If you are\npregnant or breast-feeding, think you may be pregnant or are planning to have a\nbaby, ask your doctor or pharmacist for advice before taking this medicine.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Tell your doctor immediately if you are\npregnant</span></b><span lang=\"EN-GB\"> or planning to become pregnant. \u00a0It is not\nknown whether Hepsera is safe to use during human pregnancy.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Use an effective method of contraception</span></b><span lang=\"EN-GB\"> to avoid becoming pregnant if you are a woman of child-bearing age\ntaking Hepsera.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Do not breast-feed while taking Hepsera.</span></b><span lang=\"EN-GB\"> \u00a0It is not known whether the active substance in this medicine\npasses into breast milk.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></s></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Hepsera contains lactose</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If you are\nlactose-intolerant, or if you have been told that you have an intolerance to\nsome sugars, talk to your doctor before taking Hepsera.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to take Hepsera</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Always take this\nmedicine exactly as your doctor has told you.</span></b><span lang=\"EN-GB\">\u00a0 This\nis to make sure that your medicine is fully effective and to reduce the\ndevelopment of resistance to the treatment. \u00a0Check with your doctor or pharmacist\nif you are not sure.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">The recommended dose</span></b><span lang=\"EN-GB\"> is one 10\u00a0mg tablet each day, taken with or without food.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">A different dose</span></b><span lang=\"EN-GB\">\nmay be given to patients with <b>kidney problems</b>.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">If you take more Hepsera than you should</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If you\naccidentally take too many Hepsera tablets, contact your doctor or nearest\nhospital immediately.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">If you forget to take Hepsera or you vomit</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">It is important\nnot to miss a dose.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">If you do miss a dose</span></b><span lang=\"EN-GB\"> of Hepsera, take it as soon as you can, and then take your next\nscheduled dose at its regular time.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">If it is nearly time for your next dose,</span></b><span lang=\"EN-GB\"> skip the missed dose.\u00a0 Wait and take the next dose at the regular\ntime.\u00a0 Do not take a double dose (two doses close together).</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">If you are sick (vomit) less than 1\u00a0hour\nafter taking Hepsera</span></b><span lang=\"EN-GB\"> take another tablet. \u00a0You do\nnot need to take another tablet if you are sick more than 1\u00a0hour after\ntaking Hepsera.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">If you stop taking Hepsera</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Tell your doctor immediately about any new, </span></b><span lang=\"EN-GB\">unusual or worsening symptoms that you notice after stopping\ntreatment. \u00a0See\u00a0section\u00a02 for more details.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Don\u2019t stop taking Hepsera</span></b><span lang=\"EN-GB\"> without your doctor\u2019s advice.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If you have any further\nquestions on the use of this medicine, ask your doctor or pharmacist.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side effects</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Like all\nmedicines, this medicine can cause side effects, although not everybody gets\nthem.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Very rare side effects</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">(These can affect less than 1 in 10,000\u00a0people taking Hepsera)</span></i></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Lactic acidosis is a serious but very rare\nside effect of taking Hepsera.</span></b><span lang=\"EN-GB\"> \u00a0It can cause too\nmuch lactic acid in the blood and enlargement of the liver. \u00a0Lactic acidosis\noccurs more often in women, particularly if they are very overweight. \u00a0People\nwith liver disease may also be at risk.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Some of the signs of lactic acidosis are:</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Feeling sick (nausea) and sickness (vomiting)</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Stomach pain</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><span style=\"font-family:Wingdings\">\u00e0</span><b><span lang=\"EN-GB\">Contact your doctor\nat once</span></b><span lang=\"EN-GB\"> if you get any of these symptoms. \u00a0They are\nthe same as some of the common side effects of Hepsera. \u00a0If you do get any of\nthem, it is unlikely to be serious, but you need to check. \u00a0Your doctor will\nmonitor you regularly while you take Hepsera.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Common side effects</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">(These can affect 1 to 10 in every 100\u00a0people taking Hepsera)</span></i></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Headache</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Feeling sick (nausea)</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Diarrhoea</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Digestive problems including wind or discomfort\nafter eating meals</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Stomach pain</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Kidney problems, as shown by blood tests</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><span style=\"font-family:Wingdings\">\u00e0</span><span lang=\"EN-GB\">Tell a doctor or\npharmacist if you are worried about any of these.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Very common side effects</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">(These can affect more than 10 in every 100\u00a0people taking\nHepsera)</span></i></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Weakness</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><span style=\"font-family:Wingdings\">\u00e0</span><span lang=\"EN-GB\">Tell a doctor or\npharmacist if you are worried about this.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Side effects before or after having a liver transplant</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Some patients have experienced:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Rash and itching \u2013 common</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Feeling sick (nausea) or being sick (vomiting) \u2013\ncommon</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Kidney failure \u2013 common</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Kidney problems \u2013 very common</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><span style=\"font-family:Wingdings\">\u00e0</span><span lang=\"EN-GB\">Tell a doctor or pharmacist\nif you are worried about any of these.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Also tests may show decreases in phosphate\n(common) or increases in creatinine (very common) in the blood.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Other possible side effects</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Some patients may also experience:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Kidney failure</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Damage to kidney tubule cells</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Kidney problems may lead to softening of the\nbones (which causes bone pain and sometimes leads to fractures) and muscle pain\nor weakness.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Inflammation of the pancreas (pancreatitis)</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Reporting of side effects</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">If you get any side effects, talk to your doctor or pharmacist.</span><span lang=\"EN-GB\">\u00a0 This includes any possible side effects not listed in this\nleaflet.\u00a0 You can also report side effects directly via <span style=\"color:\nblack;background:#D9D9D9\">the national reporting system listed in <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"color:black;text-decoration:none\">Appendix\u00a0V</span></a></span>.\u00a0 By\nreporting side effects you can help provide more information on the safety of\nthis medicine.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store Hepsera</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Keep this\nmedicine out of the sight and reach of children.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Do not use this\nmedicine after the expiry date which is stated on the bottle and carton after {EXP}.\u00a0\nThe expiry date refers to the last day of that month.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Do not store\nabove 30\u00baC (86\u00baF). \u00a0Store in the original package in order to protect from\nmoisture. \u00a0Keep the bottle tightly closed.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Return any left\nover tablets to your pharmacist. \u00a0Only keep them if your doctor tells you to. \u00a0Do\nnot throw away any medicines via wastewater or household waste. \u00a0Ask your\npharmacist how to throw away medicines you no longer use. \u00a0These measures will\nhelp protect the environment.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the pack and other information</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">What Hepsera contains</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">The active substance</span></b><span lang=\"EN-GB\"> in Hepsera is adefovir dipivoxil.\u00a0 Each tablet contains 10\u00a0mg\nadefovir dipivoxil.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">The other ingredients are: pregelatinised\nstarch, croscarmellose sodium, lactose monohydrate, talc and magnesium\nstearate.</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">What Hepsera looks like and contents of the pack</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Hepsera\n10\u00a0mg tablets are round, white to off\u2011white tablets.\u00a0 The tablets\nare marked with \u201cGILEAD\u201d and \u201c10\u201d on one side and a stylised shape of a liver\non the other side.\u00a0 Hepsera 10\u00a0mg tablets are supplied in bottles of\n30\u00a0tablets with silica gel desiccant.\u00a0 The silica gel desiccant is\ncontained in either a separate sachet or a small canister and should not be\nswallowed.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The following\npack sizes are available: outer cartons containing 1\u00a0bottle of\n30\u00a0tablets and outer cartons containing 90 (3\u00a0bottles of\n30)\u00a0tablets. \u00a0Not all pack sizes may be marketed.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Marketing Authorisation Holder and Manufacturer</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Marketing Authorisation Holder:</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Gilead Sciences Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Carrigtohill</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">County Cork, T45 DP77</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Ireland</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Manufacturer:</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Gilead Sciences Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">IDA Business &amp; Technology Park</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Carrigtohill</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">County Cork</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Ireland</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">For any information about this medicine, please contact the local\nrepresentative of the Marketing Authorisation Holder:</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:-1.7pt;border-collapse:collapse\" width=\"624\">\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Belgi\u00eb/Belgique/Belgien</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Belgium SPRL-BVBA</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">T\u00e9l/Tel: + 32\n  (0) 24 01 35 50</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:1.7pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Lietuva</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Poland Sp. z o.o.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 48 22\n  262 8702</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u0422\u0435\u043b.:\n  + 353 (0) 1 686 1888</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Belgium SPRL-BVBA</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">T\u00e9l/Tel: + 32\n  (0) 24 01 35 50</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u010cesk\u00e1\n  republika</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences s.r.o.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: </span><span lang=\"EN-GB\">+ 420 (0) 910 871 986</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Magyarorsz\u00e1g</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences </span><span lang=\"EN-GB\">Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Danmark</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tlf: + 46 (0)\n  8 5057 1849</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Malta</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences </span><span lang=\"EN-GB\">Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Deutschland</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences GmbH</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 49 (0)\n  89 899890-0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Nederland</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Netherlands B.V.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 31 (0)\n  20 718 36 98</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Eesti</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Poland Sp. z o.o.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 48 22\n  262 8702</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Norge</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tlf: + 46 (0)\n  8 5057 1849</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences \u0395\u03bb\u03bb\u03ac\u03c2 \u039c.\u0395\u03a0\u0395.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb:\n  + 30 210 8930 100</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00d6sterreich</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences GesmbH</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 43 1\n  260 830</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Espa\u00f1a</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences, S.L.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 34 91\n  378 98 30</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Polska</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead Sciences\n  Poland Sp. z o.o.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 48 22\n  262 8702</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">France</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">T\u00e9l: + 33 (0)\n  1 46 09 41 00</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Portugal</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences, Lda.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 351 21\n  7928790</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">Hrvatska</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Gilead Sciences </span><span lang=\"EN-GB\">Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Rom\u00e2nia</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences </span><span lang=\"EN-GB\">Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Ireland</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  214 825 999</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Slovenija</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences </span><span lang=\"EN-GB\">Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00cdsland</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">S\u00edmi: + 46 (0)\n  8 5057 1849</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Slovensk\u00e1\n  republika</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Slovakia s.r.o.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 421 (0)\n  232 121 210</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Italia</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences S.r.l.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 39 02\n  439201</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Suomi/Finland</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Puh/Tel: + 46\n  (0) 8 5057 1849</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences \u0395\u03bb\u03bb\u03ac\u03c2 \u039c.\u0395\u03a0\u0395.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb:\n  + 30 210 8930 100</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Sverige</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 46 (0)\n  8 5057 1849</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Latvija</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><a name=\"OLE_LINK1\"></a><a name=\"OLE_LINK2\"><span lang=\"EN-GB\">Gilead Sciences Poland Sp. z o.o.</span></a></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 48 22\n  262 8702</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">United\n  Kingdom</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Ltd</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 44 (0) 8000\n  113 700</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\" style=\"margin-right:-22.45pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">This leaflet was last revised in {MM/YYYY}.</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Detailed\ninformation on this medicine is available on the European Medicines Agency web\nsite: </span><span lang=\"EN-GB\">http://www.ema.europa.eu</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">This leaflet is\navailable in all EU/EEA languages on the European Medicines Agency website.</span></p>\n</div>", "ID": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5", "Styles": "None", "Classes": "['WordSection1']", "Text": "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ", "ParentId": "0db072e9-9503-43c0-bc00-48f5bf5ed93b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ccb6e03d-a9ca-406a-8b69-34fff2b9877e", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "66832511-b0b3-40d8-a2ba-56a7d6cffcd2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ccb6e03d-a9ca-406a-8b69-34fff2b9877e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f7cc8924-7e61-4ff9-99a4-9631c865d5b7", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "21c72a75-9487-4591-9ab2-0259f2fe7555", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f7cc8924-7e61-4ff9-99a4-9631c865d5b7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "baa67ccc-f710-46be-a0af-bbd0f2f20b3d", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c99c388c-b80e-4c0c-a92a-fbcfe9c21347", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "baa67ccc-f710-46be-a0af-bbd0f2f20b3d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1e0d1c07-238f-4089-bca6-c9dd69aac870", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "679817f6-badf-4239-b3a2-7b461b2c9cfd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1e0d1c07-238f-4089-bca6-c9dd69aac870"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "88b47c80-59b7-4a6b-ad54-f8452be06210", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bd870417-b4bd-4d17-adda-cd43e7984971", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "88b47c80-59b7-4a6b-ad54-f8452be06210"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3f6f47a6-1b3e-4228-8034-6610e3201dbd", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "60fdb324-065f-4a91-868e-869896974248", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3f6f47a6-1b3e-4228-8034-6610e3201dbd"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "368de48e-7e0f-442d-b6ee-14b0d469e912", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0569661b-126f-4d04-a8c2-f3a44ae67ef1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "368de48e-7e0f-442d-b6ee-14b0d469e912"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e692f26a-7e7c-4d5e-b00f-663d52d9a9bb", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0be00841-95db-4bc7-8dbb-a80b4339b28c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e692f26a-7e7c-4d5e-b00f-663d52d9a9bb"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e4f5f709-4a2c-47dd-8fc0-98dae128ec97", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7ecab442-be2a-4a6c-bd65-74f191e7c637", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e4f5f709-4a2c-47dd-8fc0-98dae128ec97"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b1cf9af7-69e1-431d-b4ff-80728faf4593", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dd1c7d7e-0ef9-4543-b66d-f367b9875797", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b1cf9af7-69e1-431d-b4ff-80728faf4593"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d0924ee2-c9f3-42ee-814d-d2c03f884417", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "87bd2e61-df3d-4b82-9b82-2d10b755d7d8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d0924ee2-c9f3-42ee-814d-d2c03f884417"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "110ff0b9-4e32-4981-98fa-533319549341", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d08c2f08-f78a-4c7b-8af0-5a802c22c845", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "110ff0b9-4e32-4981-98fa-533319549341"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3e0df938-7509-44fd-94f8-533b719cdab6", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "faf83428-27c2-4f21-92fc-59d782d03015", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3e0df938-7509-44fd-94f8-533b719cdab6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8241212e-7605-4288-bae5-5731a8fa639f", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3748f4c0-45a2-4b9c-9d39-230a2d5cbfd9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8241212e-7605-4288-bae5-5731a8fa639f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9e3eed4e-0f46-42f1-913f-23c55cc992da", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4c1c21c9-a3df-44d1-be74-613b78d631d4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9e3eed4e-0f46-42f1-913f-23c55cc992da"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b2858c84-4e84-46a2-9839-10e7aa56c9d7", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "eed3450f-d947-4527-bcf6-a9f7734c5f87", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b2858c84-4e84-46a2-9839-10e7aa56c9d7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5cf75a11-2021-4b51-813d-7938b2b1d9b3", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ceb81536-3a27-4e4a-88c0-f96e39d0cc0b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5cf75a11-2021-4b51-813d-7938b2b1d9b3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fab8132a-0cd0-4539-b5e4-9687cf97efb9", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6dca0377-3082-4912-acf7-ad4e6de39e62", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fab8132a-0cd0-4539-b5e4-9687cf97efb9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "86638a1b-c577-4310-a01f-a518cf351746", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8a7fed25-ad70-41c4-8d87-98c20f01ab2c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "86638a1b-c577-4310-a01f-a518cf351746"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5506b872-2e59-4cb7-988e-6d91e96fc385", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "94aa034e-1783-4ec5-9c2b-6ce100cc90fc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5506b872-2e59-4cb7-988e-6d91e96fc385"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "51b046d3-008b-4c47-a428-9a648c75df78", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "90b3d6c9-f41a-4b2b-8478-3f2103bd2dac", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "51b046d3-008b-4c47-a428-9a648c75df78"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4729dd6d-b914-4dcf-9ea3-d1857eee8ed4", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2b146d18-2710-4235-b136-2f434e60b006", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4729dd6d-b914-4dcf-9ea3-d1857eee8ed4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "592a87b1-d20b-4845-b3ef-29f42519b708", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "00f3400c-fd66-4871-8ce0-6f0a8573be03", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "592a87b1-d20b-4845-b3ef-29f42519b708"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">ANNEX I</span></b></p>", "ID": "a2f9d541-f4f4-4de0-b9a3-41a81a642c1a", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">ANNEX I</span></b>", "ID": "7d5cd5fa-530d-4800-9411-c2cb91f210e8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a2f9d541-f4f4-4de0-b9a3-41a81a642c1a"}, {"Element": "<span lang=\"EN-GB\">ANNEX I</span>", "ID": "9311d261-d43f-4148-a034-69b52d9337ef", "Styles": "None", "Classes": "None", "Text": "ANNEX I", "ParentId": "7d5cd5fa-530d-4800-9411-c2cb91f210e8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0d0cbb7a-b5dc-4bcc-b986-810bb332e676", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4257da7d-38c8-4f69-8e7c-0cc4be9800d3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0d0cbb7a-b5dc-4bcc-b986-810bb332e676"}, {"Element": "<p class=\"TitleA\"><span lang=\"EN-GB\">SUMMARY OF PRODUCT CHARACTERISTICS</span></p>", "ID": "38c78f18-0404-4fc1-9e4b-9ea032c80856", "Styles": "None", "Classes": "['TitleA']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">SUMMARY OF PRODUCT CHARACTERISTICS</span>", "ID": "0901bd6b-cde5-4182-a781-749b6e27b7fa", "Styles": "None", "Classes": "None", "Text": "SUMMARY OF PRODUCT CHARACTERISTICS", "ParentId": "38c78f18-0404-4fc1-9e4b-9ea032c80856"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5819dc4f-6754-4217-9ec6-fbc8a4a0d755", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "86f39387-fb5b-4774-bb80-819194c115be", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5819dc4f-6754-4217-9ec6-fbc8a4a0d755"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "0970ff24-9cbe-4624-9136-cb10c6db674e", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "b28265ca-8fca-42b0-9804-0ad5a11c9960", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "0970ff24-9cbe-4624-9136-cb10c6db674e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE\nMEDICINAL PRODUCT</span></b></p>", "ID": "690e8928-9853-46ee-9502-dbb4f3ef6004", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE\nMEDICINAL PRODUCT</span></b>", "ID": "ee6ec338-a6ef-42dd-9299-5adfd1572fc3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "690e8928-9853-46ee-9502-dbb4f3ef6004"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE\nMEDICINAL PRODUCT</span>", "ID": "872c37d9-0445-4f83-9fc5-03883a35a027", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT", "ParentId": "ee6ec338-a6ef-42dd-9299-5adfd1572fc3"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2525cb7f-50e3-487a-a2c1-32eca437d5be", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "861bd515-1ae6-45a7-89b0-bd0bbf1d8b73", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2525cb7f-50e3-487a-a2c1-32eca437d5be"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Hepsera\n10\u00a0mg tablets</span></p>", "ID": "6631f1a5-b5a8-457d-9ee7-c16c7299dc62", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Hepsera\n10\u00a0mg tablets</span>", "ID": "81b297be-560f-407f-9855-213fcdef2139", "Styles": "None", "Classes": "None", "Text": "Hepsera 10\u00a0mg tablets", "ParentId": "6631f1a5-b5a8-457d-9ee7-c16c7299dc62"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "822fe94a-521b-4b32-b35a-eb7b3dc9223c", "Styles": "line-height:normal;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a8849739-7196-4c91-9d4f-a0bfcb72f90b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "822fe94a-521b-4b32-b35a-eb7b3dc9223c"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "20a2ec7b-8002-4176-a6e3-85a040d071d8", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "151bb8dd-31ba-4926-8f74-e7c06363757e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "20a2ec7b-8002-4176-a6e3-85a040d071d8"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE AND\nQUANTITATIVE COMPOSITION</span></b></p>", "ID": "dc84e43a-66b3-482b-90e6-89c6648a1ff5", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE AND\nQUANTITATIVE COMPOSITION</span></b>", "ID": "da00b790-2a29-4a52-a238-a9df8478cf5c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dc84e43a-66b3-482b-90e6-89c6648a1ff5"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE AND\nQUANTITATIVE COMPOSITION</span>", "ID": "4ec911d2-b539-443f-bcf8-b1f55024e9d3", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE AND QUANTITATIVE COMPOSITION", "ParentId": "da00b790-2a29-4a52-a238-a9df8478cf5c"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "54a68481-7706-49b4-aca9-c3d610baf19b", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5e3733fb-c91a-42c8-825e-df05b86048da", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "54a68481-7706-49b4-aca9-c3d610baf19b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Each tablet\ncontains 10\u00a0mg adefovir dipivoxil.</span></p>", "ID": "6e326c9e-1296-47e6-86d5-69fa67b94c32", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Each tablet\ncontains 10\u00a0mg adefovir dipivoxil.</span>", "ID": "b280bca0-4b34-4637-8a78-e11dd062675f", "Styles": "None", "Classes": "None", "Text": "Each tablet contains 10\u00a0mg adefovir dipivoxil.", "ParentId": "6e326c9e-1296-47e6-86d5-69fa67b94c32"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "66139f0b-d7cd-4f56-98d6-69e224cad24e", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5cbf4f5f-6dd6-4b53-abcf-2977592b2f26", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "66139f0b-d7cd-4f56-98d6-69e224cad24e"}, {"Element": "<p align=\"left\" class=\"EMEAEnBodyText\" style=\"margin:0in;text-align:left;\npage-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Excipient(s)\nwith known effect:</span></u></p>", "ID": "72de5b0c-3a5e-423a-9036-7e89a8a6105c", "Styles": "margin:0in;text-align:left;\npage-break-after:avoid;text-autospace:none", "Classes": "['EMEAEnBodyText']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<u><span lang=\"EN-GB\">Excipient(s)\nwith known effect:</span></u>", "ID": "f48fe578-0bbe-4c2f-9536-7ae5f952900a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "72de5b0c-3a5e-423a-9036-7e89a8a6105c"}, {"Element": "<span lang=\"EN-GB\">Excipient(s)\nwith known effect:</span>", "ID": "3db0a729-71ee-4048-a67d-95fe706280af", "Styles": "None", "Classes": "None", "Text": "Excipient(s) with known effect:", "ParentId": "f48fe578-0bbe-4c2f-9536-7ae5f952900a"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "06a7e49c-1e46-4381-aa21-57e196a117ec", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c88404ac-cab2-469d-b9a1-e7a3bcfcaf24", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "06a7e49c-1e46-4381-aa21-57e196a117ec"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Each tablet\ncontains 113\u00a0mg lactose monohydrate.</span></p>", "ID": "b6c48d5d-d865-466c-b2c5-eeef7de18656", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Each tablet\ncontains 113\u00a0mg lactose monohydrate.</span>", "ID": "6204f2dd-4e9c-437b-bbcf-312a3d9cc6ea", "Styles": "None", "Classes": "None", "Text": "Each tablet contains 113\u00a0mg lactose monohydrate.", "ParentId": "b6c48d5d-d865-466c-b2c5-eeef7de18656"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "eaae46b7-864c-4bd7-b14e-4ce5b9c49d08", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f3023223-75d7-4966-adca-06daf167add7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "eaae46b7-864c-4bd7-b14e-4ce5b9c49d08"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">For the full\nlist of excipients, see section\u00a06.1.</span></p>", "ID": "883f8874-acdc-4c9c-bade-f251a44e9d97", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">For the full\nlist of excipients, see section\u00a06.1.</span>", "ID": "1e35f4bd-1d98-4133-a2e0-d4835732cc76", "Styles": "None", "Classes": "None", "Text": "For the full list of excipients, see section\u00a06.1.", "ParentId": "883f8874-acdc-4c9c-bade-f251a44e9d97"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b05931aa-20f6-4537-aa08-20206f1a4cd5", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cf60519e-bd88-4c99-a5dd-b8ef69f28cb7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b05931aa-20f6-4537-aa08-20206f1a4cd5"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "45235ed7-7b6d-4c46-a803-503f77e5ddc9", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ba1feffb-9b2d-40ca-bec6-247301c76b4a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "45235ed7-7b6d-4c46-a803-503f77e5ddc9"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL <span style=\"text-transform:uppercase\">form</span></span></b></p>", "ID": "2f216e72-f8ad-4264-99e1-d7fbf4bb32bb", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL <span style=\"text-transform:uppercase\">form</span></span></b>", "ID": "a666444f-8cf4-49c4-9aa4-7d5f13827a67", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2f216e72-f8ad-4264-99e1-d7fbf4bb32bb"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL <span style=\"text-transform:uppercase\">form</span></span>", "ID": "4ba91b9e-566e-49fd-8698-f1ff0f38a090", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL ", "ParentId": "a666444f-8cf4-49c4-9aa4-7d5f13827a67"}, {"Element": "<span style=\"text-transform:uppercase\">form</span>", "ID": "81ef883f-0168-4f65-add8-fe579ec2321f", "Styles": "text-transform:uppercase", "Classes": "None", "Text": "form", "ParentId": "4ba91b9e-566e-49fd-8698-f1ff0f38a090"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fa7b8f89-f6f6-49ca-bb6b-1d540bf52eb6", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "edfb6af7-0e3a-4961-9f2b-bb9549206c6a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fa7b8f89-f6f6-49ca-bb6b-1d540bf52eb6"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tablet.</span></p>", "ID": "cbb47f34-9c87-480b-82c1-adc3735610d8", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Tablet.</span>", "ID": "e27fe4ac-64a3-46db-8c1a-507e8e61bcbb", "Styles": "None", "Classes": "None", "Text": "Tablet.", "ParentId": "cbb47f34-9c87-480b-82c1-adc3735610d8"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "67d65a96-2252-4b7e-a821-29ca9f98b64d", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "16aa3999-1f68-434e-b0f6-e6beef4406a2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "67d65a96-2252-4b7e-a821-29ca9f98b64d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">White to off\u2011white,\nround, flat\u2011faced, bevelled\u2011edge tablets, 7\u00a0mm in diameter,\ndebossed with \u201cGILEAD\u201d and \u201c10\u201d on one side and a stylised shape of a liver on\nthe other side.</span></p>", "ID": "701ec858-888b-4a1f-b872-17b337c75d6b", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">White to off\u2011white,\nround, flat\u2011faced, bevelled\u2011edge tablets, 7\u00a0mm in diameter,\ndebossed with \u201cGILEAD\u201d and \u201c10\u201d on one side and a stylised shape of a liver on\nthe other side.</span>", "ID": "b5b03778-4ab0-4649-a24c-4973b93dca18", "Styles": "None", "Classes": "None", "Text": "White to off\u2011white, round, flat\u2011faced, bevelled\u2011edge tablets, 7\u00a0mm in diameter, debossed with \u201cGILEAD\u201d and \u201c10\u201d on one side and a stylised shape of a liver on the other side.", "ParentId": "701ec858-888b-4a1f-b872-17b337c75d6b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "13170ca9-d13c-4ea3-830a-0a34595315a3", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9c63e86b-db0a-4fb3-9990-40e52e07439d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "13170ca9-d13c-4ea3-830a-0a34595315a3"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a2b0a68d-379a-4ba7-9825-5af4bd1c24d3", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "aee8c564-35ee-47d4-92b3-3c2fb4b5df69", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a2b0a68d-379a-4ba7-9825-5af4bd1c24d3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Clinical\nparticulars</span></b></p>", "ID": "a5a4cb61-131a-4271-88e5-2fc72c6cb77b", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Clinical\nparticulars</span></b>", "ID": "f0e865b8-80d2-4287-8528-35d6e65774df", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a5a4cb61-131a-4271-88e5-2fc72c6cb77b"}, {"Element": "<span lang=\"EN-GB\" style=\"text-transform:uppercase\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Clinical\nparticulars</span>", "ID": "8eae3fa7-70ae-42f6-b1dd-cb85d9f2530a", "Styles": "text-transform:uppercase", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Clinical particulars", "ParentId": "f0e865b8-80d2-4287-8528-35d6e65774df"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8fb6a4e1-8001-4990-b424-ae58f312d1f7", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a9db5bad-6fb2-4f62-ab2d-27be61a44674", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8fb6a4e1-8001-4990-b424-ae58f312d1f7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic\nindications</span></b></p>", "ID": "4f75aec2-f065-4729-8336-a740f920d32a", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic\nindications</span></b>", "ID": "5174e866-b8ae-49fa-88f1-6bc4bf0dfc91", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4f75aec2-f065-4729-8336-a740f920d32a"}, {"Element": "<span lang=\"EN-GB\">4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic\nindications</span>", "ID": "7ffeddb5-3981-428b-8d85-2dc6510aa019", "Styles": "None", "Classes": "None", "Text": "4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic indications", "ParentId": "5174e866-b8ae-49fa-88f1-6bc4bf0dfc91"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c039a98d-67bb-4f90-9aa3-f77372bcabd8", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b8226f18-2d1e-44c1-82ef-f5a1311dc5e7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c039a98d-67bb-4f90-9aa3-f77372bcabd8"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Hepsera is\nindicated for the treatment of chronic hepatitis\u00a0B in adults with:</span></p>", "ID": "167ea931-fb94-4e54-8317-3d54daab747c", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Hepsera is\nindicated for the treatment of chronic hepatitis\u00a0B in adults with:</span>", "ID": "dbd3b88b-d5be-4284-b203-ec34c0aa025a", "Styles": "None", "Classes": "None", "Text": "Hepsera is indicated for the treatment of chronic hepatitis\u00a0B in adults with:", "ParentId": "167ea931-fb94-4e54-8317-3d54daab747c"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ac5c76cf-9e03-45c9-8a75-f297e6d55c92", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "987bca89-2785-4bd8-b95f-65db42d403a1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ac5c76cf-9e03-45c9-8a75-f297e6d55c92"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">compensated liver disease with evidence of\nactive viral replication, persistently elevated serum alanine aminotransferase\n(ALT) levels and histological evidence of active liver inflammation and\nfibrosis. \u00a0Initiation of Hepsera treatment should only be considered when the\nuse of an alternative antiviral agent with a higher genetic barrier to\nresistance is not available or appropriate (see section\u00a05.1).</span></p>", "ID": "2e08263e-de44-42e0-a00d-9aaa1f6c2595", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "6d279acd-73bf-4084-a86b-d236474c72f4", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "2e08263e-de44-42e0-a00d-9aaa1f6c2595"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "1ccdd7b9-c2ac-4246-84fa-d330574d99f4", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "6d279acd-73bf-4084-a86b-d236474c72f4"}, {"Element": "<span lang=\"EN-GB\">compensated liver disease with evidence of\nactive viral replication, persistently elevated serum alanine aminotransferase\n(ALT) levels and histological evidence of active liver inflammation and\nfibrosis. \u00a0Initiation of Hepsera treatment should only be considered when the\nuse of an alternative antiviral agent with a higher genetic barrier to\nresistance is not available or appropriate (see section\u00a05.1).</span>", "ID": "42cf0fa9-1350-412f-b98b-40c67457a729", "Styles": "None", "Classes": "None", "Text": "compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and fibrosis. \u00a0Initiation of Hepsera treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate (see section\u00a05.1).", "ParentId": "2e08263e-de44-42e0-a00d-9aaa1f6c2595"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e694a548-2738-4aa8-845d-331b85db5fa4", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8d5496f8-94ab-44a3-9570-82de5cc1cc51", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e694a548-2738-4aa8-845d-331b85db5fa4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">decompensated liver disease in combination with\na second agent without cross-resistance to Hepsera.</span></p>", "ID": "be9efc3a-4bbe-4a3a-8a6d-2ddd49ef485a", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "e1ca9210-df4a-48ce-be99-0504dc9b0287", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "be9efc3a-4bbe-4a3a-8a6d-2ddd49ef485a"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "4dfd81f6-296f-4e6a-bc37-da9adfcd23c6", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "e1ca9210-df4a-48ce-be99-0504dc9b0287"}, {"Element": "<span lang=\"EN-GB\">decompensated liver disease in combination with\na second agent without cross-resistance to Hepsera.</span>", "ID": "e15f0110-24f4-40ff-8ea1-6f62f4214a4a", "Styles": "None", "Classes": "None", "Text": "decompensated liver disease in combination with a second agent without cross-resistance to Hepsera.", "ParentId": "be9efc3a-4bbe-4a3a-8a6d-2ddd49ef485a"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6ffbbc94-6e18-48d1-8f67-d4eb6867e196", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "01f0d263-1985-49bb-9b45-65629fcd0d3e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6ffbbc94-6e18-48d1-8f67-d4eb6867e196"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.2\u00a0\u00a0\u00a0\u00a0 Posology and method\nof administration</span></b></p>", "ID": "0b578d6e-c468-476e-a1bc-35f14cd206c9", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">4.2\u00a0\u00a0\u00a0\u00a0 Posology and method\nof administration</span></b>", "ID": "f57787b5-eb74-49ae-b740-330143bd7f3b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0b578d6e-c468-476e-a1bc-35f14cd206c9"}, {"Element": "<span lang=\"EN-GB\">4.2\u00a0\u00a0\u00a0\u00a0 Posology and method\nof administration</span>", "ID": "29a57c06-3615-4067-bf8a-c6615fbd8727", "Styles": "None", "Classes": "None", "Text": "4.2\u00a0\u00a0\u00a0\u00a0 Posology and method of administration", "ParentId": "f57787b5-eb74-49ae-b740-330143bd7f3b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "249a1e1e-7689-48a8-b8a3-230e7c8328eb", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "585274cc-4fa5-4fa4-bbb4-9fbd559a4da2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "249a1e1e-7689-48a8-b8a3-230e7c8328eb"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Therapy should\nbe initiated by a physician experienced in the management of chronic\nhepatitis\u00a0B.</span></p>", "ID": "078d2cc6-8720-4cea-8b9f-6642a0780c20", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Therapy should\nbe initiated by a physician experienced in the management of chronic\nhepatitis\u00a0B.</span>", "ID": "713aa597-109e-4e30-85d1-3978b8e3ade1", "Styles": "None", "Classes": "None", "Text": "Therapy should be initiated by a physician experienced in the management of chronic hepatitis\u00a0B.", "ParentId": "078d2cc6-8720-4cea-8b9f-6642a0780c20"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4b5e18d5-409c-419e-bbff-dc4c7c6b7cbf", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5e5a630d-443d-4aed-8886-c10dbd4fd6f5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4b5e18d5-409c-419e-bbff-dc4c7c6b7cbf"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Posology</span></u></p>", "ID": "45219392-a41e-4ed7-a340-28373cbc9aa2", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<u><span lang=\"EN-GB\">Posology</span></u>", "ID": "e5cc806c-0773-4199-b5cd-494abc6ef4fb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "45219392-a41e-4ed7-a340-28373cbc9aa2"}, {"Element": "<span lang=\"EN-GB\">Posology</span>", "ID": "823fdbd9-750e-418a-83f4-3046743a84ef", "Styles": "None", "Classes": "None", "Text": "Posology", "ParentId": "e5cc806c-0773-4199-b5cd-494abc6ef4fb"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "17fa363d-b4a4-4882-a8fd-4308ce630b47", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6ddc7204-ad06-40f7-ad25-2cfe8dc5fc35", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "17fa363d-b4a4-4882-a8fd-4308ce630b47"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Adults:</span></i><span lang=\"EN-GB\"> The recommended dose of Hepsera is 10\u00a0mg (one tablet) once\ndaily taken orally with or without food.</span></p>", "ID": "04818a97-3ae5-468c-b6df-184ae0bbe878", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Adults:</span></i>", "ID": "5c28f419-14f6-4b37-a5f5-0f883a8826fc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "04818a97-3ae5-468c-b6df-184ae0bbe878"}, {"Element": "<span lang=\"EN-GB\">Adults:</span>", "ID": "35f72d23-293f-4765-8aed-2fe75c0e1626", "Styles": "None", "Classes": "None", "Text": "Adults:", "ParentId": "5c28f419-14f6-4b37-a5f5-0f883a8826fc"}, {"Element": "<span lang=\"EN-GB\"> The recommended dose of Hepsera is 10\u00a0mg (one tablet) once\ndaily taken orally with or without food.</span>", "ID": "1a4c11c5-53d6-4162-a842-d547abce06f2", "Styles": "None", "Classes": "None", "Text": " The recommended dose of Hepsera is 10\u00a0mg (one tablet) once daily taken orally with or without food.", "ParentId": "04818a97-3ae5-468c-b6df-184ae0bbe878"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7fcbf69a-344b-4e8e-b9c4-3c28cb7dc360", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "94a9101b-baec-4bdd-8e22-700e55b4f482", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7fcbf69a-344b-4e8e-b9c4-3c28cb7dc360"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Higher doses\nmust not be administered.</span></p>", "ID": "4f2e6857-4ae3-4490-8939-e59705a00d32", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Higher doses\nmust not be administered.</span>", "ID": "dabe66bd-19f5-42dc-b7bf-37708638d3bf", "Styles": "None", "Classes": "None", "Text": "Higher doses must not be administered.", "ParentId": "4f2e6857-4ae3-4490-8939-e59705a00d32"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5f00f0dd-55ee-4923-a5ca-5795889ff705", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ea47a9b6-0ae3-4766-bbf2-ef5f49d02e5f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5f00f0dd-55ee-4923-a5ca-5795889ff705"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The optimum\nduration of treatment is unknown.\u00a0 The relationship between treatment response\nand long\u2011term outcomes such as hepatocellular carcinoma or decompensated\ncirrhosis is not known.</span></p>", "ID": "ae3f75b2-a7c3-49cd-a3ae-307cd7eba82d", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">The optimum\nduration of treatment is unknown.\u00a0 The relationship between treatment response\nand long\u2011term outcomes such as hepatocellular carcinoma or decompensated\ncirrhosis is not known.</span>", "ID": "130d4603-0f0a-4e8b-87d6-a49509ff5faf", "Styles": "None", "Classes": "None", "Text": "The optimum duration of treatment is unknown.\u00a0 The relationship between treatment response and long\u2011term outcomes such as hepatocellular carcinoma or decompensated cirrhosis is not known.", "ParentId": "ae3f75b2-a7c3-49cd-a3ae-307cd7eba82d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6864b15d-43b1-428c-96f0-e71789e17c63", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d4cbea32-85e9-4bf3-ad7d-b8ec7add658a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6864b15d-43b1-428c-96f0-e71789e17c63"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In patients with\ndecompensated liver disease, adefovir should always be used in combination with\na second agent, without cross-resistance to adefovir, to reduce the risk of\nresistance and to achieve rapid viral suppression.</span></p>", "ID": "a17d4242-5ae4-4bcf-9c25-776d3cf1f491", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">In patients with\ndecompensated liver disease, adefovir should always be used in combination with\na second agent, without cross-resistance to adefovir, to reduce the risk of\nresistance and to achieve rapid viral suppression.</span>", "ID": "d2bbf495-2f5b-41c7-8a61-538dd409859b", "Styles": "None", "Classes": "None", "Text": "In patients with decompensated liver disease, adefovir should always be used in combination with a second agent, without cross-resistance to adefovir, to reduce the risk of resistance and to achieve rapid viral suppression.", "ParentId": "a17d4242-5ae4-4bcf-9c25-776d3cf1f491"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a097586b-6474-4590-8d54-f2b737a55e96", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5ccc6942-2c2c-40f2-8b2b-1272c3f5d2d0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a097586b-6474-4590-8d54-f2b737a55e96"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Patients should\nbe monitored every six months for hepatitis\u00a0B biochemical, virological and\nserological markers.</span></p>", "ID": "1a7f6f59-2812-471e-a729-927d2b133616", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Patients should\nbe monitored every six months for hepatitis\u00a0B biochemical, virological and\nserological markers.</span>", "ID": "59eec933-5eb7-4a0c-b496-3fdd672be1f0", "Styles": "None", "Classes": "None", "Text": "Patients should be monitored every six months for hepatitis\u00a0B biochemical, virological and serological markers.", "ParentId": "1a7f6f59-2812-471e-a729-927d2b133616"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8fc0876d-016c-4381-a7b7-fe3605d13d8c", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f4bab10b-d17c-4501-a473-3bc7f74e14f2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8fc0876d-016c-4381-a7b7-fe3605d13d8c"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Treatment discontinuation may be considered as follows:</span></i></p>", "ID": "835cdcb4-4cd2-44dc-8f3a-39cb82774bdf", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Treatment discontinuation may be considered as follows:</span></i>", "ID": "b1580e62-91ff-48e5-b3ae-92ab552edbd2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "835cdcb4-4cd2-44dc-8f3a-39cb82774bdf"}, {"Element": "<span lang=\"EN-GB\">Treatment discontinuation may be considered as follows:</span>", "ID": "8844d4c4-4cdc-4b2b-8438-58fa4f71bcc4", "Styles": "None", "Classes": "None", "Text": "Treatment discontinuation may be considered as follows:", "ParentId": "b1580e62-91ff-48e5-b3ae-92ab552edbd2"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7a805347-2a84-429d-916e-d9439f944bb0", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "66460354-191b-45a3-8b3f-dfc5f48da5f6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7a805347-2a84-429d-916e-d9439f944bb0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 In HBeAg\u00a0positive patients without\ncirrhosis, treatment should be administered for at least 6\u201112\u00a0months\nafter HBe\u00a0seroconversion (HBeAg\u00a0loss and HBV\u00a0DNA loss with anti\u2011HBe\u00a0detection)\nis confirmed or until HBs\u00a0seroconversion or there is loss of efficacy\n(see\u00a0section\u00a04.4). \u00a0Serum ALT and HBV\u00a0DNA levels should be\nfollowed regularly after treatment discontinuation to detect any late\nvirological relapse.</span></p>", "ID": "7650f5c4-8423-4999-bae1-0888f69c799e", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 In HBeAg\u00a0positive patients without\ncirrhosis, treatment should be administered for at least 6\u201112\u00a0months\nafter HBe\u00a0seroconversion (HBeAg\u00a0loss and HBV\u00a0DNA loss with anti\u2011HBe\u00a0detection)\nis confirmed or until HBs\u00a0seroconversion or there is loss of efficacy\n(see\u00a0section\u00a04.4). \u00a0Serum ALT and HBV\u00a0DNA levels should be\nfollowed regularly after treatment discontinuation to detect any late\nvirological relapse.</span>", "ID": "708ba01c-ed44-43b6-85f1-47aa1db835a7", "Styles": "None", "Classes": "None", "Text": "-\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 In HBeAg\u00a0positive patients without cirrhosis, treatment should be administered for at least 6\u201112\u00a0months after HBe\u00a0seroconversion (HBeAg\u00a0loss and HBV\u00a0DNA loss with anti\u2011HBe\u00a0detection) is confirmed or until HBs\u00a0seroconversion or there is loss of efficacy (see\u00a0section\u00a04.4). \u00a0Serum ALT and HBV\u00a0DNA levels should be followed regularly after treatment discontinuation to detect any late virological relapse.", "ParentId": "7650f5c4-8423-4999-bae1-0888f69c799e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f59278ca-2b41-43fe-ae7c-47943384b9bb", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a8615f5d-e3c5-46d3-9760-a5b59205de92", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f59278ca-2b41-43fe-ae7c-47943384b9bb"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 In HBeAg\u00a0negative patients without\ncirrhosis, treatment should be administered at least until\nHBs\u00a0seroconversion or there is evidence of loss of efficacy. \u00a0With\nprolonged treatment for more than 2\u00a0years, regular reassessment is\nrecommended to confirm that continuing the selected therapy remains appropriate\nfor the patient.</span></p>", "ID": "52281480-c86e-491e-afcf-10da3c6e8754", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 In HBeAg\u00a0negative patients without\ncirrhosis, treatment should be administered at least until\nHBs\u00a0seroconversion or there is evidence of loss of efficacy. \u00a0With\nprolonged treatment for more than 2\u00a0years, regular reassessment is\nrecommended to confirm that continuing the selected therapy remains appropriate\nfor the patient.</span>", "ID": "a22a3d17-7035-4348-9dbc-21f799d174f3", "Styles": "None", "Classes": "None", "Text": "-\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 In HBeAg\u00a0negative patients without cirrhosis, treatment should be administered at least until HBs\u00a0seroconversion or there is evidence of loss of efficacy. \u00a0With prolonged treatment for more than 2\u00a0years, regular reassessment is recommended to confirm that continuing the selected therapy remains appropriate for the patient.", "ParentId": "52281480-c86e-491e-afcf-10da3c6e8754"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1c2f5c4d-0ec9-4f05-9f4a-d912d6f9803b", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d7d216c2-f39f-43d4-84a6-aa5526d5793c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1c2f5c4d-0ec9-4f05-9f4a-d912d6f9803b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In patients with\ndecompensated liver disease or cirrhosis, treatment cessation is not\nrecommended (see\u00a0section\u00a04.4).</span></p>", "ID": "457effea-0d32-4852-8f62-d366ec548ea7", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">In patients with\ndecompensated liver disease or cirrhosis, treatment cessation is not\nrecommended (see\u00a0section\u00a04.4).</span>", "ID": "6dc5c022-a174-475b-b0a5-11b17048055c", "Styles": "None", "Classes": "None", "Text": "In patients with decompensated liver disease or cirrhosis, treatment cessation is not recommended (see\u00a0section\u00a04.4).", "ParentId": "457effea-0d32-4852-8f62-d366ec548ea7"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f6625d49-0f30-4fd0-86e4-f10f36342f93", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a78f95ac-d7f3-447f-9c6f-ba2d8dbd3b12", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f6625d49-0f30-4fd0-86e4-f10f36342f93"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Special populations</span></u></i></p>", "ID": "abda814b-dbe8-4bc7-a8c7-41268a0bcca1", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><u><span lang=\"EN-GB\">Special populations</span></u></i>", "ID": "ccdab557-e74a-48e3-a245-4d864b544b8c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "abda814b-dbe8-4bc7-a8c7-41268a0bcca1"}, {"Element": "<u><span lang=\"EN-GB\">Special populations</span></u>", "ID": "580e280e-02d1-4b0e-8ab0-9f3ce53ce410", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ccdab557-e74a-48e3-a245-4d864b544b8c"}, {"Element": "<span lang=\"EN-GB\">Special populations</span>", "ID": "2e5e1753-5194-457c-8c4d-ff0cc6c55477", "Styles": "None", "Classes": "None", "Text": "Special populations", "ParentId": "580e280e-02d1-4b0e-8ab0-9f3ce53ce410"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Elderly:</span></i><span lang=\"EN-GB\"> No data are available to support a dose recommendation for patients\nover the age of 65\u00a0years (see\u00a0section\u00a04.4).</span></p>", "ID": "d10bfd7c-aa73-47aa-810a-9d9e291f1f7f", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Elderly:</span></i>", "ID": "4b295233-64a1-4b03-91a3-143ddd170002", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d10bfd7c-aa73-47aa-810a-9d9e291f1f7f"}, {"Element": "<span lang=\"EN-GB\">Elderly:</span>", "ID": "87ee43d6-a27e-4c4c-b800-97f96386274e", "Styles": "None", "Classes": "None", "Text": "Elderly:", "ParentId": "4b295233-64a1-4b03-91a3-143ddd170002"}, {"Element": "<span lang=\"EN-GB\"> No data are available to support a dose recommendation for patients\nover the age of 65\u00a0years (see\u00a0section\u00a04.4).</span>", "ID": "cda2eb84-1d86-4e2b-bb0f-3c6b6a5e708b", "Styles": "None", "Classes": "None", "Text": " No data are available to support a dose recommendation for patients over the age of 65\u00a0years (see\u00a0section\u00a04.4).", "ParentId": "d10bfd7c-aa73-47aa-810a-9d9e291f1f7f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2d439ae0-0b05-495f-9bf0-83c8c2014af5", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6d183634-c182-4246-a441-7086172c0e86", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2d439ae0-0b05-495f-9bf0-83c8c2014af5"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Renal impairment:</span></i><span lang=\"EN-GB\"> Adefovir is eliminated by renal excretion and adjustments of the\ndosing interval are required in patients with a creatinine clearance\n&lt;\u00a050\u00a0ml/min or on dialysis.\u00a0 The recommended dosing frequency\naccording to renal function must not be exceeded (see\u00a0sections\u00a04.4\nand 5.2).\u00a0 The proposed dose interval modification is based on extrapolation of\nlimited data in patients with end stage renal disease (ESRD) and may not be\noptimal.</span></p>", "ID": "1bf70dce-6432-4de6-8ce9-9d168bc04202", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Renal impairment:</span></i>", "ID": "b0779035-9004-4116-9d77-d45af4ed63fc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1bf70dce-6432-4de6-8ce9-9d168bc04202"}, {"Element": "<span lang=\"EN-GB\">Renal impairment:</span>", "ID": "13a7bada-ecc9-4a35-ad1a-96da1632c855", "Styles": "None", "Classes": "None", "Text": "Renal impairment:", "ParentId": "b0779035-9004-4116-9d77-d45af4ed63fc"}, {"Element": "<span lang=\"EN-GB\"> Adefovir is eliminated by renal excretion and adjustments of the\ndosing interval are required in patients with a creatinine clearance\n&lt;\u00a050\u00a0ml/min or on dialysis.\u00a0 The recommended dosing frequency\naccording to renal function must not be exceeded (see\u00a0sections\u00a04.4\nand 5.2).\u00a0 The proposed dose interval modification is based on extrapolation of\nlimited data in patients with end stage renal disease (ESRD) and may not be\noptimal.</span>", "ID": "d476332c-5f0a-4fc6-808d-a008da20c8cf", "Styles": "None", "Classes": "None", "Text": " Adefovir is eliminated by renal excretion and adjustments of the dosing interval are required in patients with a creatinine clearance <\u00a050\u00a0ml/min or on dialysis.\u00a0 The recommended dosing frequency according to renal function must not be exceeded (see\u00a0sections\u00a04.4 and 5.2).\u00a0 The proposed dose interval modification is based on extrapolation of limited data in patients with end stage renal disease (ESRD) and may not be optimal.", "ParentId": "1bf70dce-6432-4de6-8ce9-9d168bc04202"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "beeb5e22-c88e-4300-a61a-142dcab72149", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "61bba563-0da0-4c84-922a-2a2be185f6af", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "beeb5e22-c88e-4300-a61a-142dcab72149"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Patients with creatinine clearance between 30 and 49\u00a0ml/min:</span></i></p>", "ID": "1523120a-35fc-4b2e-b526-f22e74a862c0", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Patients with creatinine clearance between 30 and 49\u00a0ml/min:</span></i>", "ID": "60a04c0c-4a81-4ccb-b97e-e67153741142", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1523120a-35fc-4b2e-b526-f22e74a862c0"}, {"Element": "<span lang=\"EN-GB\">Patients with creatinine clearance between 30 and 49\u00a0ml/min:</span>", "ID": "b694ca4f-5e24-4f9b-b75e-da16d99c3be9", "Styles": "None", "Classes": "None", "Text": "Patients with creatinine clearance between 30 and 49\u00a0ml/min:", "ParentId": "60a04c0c-4a81-4ccb-b97e-e67153741142"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">It is\nrecommended to administer adefovir dipivoxil (one 10\u00a0mg tablet) every 48\u00a0hours\nin these patients. \u00a0There are only limited data on the safety and efficacy of\nthis dosing interval adjustment guideline.\u00a0 </span><span lang=\"EN-GB\">Therefore,\nclinical response to treatment and renal function should be closely monitored\nin these patients (see\u00a0section\u00a04.4).</span></p>", "ID": "96bc707c-48b6-4c8c-8016-42755a2e0be2", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">It is\nrecommended to administer adefovir dipivoxil (one 10\u00a0mg tablet) every 48\u00a0hours\nin these patients. \u00a0There are only limited data on the safety and efficacy of\nthis dosing interval adjustment guideline.\u00a0 </span>", "ID": "035424c2-f4c4-4c6e-a872-4db78e67b14f", "Styles": "None", "Classes": "None", "Text": "It is recommended to administer adefovir dipivoxil (one 10\u00a0mg tablet) every 48\u00a0hours in these patients. \u00a0There are only limited data on the safety and efficacy of this dosing interval adjustment guideline.\u00a0 ", "ParentId": "96bc707c-48b6-4c8c-8016-42755a2e0be2"}, {"Element": "<span lang=\"EN-GB\">Therefore,\nclinical response to treatment and renal function should be closely monitored\nin these patients (see\u00a0section\u00a04.4).</span>", "ID": "fcf9b37e-1c3a-416b-9428-bc2fdfd40678", "Styles": "None", "Classes": "None", "Text": "Therefore, clinical response to treatment and renal function should be closely monitored in these patients (see\u00a0section\u00a04.4).", "ParentId": "96bc707c-48b6-4c8c-8016-42755a2e0be2"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1ba9b0ed-2446-4176-be3b-4973702a2671", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7b4bf07a-0cf2-4082-9aba-6a8198c0fbfa", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1ba9b0ed-2446-4176-be3b-4973702a2671"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Patients with creatinine clearance &lt;\u00a030\u00a0ml/min and\ndialysis patients:</span></i></p>", "ID": "95aab62b-3dea-43e4-8a5e-582ce8f50f3c", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Patients with creatinine clearance &lt;\u00a030\u00a0ml/min and\ndialysis patients:</span></i>", "ID": "3c31ac41-8348-46d6-a2b5-6f0ea0452fe4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "95aab62b-3dea-43e4-8a5e-582ce8f50f3c"}, {"Element": "<span lang=\"EN-GB\">Patients with creatinine clearance &lt;\u00a030\u00a0ml/min and\ndialysis patients:</span>", "ID": "f28058aa-a85b-4f37-ae21-fe7f39e9609d", "Styles": "None", "Classes": "None", "Text": "Patients with creatinine clearance <\u00a030\u00a0ml/min and dialysis patients:", "ParentId": "3c31ac41-8348-46d6-a2b5-6f0ea0452fe4"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">There are no\nsafety and efficacy data to support the use of adefovir dipivoxil in patients\nwith a creatinine clearance &lt;\u00a030\u00a0ml/min or on dialysis.\u00a0\nTherefore, use of adefovir dipivoxil is not recommended in these patients and\nshould only be considered if the potential benefits outweigh the potential\nrisks. \u00a0In that case, the limited data available suggest that for patients with\ncreatinine clearance between 10 and 29\u00a0ml/min, adefovir dipivoxil (one\n10\u00a0mg tablet) may be administered every 72\u00a0hours; for haemodialysis\npatients, adefovir dipivoxil (one 10\u00a0mg tablet) may be administered every\n7\u00a0days following 12\u00a0hours continuous dialysis (or 3\u00a0dialysis\nsessions, each of 4\u00a0hours duration). \u00a0These patients should be closely\nmonitored for possible adverse reactions and to ensure efficacy is maintained\n(see\u00a0sections\u00a04.4 and 4.8).</span><span lang=\"EN-GB\">\u00a0 </span><span lang=\"EN-GB\">No dosing interval recommendations are available for other dialysis\npatients (e.g. ambulatory peritoneal dialysis patients) or non\u2011haemodialysed\npatients with creatinine clearance less than 10\u00a0ml/min.</span></p>", "ID": "1afa1eac-d46b-4760-ad48-360811b15137", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">There are no\nsafety and efficacy data to support the use of adefovir dipivoxil in patients\nwith a creatinine clearance &lt;\u00a030\u00a0ml/min or on dialysis.\u00a0\nTherefore, use of adefovir dipivoxil is not recommended in these patients and\nshould only be considered if the potential benefits outweigh the potential\nrisks. \u00a0In that case, the limited data available suggest that for patients with\ncreatinine clearance between 10 and 29\u00a0ml/min, adefovir dipivoxil (one\n10\u00a0mg tablet) may be administered every 72\u00a0hours; for haemodialysis\npatients, adefovir dipivoxil (one 10\u00a0mg tablet) may be administered every\n7\u00a0days following 12\u00a0hours continuous dialysis (or 3\u00a0dialysis\nsessions, each of 4\u00a0hours duration). \u00a0These patients should be closely\nmonitored for possible adverse reactions and to ensure efficacy is maintained\n(see\u00a0sections\u00a04.4 and 4.8).</span>", "ID": "5cb24a9b-d70f-4ef8-9796-063adc033a90", "Styles": "None", "Classes": "None", "Text": "There are no safety and efficacy data to support the use of adefovir dipivoxil in patients with a creatinine clearance <\u00a030\u00a0ml/min or on dialysis.\u00a0 Therefore, use of adefovir dipivoxil is not recommended in these patients and should only be considered if the potential benefits outweigh the potential risks. \u00a0In that case, the limited data available suggest that for patients with creatinine clearance between 10 and 29\u00a0ml/min, adefovir dipivoxil (one 10\u00a0mg tablet) may be administered every 72\u00a0hours; for haemodialysis patients, adefovir dipivoxil (one 10\u00a0mg tablet) may be administered every 7\u00a0days following 12\u00a0hours continuous dialysis (or 3\u00a0dialysis sessions, each of 4\u00a0hours duration). \u00a0These patients should be closely monitored for possible adverse reactions and to ensure efficacy is maintained (see\u00a0sections\u00a04.4 and 4.8).", "ParentId": "1afa1eac-d46b-4760-ad48-360811b15137"}, {"Element": "<span lang=\"EN-GB\">\u00a0 </span>", "ID": "08e667e3-fcd4-49bb-9c6e-e9e5d7dab35d", "Styles": "None", "Classes": "None", "Text": "\u00a0 ", "ParentId": "1afa1eac-d46b-4760-ad48-360811b15137"}, {"Element": "<span lang=\"EN-GB\">No dosing interval recommendations are available for other dialysis\npatients (e.g. ambulatory peritoneal dialysis patients) or non\u2011haemodialysed\npatients with creatinine clearance less than 10\u00a0ml/min.</span>", "ID": "170edb2f-17e6-4186-9ce2-785b0a845550", "Styles": "None", "Classes": "None", "Text": "No dosing interval recommendations are available for other dialysis patients (e.g. ambulatory peritoneal dialysis patients) or non\u2011haemodialysed patients with creatinine clearance less than 10\u00a0ml/min.", "ParentId": "1afa1eac-d46b-4760-ad48-360811b15137"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a2f3a7c3-206f-475b-93ec-4f196270a73a", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "87c1de96-56b4-4149-be4f-5b90f27a6b9b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a2f3a7c3-206f-475b-93ec-4f196270a73a"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Hepatic\nimpairment:</span></i><span lang=\"EN-GB\"> No dose adjustment is required in\npatients with hepatic impairment (see\u00a0section\u00a05.2).</span></p>", "ID": "d1c60628-330d-414e-a24c-f94764ec4080", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Hepatic\nimpairment:</span></i>", "ID": "bb327444-a3dd-460f-9cdc-f756451b3977", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d1c60628-330d-414e-a24c-f94764ec4080"}, {"Element": "<span lang=\"EN-GB\">Hepatic\nimpairment:</span>", "ID": "6cd27bc4-3b61-4720-af42-a6e19a1d6f04", "Styles": "None", "Classes": "None", "Text": "Hepatic impairment:", "ParentId": "bb327444-a3dd-460f-9cdc-f756451b3977"}, {"Element": "<span lang=\"EN-GB\"> No dose adjustment is required in\npatients with hepatic impairment (see\u00a0section\u00a05.2).</span>", "ID": "d0be7e92-cdfe-4725-bf89-f3b647df6a99", "Styles": "None", "Classes": "None", "Text": " No dose adjustment is required in patients with hepatic impairment (see\u00a0section\u00a05.2).", "ParentId": "d1c60628-330d-414e-a24c-f94764ec4080"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "33bd987d-1d7c-4e15-a1d4-48b11e52d733", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b7ada5f3-71c1-4dfd-a4f4-ff57519e0a33", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "33bd987d-1d7c-4e15-a1d4-48b11e52d733"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Clinical\nresistance:</span></i><span lang=\"EN-GB\"> Lamivudine\u2011refractory patients\nand patients harbouring HBV with evidence of resistance to lamivudine\n(mutations at rtL180M, rtA181T and/or rtM204I/V) should not be treated with\nadefovir dipivoxil monotherapy in order to reduce the risk of resistance to\nadefovir. \u00a0Adefovir may be used in combination with lamivudine in lamivudine\u2011refractory\npatients and in patients harbouring HBV with mutations at rtL180M and/or\nrtM204I/V. \u00a0However, for patients harbouring HBV that contains the rtA181T\nmutation, consideration should be given to alternative treatment regimens due\nto the risk of reduced susceptibility to adefovir (see\u00a0section\u00a05.1).</span></p>", "ID": "9ff24d0c-263e-4b93-b5a9-1bb6d932a253", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Clinical\nresistance:</span></i>", "ID": "71964732-ac5e-4822-82ed-2fa8389ff668", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9ff24d0c-263e-4b93-b5a9-1bb6d932a253"}, {"Element": "<span lang=\"EN-GB\">Clinical\nresistance:</span>", "ID": "4a9d778f-c086-4fff-99a9-0d9d562b99bf", "Styles": "None", "Classes": "None", "Text": "Clinical resistance:", "ParentId": "71964732-ac5e-4822-82ed-2fa8389ff668"}, {"Element": "<span lang=\"EN-GB\"> Lamivudine\u2011refractory patients\nand patients harbouring HBV with evidence of resistance to lamivudine\n(mutations at rtL180M, rtA181T and/or rtM204I/V) should not be treated with\nadefovir dipivoxil monotherapy in order to reduce the risk of resistance to\nadefovir. \u00a0Adefovir may be used in combination with lamivudine in lamivudine\u2011refractory\npatients and in patients harbouring HBV with mutations at rtL180M and/or\nrtM204I/V. \u00a0However, for patients harbouring HBV that contains the rtA181T\nmutation, consideration should be given to alternative treatment regimens due\nto the risk of reduced susceptibility to adefovir (see\u00a0section\u00a05.1).</span>", "ID": "febd5652-708d-40e9-9302-9fc882f2d39f", "Styles": "None", "Classes": "None", "Text": " Lamivudine\u2011refractory patients and patients harbouring HBV with evidence of resistance to lamivudine (mutations at rtL180M, rtA181T and/or rtM204I/V) should not be treated with adefovir dipivoxil monotherapy in order to reduce the risk of resistance to adefovir. \u00a0Adefovir may be used in combination with lamivudine in lamivudine\u2011refractory patients and in patients harbouring HBV with mutations at rtL180M and/or rtM204I/V. \u00a0However, for patients harbouring HBV that contains the rtA181T mutation, consideration should be given to alternative treatment regimens due to the risk of reduced susceptibility to adefovir (see\u00a0section\u00a05.1).", "ParentId": "9ff24d0c-263e-4b93-b5a9-1bb6d932a253"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dc2165a1-01b3-43c2-8800-f3b4e8c1917e", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "982649b0-1003-49f3-aa8b-769c6fb1c43b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dc2165a1-01b3-43c2-8800-f3b4e8c1917e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In order to\nreduce the risk of resistance in patients receiving adefovir dipivoxil\nmonotherapy, a modification of treatment should be considered if serum\nHBV\u00a0DNA remains above 1,000\u00a0copies/ml at or beyond 1\u00a0year of\ntreatment.</span></p>", "ID": "7a3ac80a-dc51-41d9-9e5e-6b31665bde0b", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">In order to\nreduce the risk of resistance in patients receiving adefovir dipivoxil\nmonotherapy, a modification of treatment should be considered if serum\nHBV\u00a0DNA remains above 1,000\u00a0copies/ml at or beyond 1\u00a0year of\ntreatment.</span>", "ID": "2e381b8a-ebb6-4d8f-a8db-7c592d0161d9", "Styles": "None", "Classes": "None", "Text": "In order to reduce the risk of resistance in patients receiving adefovir dipivoxil monotherapy, a modification of treatment should be considered if serum HBV\u00a0DNA remains above 1,000\u00a0copies/ml at or beyond 1\u00a0year of treatment.", "ParentId": "7a3ac80a-dc51-41d9-9e5e-6b31665bde0b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9b2fdf82-62b7-4c35-a4dd-1e2dbf0ea069", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "07ea2584-3cf2-419a-b222-be49d5be98a7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9b2fdf82-62b7-4c35-a4dd-1e2dbf0ea069"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Paediatric\npopulation:</span></i><span lang=\"EN-GB\"> Hepsera is not recommended for use in\nchildren below the age of 18\u00a0years due to limitations of the available\ndata on safety and efficacy (see section\u00a05.1).</span></p>", "ID": "6da37add-173d-4a8d-85a3-ef9602d74148", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Paediatric\npopulation:</span></i>", "ID": "7edf4e7c-8474-4692-a583-7a036bbedf17", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6da37add-173d-4a8d-85a3-ef9602d74148"}, {"Element": "<span lang=\"EN-GB\">Paediatric\npopulation:</span>", "ID": "b9a96fe0-bca9-4ff5-a05a-7b2c5f25454f", "Styles": "None", "Classes": "None", "Text": "Paediatric population:", "ParentId": "7edf4e7c-8474-4692-a583-7a036bbedf17"}, {"Element": "<span lang=\"EN-GB\"> Hepsera is not recommended for use in\nchildren below the age of 18\u00a0years due to limitations of the available\ndata on safety and efficacy (see section\u00a05.1).</span>", "ID": "22b46641-4072-443b-a151-bfe3c1cd90ed", "Styles": "None", "Classes": "None", "Text": " Hepsera is not recommended for use in children below the age of 18\u00a0years due to limitations of the available data on safety and efficacy (see section\u00a05.1).", "ParentId": "6da37add-173d-4a8d-85a3-ef9602d74148"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f11e1386-8b5e-41c5-a33b-8f2033aec5b7", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "68aa7d98-2e56-49e8-946a-00ed65d4925e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f11e1386-8b5e-41c5-a33b-8f2033aec5b7"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Method of administration</span></u></p>", "ID": "888667a0-7133-47cd-a0f1-f12d596ad280", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<u><span lang=\"EN-GB\">Method of administration</span></u>", "ID": "a2e77608-3c7c-4568-9ad1-861a4970d4d9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "888667a0-7133-47cd-a0f1-f12d596ad280"}, {"Element": "<span lang=\"EN-GB\">Method of administration</span>", "ID": "597c3862-2761-40db-abdb-efb81fcbf431", "Styles": "None", "Classes": "None", "Text": "Method of administration", "ParentId": "a2e77608-3c7c-4568-9ad1-861a4970d4d9"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Hepsera tablets\nshould be taken once daily, orally with or without food.</span></p>", "ID": "b066825c-b2db-4e19-86c3-45d0a030458e", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Hepsera tablets\nshould be taken once daily, orally with or without food.</span>", "ID": "69bdabdb-42b3-483f-9b71-a59b9c503656", "Styles": "None", "Classes": "None", "Text": "Hepsera tablets should be taken once daily, orally with or without food.", "ParentId": "b066825c-b2db-4e19-86c3-45d0a030458e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5d83c173-7fb0-4272-bd5a-b64460934bca", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5a7e4a9c-e96b-4ae3-9487-ea28dec34123", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5d83c173-7fb0-4272-bd5a-b64460934bca"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.3\u00a0\u00a0\u00a0\u00a0 Contraindications</span></b></p>", "ID": "bcc7e123-ee97-4451-8aa6-84f0c395d0d9", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">4.3\u00a0\u00a0\u00a0\u00a0 Contraindications</span></b>", "ID": "1dac425c-160f-4516-b9d2-a9806ddd365d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bcc7e123-ee97-4451-8aa6-84f0c395d0d9"}, {"Element": "<span lang=\"EN-GB\">4.3\u00a0\u00a0\u00a0\u00a0 Contraindications</span>", "ID": "5c34b6c3-8d7a-459b-9903-d91391e3b197", "Styles": "None", "Classes": "None", "Text": "4.3\u00a0\u00a0\u00a0\u00a0 Contraindications", "ParentId": "1dac425c-160f-4516-b9d2-a9806ddd365d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "55e565ea-72e7-4f3f-bf50-c77dd4471d58", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2a3efd36-1d97-4c30-9ee9-5a591c16dfce", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "55e565ea-72e7-4f3f-bf50-c77dd4471d58"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Hypersensitivity to the active substance or to\nany of the excipients listed in section\u00a06.1.</span></p>", "ID": "22f114f5-93c0-4a6f-b746-b3a6c062304f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "4f291608-cd21-4253-8af6-cd1b1110a2a8", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "22f114f5-93c0-4a6f-b746-b3a6c062304f"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "0cbcd5c1-2a3e-49cd-965b-4285326a2171", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "4f291608-cd21-4253-8af6-cd1b1110a2a8"}, {"Element": "<span lang=\"EN-GB\">Hypersensitivity to the active substance or to\nany of the excipients listed in section\u00a06.1.</span>", "ID": "ae311202-98fc-4ac0-854a-fd63ab5cfc50", "Styles": "None", "Classes": "None", "Text": "Hypersensitivity to the active substance or to any of the excipients listed in section\u00a06.1.", "ParentId": "22f114f5-93c0-4a6f-b746-b3a6c062304f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cd2bb5c4-8527-451d-961b-9d2610dcc44e", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9b909dd7-9050-49c4-896c-1957a4ec5800", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cd2bb5c4-8527-451d-961b-9d2610dcc44e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.4\u00a0\u00a0\u00a0\u00a0 Special warnings and precautions for use</span></b></p>", "ID": "6b4e8dbb-d4b3-46ab-a656-e9f0d98dba54", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">4.4\u00a0\u00a0\u00a0\u00a0 Special warnings and precautions for use</span></b>", "ID": "d78eaa9e-2db2-484d-860c-f1d4d9fc1400", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6b4e8dbb-d4b3-46ab-a656-e9f0d98dba54"}, {"Element": "<span lang=\"EN-GB\">4.4\u00a0\u00a0\u00a0\u00a0 Special warnings and precautions for use</span>", "ID": "08bb51bc-2a87-4bcf-b83f-71e6682ff9cc", "Styles": "None", "Classes": "None", "Text": "4.4\u00a0\u00a0\u00a0\u00a0 Special warnings and precautions for use", "ParentId": "d78eaa9e-2db2-484d-860c-f1d4d9fc1400"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bbdad593-169c-46e3-acba-73002acafa5a", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "532c45a1-6519-4a86-b636-f67f96c2447b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bbdad593-169c-46e3-acba-73002acafa5a"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">General:</span></i><span lang=\"EN-GB\"> Patients should be advised that therapy with adefovir dipivoxil has\nnot been proven to reduce the risk of transmission of hepatitis\u00a0B virus to\nothers and therefore appropriate precautions should still be taken.</span></p>", "ID": "7b76e787-d038-418e-a6f1-21cf68b70f93", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">General:</span></i>", "ID": "977013b1-609d-4044-8232-1f748551b23d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7b76e787-d038-418e-a6f1-21cf68b70f93"}, {"Element": "<span lang=\"EN-GB\">General:</span>", "ID": "3ec46327-dfa2-4f97-a395-916471d61c15", "Styles": "None", "Classes": "None", "Text": "General:", "ParentId": "977013b1-609d-4044-8232-1f748551b23d"}, {"Element": "<span lang=\"EN-GB\"> Patients should be advised that therapy with adefovir dipivoxil has\nnot been proven to reduce the risk of transmission of hepatitis\u00a0B virus to\nothers and therefore appropriate precautions should still be taken.</span>", "ID": "d5047593-4ae9-47c6-8eee-3dd93ea29f8b", "Styles": "None", "Classes": "None", "Text": " Patients should be advised that therapy with adefovir dipivoxil has not been proven to reduce the risk of transmission of hepatitis\u00a0B virus to others and therefore appropriate precautions should still be taken.", "ParentId": "7b76e787-d038-418e-a6f1-21cf68b70f93"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "1de0b893-a7f2-4212-8f5a-99b287069fdc", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "6f0b4313-91e0-4a9d-9a67-e6d7f946ec9b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1de0b893-a7f2-4212-8f5a-99b287069fdc"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "aadfb10a-5ccb-435b-9171-8f23576e6aa3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6f0b4313-91e0-4a9d-9a67-e6d7f946ec9b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Renal\nfunction:</span></i><span lang=\"EN-GB\"> Adefovir is excreted renally, by a\ncombination of glomerular filtration and active tubular secretion.\u00a0 Treatment\nwith adefovir dipivoxil may result in renal impairment.\u00a0 Long\u2011term\ntreatment with adefovir dipivoxil may increase the risk of renal impairment.\u00a0 While\nthe overall risk of renal impairment in patients with adequate renal function\nis low, this is of special importance in patients both at risk of or having\nunderlying renal dysfunction, and also in patients <span style=\"layout-grid-mode:\nline\">receiving medicinal products that may affect renal function.</span></span></p>", "ID": "d0bae044-4481-4817-b2c0-51cf225bb5ee", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Renal\nfunction:</span></i>", "ID": "e9230c9b-35d7-4924-af30-47fd24161805", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d0bae044-4481-4817-b2c0-51cf225bb5ee"}, {"Element": "<span lang=\"EN-GB\">Renal\nfunction:</span>", "ID": "5ae6d525-359b-4380-b598-018705a7c7ea", "Styles": "None", "Classes": "None", "Text": "Renal function:", "ParentId": "e9230c9b-35d7-4924-af30-47fd24161805"}, {"Element": "<span lang=\"EN-GB\"> Adefovir is excreted renally, by a\ncombination of glomerular filtration and active tubular secretion.\u00a0 Treatment\nwith adefovir dipivoxil may result in renal impairment.\u00a0 Long\u2011term\ntreatment with adefovir dipivoxil may increase the risk of renal impairment.\u00a0 While\nthe overall risk of renal impairment in patients with adequate renal function\nis low, this is of special importance in patients both at risk of or having\nunderlying renal dysfunction, and also in patients <span style=\"layout-grid-mode:\nline\">receiving medicinal products that may affect renal function.</span></span>", "ID": "59c922d3-2d81-428e-801f-3b73623999b0", "Styles": "None", "Classes": "None", "Text": " Adefovir is excreted renally, by a combination of glomerular filtration and active tubular secretion.\u00a0 Treatment with adefovir dipivoxil may result in renal impairment.\u00a0 Long\u2011term treatment with adefovir dipivoxil may increase the risk of renal impairment.\u00a0 While the overall risk of renal impairment in patients with adequate renal function is low, this is of special importance in patients both at risk of or having underlying renal dysfunction, and also in patients ", "ParentId": "d0bae044-4481-4817-b2c0-51cf225bb5ee"}, {"Element": "<span style=\"layout-grid-mode:\nline\">receiving medicinal products that may affect renal function.</span>", "ID": "d64ce954-6927-4efc-bccb-c633cb78bb23", "Styles": "layout-grid-mode:\nline", "Classes": "None", "Text": "receiving medicinal products that may affect renal function.", "ParentId": "59c922d3-2d81-428e-801f-3b73623999b0"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>", "ID": "f25ce897-8ce4-4059-8f53-0689d20d0645", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span>", "ID": "3352026a-9da5-40e7-b3a4-bdc9d97b7e2c", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "\u00a0", "ParentId": "f25ce897-8ce4-4059-8f53-0689d20d0645"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">It is recommended that creatinine\nclearance is calculated in all patients prior to initiating therapy with\nadefovir dipivoxil </span><span lang=\"EN-GB\">and that renal function (creatinine\nclearance and serum phosphate) be monitored every four weeks during the first\nyear and then every three months thereafter.\u00a0 In patients at risk for renal\nimpairment, consideration should be given to more frequent monitoring of renal\nfunction.</span></p>", "ID": "35e009f7-ce07-4ed5-a218-c463dd616f2c", "Styles": "line-height:normal;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">It is recommended that creatinine\nclearance is calculated in all patients prior to initiating therapy with\nadefovir dipivoxil </span>", "ID": "6b2c8a18-896c-43d9-92b3-3609dc1f033e", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "It is recommended that creatinine clearance is calculated in all patients prior to initiating therapy with adefovir dipivoxil ", "ParentId": "35e009f7-ce07-4ed5-a218-c463dd616f2c"}, {"Element": "<span lang=\"EN-GB\">and that renal function (creatinine\nclearance and serum phosphate) be monitored every four weeks during the first\nyear and then every three months thereafter.\u00a0 In patients at risk for renal\nimpairment, consideration should be given to more frequent monitoring of renal\nfunction.</span>", "ID": "d991793a-dc3e-4b71-80ae-9ad028fe8ea1", "Styles": "None", "Classes": "None", "Text": "and that renal function (creatinine clearance and serum phosphate) be monitored every four weeks during the first year and then every three months thereafter.\u00a0 In patients at risk for renal impairment, consideration should be given to more frequent monitoring of renal function.", "ParentId": "35e009f7-ce07-4ed5-a218-c463dd616f2c"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>", "ID": "4e2599a2-f591-4757-97b6-31fd31c2a803", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span>", "ID": "2148fc9e-a6f7-441a-b2e3-8e6274326ff6", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "\u00a0", "ParentId": "4e2599a2-f591-4757-97b6-31fd31c2a803"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In patients who\ndevelop renal insufficiency and have advanced liver disease or cirrhosis,\ndosing interval adjustment of adefovir or switch to an alternative therapy for\nhepatitis\u00a0B infection should be considered.\u00a0 Treatment cessation for\nchronic hepatitis\u00a0B in these patients is not recommended.</span></p>", "ID": "eb5d112f-4f69-410f-ba18-c687047c4dec", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">In patients who\ndevelop renal insufficiency and have advanced liver disease or cirrhosis,\ndosing interval adjustment of adefovir or switch to an alternative therapy for\nhepatitis\u00a0B infection should be considered.\u00a0 Treatment cessation for\nchronic hepatitis\u00a0B in these patients is not recommended.</span>", "ID": "c06cb276-e837-4903-92a7-43886e4119f9", "Styles": "None", "Classes": "None", "Text": "In patients who develop renal insufficiency and have advanced liver disease or cirrhosis, dosing interval adjustment of adefovir or switch to an alternative therapy for hepatitis\u00a0B infection should be considered.\u00a0 Treatment cessation for chronic hepatitis\u00a0B in these patients is not recommended.", "ParentId": "eb5d112f-4f69-410f-ba18-c687047c4dec"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8557c240-999c-4b8d-b443-0e2fa97a89e0", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1a867812-d350-4f0a-9d04-9995a67eb678", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8557c240-999c-4b8d-b443-0e2fa97a89e0"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Patients with creatinine clearance between 30 and\u00a049\u00a0ml/min:</span></i></p>", "ID": "818c6cd3-b0f5-4d5d-945a-3290d5bdf01c", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Patients with creatinine clearance between 30 and\u00a049\u00a0ml/min:</span></i>", "ID": "131d4cd9-e895-489e-83c9-8bf3e1ec2dd4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "818c6cd3-b0f5-4d5d-945a-3290d5bdf01c"}, {"Element": "<span lang=\"EN-GB\">Patients with creatinine clearance between 30 and\u00a049\u00a0ml/min:</span>", "ID": "341af01a-8eac-467b-adea-ec0e4218fee0", "Styles": "None", "Classes": "None", "Text": "Patients with creatinine clearance between 30 and\u00a049\u00a0ml/min:", "ParentId": "131d4cd9-e895-489e-83c9-8bf3e1ec2dd4"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The dosing\ninterval of adefovir dipivoxil should be adjusted in these patients (see\u00a0section\u00a04.2).\n\u00a0In addition, renal function should be closely monitored with a frequency\ntailored to the individual patient\u2019s medical condition.</span></p>", "ID": "c2bcaf58-4871-4278-8c04-d3ea597dd4e7", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">The dosing\ninterval of adefovir dipivoxil should be adjusted in these patients (see\u00a0section\u00a04.2).\n\u00a0In addition, renal function should be closely monitored with a frequency\ntailored to the individual patient\u2019s medical condition.</span>", "ID": "d62f1ac8-8f8f-4ce7-9c94-e0d455065bc1", "Styles": "None", "Classes": "None", "Text": "The dosing interval of adefovir dipivoxil should be adjusted in these patients (see\u00a0section\u00a04.2). \u00a0In addition, renal function should be closely monitored with a frequency tailored to the individual patient\u2019s medical condition.", "ParentId": "c2bcaf58-4871-4278-8c04-d3ea597dd4e7"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "e7c42d59-3e47-463a-b385-8ef2e26a4d3c", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "a70c7634-fe5b-404a-a837-0a9ce70e8927", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e7c42d59-3e47-463a-b385-8ef2e26a4d3c"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "723e016d-b04f-4a51-80aa-a2a724ec6aac", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a70c7634-fe5b-404a-a837-0a9ce70e8927"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "a878d11c-33db-4108-81f8-f3e1d01fd839", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "723e016d-b04f-4a51-80aa-a2a724ec6aac"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Patients with creatinine clearance &lt;\u00a030\u00a0ml/min and\ndialysis patients:</span></i></p>", "ID": "95eeb455-2015-4deb-a376-587107945d8f", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Patients with creatinine clearance &lt;\u00a030\u00a0ml/min and\ndialysis patients:</span></i>", "ID": "7ed08d4d-17fc-4e20-a499-348a9a801eed", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "95eeb455-2015-4deb-a376-587107945d8f"}, {"Element": "<span lang=\"EN-GB\">Patients with creatinine clearance &lt;\u00a030\u00a0ml/min and\ndialysis patients:</span>", "ID": "d534fde9-f1a1-4be5-9633-d8cb30fca9f3", "Styles": "None", "Classes": "None", "Text": "Patients with creatinine clearance <\u00a030\u00a0ml/min and dialysis patients:", "ParentId": "7ed08d4d-17fc-4e20-a499-348a9a801eed"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adefovir\ndipivoxil is not recommended in patients with a creatinine clearance of\n&lt;\u00a030\u00a0ml/min or on dialysis. \u00a0Administration of adefovir dipivoxil\nin these patients should only be considered if the potential benefits outweigh\nthe potential risks. \u00a0If treatment with adefovir dipivoxil is considered\nessential, then the dosing interval should be adjusted (see\u00a0section\u00a04.2).\u00a0\nThese patients should be closely monitored for possible adverse reactions and\nto ensure efficacy is maintained.</span></p>", "ID": "7393605c-6e6c-42e0-8c65-d46c07250944", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Adefovir\ndipivoxil is not recommended in patients with a creatinine clearance of\n&lt;\u00a030\u00a0ml/min or on dialysis. \u00a0Administration of adefovir dipivoxil\nin these patients should only be considered if the potential benefits outweigh\nthe potential risks. \u00a0If treatment with adefovir dipivoxil is considered\nessential, then the dosing interval should be adjusted (see\u00a0section\u00a04.2).\u00a0\nThese patients should be closely monitored for possible adverse reactions and\nto ensure efficacy is maintained.</span>", "ID": "12ef56d9-1166-4230-b4a0-2646a555dba3", "Styles": "None", "Classes": "None", "Text": "Adefovir dipivoxil is not recommended in patients with a creatinine clearance of <\u00a030\u00a0ml/min or on dialysis. \u00a0Administration of adefovir dipivoxil in these patients should only be considered if the potential benefits outweigh the potential risks. \u00a0If treatment with adefovir dipivoxil is considered essential, then the dosing interval should be adjusted (see\u00a0section\u00a04.2).\u00a0 These patients should be closely monitored for possible adverse reactions and to ensure efficacy is maintained.", "ParentId": "7393605c-6e6c-42e0-8c65-d46c07250944"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "20423616-2652-47a7-b3f1-a0668350fc43", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "85986d7b-97ae-4492-bde7-b32f08b33131", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "20423616-2652-47a7-b3f1-a0668350fc43"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Patients receiving medicinal products that may affect renal\nfunction:</span></i></p>", "ID": "31537b4b-a57c-4ebe-be2b-8d155482d9dd", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Patients receiving medicinal products that may affect renal\nfunction:</span></i>", "ID": "5aa1f65a-bced-4d6d-a225-2e422bedc9a0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "31537b4b-a57c-4ebe-be2b-8d155482d9dd"}, {"Element": "<span lang=\"EN-GB\">Patients receiving medicinal products that may affect renal\nfunction:</span>", "ID": "052bcec5-298e-4f98-ab41-b5775a9286d0", "Styles": "None", "Classes": "None", "Text": "Patients receiving medicinal products that may affect renal function:", "ParentId": "5aa1f65a-bced-4d6d-a225-2e422bedc9a0"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adefovir\ndipivoxil should not be administered concurrently with tenofovir disoproxil\nfumarate (Viread).</span></p>", "ID": "b869d76e-b4b8-4727-9385-842b8d5288eb", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Adefovir\ndipivoxil should not be administered concurrently with tenofovir disoproxil\nfumarate (Viread).</span>", "ID": "671a09e2-1f12-48e5-934c-8e5ef9d86595", "Styles": "None", "Classes": "None", "Text": "Adefovir dipivoxil should not be administered concurrently with tenofovir disoproxil fumarate (Viread).", "ParentId": "b869d76e-b4b8-4727-9385-842b8d5288eb"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e00db4fa-fdfb-49c1-b59b-a19acd40b9cc", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b7d48055-6c2d-487d-a0a7-bf42813c34c7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e00db4fa-fdfb-49c1-b59b-a19acd40b9cc"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Caution is\nadvised in patients receiving other medicinal products that may affect renal\nfunction or are excreted renally (e.g. cyclosporin and tacrolimus, intravenous\naminoglycosides, amphotericin\u00a0B, foscarnet, pentamidine, vancomycin, or\nmedicinal products which are secreted by the same renal transporter, human\nOrganic Anion Transporter\u00a01 (hOAT1), such as cidofovir). \u00a0Co\u2011administration\nof 10\u00a0mg adefovir dipivoxil with medicinal products in these patients may\nlead to an increase in serum concentrations of either adefovir or a co\u2011administered\nmedicinal product. \u00a0The renal function of these patients should be closely\nmonitored with a frequency tailored to the individual patient\u2019s medical\ncondition.</span></p>", "ID": "1cd37a1d-8ebc-4f56-967e-fffedb8e46cb", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Caution is\nadvised in patients receiving other medicinal products that may affect renal\nfunction or are excreted renally (e.g. cyclosporin and tacrolimus, intravenous\naminoglycosides, amphotericin\u00a0B, foscarnet, pentamidine, vancomycin, or\nmedicinal products which are secreted by the same renal transporter, human\nOrganic Anion Transporter\u00a01 (hOAT1), such as cidofovir). \u00a0Co\u2011administration\nof 10\u00a0mg adefovir dipivoxil with medicinal products in these patients may\nlead to an increase in serum concentrations of either adefovir or a co\u2011administered\nmedicinal product. \u00a0The renal function of these patients should be closely\nmonitored with a frequency tailored to the individual patient\u2019s medical\ncondition.</span>", "ID": "e90602bb-475c-42e8-8cb8-a0c7352a7fb9", "Styles": "None", "Classes": "None", "Text": "Caution is advised in patients receiving other medicinal products that may affect renal function or are excreted renally (e.g. cyclosporin and tacrolimus, intravenous aminoglycosides, amphotericin\u00a0B, foscarnet, pentamidine, vancomycin, or medicinal products which are secreted by the same renal transporter, human Organic Anion Transporter\u00a01 (hOAT1), such as cidofovir). \u00a0Co\u2011administration of 10\u00a0mg adefovir dipivoxil with medicinal products in these patients may lead to an increase in serum concentrations of either adefovir or a co\u2011administered medicinal product. \u00a0The renal function of these patients should be closely monitored with a frequency tailored to the individual patient\u2019s medical condition.", "ParentId": "1cd37a1d-8ebc-4f56-967e-fffedb8e46cb"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1bf7bd61-e673-4f56-bc72-6e1e1d101bc0", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f397d8db-a36c-4a3c-a2db-b04346629c2a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1bf7bd61-e673-4f56-bc72-6e1e1d101bc0"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">For renal safety\nin patients pre\u2011 and post\u2011transplantation with lamivudine-resistant\u00a0HBV,\nsee\u00a0</span><span lang=\"EN-GB\">section\u00a04.8.</span></p>", "ID": "d3701ce0-3ef6-41cd-a314-e0cc37b5c54b", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">For renal safety\nin patients pre\u2011 and post\u2011transplantation with lamivudine-resistant\u00a0HBV,\nsee\u00a0</span>", "ID": "f457c423-3467-4d4f-a83f-9d4ee723e908", "Styles": "None", "Classes": "None", "Text": "For renal safety in patients pre\u2011 and post\u2011transplantation with lamivudine-resistant\u00a0HBV, see\u00a0", "ParentId": "d3701ce0-3ef6-41cd-a314-e0cc37b5c54b"}, {"Element": "<span lang=\"EN-GB\">section\u00a04.8.</span>", "ID": "fa6123c2-7f53-4065-97e4-4b23fca04a4f", "Styles": "None", "Classes": "None", "Text": "section\u00a04.8.", "ParentId": "d3701ce0-3ef6-41cd-a314-e0cc37b5c54b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9fe4c0c3-a092-4133-a026-507047179111", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3303c6cd-10d9-451a-971a-9c250d238cdd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9fe4c0c3-a092-4133-a026-507047179111"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Hepatic\nfunction:</span></i><span lang=\"EN-GB\"> Spontaneous exacerbations in chronic\nhepatitis\u00a0B are relatively common and are characterised by transient\nincreases in serum ALT.\u00a0 After initiating antiviral therapy, serum ALT may\nincrease in some patients as serum HBV\u00a0DNA levels decline.\u00a0 In patients\nwith compensated liver disease, these increases in serum ALT are generally not\naccompanied by an increase in serum bilirubin concentrations or hepatic\ndecompensation (see\u00a0section\u00a04.8).</span></p>", "ID": "80f8d080-d219-4210-a428-cf1b19b22097", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Hepatic\nfunction:</span></i>", "ID": "2c51191e-a8e5-4d46-88c6-ee4da548fcfb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "80f8d080-d219-4210-a428-cf1b19b22097"}, {"Element": "<span lang=\"EN-GB\">Hepatic\nfunction:</span>", "ID": "7bc9c2a5-33a0-4869-a037-47e4f7294524", "Styles": "None", "Classes": "None", "Text": "Hepatic function:", "ParentId": "2c51191e-a8e5-4d46-88c6-ee4da548fcfb"}, {"Element": "<span lang=\"EN-GB\"> Spontaneous exacerbations in chronic\nhepatitis\u00a0B are relatively common and are characterised by transient\nincreases in serum ALT.\u00a0 After initiating antiviral therapy, serum ALT may\nincrease in some patients as serum HBV\u00a0DNA levels decline.\u00a0 In patients\nwith compensated liver disease, these increases in serum ALT are generally not\naccompanied by an increase in serum bilirubin concentrations or hepatic\ndecompensation (see\u00a0section\u00a04.8).</span>", "ID": "e9c40e07-1974-4b10-bacd-7890f2b351e4", "Styles": "None", "Classes": "None", "Text": " Spontaneous exacerbations in chronic hepatitis\u00a0B are relatively common and are characterised by transient increases in serum ALT.\u00a0 After initiating antiviral therapy, serum ALT may increase in some patients as serum HBV\u00a0DNA levels decline.\u00a0 In patients with compensated liver disease, these increases in serum ALT are generally not accompanied by an increase in serum bilirubin concentrations or hepatic decompensation (see\u00a0section\u00a04.8).", "ParentId": "80f8d080-d219-4210-a428-cf1b19b22097"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bf3676b8-a00b-495b-b5a8-b257cbeb2b4e", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8e5f96b0-8d4e-45ba-9437-1327a88880db", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bf3676b8-a00b-495b-b5a8-b257cbeb2b4e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Patients with\nadvanced liver disease or cirrhosis may be at a higher risk for hepatic\ndecompensation following hepatitis exacerbation which may be fatal.\u00a0 In these\npatients, including patients with decompensated liver disease, treatment\ncessation is not recommended and these patients should be monitored closely\nduring therapy.</span></p>", "ID": "e426ebc5-1879-4d5b-ae76-b54568da5005", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Patients with\nadvanced liver disease or cirrhosis may be at a higher risk for hepatic\ndecompensation following hepatitis exacerbation which may be fatal.\u00a0 In these\npatients, including patients with decompensated liver disease, treatment\ncessation is not recommended and these patients should be monitored closely\nduring therapy.</span>", "ID": "a10e57fc-873a-4301-a04d-7b805fe23291", "Styles": "None", "Classes": "None", "Text": "Patients with advanced liver disease or cirrhosis may be at a higher risk for hepatic decompensation following hepatitis exacerbation which may be fatal.\u00a0 In these patients, including patients with decompensated liver disease, treatment cessation is not recommended and these patients should be monitored closely during therapy.", "ParentId": "e426ebc5-1879-4d5b-ae76-b54568da5005"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "72f91ad3-0cd6-4808-a033-bf2999461540", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "edb0ba22-3127-4fee-9c37-8696525b8e88", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "72f91ad3-0cd6-4808-a033-bf2999461540"}, {"Element": "<p class=\"MsoEndnoteText\"><span lang=\"EN-GB\">In the event of these patients\ndeveloping renal insufficiency, see above <i>Renal function</i>.</span></p>", "ID": "12ea28d8-769d-4e70-90ef-49b9a0907d00", "Styles": "None", "Classes": "['MsoEndnoteText']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">In the event of these patients\ndeveloping renal insufficiency, see above <i>Renal function</i>.</span>", "ID": "8376038f-da52-4f9a-8ffe-752c9ab50781", "Styles": "None", "Classes": "None", "Text": "In the event of these patients developing renal insufficiency, see above .", "ParentId": "12ea28d8-769d-4e70-90ef-49b9a0907d00"}, {"Element": "<i>Renal function</i>", "ID": "6428fe72-1129-48cc-bda0-5880e727fddd", "Styles": "None", "Classes": "None", "Text": "Renal function", "ParentId": "8376038f-da52-4f9a-8ffe-752c9ab50781"}, {"Element": "<p class=\"MsoEndnoteText\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4f982688-5643-404f-af1e-26150df310b4", "Styles": "None", "Classes": "['MsoEndnoteText']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "55820f54-b0a1-4d91-8fc2-e096512299b8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4f982688-5643-404f-af1e-26150df310b4"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If treatment\ncessation is necessary, patients should be closely monitored for several months\nafter stopping treatment as exacerbations of hepatitis have occurred after\ndiscontinuation of 10\u00a0mg adefovir dipivoxil.\u00a0 These exacerbations occurred\nin the absence of HBeAg seroconversion and presented as serum ALT elevations\nand increases in serum HBV\u00a0DNA.\u00a0 Elevations in serum ALT that occurred in\npatients with compensated liver function treated with 10\u00a0mg adefovir\ndipivoxil were not accompanied by clinical and laboratory changes associated\nwith liver decompensation.\u00a0 Patients should be closely monitored after stopping\ntreatment.\u00a0 Most post\u2011treatment exacerbations of hepatitis were seen\nwithin 12\u00a0weeks of discontinuation of 10\u00a0mg adefovir dipivoxil.</span></p>", "ID": "a0f9df31-a1d1-49b4-b6a1-16f24b8f0019", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">If treatment\ncessation is necessary, patients should be closely monitored for several months\nafter stopping treatment as exacerbations of hepatitis have occurred after\ndiscontinuation of 10\u00a0mg adefovir dipivoxil.\u00a0 These exacerbations occurred\nin the absence of HBeAg seroconversion and presented as serum ALT elevations\nand increases in serum HBV\u00a0DNA.\u00a0 Elevations in serum ALT that occurred in\npatients with compensated liver function treated with 10\u00a0mg adefovir\ndipivoxil were not accompanied by clinical and laboratory changes associated\nwith liver decompensation.\u00a0 Patients should be closely monitored after stopping\ntreatment.\u00a0 Most post\u2011treatment exacerbations of hepatitis were seen\nwithin 12\u00a0weeks of discontinuation of 10\u00a0mg adefovir dipivoxil.</span>", "ID": "f18c44d3-91c3-4e7c-9841-8008cccd0eeb", "Styles": "None", "Classes": "None", "Text": "If treatment cessation is necessary, patients should be closely monitored for several months after stopping treatment as exacerbations of hepatitis have occurred after discontinuation of 10\u00a0mg adefovir dipivoxil.\u00a0 These exacerbations occurred in the absence of HBeAg seroconversion and presented as serum ALT elevations and increases in serum HBV\u00a0DNA.\u00a0 Elevations in serum ALT that occurred in patients with compensated liver function treated with 10\u00a0mg adefovir dipivoxil were not accompanied by clinical and laboratory changes associated with liver decompensation.\u00a0 Patients should be closely monitored after stopping treatment.\u00a0 Most post\u2011treatment exacerbations of hepatitis were seen within 12\u00a0weeks of discontinuation of 10\u00a0mg adefovir dipivoxil.", "ParentId": "a0f9df31-a1d1-49b4-b6a1-16f24b8f0019"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "44c65a40-b918-4966-932a-700406106a44", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "57096061-861e-45cf-8c3b-ac96603b73f5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "44c65a40-b918-4966-932a-700406106a44"}, {"Element": "<p class=\"MsoEndnoteText\"><i><span lang=\"EN-GB\">Lactic acidosis and severe\nhepatomegaly with steatosis:</span></i><span lang=\"EN-GB\"> Occurrences of lactic\nacidosis (in the absence of hypoxaemia), sometimes fatal, usually associated\nwith severe hepatomegaly and hepatic steatosis, have been reported with the use\nof nucleoside analogues.\u00a0 As adefovir is structurally related to nucleoside\nanalogues, this risk cannot be excluded.\u00a0 Treatment with nucleoside analogues\nshould be discontinued when rapidly elevating aminotransferase levels,\nprogressive hepatomegaly or metabolic/lactic acidosis of unknown aetiology\noccur.\u00a0 Benign digestive symptoms, such as nausea, vomiting and abdominal pain,\nmight be indicative of lactic acidosis development.\u00a0 Severe cases, sometimes\nwith fatal outcome, were associated with pancreatitis, liver failure/hepatic\nsteatosis, renal failure and higher levels of serum lactate.\u00a0 Caution should be\nexercised when prescribing nucleoside analogues to any patient (particularly\nobese women) with hepatomegaly, hepatitis or other known risk factors for liver\ndisease.\u00a0 These patients should be followed closely.</span></p>", "ID": "80bb563f-6f67-47d5-822d-7257e0e5a15c", "Styles": "None", "Classes": "['MsoEndnoteText']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Lactic acidosis and severe\nhepatomegaly with steatosis:</span></i>", "ID": "95efa618-5f6b-4298-8bc0-9e86b1dc469d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "80bb563f-6f67-47d5-822d-7257e0e5a15c"}, {"Element": "<span lang=\"EN-GB\">Lactic acidosis and severe\nhepatomegaly with steatosis:</span>", "ID": "9f57e7cf-4d94-4590-8baa-d1bc11e4603b", "Styles": "None", "Classes": "None", "Text": "Lactic acidosis and severe hepatomegaly with steatosis:", "ParentId": "95efa618-5f6b-4298-8bc0-9e86b1dc469d"}, {"Element": "<span lang=\"EN-GB\"> Occurrences of lactic\nacidosis (in the absence of hypoxaemia), sometimes fatal, usually associated\nwith severe hepatomegaly and hepatic steatosis, have been reported with the use\nof nucleoside analogues.\u00a0 As adefovir is structurally related to nucleoside\nanalogues, this risk cannot be excluded.\u00a0 Treatment with nucleoside analogues\nshould be discontinued when rapidly elevating aminotransferase levels,\nprogressive hepatomegaly or metabolic/lactic acidosis of unknown aetiology\noccur.\u00a0 Benign digestive symptoms, such as nausea, vomiting and abdominal pain,\nmight be indicative of lactic acidosis development.\u00a0 Severe cases, sometimes\nwith fatal outcome, were associated with pancreatitis, liver failure/hepatic\nsteatosis, renal failure and higher levels of serum lactate.\u00a0 Caution should be\nexercised when prescribing nucleoside analogues to any patient (particularly\nobese women) with hepatomegaly, hepatitis or other known risk factors for liver\ndisease.\u00a0 These patients should be followed closely.</span>", "ID": "8432fd64-c9e2-4d73-98dd-b25649e6478f", "Styles": "None", "Classes": "None", "Text": " Occurrences of lactic acidosis (in the absence of hypoxaemia), sometimes fatal, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues.\u00a0 As adefovir is structurally related to nucleoside analogues, this risk cannot be excluded.\u00a0 Treatment with nucleoside analogues should be discontinued when rapidly elevating aminotransferase levels, progressive hepatomegaly or metabolic/lactic acidosis of unknown aetiology occur.\u00a0 Benign digestive symptoms, such as nausea, vomiting and abdominal pain, might be indicative of lactic acidosis development.\u00a0 Severe cases, sometimes with fatal outcome, were associated with pancreatitis, liver failure/hepatic steatosis, renal failure and higher levels of serum lactate.\u00a0 Caution should be exercised when prescribing nucleoside analogues to any patient (particularly obese women) with hepatomegaly, hepatitis or other known risk factors for liver disease.\u00a0 These patients should be followed closely.", "ParentId": "80bb563f-6f67-47d5-822d-7257e0e5a15c"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5428cb17-f2ca-47c2-b036-6d84befb394f", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3652e096-dc1d-45ad-96bc-dfa3ea7a45b4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5428cb17-f2ca-47c2-b036-6d84befb394f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">To differentiate\nbetween elevations in transaminases due to response to treatment and increases\npotentially related to lactic acidosis, physicians should ensure that changes\nin ALT are associated with improvements in other laboratory markers of chronic\nhepatitis\u00a0B.</span></p>", "ID": "082e67a8-4674-4159-ab53-437000b4b2a3", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">To differentiate\nbetween elevations in transaminases due to response to treatment and increases\npotentially related to lactic acidosis, physicians should ensure that changes\nin ALT are associated with improvements in other laboratory markers of chronic\nhepatitis\u00a0B.</span>", "ID": "1baebdda-8b71-4ab8-b09f-3687838dd870", "Styles": "None", "Classes": "None", "Text": "To differentiate between elevations in transaminases due to response to treatment and increases potentially related to lactic acidosis, physicians should ensure that changes in ALT are associated with improvements in other laboratory markers of chronic hepatitis\u00a0B.", "ParentId": "082e67a8-4674-4159-ab53-437000b4b2a3"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "28fe9f8a-dc49-4d97-ab9f-f2e3a8ccb105", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e9a05ab6-0739-4829-b5ce-c63485ea0c5c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "28fe9f8a-dc49-4d97-ab9f-f2e3a8ccb105"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Co\u2011infection\nwith hepatitis\u00a0C or D:</span></i><span lang=\"EN-GB\"> There are no data on\nthe efficacy of adefovir dipivoxil in patients co\u2011infected with\nhepatitis\u00a0C or hepatitis\u00a0D.</span></p>", "ID": "a2a08fc4-a6c5-48bc-b3d9-846f7fa6a437", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Co\u2011infection\nwith hepatitis\u00a0C or D:</span></i>", "ID": "11fe5f12-a9ae-4763-8bc8-35c13e1bb935", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a2a08fc4-a6c5-48bc-b3d9-846f7fa6a437"}, {"Element": "<span lang=\"EN-GB\">Co\u2011infection\nwith hepatitis\u00a0C or D:</span>", "ID": "58dab14e-c40c-46d9-b646-c3a44db7671d", "Styles": "None", "Classes": "None", "Text": "Co\u2011infection with hepatitis\u00a0C or D:", "ParentId": "11fe5f12-a9ae-4763-8bc8-35c13e1bb935"}, {"Element": "<span lang=\"EN-GB\"> There are no data on\nthe efficacy of adefovir dipivoxil in patients co\u2011infected with\nhepatitis\u00a0C or hepatitis\u00a0D.</span>", "ID": "34c12c2f-7ec7-4e16-a0ff-ce6027b03afe", "Styles": "None", "Classes": "None", "Text": " There are no data on the efficacy of adefovir dipivoxil in patients co\u2011infected with hepatitis\u00a0C or hepatitis\u00a0D.", "ParentId": "a2a08fc4-a6c5-48bc-b3d9-846f7fa6a437"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d0fee13e-55de-49a2-a907-10590cd8e3e5", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "82e452c6-4667-4bb4-b4ef-cd2661b76590", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d0fee13e-55de-49a2-a907-10590cd8e3e5"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Co\u2011infection\nwith HIV:</span></i><span lang=\"EN-GB\"> Limited data are available on the safety\nand efficacy of 10\u00a0mg adefovir dipivoxil in patients with chronic\nhepatitis\u00a0B, co\u2011infected with HIV.\u00a0 To date there is no evidence\nthat daily dosing with 10\u00a0mg adefovir dipivoxil results in emergence of\nadefovir-associated resistance mutations in the HIV\u00a0reverse\ntranscriptase.\u00a0 Nonetheless, there is a potential risk of selection of\nHIV\u00a0strains resistant to adefovir with possible cross\u2011resistance to\nother antiviral medicinal products.</span></p>", "ID": "2f62b63a-92fa-4f40-bd18-2330b51a0ae3", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Co\u2011infection\nwith HIV:</span></i>", "ID": "6741c807-e76c-40a6-a1f7-dd0ee059a300", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2f62b63a-92fa-4f40-bd18-2330b51a0ae3"}, {"Element": "<span lang=\"EN-GB\">Co\u2011infection\nwith HIV:</span>", "ID": "e1e2b43d-bd83-4dcd-92c1-aece50f53758", "Styles": "None", "Classes": "None", "Text": "Co\u2011infection with HIV:", "ParentId": "6741c807-e76c-40a6-a1f7-dd0ee059a300"}, {"Element": "<span lang=\"EN-GB\"> Limited data are available on the safety\nand efficacy of 10\u00a0mg adefovir dipivoxil in patients with chronic\nhepatitis\u00a0B, co\u2011infected with HIV.\u00a0 To date there is no evidence\nthat daily dosing with 10\u00a0mg adefovir dipivoxil results in emergence of\nadefovir-associated resistance mutations in the HIV\u00a0reverse\ntranscriptase.\u00a0 Nonetheless, there is a potential risk of selection of\nHIV\u00a0strains resistant to adefovir with possible cross\u2011resistance to\nother antiviral medicinal products.</span>", "ID": "fd4fbc47-827a-4447-86a0-284ce3eb2cf1", "Styles": "None", "Classes": "None", "Text": " Limited data are available on the safety and efficacy of 10\u00a0mg adefovir dipivoxil in patients with chronic hepatitis\u00a0B, co\u2011infected with HIV.\u00a0 To date there is no evidence that daily dosing with 10\u00a0mg adefovir dipivoxil results in emergence of adefovir-associated resistance mutations in the HIV\u00a0reverse transcriptase.\u00a0 Nonetheless, there is a potential risk of selection of HIV\u00a0strains resistant to adefovir with possible cross\u2011resistance to other antiviral medicinal products.", "ParentId": "2f62b63a-92fa-4f40-bd18-2330b51a0ae3"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "7bd78b79-39b2-4192-b327-a217c3d60a57", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "8ff7d9e7-ee3c-45f8-a1ef-7c725bbc1358", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7bd78b79-39b2-4192-b327-a217c3d60a57"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "177936fe-c04f-4dac-bb4c-44491cd83267", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8ff7d9e7-ee3c-45f8-a1ef-7c725bbc1358"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "e430c11d-c977-4fb3-868e-4a19a0f348b2", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "177936fe-c04f-4dac-bb4c-44491cd83267"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">As far as\npossible, treatment of hepatitis\u00a0B by adefovir dipivoxil in an HIV\u00a0co\u2011infected\npatient should be reserved for patients whose HIV\u00a0RNA is controlled.\u00a0\nTreatment with 10\u00a0mg adefovir dipivoxil has not been shown to be effective\nagainst HIV\u00a0replication and therefore should not be used to control\nHIV\u00a0infection.</span></p>", "ID": "d00fc596-460b-4c29-b442-9803f6b349d0", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">As far as\npossible, treatment of hepatitis\u00a0B by adefovir dipivoxil in an HIV\u00a0co\u2011infected\npatient should be reserved for patients whose HIV\u00a0RNA is controlled.\u00a0\nTreatment with 10\u00a0mg adefovir dipivoxil has not been shown to be effective\nagainst HIV\u00a0replication and therefore should not be used to control\nHIV\u00a0infection.</span>", "ID": "797011c5-5e04-4edb-8756-91307954ba82", "Styles": "None", "Classes": "None", "Text": "As far as possible, treatment of hepatitis\u00a0B by adefovir dipivoxil in an HIV\u00a0co\u2011infected patient should be reserved for patients whose HIV\u00a0RNA is controlled.\u00a0 Treatment with 10\u00a0mg adefovir dipivoxil has not been shown to be effective against HIV\u00a0replication and therefore should not be used to control HIV\u00a0infection.", "ParentId": "d00fc596-460b-4c29-b442-9803f6b349d0"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "0e0e742c-4b37-4644-be6d-5cfd91ceb4db", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "1de32820-3048-4447-a662-bfdf07520cb8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0e0e742c-4b37-4644-be6d-5cfd91ceb4db"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "afe171b9-3d02-443f-9bc7-7dede1454a42", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1de32820-3048-4447-a662-bfdf07520cb8"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "558c7979-1f39-4f5f-bf89-c9e01316cd9e", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "afe171b9-3d02-443f-9bc7-7dede1454a42"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Elderly:</span></i><span lang=\"EN-GB\"> The clinical experience in patients &gt;\u00a065\u00a0years of age\nis very limited.\u00a0 Caution should be exercised when prescribing adefovir\ndipivoxil to the elderly, keeping in mind the greater frequency of decreased\nrenal or cardiac function in these patients, and the increase in concomitant\ndiseases or concomitant use of other medicinal products in the elderly.</span></p>", "ID": "f5c5d51f-bcb0-48f2-a6b3-69ce7a56f5b6", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Elderly:</span></i>", "ID": "12744243-303b-4e4e-bf09-88785a656bf2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f5c5d51f-bcb0-48f2-a6b3-69ce7a56f5b6"}, {"Element": "<span lang=\"EN-GB\">Elderly:</span>", "ID": "a448be90-e3e2-422d-a07c-bf18e9a2f400", "Styles": "None", "Classes": "None", "Text": "Elderly:", "ParentId": "12744243-303b-4e4e-bf09-88785a656bf2"}, {"Element": "<span lang=\"EN-GB\"> The clinical experience in patients &gt;\u00a065\u00a0years of age\nis very limited.\u00a0 Caution should be exercised when prescribing adefovir\ndipivoxil to the elderly, keeping in mind the greater frequency of decreased\nrenal or cardiac function in these patients, and the increase in concomitant\ndiseases or concomitant use of other medicinal products in the elderly.</span>", "ID": "9ee5a94d-9eab-42fc-89f3-bc44d896fc40", "Styles": "None", "Classes": "None", "Text": " The clinical experience in patients >\u00a065\u00a0years of age is very limited.\u00a0 Caution should be exercised when prescribing adefovir dipivoxil to the elderly, keeping in mind the greater frequency of decreased renal or cardiac function in these patients, and the increase in concomitant diseases or concomitant use of other medicinal products in the elderly.", "ParentId": "f5c5d51f-bcb0-48f2-a6b3-69ce7a56f5b6"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7bcb0cee-d3c2-4baa-886b-806a10407f3e", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d006a4f3-e7ce-45b2-8f44-dd593dfaa5d6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7bcb0cee-d3c2-4baa-886b-806a10407f3e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Resistance:</span></i><span lang=\"EN-GB\"> Resistance to adefovir dipivoxil (see\u00a0section\u00a05.1) can\nresult in viral load rebound which may result in exacerbation of\nhepatitis\u00a0B and, in the setting of diminished hepatic function, lead to\nliver decompensation and possible fatal outcome. \u00a0Virological response should\nbe closely monitored in patients treated with adefovir dipivoxil, with\nHBV\u00a0DNA measured every 3\u00a0months. \u00a0If viral rebound occurs, resistance\ntesting should be performed. \u00a0In case of emergence of resistance, treatment\nshould be modified.</span></p>", "ID": "ca5be730-f29d-4174-bb95-931926366f03", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Resistance:</span></i>", "ID": "67954cbb-221f-4472-ae16-3d53b65a8e99", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ca5be730-f29d-4174-bb95-931926366f03"}, {"Element": "<span lang=\"EN-GB\">Resistance:</span>", "ID": "b567ccd1-eab8-43c3-a815-9bcfdc1691b4", "Styles": "None", "Classes": "None", "Text": "Resistance:", "ParentId": "67954cbb-221f-4472-ae16-3d53b65a8e99"}, {"Element": "<span lang=\"EN-GB\"> Resistance to adefovir dipivoxil (see\u00a0section\u00a05.1) can\nresult in viral load rebound which may result in exacerbation of\nhepatitis\u00a0B and, in the setting of diminished hepatic function, lead to\nliver decompensation and possible fatal outcome. \u00a0Virological response should\nbe closely monitored in patients treated with adefovir dipivoxil, with\nHBV\u00a0DNA measured every 3\u00a0months. \u00a0If viral rebound occurs, resistance\ntesting should be performed. \u00a0In case of emergence of resistance, treatment\nshould be modified.</span>", "ID": "d5d9ed13-fcbe-4c9f-807b-1630c051b0a9", "Styles": "None", "Classes": "None", "Text": " Resistance to adefovir dipivoxil (see\u00a0section\u00a05.1) can result in viral load rebound which may result in exacerbation of hepatitis\u00a0B and, in the setting of diminished hepatic function, lead to liver decompensation and possible fatal outcome. \u00a0Virological response should be closely monitored in patients treated with adefovir dipivoxil, with HBV\u00a0DNA measured every 3\u00a0months. \u00a0If viral rebound occurs, resistance testing should be performed. \u00a0In case of emergence of resistance, treatment should be modified.", "ParentId": "ca5be730-f29d-4174-bb95-931926366f03"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "585d0eff-b528-4f09-8f8b-9cb7a46e04d6", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f531d502-8a6f-486a-a111-0c84a4b6f095", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "585d0eff-b528-4f09-8f8b-9cb7a46e04d6"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Hepsera contains\nlactose monohydrate.\u00a0 Consequently, patients with rare hereditary problems of\ngalactose intolerance, the Lapp lactase deficiency, or glucose\u2011galactose\nmalabsorption should not take this medicinal product.</span></p>", "ID": "69c5583d-a607-43db-8841-9cf76338cb9a", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Hepsera contains\nlactose monohydrate.\u00a0 Consequently, patients with rare hereditary problems of\ngalactose intolerance, the Lapp lactase deficiency, or glucose\u2011galactose\nmalabsorption should not take this medicinal product.</span>", "ID": "959a564c-a5e6-4949-9bd2-486f057e8e3f", "Styles": "None", "Classes": "None", "Text": "Hepsera contains lactose monohydrate.\u00a0 Consequently, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose\u2011galactose malabsorption should not take this medicinal product.", "ParentId": "69c5583d-a607-43db-8841-9cf76338cb9a"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "37ab19a5-3826-48fa-a6e6-0ae2bbdbc022", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0c3487aa-5db4-429c-9954-198566189194", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "37ab19a5-3826-48fa-a6e6-0ae2bbdbc022"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.5\u00a0\u00a0\u00a0\u00a0 Interaction with other medicinal products and other forms of\ninteraction</span></b></p>", "ID": "70843bc4-838f-4cdd-affd-b546316d9c1c", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">4.5\u00a0\u00a0\u00a0\u00a0 Interaction with other medicinal products and other forms of\ninteraction</span></b>", "ID": "0943dcb2-17d5-46be-b9a8-616648bcbf6a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "70843bc4-838f-4cdd-affd-b546316d9c1c"}, {"Element": "<span lang=\"EN-GB\">4.5\u00a0\u00a0\u00a0\u00a0 Interaction with other medicinal products and other forms of\ninteraction</span>", "ID": "23f05108-2edb-49ce-883e-dfc8ba973cf1", "Styles": "None", "Classes": "None", "Text": "4.5\u00a0\u00a0\u00a0\u00a0 Interaction with other medicinal products and other forms of interaction", "ParentId": "0943dcb2-17d5-46be-b9a8-616648bcbf6a"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2fb63893-5949-471c-8091-8a238b56114f", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1aba39e0-675e-473f-8697-d459e27db921", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2fb63893-5949-471c-8091-8a238b56114f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Interaction\nstudies have only been performed in adults.</span></p>", "ID": "b45241ef-d0bb-4537-9504-7268bf761cd5", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Interaction\nstudies have only been performed in adults.</span>", "ID": "bf25f881-e583-4c63-9902-377386b1428b", "Styles": "None", "Classes": "None", "Text": "Interaction studies have only been performed in adults.", "ParentId": "b45241ef-d0bb-4537-9504-7268bf761cd5"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c80710e7-8cd1-4373-bad9-87d6925115ab", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7d51155f-1cc3-4d77-a024-b0dcb53afc19", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c80710e7-8cd1-4373-bad9-87d6925115ab"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The potential\nfor CYP450 mediated interactions involving adefovir with other medicinal\nproducts is low, based on the results of <i>in\u00a0vitro</i> experiments in\nwhich adefovir did not influence any of the common CYP isoforms known to be\ninvolved in human drug metabolism and based on the known elimination pathway of\nadefovir.\u00a0 A clinical study in liver\u2011transplant patients has shown that\nno pharmacokinetic interaction occurs when adefovir dipivoxil 10\u00a0mg once\ndaily is administered concomitantly with tacrolimus, an immunosuppressant which\nis predominantly metabolised via the CYP450 system.\u00a0 A pharmacokinetic\ninteraction between adefovir and the immunosuppressant, cyclosporin, is also\nconsidered unlikely as cyclosporin shares the same metabolic pathway as\ntacrolimus.\u00a0 Nevertheless, given that tacrolimus and cyclosporin can affect\nrenal function, close monitoring is recommended when either of these agents is\ncoadministered with adefovir dipivoxil (see\u00a0section\u00a04.4).</span></p>", "ID": "230ce1cd-9367-483a-9f9b-702305cdc989", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">The potential\nfor CYP450 mediated interactions involving adefovir with other medicinal\nproducts is low, based on the results of <i>in\u00a0vitro</i> experiments in\nwhich adefovir did not influence any of the common CYP isoforms known to be\ninvolved in human drug metabolism and based on the known elimination pathway of\nadefovir.\u00a0 A clinical study in liver\u2011transplant patients has shown that\nno pharmacokinetic interaction occurs when adefovir dipivoxil 10\u00a0mg once\ndaily is administered concomitantly with tacrolimus, an immunosuppressant which\nis predominantly metabolised via the CYP450 system.\u00a0 A pharmacokinetic\ninteraction between adefovir and the immunosuppressant, cyclosporin, is also\nconsidered unlikely as cyclosporin shares the same metabolic pathway as\ntacrolimus.\u00a0 Nevertheless, given that tacrolimus and cyclosporin can affect\nrenal function, close monitoring is recommended when either of these agents is\ncoadministered with adefovir dipivoxil (see\u00a0section\u00a04.4).</span>", "ID": "b2f9407a-29a0-40b4-9975-6b870181d358", "Styles": "None", "Classes": "None", "Text": "The potential for CYP450 mediated interactions involving adefovir with other medicinal products is low, based on the results of  experiments in which adefovir did not influence any of the common CYP isoforms known to be involved in human drug metabolism and based on the known elimination pathway of adefovir.\u00a0 A clinical study in liver\u2011transplant patients has shown that no pharmacokinetic interaction occurs when adefovir dipivoxil 10\u00a0mg once daily is administered concomitantly with tacrolimus, an immunosuppressant which is predominantly metabolised via the CYP450 system.\u00a0 A pharmacokinetic interaction between adefovir and the immunosuppressant, cyclosporin, is also considered unlikely as cyclosporin shares the same metabolic pathway as tacrolimus.\u00a0 Nevertheless, given that tacrolimus and cyclosporin can affect renal function, close monitoring is recommended when either of these agents is coadministered with adefovir dipivoxil (see\u00a0section\u00a04.4).", "ParentId": "230ce1cd-9367-483a-9f9b-702305cdc989"}, {"Element": "<i>in\u00a0vitro</i>", "ID": "9d63666f-0835-473a-b6e5-253e29c10ff6", "Styles": "None", "Classes": "None", "Text": "in\u00a0vitro", "ParentId": "b2f9407a-29a0-40b4-9975-6b870181d358"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6b633d4a-93d3-4f8a-a22a-a3d2a56aa923", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "caff0176-c165-4bc0-9634-c0f4873ac8ae", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6b633d4a-93d3-4f8a-a22a-a3d2a56aa923"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Concomitant\nadministration of 10\u00a0mg adefovir dipivoxil and 100\u00a0mg lamivudine did\nnot alter the pharmacokinetic profile of either medicinal product.</span></p>", "ID": "f9f0f28d-be6a-474a-ac1f-4852d106b343", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Concomitant\nadministration of 10\u00a0mg adefovir dipivoxil and 100\u00a0mg lamivudine did\nnot alter the pharmacokinetic profile of either medicinal product.</span>", "ID": "e9d3fc21-2532-4495-8953-520671b84510", "Styles": "None", "Classes": "None", "Text": "Concomitant administration of 10\u00a0mg adefovir dipivoxil and 100\u00a0mg lamivudine did not alter the pharmacokinetic profile of either medicinal product.", "ParentId": "f9f0f28d-be6a-474a-ac1f-4852d106b343"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "35e9a7c0-e5b2-4139-a78a-81ad10795e84", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "57cf9f17-015e-41a4-a406-7a6c15aab25d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "35e9a7c0-e5b2-4139-a78a-81ad10795e84"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adefovir is\nexcreted renally, by a combination of glomerular filtration and active tubular\nsecretion.\u00a0 Co\u2011administration of 10\u00a0mg adefovir dipivoxil with other\nmedicinal products that are eliminated by tubular secretion or alter tubular\nfunction may increase serum concentrations of either adefovir or the co\u2011administered\nmedicinal product (see\u00a0section\u00a04.4).</span></p>", "ID": "4b31d4a8-78c4-4d71-868d-bec574c08c22", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Adefovir is\nexcreted renally, by a combination of glomerular filtration and active tubular\nsecretion.\u00a0 Co\u2011administration of 10\u00a0mg adefovir dipivoxil with other\nmedicinal products that are eliminated by tubular secretion or alter tubular\nfunction may increase serum concentrations of either adefovir or the co\u2011administered\nmedicinal product (see\u00a0section\u00a04.4).</span>", "ID": "16bdc2ac-e56a-4bdd-91c1-2ff62331c4c0", "Styles": "None", "Classes": "None", "Text": "Adefovir is excreted renally, by a combination of glomerular filtration and active tubular secretion.\u00a0 Co\u2011administration of 10\u00a0mg adefovir dipivoxil with other medicinal products that are eliminated by tubular secretion or alter tubular function may increase serum concentrations of either adefovir or the co\u2011administered medicinal product (see\u00a0section\u00a04.4).", "ParentId": "4b31d4a8-78c4-4d71-868d-bec574c08c22"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7c171a56-325b-4b46-b006-0011292d6b4f", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d29668de-c839-43a9-a14d-854a41af86b3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7c171a56-325b-4b46-b006-0011292d6b4f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Due to the high\npharmacokinetic variability of pegylated interferon, no definitive conclusion\ncan be drawn regarding the effect of adefovir and pegylated interferon co\u2011administration\non the pharmacokinetic profile of either medicinal product.\u00a0 Even though a\npharmacokinetic interaction is unlikely given the two products are eliminated\nvia different pathways, caution is recommended if both products are co\u2011administered.</span></p>", "ID": "67477bc9-e322-4659-9c23-2848bbe121f3", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Due to the high\npharmacokinetic variability of pegylated interferon, no definitive conclusion\ncan be drawn regarding the effect of adefovir and pegylated interferon co\u2011administration\non the pharmacokinetic profile of either medicinal product.\u00a0 Even though a\npharmacokinetic interaction is unlikely given the two products are eliminated\nvia different pathways, caution is recommended if both products are co\u2011administered.</span>", "ID": "5f4bc4a0-e60a-49ca-aa6f-c328d71ef417", "Styles": "None", "Classes": "None", "Text": "Due to the high pharmacokinetic variability of pegylated interferon, no definitive conclusion can be drawn regarding the effect of adefovir and pegylated interferon co\u2011administration on the pharmacokinetic profile of either medicinal product.\u00a0 Even though a pharmacokinetic interaction is unlikely given the two products are eliminated via different pathways, caution is recommended if both products are co\u2011administered.", "ParentId": "67477bc9-e322-4659-9c23-2848bbe121f3"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bfc55ec9-238f-4c04-8bb1-2309315f6184", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5d6105a3-bafd-4328-a46d-6e89816a1d05", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bfc55ec9-238f-4c04-8bb1-2309315f6184"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.6\u00a0\u00a0\u00a0\u00a0 Fertility, pregnancy\nand lactation</span></b></p>", "ID": "71a862fa-567d-481b-99e4-924e162f61c2", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">4.6\u00a0\u00a0\u00a0\u00a0 Fertility, pregnancy\nand lactation</span></b>", "ID": "e07db5ab-76f7-49f5-9b8d-614c32724f7d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "71a862fa-567d-481b-99e4-924e162f61c2"}, {"Element": "<span lang=\"EN-GB\">4.6\u00a0\u00a0\u00a0\u00a0 Fertility, pregnancy\nand lactation</span>", "ID": "bac787cd-c495-4c19-80c5-b1eeb1a1bfa5", "Styles": "None", "Classes": "None", "Text": "4.6\u00a0\u00a0\u00a0\u00a0 Fertility, pregnancy and lactation", "ParentId": "e07db5ab-76f7-49f5-9b8d-614c32724f7d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "54c2705c-6a79-4ec8-bf26-40a9a9d80dec", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "95bf07b9-7932-421a-a48a-79c6af413fce", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "54c2705c-6a79-4ec8-bf26-40a9a9d80dec"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The use of\nadefovir dipivoxil must be accompanied by the use of effective contraception.</span></p>", "ID": "ebcb0263-84ca-4754-9e68-5ecb09e4a691", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">The use of\nadefovir dipivoxil must be accompanied by the use of effective contraception.</span>", "ID": "4e8a80ab-b46a-4b94-967b-e74643d5ebc8", "Styles": "None", "Classes": "None", "Text": "The use of adefovir dipivoxil must be accompanied by the use of effective contraception.", "ParentId": "ebcb0263-84ca-4754-9e68-5ecb09e4a691"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">\u00a0</span></i></p>", "ID": "96c2f3e0-f338-4df2-8297-00847933447f", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">\u00a0</span></i>", "ID": "804a3346-6935-4860-8065-e84d8af24800", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "96c2f3e0-f338-4df2-8297-00847933447f"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d819b96a-75d7-4f34-aa13-509d760c85c3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "804a3346-6935-4860-8065-e84d8af24800"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Pregnancy</span></u></i></p>", "ID": "fe81995e-2a2c-4859-9ca1-038c2408a5c8", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><u><span lang=\"EN-GB\">Pregnancy</span></u></i>", "ID": "1fa8abea-6997-4836-8f76-7a6ad6bfe5ce", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fe81995e-2a2c-4859-9ca1-038c2408a5c8"}, {"Element": "<u><span lang=\"EN-GB\">Pregnancy</span></u>", "ID": "2d7c783a-f61a-4cab-a6c7-1394682caffc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1fa8abea-6997-4836-8f76-7a6ad6bfe5ce"}, {"Element": "<span lang=\"EN-GB\">Pregnancy</span>", "ID": "29edaec9-ff22-402d-82b9-45fe93e14185", "Styles": "None", "Classes": "None", "Text": "Pregnancy", "ParentId": "2d7c783a-f61a-4cab-a6c7-1394682caffc"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">There are limited\ndata on the use of adefovir dipivoxil in pregnant women.</span></p>", "ID": "4425258f-8673-4a95-a11c-c7eff0761846", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">There are limited\ndata on the use of adefovir dipivoxil in pregnant women.</span>", "ID": "ea62e596-c75d-405a-b2e9-279cdfbb91d4", "Styles": "None", "Classes": "None", "Text": "There are limited data on the use of adefovir dipivoxil in pregnant women.", "ParentId": "4425258f-8673-4a95-a11c-c7eff0761846"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "99e157c4-51aa-4fc4-9bcf-499c2e3f76d8", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "644263f9-7409-49c1-9c4d-feca79469b80", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "99e157c4-51aa-4fc4-9bcf-499c2e3f76d8"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Studies in\nanimals administered adefovir intravenously have shown reproductive toxicity\n(see\u00a0section\u00a05.3).\u00a0 Studies in orally dosed animals do not indicate\nteratogenic or foetotoxic effects.</span></p>", "ID": "27136334-2aa9-4cfb-abd4-df528703605c", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Studies in\nanimals administered adefovir intravenously have shown reproductive toxicity\n(see\u00a0section\u00a05.3).\u00a0 Studies in orally dosed animals do not indicate\nteratogenic or foetotoxic effects.</span>", "ID": "4a80ddb2-ab7d-4afd-8551-c320308192ee", "Styles": "None", "Classes": "None", "Text": "Studies in animals administered adefovir intravenously have shown reproductive toxicity (see\u00a0section\u00a05.3).\u00a0 Studies in orally dosed animals do not indicate teratogenic or foetotoxic effects.", "ParentId": "27136334-2aa9-4cfb-abd4-df528703605c"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8f0efcc5-8796-4c2e-b7bc-4e6f7a4c804e", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3372ff81-ea2c-40b0-b874-c9b93b806539", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8f0efcc5-8796-4c2e-b7bc-4e6f7a4c804e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adefovir\ndipivoxil is not recommended during pregnancy and in women of childbearing\npotential not using contraception.\u00a0 Adefovir dipivoxil should be used during pregnancy\nonly if the potential benefit justifies the potential risk to the foetus.</span></p>", "ID": "46ff94d8-adcf-478c-ab87-3aa8fbc6b8e4", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Adefovir\ndipivoxil is not recommended during pregnancy and in women of childbearing\npotential not using contraception.\u00a0 Adefovir dipivoxil should be used during pregnancy\nonly if the potential benefit justifies the potential risk to the foetus.</span>", "ID": "a24507ab-ae0a-4225-908c-ff32ad1d288e", "Styles": "None", "Classes": "None", "Text": "Adefovir dipivoxil is not recommended during pregnancy and in women of childbearing potential not using contraception.\u00a0 Adefovir dipivoxil should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.", "ParentId": "46ff94d8-adcf-478c-ab87-3aa8fbc6b8e4"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "daa1c238-6b54-4a8b-bd3b-ad945ca48bc3", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "dc1a6640-8dfd-4979-93e0-52c152d9cbf7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "daa1c238-6b54-4a8b-bd3b-ad945ca48bc3"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "c87877bc-a96f-418d-997b-a3b3d7329ca4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dc1a6640-8dfd-4979-93e0-52c152d9cbf7"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "cd6ded5c-9497-4834-a82b-783ca9ea7f42", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "c87877bc-a96f-418d-997b-a3b3d7329ca4"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">There are no\ndata on the effect of adefovir dipivoxil on transmission of HBV from mother to\ninfant.\u00a0 Therefore, the standard recommended procedures for immunisation of\ninfants should be followed to prevent neonatal acquisition of HBV.</span></p>", "ID": "caa7b97a-2999-4127-a675-33f15f7cc9d8", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">There are no\ndata on the effect of adefovir dipivoxil on transmission of HBV from mother to\ninfant.\u00a0 Therefore, the standard recommended procedures for immunisation of\ninfants should be followed to prevent neonatal acquisition of HBV.</span>", "ID": "1e95631e-1b26-4cf6-9bdf-fae069a2ef43", "Styles": "None", "Classes": "None", "Text": "There are no data on the effect of adefovir dipivoxil on transmission of HBV from mother to infant.\u00a0 Therefore, the standard recommended procedures for immunisation of infants should be followed to prevent neonatal acquisition of HBV.", "ParentId": "caa7b97a-2999-4127-a675-33f15f7cc9d8"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bbbc1797-b1de-488a-baf6-e24dc3db0d50", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7ea56379-02d3-4296-9968-556dcd09a54b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bbbc1797-b1de-488a-baf6-e24dc3db0d50"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Breast\u2011feeding</span></u></i></p>", "ID": "c996446c-8fdd-42a9-976a-4e5d66428dd4", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><u><span lang=\"EN-GB\">Breast\u2011feeding</span></u></i>", "ID": "fb3a0a75-28c7-45ba-85bf-3f516073daeb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c996446c-8fdd-42a9-976a-4e5d66428dd4"}, {"Element": "<u><span lang=\"EN-GB\">Breast\u2011feeding</span></u>", "ID": "69a0268c-b712-4bb3-8906-489b3d3d48e5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fb3a0a75-28c7-45ba-85bf-3f516073daeb"}, {"Element": "<span lang=\"EN-GB\">Breast\u2011feeding</span>", "ID": "9eca5bc5-a9fb-444f-bb3e-56ce38d0d052", "Styles": "None", "Classes": "None", "Text": "Breast\u2011feeding", "ParentId": "69a0268c-b712-4bb3-8906-489b3d3d48e5"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">A risk to the\nnewborns/infants cannot be excluded.\u00a0 It is recommended that mothers being\ntreated with adefovir dipivoxil do not breast\u2011feed their infants.</span></p>", "ID": "71666bfc-50c2-4f39-ade0-6b283e21276c", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">A risk to the\nnewborns/infants cannot be excluded.\u00a0 It is recommended that mothers being\ntreated with adefovir dipivoxil do not breast\u2011feed their infants.</span>", "ID": "31e5381c-3317-41f7-9f9f-90431bf3539e", "Styles": "None", "Classes": "None", "Text": "A risk to the newborns/infants cannot be excluded.\u00a0 It is recommended that mothers being treated with adefovir dipivoxil do not breast\u2011feed their infants.", "ParentId": "71666bfc-50c2-4f39-ade0-6b283e21276c"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "48888ab1-ebe1-4363-9e6f-193bbc6f5191", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "970e544e-2bd2-4c3f-b6d8-e46e9db13a85", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "48888ab1-ebe1-4363-9e6f-193bbc6f5191"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Fertility</span></u></i></p>", "ID": "010fe1df-0186-4a85-82db-135afbf8a668", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><u><span lang=\"EN-GB\">Fertility</span></u></i>", "ID": "45190eb8-f3a5-4f86-8e77-347333e359f8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "010fe1df-0186-4a85-82db-135afbf8a668"}, {"Element": "<u><span lang=\"EN-GB\">Fertility</span></u>", "ID": "0ad09bee-c930-4f54-a581-69d6321e31b0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "45190eb8-f3a5-4f86-8e77-347333e359f8"}, {"Element": "<span lang=\"EN-GB\">Fertility</span>", "ID": "380c1dd6-043d-46c6-9d54-cea253c82778", "Styles": "None", "Classes": "None", "Text": "Fertility", "ParentId": "0ad09bee-c930-4f54-a581-69d6321e31b0"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">No human data on\nthe effect of adefovir dipivoxil on fertility are available.\u00a0 Animal studies do\nnot indicate harmful effects of adefovir dipivoxil on male and female\nfertility.</span></p>", "ID": "093d6b80-f48e-4aea-b9a9-45e3cd3d1ff9", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">No human data on\nthe effect of adefovir dipivoxil on fertility are available.\u00a0 Animal studies do\nnot indicate harmful effects of adefovir dipivoxil on male and female\nfertility.</span>", "ID": "4872d214-d0e2-4137-bc58-b498da4e88bc", "Styles": "None", "Classes": "None", "Text": "No human data on the effect of adefovir dipivoxil on fertility are available.\u00a0 Animal studies do not indicate harmful effects of adefovir dipivoxil on male and female fertility.", "ParentId": "093d6b80-f48e-4aea-b9a9-45e3cd3d1ff9"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9342cb32-29bf-4192-894e-e23f3a939fc9", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f971cd6d-b07c-4ddf-bdb2-be0bb4864e30", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9342cb32-29bf-4192-894e-e23f3a939fc9"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.7\u00a0\u00a0\u00a0\u00a0 Effects on ability to drive and use machines</span></b></p>", "ID": "bdea647c-7c89-452a-b7e5-227f5e02a80f", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">4.7\u00a0\u00a0\u00a0\u00a0 Effects on ability to drive and use machines</span></b>", "ID": "6e53484c-c445-48ed-8d70-431dc6d5c120", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bdea647c-7c89-452a-b7e5-227f5e02a80f"}, {"Element": "<span lang=\"EN-GB\">4.7\u00a0\u00a0\u00a0\u00a0 Effects on ability to drive and use machines</span>", "ID": "63987c4c-71bc-48e6-bce9-3f755cb43f76", "Styles": "None", "Classes": "None", "Text": "4.7\u00a0\u00a0\u00a0\u00a0 Effects on ability to drive and use machines", "ParentId": "6e53484c-c445-48ed-8d70-431dc6d5c120"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "da573444-24ed-440a-9ce5-20a062b4cc29", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "92784801-c4b8-4fda-a45e-52c291ac3ed9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "da573444-24ed-440a-9ce5-20a062b4cc29"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">No studies on\nthe effects on the ability to drive and use machines have been performed.\u00a0\nHowever, based on the safety profile and mechanism of action, adefovir\ndipivoxil is expected to have no or negligible influence on these abilities.</span></p>", "ID": "2276a372-7159-491d-a647-87c02422a1f6", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">No studies on\nthe effects on the ability to drive and use machines have been performed.\u00a0\nHowever, based on the safety profile and mechanism of action, adefovir\ndipivoxil is expected to have no or negligible influence on these abilities.</span>", "ID": "de6616c5-bcb5-4485-aa29-4d24729c8785", "Styles": "None", "Classes": "None", "Text": "No studies on the effects on the ability to drive and use machines have been performed.\u00a0 However, based on the safety profile and mechanism of action, adefovir dipivoxil is expected to have no or negligible influence on these abilities.", "ParentId": "2276a372-7159-491d-a647-87c02422a1f6"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "705a1f35-f521-4e5c-8acd-678b178ed8fb", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "93e4604b-44ee-4993-b6ad-5a9ca2ab7675", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "705a1f35-f521-4e5c-8acd-678b178ed8fb"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.8\u00a0\u00a0\u00a0\u00a0 Undesirable effects</span></b></p>", "ID": "0af9121f-9797-489a-a849-6e5d6dbeabac", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">4.8\u00a0\u00a0\u00a0\u00a0 Undesirable effects</span></b>", "ID": "e87b3119-c469-43bd-8c2d-ae3a4856f099", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0af9121f-9797-489a-a849-6e5d6dbeabac"}, {"Element": "<span lang=\"EN-GB\">4.8\u00a0\u00a0\u00a0\u00a0 Undesirable effects</span>", "ID": "82abd0ac-e4af-4e0a-9f96-1cd692d61e5f", "Styles": "None", "Classes": "None", "Text": "4.8\u00a0\u00a0\u00a0\u00a0 Undesirable effects", "ParentId": "e87b3119-c469-43bd-8c2d-ae3a4856f099"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a007f656-b844-42d7-bba9-e6327e30d3c6", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "951fb848-d6e6-4c56-ba40-fbc300ed1d22", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a007f656-b844-42d7-bba9-e6327e30d3c6"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><i><span lang=\"EN-GB\">a. Summary of the safety profile</span></i></b></p>", "ID": "7d132a71-fa39-4f23-8e67-3ca6dfd56a0f", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><i><span lang=\"EN-GB\">a. Summary of the safety profile</span></i></b>", "ID": "d486ca33-cee2-44e9-ae9b-3debf2b6d43e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7d132a71-fa39-4f23-8e67-3ca6dfd56a0f"}, {"Element": "<i><span lang=\"EN-GB\">a. Summary of the safety profile</span></i>", "ID": "1052cb44-06df-426e-bfb5-5f0e0f5bb41d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d486ca33-cee2-44e9-ae9b-3debf2b6d43e"}, {"Element": "<span lang=\"EN-GB\">a. Summary of the safety profile</span>", "ID": "a3a800b5-b4ce-431f-afd0-ca2520c1eb02", "Styles": "None", "Classes": "None", "Text": "a. Summary of the safety profile", "ParentId": "1052cb44-06df-426e-bfb5-5f0e0f5bb41d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In patients with\ncompensated liver disease, the most frequently reported adverse reactions\nduring 48\u00a0weeks of adefovir dipivoxil therapy were asthenia (13\u00a0%),\nheadache (9\u00a0%), abdominal pain (9\u00a0%) and nausea (5\u00a0%).</span></p>", "ID": "cfedfdda-e3d9-46af-b3fb-73508b9a1454", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">In patients with\ncompensated liver disease, the most frequently reported adverse reactions\nduring 48\u00a0weeks of adefovir dipivoxil therapy were asthenia (13\u00a0%),\nheadache (9\u00a0%), abdominal pain (9\u00a0%) and nausea (5\u00a0%).</span>", "ID": "62c8cfdf-e4a5-4697-b67b-f6fe5187f252", "Styles": "None", "Classes": "None", "Text": "In patients with compensated liver disease, the most frequently reported adverse reactions during 48\u00a0weeks of adefovir dipivoxil therapy were asthenia (13\u00a0%), headache (9\u00a0%), abdominal pain (9\u00a0%) and nausea (5\u00a0%).", "ParentId": "cfedfdda-e3d9-46af-b3fb-73508b9a1454"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In patients with\ndecompensated liver disease, the most frequently reported adverse reactions\nduring up to 203\u00a0weeks of adefovir dipivoxil therapy were increased\ncreatinine (7\u00a0%) and asthenia (5\u00a0%).</span></p>", "ID": "b6b0bb89-474c-432d-8b93-c414af630f46", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">In patients with\ndecompensated liver disease, the most frequently reported adverse reactions\nduring up to 203\u00a0weeks of adefovir dipivoxil therapy were increased\ncreatinine (7\u00a0%) and asthenia (5\u00a0%).</span>", "ID": "30804611-f3f5-4af3-8bbf-a683b6e42b08", "Styles": "None", "Classes": "None", "Text": "In patients with decompensated liver disease, the most frequently reported adverse reactions during up to 203\u00a0weeks of adefovir dipivoxil therapy were increased creatinine (7\u00a0%) and asthenia (5\u00a0%).", "ParentId": "b6b0bb89-474c-432d-8b93-c414af630f46"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0a434fe0-4737-4ec8-bd63-4fc3ff1c572d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "234d1666-0a5c-4aba-903a-808c1510e395", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0a434fe0-4737-4ec8-bd63-4fc3ff1c572d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><i><span lang=\"EN-GB\">b. Tabulated summary of adverse reactions</span></i></b></p>", "ID": "c4aa1fe9-ac1c-438f-8756-9964a99bddba", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><i><span lang=\"EN-GB\">b. Tabulated summary of adverse reactions</span></i></b>", "ID": "93af8b8e-2650-4da5-a46c-c21678fedeec", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c4aa1fe9-ac1c-438f-8756-9964a99bddba"}, {"Element": "<i><span lang=\"EN-GB\">b. Tabulated summary of adverse reactions</span></i>", "ID": "a24bafe2-d791-48d2-9df6-cc6b4096281c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "93af8b8e-2650-4da5-a46c-c21678fedeec"}, {"Element": "<span lang=\"EN-GB\">b. Tabulated summary of adverse reactions</span>", "ID": "b084b7c6-b1fc-43e0-a606-335f5aac9dad", "Styles": "None", "Classes": "None", "Text": "b. Tabulated summary of adverse reactions", "ParentId": "a24bafe2-d791-48d2-9df6-cc6b4096281c"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Assessment of adverse reactions is based on experience from\npost-marketing surveillance and from three pivotal clinical studies in patients\nwith chronic hepatitis\u00a0B:</span></p>", "ID": "e8b213c9-9785-4421-9419-6953f513e84c", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Assessment of adverse reactions is based on experience from\npost-marketing surveillance and from three pivotal clinical studies in patients\nwith chronic hepatitis\u00a0B:</span>", "ID": "ef0a3494-e081-489c-92bb-3a65abc2b2aa", "Styles": "None", "Classes": "None", "Text": "Assessment of adverse reactions is based on experience from post-marketing surveillance and from three pivotal clinical studies in patients with chronic hepatitis\u00a0B:", "ParentId": "e8b213c9-9785-4421-9419-6953f513e84c"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a6a610de-9bbc-4c54-835b-34dc18d6d72b", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bb28d77f-37c9-4e70-83f4-c95bafeff220", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a6a610de-9bbc-4c54-835b-34dc18d6d72b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">two placebo\u2011controlled studies in which\n522\u00a0patients with chronic hepatitis\u00a0B and compensated liver disease\nreceived double-blind treatment with 10\u00a0mg adefovir dipivoxil (n=294) or\nplacebo (n=228) for 48\u00a0weeks.</span></p>", "ID": "7ef0a492-4c5f-47d9-8570-4c75754e767a", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "0750a439-1584-4bf4-b6f0-4158903dafea", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "7ef0a492-4c5f-47d9-8570-4c75754e767a"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "c366a00c-52a6-498c-952a-80da7cb2b48d", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "0750a439-1584-4bf4-b6f0-4158903dafea"}, {"Element": "<span lang=\"EN-GB\">two placebo\u2011controlled studies in which\n522\u00a0patients with chronic hepatitis\u00a0B and compensated liver disease\nreceived double-blind treatment with 10\u00a0mg adefovir dipivoxil (n=294) or\nplacebo (n=228) for 48\u00a0weeks.</span>", "ID": "2e7c64d6-1b7d-4644-84c2-cfea14075821", "Styles": "None", "Classes": "None", "Text": "two placebo\u2011controlled studies in which 522\u00a0patients with chronic hepatitis\u00a0B and compensated liver disease received double-blind treatment with 10\u00a0mg adefovir dipivoxil (n=294) or placebo (n=228) for 48\u00a0weeks.", "ParentId": "7ef0a492-4c5f-47d9-8570-4c75754e767a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">an open-label study in which pre\u2011 (n=226)\nand post\u2011liver transplantation patients (n=241) with lamivudine-resistant\nHBV were treated with 10\u00a0mg adefovir dipivoxil once daily, for up to\n203\u00a0weeks (median 51 and 99\u00a0weeks, respectively).</span></p>", "ID": "5c32a956-174a-42b1-9e2c-6071a8ca504d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "d0c9ae8e-25fc-467d-b839-d50dc4fe9b94", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "5c32a956-174a-42b1-9e2c-6071a8ca504d"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "ec56bb06-8bfc-41c3-b864-c4e8fdd920a9", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "d0c9ae8e-25fc-467d-b839-d50dc4fe9b94"}, {"Element": "<span lang=\"EN-GB\">an open-label study in which pre\u2011 (n=226)\nand post\u2011liver transplantation patients (n=241) with lamivudine-resistant\nHBV were treated with 10\u00a0mg adefovir dipivoxil once daily, for up to\n203\u00a0weeks (median 51 and 99\u00a0weeks, respectively).</span>", "ID": "0c966c57-ef62-4929-8f2c-bd05e44ba629", "Styles": "None", "Classes": "None", "Text": "an open-label study in which pre\u2011 (n=226) and post\u2011liver transplantation patients (n=241) with lamivudine-resistant HBV were treated with 10\u00a0mg adefovir dipivoxil once daily, for up to 203\u00a0weeks (median 51 and 99\u00a0weeks, respectively).", "ParentId": "5c32a956-174a-42b1-9e2c-6071a8ca504d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4b9743b2-e6e7-49e3-bfd4-8e1f95362d04", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6cf661d2-bbd8-42a5-a0d9-ca90e7f537df", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4b9743b2-e6e7-49e3-bfd4-8e1f95362d04"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The adverse\nreactions considered at least possibly related to treatment are listed below,\nby body system organ class, and frequency (see Table\u00a01).\u00a0 Within each\nfrequency grouping, undesirable effects are presented in order of decreasing\nseriousness.\u00a0 Frequencies are defined as very common (\u2265\u00a01/10),\ncommon (\u2265\u00a01/100, &lt;\u00a01/10) or not known (identified through\npost-marketing safety surveillance and the frequency cannot be estimated from\nthe available data).</span></p>", "ID": "5e985d55-427e-4ee1-b4e6-934c284dc6e3", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">The adverse\nreactions considered at least possibly related to treatment are listed below,\nby body system organ class, and frequency (see Table\u00a01).\u00a0 Within each\nfrequency grouping, undesirable effects are presented in order of decreasing\nseriousness.\u00a0 Frequencies are defined as very common (\u2265\u00a01/10),\ncommon (\u2265\u00a01/100, &lt;\u00a01/10) or not known (identified through\npost-marketing safety surveillance and the frequency cannot be estimated from\nthe available data).</span>", "ID": "b3fcf215-92a6-449b-b630-b7a670eab0b6", "Styles": "None", "Classes": "None", "Text": "The adverse reactions considered at least possibly related to treatment are listed below, by body system organ class, and frequency (see Table\u00a01).\u00a0 Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.\u00a0 Frequencies are defined as very common (\u2265\u00a01/10), common (\u2265\u00a01/100, <\u00a01/10) or not known (identified through post-marketing safety surveillance and the frequency cannot be estimated from the available data).", "ParentId": "5e985d55-427e-4ee1-b4e6-934c284dc6e3"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "36a46409-59c1-4be0-b0f6-ca80b84dd2d4", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "babd5f40-f949-49e7-a113-3a1685e1f169", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "36a46409-59c1-4be0-b0f6-ca80b84dd2d4"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><a name=\"OLE_LINK7\"></a><a name=\"OLE_LINK8\"><b><span lang=\"EN-GB\">Table\u00a01:\nTabulated summary of adverse reactions associated with adefovir dipivoxil based\non clinical study and post\u2011marketing experience</span></b></a></p>", "ID": "f8edbe28-1f5e-46be-b713-5b3c3d289ead", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<a name=\"OLE_LINK7\"></a>", "ID": "e862cd59-9904-480b-b4d8-0a6e10615836", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f8edbe28-1f5e-46be-b713-5b3c3d289ead"}, {"Element": "<a name=\"OLE_LINK8\"><b><span lang=\"EN-GB\">Table\u00a01:\nTabulated summary of adverse reactions associated with adefovir dipivoxil based\non clinical study and post\u2011marketing experience</span></b></a>", "ID": "6b90b2ab-aa84-42a0-a7d0-c3171c9eebbd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f8edbe28-1f5e-46be-b713-5b3c3d289ead"}, {"Element": "<b><span lang=\"EN-GB\">Table\u00a01:\nTabulated summary of adverse reactions associated with adefovir dipivoxil based\non clinical study and post\u2011marketing experience</span></b>", "ID": "66f93819-52e4-4d36-80c6-97aa6cd45e60", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6b90b2ab-aa84-42a0-a7d0-c3171c9eebbd"}, {"Element": "<span lang=\"EN-GB\">Table\u00a01:\nTabulated summary of adverse reactions associated with adefovir dipivoxil based\non clinical study and post\u2011marketing experience</span>", "ID": "f95f7de3-3f02-4d66-a68c-8bca2f566e4f", "Styles": "None", "Classes": "None", "Text": "Table\u00a01: Tabulated summary of adverse reactions associated with adefovir dipivoxil based on clinical study and post\u2011marketing experience", "ParentId": "66f93819-52e4-4d36-80c6-97aa6cd45e60"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "d5b4e5c1-97ba-4d27-aa25-7533e09ff33d", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "a91a0af5-9d68-46d9-b7f2-ace28b3c61d0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d5b4e5c1-97ba-4d27-aa25-7533e09ff33d"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "47ef780d-0816-4448-96bf-79e8d043cb9d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a91a0af5-9d68-46d9-b7f2-ace28b3c61d0"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:100.0%;border-collapse:collapse;border:none\" width=\"100%\">\n<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;padding:\n  0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Frequency</span></b></p>\n</td>\n<td style=\"width:80.52%;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Adefovir dipivoxil</span></b></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Nervous system disorders:</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:80.52%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Headache</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Gastrointestinal disorders:</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:80.52%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Diarrhoea, vomiting,\n  abdominal pain, dyspepsia, nausea, flatulence</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Not known:</span></p>\n</td>\n<td style=\"width:80.52%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Pancreatitis</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Skin and subcutaneous tissue disorders:</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:80.52%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Rash, pruritus</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Musculoskeletal and connective tissue\n  disorders:</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Not known:</span></p>\n</td>\n<td style=\"width:80.52%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Osteomalacia (manifested as bone pain and infrequently\n  contributing to fractures) and myopathy, both associated with proximal renal\n  tubulopathy</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Renal and urinary disorders:</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Very common:</span></p>\n</td>\n<td style=\"width:80.52%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Increases in\n  creatinine</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:80.52%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Renal failure, abnormal renal function, hypophosphatemia</span></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Not known:</span></p>\n</td>\n<td style=\"width:80.52%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Fanconi syndrome, proximal renal tubulopathy</span></p>\n</td>\n</tr>\n<tr>\n<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">General disorders and administration site\n  conditions:</span></i></p>\n</td>\n</tr>\n<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Very common:</span></p>\n</td>\n<td style=\"width:80.52%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Asthenia</span></p>\n</td>\n</tr>\n</table>", "ID": "320ff142-4955-4ad4-9601-609171db89a2", "Styles": "width:100.0%;border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "                 ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;padding:\n  0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Frequency</span></b></p>\n</td>\n<td style=\"width:80.52%;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Adefovir dipivoxil</span></b></p>\n</td>\n</tr>", "ID": "b9cc57c6-b4ba-4905-a44c-325376d4bcf9", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "320ff142-4955-4ad4-9601-609171db89a2"}, {"Element": "<td style=\"width:19.48%;border:solid windowtext 1.0pt;padding:\n  0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Frequency</span></b></p>\n</td>", "ID": "fe909428-edd0-4553-9fb9-0c469f10e3aa", "Styles": "width:19.48%;border:solid windowtext 1.0pt;padding:\n  0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b9cc57c6-b4ba-4905-a44c-325376d4bcf9"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Frequency</span></b></p>", "ID": "941d9fc1-85b1-4679-b1b1-723f35fae644", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fe909428-edd0-4553-9fb9-0c469f10e3aa"}, {"Element": "<b><span lang=\"EN-GB\">Frequency</span></b>", "ID": "36a30e34-6ff7-42dc-a558-8b26f50b68dc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "941d9fc1-85b1-4679-b1b1-723f35fae644"}, {"Element": "<span lang=\"EN-GB\">Frequency</span>", "ID": "ee114bdc-1326-441b-9712-7fa0d1f33cd2", "Styles": "None", "Classes": "None", "Text": "Frequency", "ParentId": "36a30e34-6ff7-42dc-a558-8b26f50b68dc"}, {"Element": "<td style=\"width:80.52%;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Adefovir dipivoxil</span></b></p>\n</td>", "ID": "7a0096f1-60c4-4859-b2ce-de9e37450265", "Styles": "width:80.52%;border:solid windowtext 1.0pt;border-left:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b9cc57c6-b4ba-4905-a44c-325376d4bcf9"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Adefovir dipivoxil</span></b></p>", "ID": "4f481354-3b34-4200-b1b8-f841554dba60", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7a0096f1-60c4-4859-b2ce-de9e37450265"}, {"Element": "<b><span lang=\"EN-GB\">Adefovir dipivoxil</span></b>", "ID": "2ae06682-5f6a-40ea-bdea-7b2176cc65fa", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4f481354-3b34-4200-b1b8-f841554dba60"}, {"Element": "<span lang=\"EN-GB\">Adefovir dipivoxil</span>", "ID": "f9b95d8d-b5ff-4943-a6cf-f36253b272a6", "Styles": "None", "Classes": "None", "Text": "Adefovir dipivoxil", "ParentId": "2ae06682-5f6a-40ea-bdea-7b2176cc65fa"}, {"Element": "<tr>\n<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Nervous system disorders:</span></i></p>\n</td>\n</tr>", "ID": "01e0364a-0c45-49eb-8f4c-44d0f675823e", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "320ff142-4955-4ad4-9601-609171db89a2"}, {"Element": "<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Nervous system disorders:</span></i></p>\n</td>", "ID": "dbb016b8-661b-43ba-8557-7f87c75fbaf8", "Styles": "width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "01e0364a-0c45-49eb-8f4c-44d0f675823e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Nervous system disorders:</span></i></p>", "ID": "8a2145e8-d7ce-4f7c-8a1b-4e02adb7fd4a", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dbb016b8-661b-43ba-8557-7f87c75fbaf8"}, {"Element": "<i><span lang=\"EN-GB\" style=\"color:black\">Nervous system disorders:</span></i>", "ID": "c0e5fc62-24b8-4b04-bfe0-50778307dbd2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8a2145e8-d7ce-4f7c-8a1b-4e02adb7fd4a"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Nervous system disorders:</span>", "ID": "57671a4c-4bd7-421c-a667-7edb7e68fa80", "Styles": "color:black", "Classes": "None", "Text": "Nervous system disorders:", "ParentId": "c0e5fc62-24b8-4b04-bfe0-50778307dbd2"}, {"Element": "<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:80.52%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Headache</span></p>\n</td>\n</tr>", "ID": "9fd79ddd-c0e2-4e58-b112-9ae112c4c55a", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "320ff142-4955-4ad4-9601-609171db89a2"}, {"Element": "<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p>\n</td>", "ID": "978c26d6-3ba0-4a7c-b4ee-0c197e35d0ea", "Styles": "width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "9fd79ddd-c0e2-4e58-b112-9ae112c4c55a"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p>", "ID": "66aed0fa-7df8-497d-926a-d70446d43f1f", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "978c26d6-3ba0-4a7c-b4ee-0c197e35d0ea"}, {"Element": "<span lang=\"EN-GB\">Common:</span>", "ID": "39e5836e-8c6f-44bc-b831-42a85cfcf056", "Styles": "None", "Classes": "None", "Text": "Common:", "ParentId": "66aed0fa-7df8-497d-926a-d70446d43f1f"}, {"Element": "<td style=\"width:80.52%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Headache</span></p>\n</td>", "ID": "1a682995-c7c4-441d-8461-98c29cc94411", "Styles": "width:80.52%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "9fd79ddd-c0e2-4e58-b112-9ae112c4c55a"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Headache</span></p>", "ID": "6da8670c-e036-4a86-a74f-1dad12413a63", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1a682995-c7c4-441d-8461-98c29cc94411"}, {"Element": "<span lang=\"EN-GB\">Headache</span>", "ID": "ffab1387-04e9-4762-9933-c0eb09ad7de2", "Styles": "None", "Classes": "None", "Text": "Headache", "ParentId": "6da8670c-e036-4a86-a74f-1dad12413a63"}, {"Element": "<tr>\n<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Gastrointestinal disorders:</span></i></p>\n</td>\n</tr>", "ID": "6612b42a-982c-4bc2-9663-22b3dae337ed", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "320ff142-4955-4ad4-9601-609171db89a2"}, {"Element": "<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Gastrointestinal disorders:</span></i></p>\n</td>", "ID": "d5d96ad3-6fe5-49ae-b61c-6c5913ebe11f", "Styles": "width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6612b42a-982c-4bc2-9663-22b3dae337ed"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Gastrointestinal disorders:</span></i></p>", "ID": "d7102258-3fef-473e-80d6-d7bdd798202e", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d5d96ad3-6fe5-49ae-b61c-6c5913ebe11f"}, {"Element": "<i><span lang=\"EN-GB\" style=\"color:black\">Gastrointestinal disorders:</span></i>", "ID": "17409aec-cc60-40da-b829-a8265dff5194", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d7102258-3fef-473e-80d6-d7bdd798202e"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Gastrointestinal disorders:</span>", "ID": "bdfdfd54-5881-42ec-a54d-1b97049232ab", "Styles": "color:black", "Classes": "None", "Text": "Gastrointestinal disorders:", "ParentId": "17409aec-cc60-40da-b829-a8265dff5194"}, {"Element": "<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:80.52%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Diarrhoea, vomiting,\n  abdominal pain, dyspepsia, nausea, flatulence</span></p>\n</td>\n</tr>", "ID": "3a4c527a-2f49-4608-b3a8-702dc3076b83", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "320ff142-4955-4ad4-9601-609171db89a2"}, {"Element": "<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p>\n</td>", "ID": "1bc8a78c-a086-4395-9834-8649537fd4ea", "Styles": "width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3a4c527a-2f49-4608-b3a8-702dc3076b83"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p>", "ID": "ad917880-0304-4b26-8b5b-f8a45782d72a", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1bc8a78c-a086-4395-9834-8649537fd4ea"}, {"Element": "<span lang=\"EN-GB\">Common:</span>", "ID": "6ba500f2-88e2-4845-900b-5947def482f9", "Styles": "None", "Classes": "None", "Text": "Common:", "ParentId": "ad917880-0304-4b26-8b5b-f8a45782d72a"}, {"Element": "<td style=\"width:80.52%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Diarrhoea, vomiting,\n  abdominal pain, dyspepsia, nausea, flatulence</span></p>\n</td>", "ID": "61222243-1d45-4383-94f8-9c38d8b07e13", "Styles": "width:80.52%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3a4c527a-2f49-4608-b3a8-702dc3076b83"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Diarrhoea, vomiting,\n  abdominal pain, dyspepsia, nausea, flatulence</span></p>", "ID": "bcae3e25-64e8-4e4b-8bb4-cad0084f8001", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "61222243-1d45-4383-94f8-9c38d8b07e13"}, {"Element": "<span lang=\"EN-GB\">Diarrhoea, vomiting,\n  abdominal pain, dyspepsia, nausea, flatulence</span>", "ID": "f118631c-8c4b-45ad-99c9-244676249b91", "Styles": "None", "Classes": "None", "Text": "Diarrhoea, vomiting,   abdominal pain, dyspepsia, nausea, flatulence", "ParentId": "bcae3e25-64e8-4e4b-8bb4-cad0084f8001"}, {"Element": "<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Not known:</span></p>\n</td>\n<td style=\"width:80.52%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Pancreatitis</span></p>\n</td>\n</tr>", "ID": "6612846c-d169-4b92-931b-6c52b3fb15f6", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "320ff142-4955-4ad4-9601-609171db89a2"}, {"Element": "<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Not known:</span></p>\n</td>", "ID": "394a4883-348e-4c34-9d1a-de29d4fc61f4", "Styles": "width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6612846c-d169-4b92-931b-6c52b3fb15f6"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Not known:</span></p>", "ID": "8d731264-923f-44a3-9c1a-8a4989ac5922", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "394a4883-348e-4c34-9d1a-de29d4fc61f4"}, {"Element": "<span lang=\"EN-GB\">Not known:</span>", "ID": "d6a6d644-1b42-464b-a3f8-2bd7db86e08e", "Styles": "None", "Classes": "None", "Text": "Not known:", "ParentId": "8d731264-923f-44a3-9c1a-8a4989ac5922"}, {"Element": "<td style=\"width:80.52%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Pancreatitis</span></p>\n</td>", "ID": "70273e36-88c6-4543-ab39-31b2019a15b7", "Styles": "width:80.52%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6612846c-d169-4b92-931b-6c52b3fb15f6"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Pancreatitis</span></p>", "ID": "94b4ad61-fbed-423b-9a02-6acc2b908ab2", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "70273e36-88c6-4543-ab39-31b2019a15b7"}, {"Element": "<span lang=\"EN-GB\">Pancreatitis</span>", "ID": "996ad38a-fe00-415c-b521-5090a827141e", "Styles": "None", "Classes": "None", "Text": "Pancreatitis", "ParentId": "94b4ad61-fbed-423b-9a02-6acc2b908ab2"}, {"Element": "<tr>\n<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Skin and subcutaneous tissue disorders:</span></i></p>\n</td>\n</tr>", "ID": "af9084ae-808e-469b-b56b-a6f07c8bb24e", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "320ff142-4955-4ad4-9601-609171db89a2"}, {"Element": "<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Skin and subcutaneous tissue disorders:</span></i></p>\n</td>", "ID": "1d859276-5743-473e-b2ec-c1f376dff0ab", "Styles": "width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "af9084ae-808e-469b-b56b-a6f07c8bb24e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Skin and subcutaneous tissue disorders:</span></i></p>", "ID": "5a7935ec-90f0-4da7-8c2f-4c5379b0effb", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1d859276-5743-473e-b2ec-c1f376dff0ab"}, {"Element": "<i><span lang=\"EN-GB\" style=\"color:black\">Skin and subcutaneous tissue disorders:</span></i>", "ID": "bfc2bd70-b82a-4307-b395-b481cbe67796", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5a7935ec-90f0-4da7-8c2f-4c5379b0effb"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Skin and subcutaneous tissue disorders:</span>", "ID": "dab89000-6344-4262-add3-1df9c96833cd", "Styles": "color:black", "Classes": "None", "Text": "Skin and subcutaneous tissue disorders:", "ParentId": "bfc2bd70-b82a-4307-b395-b481cbe67796"}, {"Element": "<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:80.52%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Rash, pruritus</span></p>\n</td>\n</tr>", "ID": "7cf07a74-b0e4-4199-bab1-c15d08306405", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "320ff142-4955-4ad4-9601-609171db89a2"}, {"Element": "<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p>\n</td>", "ID": "43761c38-a58c-4e00-bfc5-9ea86b34c07c", "Styles": "width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7cf07a74-b0e4-4199-bab1-c15d08306405"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p>", "ID": "e0e7e33b-c1de-470d-8ef4-d32cb2ddba0c", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "43761c38-a58c-4e00-bfc5-9ea86b34c07c"}, {"Element": "<span lang=\"EN-GB\">Common:</span>", "ID": "d55c377f-9768-4ab4-b7fe-b9cebe9ec946", "Styles": "None", "Classes": "None", "Text": "Common:", "ParentId": "e0e7e33b-c1de-470d-8ef4-d32cb2ddba0c"}, {"Element": "<td style=\"width:80.52%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Rash, pruritus</span></p>\n</td>", "ID": "5570b96d-31f2-4b53-9af5-f884d3a7c7cf", "Styles": "width:80.52%;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7cf07a74-b0e4-4199-bab1-c15d08306405"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Rash, pruritus</span></p>", "ID": "55214697-14c0-431f-8301-7d8e2a314a01", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5570b96d-31f2-4b53-9af5-f884d3a7c7cf"}, {"Element": "<span lang=\"EN-GB\">Rash, pruritus</span>", "ID": "ef336235-677c-4d9e-a004-c509e4d0f397", "Styles": "None", "Classes": "None", "Text": "Rash, pruritus", "ParentId": "55214697-14c0-431f-8301-7d8e2a314a01"}, {"Element": "<tr>\n<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Musculoskeletal and connective tissue\n  disorders:</span></i></p>\n</td>\n</tr>", "ID": "82b5925c-c12e-4d66-bf39-4171320841ee", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "320ff142-4955-4ad4-9601-609171db89a2"}, {"Element": "<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Musculoskeletal and connective tissue\n  disorders:</span></i></p>\n</td>", "ID": "bbe62cfb-211e-4b68-a489-2f8c5c9ea80f", "Styles": "width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "82b5925c-c12e-4d66-bf39-4171320841ee"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Musculoskeletal and connective tissue\n  disorders:</span></i></p>", "ID": "77fcf4d1-2ec3-4ee1-bfbf-ad117a5cb77a", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bbe62cfb-211e-4b68-a489-2f8c5c9ea80f"}, {"Element": "<i><span lang=\"EN-GB\" style=\"color:black\">Musculoskeletal and connective tissue\n  disorders:</span></i>", "ID": "99a77b14-6a23-432d-a933-537a4de40738", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "77fcf4d1-2ec3-4ee1-bfbf-ad117a5cb77a"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Musculoskeletal and connective tissue\n  disorders:</span>", "ID": "bad497d6-3f4a-47f5-9735-b9cfdaae1f32", "Styles": "color:black", "Classes": "None", "Text": "Musculoskeletal and connective tissue   disorders:", "ParentId": "99a77b14-6a23-432d-a933-537a4de40738"}, {"Element": "<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Not known:</span></p>\n</td>\n<td style=\"width:80.52%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Osteomalacia (manifested as bone pain and infrequently\n  contributing to fractures) and myopathy, both associated with proximal renal\n  tubulopathy</span></p>\n</td>\n</tr>", "ID": "d90b8260-c719-47f1-88c5-402fc1f6b6dc", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "320ff142-4955-4ad4-9601-609171db89a2"}, {"Element": "<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Not known:</span></p>\n</td>", "ID": "ec0050b5-059f-4dd8-8ea9-ec5b1e0f1e12", "Styles": "width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d90b8260-c719-47f1-88c5-402fc1f6b6dc"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Not known:</span></p>", "ID": "907f1cba-754f-4616-b484-01afdd239e4f", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ec0050b5-059f-4dd8-8ea9-ec5b1e0f1e12"}, {"Element": "<span lang=\"EN-GB\">Not known:</span>", "ID": "9b743913-bc9d-4557-964b-c52c4697de67", "Styles": "None", "Classes": "None", "Text": "Not known:", "ParentId": "907f1cba-754f-4616-b484-01afdd239e4f"}, {"Element": "<td style=\"width:80.52%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Osteomalacia (manifested as bone pain and infrequently\n  contributing to fractures) and myopathy, both associated with proximal renal\n  tubulopathy</span></p>\n</td>", "ID": "f796f795-887c-4c76-b7a8-0cdce4d8dc30", "Styles": "width:80.52%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d90b8260-c719-47f1-88c5-402fc1f6b6dc"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Osteomalacia (manifested as bone pain and infrequently\n  contributing to fractures) and myopathy, both associated with proximal renal\n  tubulopathy</span></p>", "ID": "442381d3-01c5-4456-b6a0-31537fa2ca64", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f796f795-887c-4c76-b7a8-0cdce4d8dc30"}, {"Element": "<span lang=\"EN-GB\">Osteomalacia (manifested as bone pain and infrequently\n  contributing to fractures) and myopathy, both associated with proximal renal\n  tubulopathy</span>", "ID": "5d3f4409-345a-4bd6-a05e-bc5a4d4c815c", "Styles": "None", "Classes": "None", "Text": "Osteomalacia (manifested as bone pain and infrequently   contributing to fractures) and myopathy, both associated with proximal renal   tubulopathy", "ParentId": "442381d3-01c5-4456-b6a0-31537fa2ca64"}, {"Element": "<tr>\n<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Renal and urinary disorders:</span></i></p>\n</td>\n</tr>", "ID": "0fc4f836-3a34-473a-84f9-29c0c3002fb3", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "320ff142-4955-4ad4-9601-609171db89a2"}, {"Element": "<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Renal and urinary disorders:</span></i></p>\n</td>", "ID": "f2cb1509-f9a6-43ac-8459-c33d0e200310", "Styles": "width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "0fc4f836-3a34-473a-84f9-29c0c3002fb3"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">Renal and urinary disorders:</span></i></p>", "ID": "a4e70a5b-2c4f-4102-91f8-45f68b923822", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f2cb1509-f9a6-43ac-8459-c33d0e200310"}, {"Element": "<i><span lang=\"EN-GB\" style=\"color:black\">Renal and urinary disorders:</span></i>", "ID": "3d5160c8-efdb-4df0-8101-14d18468b324", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a4e70a5b-2c4f-4102-91f8-45f68b923822"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Renal and urinary disorders:</span>", "ID": "35dff460-762a-4c37-bce4-bb885b9ee29d", "Styles": "color:black", "Classes": "None", "Text": "Renal and urinary disorders:", "ParentId": "3d5160c8-efdb-4df0-8101-14d18468b324"}, {"Element": "<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Very common:</span></p>\n</td>\n<td style=\"width:80.52%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Increases in\n  creatinine</span></p>\n</td>\n</tr>", "ID": "2ae1bfbd-84bd-423e-bd44-38d09c7deeb6", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "320ff142-4955-4ad4-9601-609171db89a2"}, {"Element": "<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Very common:</span></p>\n</td>", "ID": "b0484d95-20af-43b3-b189-07eb53ef7af7", "Styles": "width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2ae1bfbd-84bd-423e-bd44-38d09c7deeb6"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Very common:</span></p>", "ID": "2a5a988d-21ea-46ca-bf33-b66de37c9d5f", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b0484d95-20af-43b3-b189-07eb53ef7af7"}, {"Element": "<span lang=\"EN-GB\">Very common:</span>", "ID": "76aac168-a1e2-4b14-bde2-d64d5a71d05f", "Styles": "None", "Classes": "None", "Text": "Very common:", "ParentId": "2a5a988d-21ea-46ca-bf33-b66de37c9d5f"}, {"Element": "<td style=\"width:80.52%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Increases in\n  creatinine</span></p>\n</td>", "ID": "f54c8d71-11ec-40dc-9e88-cc3e2271359e", "Styles": "width:80.52%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2ae1bfbd-84bd-423e-bd44-38d09c7deeb6"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Increases in\n  creatinine</span></p>", "ID": "bc39fae3-0493-4a43-a065-246833fdf8cb", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f54c8d71-11ec-40dc-9e88-cc3e2271359e"}, {"Element": "<span lang=\"EN-GB\">Increases in\n  creatinine</span>", "ID": "b53ef151-073c-4630-b083-32dfc14d4a54", "Styles": "None", "Classes": "None", "Text": "Increases in   creatinine", "ParentId": "bc39fae3-0493-4a43-a065-246833fdf8cb"}, {"Element": "<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:80.52%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Renal failure, abnormal renal function, hypophosphatemia</span></p>\n</td>\n</tr>", "ID": "d661e1a8-ba1f-451c-88fa-11dd107c2f64", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "320ff142-4955-4ad4-9601-609171db89a2"}, {"Element": "<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p>\n</td>", "ID": "7e1ac2a1-71dd-43d4-9b03-44c64b53e6a5", "Styles": "width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d661e1a8-ba1f-451c-88fa-11dd107c2f64"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Common:</span></p>", "ID": "6ea61947-df10-4b00-b9ef-3c055888db6c", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7e1ac2a1-71dd-43d4-9b03-44c64b53e6a5"}, {"Element": "<span lang=\"EN-GB\">Common:</span>", "ID": "8e8f9575-efe3-4cb1-b87e-ff2b5da19d0a", "Styles": "None", "Classes": "None", "Text": "Common:", "ParentId": "6ea61947-df10-4b00-b9ef-3c055888db6c"}, {"Element": "<td style=\"width:80.52%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Renal failure, abnormal renal function, hypophosphatemia</span></p>\n</td>", "ID": "fd9f3672-cef8-4ba5-88ab-1b69b8f267a8", "Styles": "width:80.52%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d661e1a8-ba1f-451c-88fa-11dd107c2f64"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Renal failure, abnormal renal function, hypophosphatemia</span></p>", "ID": "5122beb0-0db3-4beb-a91e-d469c4ec01a5", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fd9f3672-cef8-4ba5-88ab-1b69b8f267a8"}, {"Element": "<span lang=\"EN-GB\">Renal failure, abnormal renal function, hypophosphatemia</span>", "ID": "95deac6a-5c03-4b65-9ec8-c9cb42f30d3a", "Styles": "None", "Classes": "None", "Text": "Renal failure, abnormal renal function, hypophosphatemia", "ParentId": "5122beb0-0db3-4beb-a91e-d469c4ec01a5"}, {"Element": "<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Not known:</span></p>\n</td>\n<td style=\"width:80.52%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Fanconi syndrome, proximal renal tubulopathy</span></p>\n</td>\n</tr>", "ID": "fb885b30-badc-45b0-a4aa-9a3d293f77a0", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "320ff142-4955-4ad4-9601-609171db89a2"}, {"Element": "<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Not known:</span></p>\n</td>", "ID": "aa1143ad-2dcb-450a-82f1-4fc30fad07fe", "Styles": "width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "fb885b30-badc-45b0-a4aa-9a3d293f77a0"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Not known:</span></p>", "ID": "e8fd702b-5523-408e-8e9d-442210c69cb7", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "aa1143ad-2dcb-450a-82f1-4fc30fad07fe"}, {"Element": "<span lang=\"EN-GB\">Not known:</span>", "ID": "2cbc94f0-3966-4888-83af-ac398c9d3490", "Styles": "None", "Classes": "None", "Text": "Not known:", "ParentId": "e8fd702b-5523-408e-8e9d-442210c69cb7"}, {"Element": "<td style=\"width:80.52%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Fanconi syndrome, proximal renal tubulopathy</span></p>\n</td>", "ID": "3cf6ac04-ca9a-4d83-a1ec-9fbcaefe62c4", "Styles": "width:80.52%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "fb885b30-badc-45b0-a4aa-9a3d293f77a0"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Fanconi syndrome, proximal renal tubulopathy</span></p>", "ID": "91e16a61-603d-4b96-a906-ed0709ecce36", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3cf6ac04-ca9a-4d83-a1ec-9fbcaefe62c4"}, {"Element": "<span lang=\"EN-GB\">Fanconi syndrome, proximal renal tubulopathy</span>", "ID": "d96e87a3-d661-4684-8acc-2937cdeda408", "Styles": "None", "Classes": "None", "Text": "Fanconi syndrome, proximal renal tubulopathy", "ParentId": "91e16a61-603d-4b96-a906-ed0709ecce36"}, {"Element": "<tr>\n<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">General disorders and administration site\n  conditions:</span></i></p>\n</td>\n</tr>", "ID": "452bc911-1545-4f83-9352-c31418d2dbb5", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "320ff142-4955-4ad4-9601-609171db89a2"}, {"Element": "<td colspan=\"2\" style=\"width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">General disorders and administration site\n  conditions:</span></i></p>\n</td>", "ID": "e6ee0499-11d3-438d-bbd8-20259b0b9d17", "Styles": "width:100.0%;border:solid windowtext 1.0pt;\n  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "452bc911-1545-4f83-9352-c31418d2dbb5"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\" style=\"color:black\">General disorders and administration site\n  conditions:</span></i></p>", "ID": "42ea5442-ff5e-4001-b45a-aa6cf9b77b98", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e6ee0499-11d3-438d-bbd8-20259b0b9d17"}, {"Element": "<i><span lang=\"EN-GB\" style=\"color:black\">General disorders and administration site\n  conditions:</span></i>", "ID": "9854c279-fd79-419a-8573-bfc06fbc2a03", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "42ea5442-ff5e-4001-b45a-aa6cf9b77b98"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">General disorders and administration site\n  conditions:</span>", "ID": "3a585198-0285-48b3-87ca-27afcda070f1", "Styles": "color:black", "Classes": "None", "Text": "General disorders and administration site   conditions:", "ParentId": "9854c279-fd79-419a-8573-bfc06fbc2a03"}, {"Element": "<tr>\n<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Very common:</span></p>\n</td>\n<td style=\"width:80.52%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Asthenia</span></p>\n</td>\n</tr>", "ID": "3ebb7dbc-a9ec-42e8-9c32-06982c41e8ab", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "320ff142-4955-4ad4-9601-609171db89a2"}, {"Element": "<td style=\"width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt\" width=\"19%\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Very common:</span></p>\n</td>", "ID": "085970f0-cc5c-4db1-87a9-cdc9a73853f6", "Styles": "width:19.48%;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3ebb7dbc-a9ec-42e8-9c32-06982c41e8ab"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Very common:</span></p>", "ID": "c6b3450c-dd80-48a2-bbd9-a5b4325fd08a", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "085970f0-cc5c-4db1-87a9-cdc9a73853f6"}, {"Element": "<span lang=\"EN-GB\">Very common:</span>", "ID": "0002a295-8ff7-4d65-a530-098286363ad7", "Styles": "None", "Classes": "None", "Text": "Very common:", "ParentId": "c6b3450c-dd80-48a2-bbd9-a5b4325fd08a"}, {"Element": "<td style=\"width:80.52%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80%\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Asthenia</span></p>\n</td>", "ID": "4e996550-0068-41d2-8260-8793b4e4dd96", "Styles": "width:80.52%;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3ebb7dbc-a9ec-42e8-9c32-06982c41e8ab"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Asthenia</span></p>", "ID": "c3c51c9f-9802-4839-be36-69306ef2d5a4", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4e996550-0068-41d2-8260-8793b4e4dd96"}, {"Element": "<span lang=\"EN-GB\">Asthenia</span>", "ID": "2f9b7ddf-abe6-4428-83fc-87fcfa7a3883", "Styles": "None", "Classes": "None", "Text": "Asthenia", "ParentId": "c3c51c9f-9802-4839-be36-69306ef2d5a4"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cb879f79-3c8b-4c4c-90a6-9e94b4d7101f", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8f427742-fd85-4b86-9dd2-0033cf635531", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cb879f79-3c8b-4c4c-90a6-9e94b4d7101f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><i><span lang=\"EN-GB\">c. Description of selected adverse reactions</span></i></b></p>", "ID": "d89a020e-e5f0-4ace-9667-d1ff8ee1f3a4", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><i><span lang=\"EN-GB\">c. Description of selected adverse reactions</span></i></b>", "ID": "5a445583-9d29-437a-92af-79b7ca4cedb0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d89a020e-e5f0-4ace-9667-d1ff8ee1f3a4"}, {"Element": "<i><span lang=\"EN-GB\">c. Description of selected adverse reactions</span></i>", "ID": "4fb85e0f-96e1-4bd6-b524-3e2b869264d6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5a445583-9d29-437a-92af-79b7ca4cedb0"}, {"Element": "<span lang=\"EN-GB\">c. Description of selected adverse reactions</span>", "ID": "2827f730-c4cd-4501-8289-49e1e6c3ce7d", "Styles": "None", "Classes": "None", "Text": "c. Description of selected adverse reactions", "ParentId": "4fb85e0f-96e1-4bd6-b524-3e2b869264d6"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Exacerbation of hepatitis:</span></i></p>", "ID": "82d5be37-7c17-44ff-9633-8e6bfd9ecefa", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Exacerbation of hepatitis:</span></i>", "ID": "1b51359a-7334-4122-ae31-b9f723a90581", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "82d5be37-7c17-44ff-9633-8e6bfd9ecefa"}, {"Element": "<span lang=\"EN-GB\">Exacerbation of hepatitis:</span>", "ID": "1e01a831-77c0-423a-9176-cd55b704821f", "Styles": "None", "Classes": "None", "Text": "Exacerbation of hepatitis:", "ParentId": "1b51359a-7334-4122-ae31-b9f723a90581"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Clinical and\nlaboratory evidence of exacerbations of hepatitis have occurred after\ndiscontinuation of treatment with 10\u00a0mg adefovir dipivoxil\n(see\u00a0section\u00a04.4).</span></p>", "ID": "13da4b08-0be2-460a-8c76-403b1e863a98", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Clinical and\nlaboratory evidence of exacerbations of hepatitis have occurred after\ndiscontinuation of treatment with 10\u00a0mg adefovir dipivoxil\n(see\u00a0section\u00a04.4).</span>", "ID": "b722d8be-7722-4606-b584-3fa12ecf4d50", "Styles": "None", "Classes": "None", "Text": "Clinical and laboratory evidence of exacerbations of hepatitis have occurred after discontinuation of treatment with 10\u00a0mg adefovir dipivoxil (see\u00a0section\u00a04.4).", "ParentId": "13da4b08-0be2-460a-8c76-403b1e863a98"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "03956409-103d-42d6-9b14-f6eb3f541541", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0186427d-33a8-4378-b66f-3b73891edb82", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "03956409-103d-42d6-9b14-f6eb3f541541"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Long\u2011term safety data in patients with compensated disease:</span></i></p>", "ID": "70b820d9-6901-4b7a-9e81-a70c93feb606", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Long\u2011term safety data in patients with compensated disease:</span></i>", "ID": "1887293e-6226-4bc6-a60d-115afbb0aceb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "70b820d9-6901-4b7a-9e81-a70c93feb606"}, {"Element": "<span lang=\"EN-GB\">Long\u2011term safety data in patients with compensated disease:</span>", "ID": "4b2b6186-84d3-4488-9abe-dfc0230f0a97", "Styles": "None", "Classes": "None", "Text": "Long\u2011term safety data in patients with compensated disease:", "ParentId": "1887293e-6226-4bc6-a60d-115afbb0aceb"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In a long\u2011term\nsafety study of 125\u00a0HBeAg negative patients with compensated liver\ndisease, the adverse event profile was overall unchanged after a median\nexposure of 226\u00a0weeks.\u00a0 No clinically significant changes in renal\nfunction were observed.\u00a0 However, mild to moderate increases in serum\ncreatinine concentrations, hypophosphatemia and a decrease in carnitine concentrations\nwere reported in 3\u00a0%, 4\u00a0% and 6\u00a0% of patients, respectively, on\nextended treatment.</span></p>", "ID": "2dc225a2-a9c6-4ec2-aea7-3720efef57aa", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">In a long\u2011term\nsafety study of 125\u00a0HBeAg negative patients with compensated liver\ndisease, the adverse event profile was overall unchanged after a median\nexposure of 226\u00a0weeks.\u00a0 No clinically significant changes in renal\nfunction were observed.\u00a0 However, mild to moderate increases in serum\ncreatinine concentrations, hypophosphatemia and a decrease in carnitine concentrations\nwere reported in 3\u00a0%, 4\u00a0% and 6\u00a0% of patients, respectively, on\nextended treatment.</span>", "ID": "6f366728-b160-4a3f-b800-57f7857e83c5", "Styles": "None", "Classes": "None", "Text": "In a long\u2011term safety study of 125\u00a0HBeAg negative patients with compensated liver disease, the adverse event profile was overall unchanged after a median exposure of 226\u00a0weeks.\u00a0 No clinically significant changes in renal function were observed.\u00a0 However, mild to moderate increases in serum creatinine concentrations, hypophosphatemia and a decrease in carnitine concentrations were reported in 3\u00a0%, 4\u00a0% and 6\u00a0% of patients, respectively, on extended treatment.", "ParentId": "2dc225a2-a9c6-4ec2-aea7-3720efef57aa"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2539e31d-503f-4189-8866-555585abb4c3", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "27bd2c59-17a8-402f-9676-98286c4a5785", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2539e31d-503f-4189-8866-555585abb4c3"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In a long\u2011term\nsafety study of 65\u00a0HBeAg positive patients with compensated liver disease\n(after a median exposure of 234\u00a0weeks), 6\u00a0patients (9\u00a0%) had\nconfirmed increases in serum creatinine of at least 0.5\u00a0mg/dl from\nbaseline with 2\u00a0patients discontinuing from the study due to the elevated\nserum creatinine concentration.\u00a0 Patients with a confirmed increase in\ncreatinine of \u2265\u00a00.3\u00a0mg/dl by week\u00a048 were at a\nstatistically significant higher risk of a subsequent confirmed increase in\ncreatinine of \u2265\u00a00.5\u00a0mg/dl.\u00a0 Hypophosphatemia and a decrease in\ncarnitine concentrations were reported each in 3\u00a0% of patients on extended\ntreatment.</span></p>", "ID": "1b3d9055-59d2-4c90-81fb-93a550099197", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">In a long\u2011term\nsafety study of 65\u00a0HBeAg positive patients with compensated liver disease\n(after a median exposure of 234\u00a0weeks), 6\u00a0patients (9\u00a0%) had\nconfirmed increases in serum creatinine of at least 0.5\u00a0mg/dl from\nbaseline with 2\u00a0patients discontinuing from the study due to the elevated\nserum creatinine concentration.\u00a0 Patients with a confirmed increase in\ncreatinine of \u2265\u00a00.3\u00a0mg/dl by week\u00a048 were at a\nstatistically significant higher risk of a subsequent confirmed increase in\ncreatinine of \u2265\u00a00.5\u00a0mg/dl.\u00a0 Hypophosphatemia and a decrease in\ncarnitine concentrations were reported each in 3\u00a0% of patients on extended\ntreatment.</span>", "ID": "574cc96c-d0db-47b5-8369-75c694565497", "Styles": "None", "Classes": "None", "Text": "In a long\u2011term safety study of 65\u00a0HBeAg positive patients with compensated liver disease (after a median exposure of 234\u00a0weeks), 6\u00a0patients (9\u00a0%) had confirmed increases in serum creatinine of at least 0.5\u00a0mg/dl from baseline with 2\u00a0patients discontinuing from the study due to the elevated serum creatinine concentration.\u00a0 Patients with a confirmed increase in creatinine of \u2265\u00a00.3\u00a0mg/dl by week\u00a048 were at a statistically significant higher risk of a subsequent confirmed increase in creatinine of \u2265\u00a00.5\u00a0mg/dl.\u00a0 Hypophosphatemia and a decrease in carnitine concentrations were reported each in 3\u00a0% of patients on extended treatment.", "ParentId": "1b3d9055-59d2-4c90-81fb-93a550099197"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7be63d18-3366-453e-b517-5823b211c9f7", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "eeff9fe6-9800-476e-a2b9-53a0eda14a21", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7be63d18-3366-453e-b517-5823b211c9f7"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Based on\npost-marketing data, long\u2011term treatment with adefovir dipivoxil may lead\nto progressive alteration of renal function resulting in renal impairment (see\nsection\u00a04.4).</span></p>", "ID": "27083560-7b44-4ec5-b495-009129c1c255", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Based on\npost-marketing data, long\u2011term treatment with adefovir dipivoxil may lead\nto progressive alteration of renal function resulting in renal impairment (see\nsection\u00a04.4).</span>", "ID": "bef3e8ec-e2cc-4ac2-aef5-aa7c1df39675", "Styles": "None", "Classes": "None", "Text": "Based on post-marketing data, long\u2011term treatment with adefovir dipivoxil may lead to progressive alteration of renal function resulting in renal impairment (see section\u00a04.4).", "ParentId": "27083560-7b44-4ec5-b495-009129c1c255"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cf23400c-18e7-48c0-a27f-c45a8bb9c037", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "785a79b4-f874-452e-a7b2-6ad5a4ae8922", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cf23400c-18e7-48c0-a27f-c45a8bb9c037"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Safety in patients with decompensated disease:</span></i></p>", "ID": "78e4d5ed-e41d-4a52-860c-b8edec77a697", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Safety in patients with decompensated disease:</span></i>", "ID": "20df9373-9878-498b-aab5-affbfc901015", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "78e4d5ed-e41d-4a52-860c-b8edec77a697"}, {"Element": "<span lang=\"EN-GB\">Safety in patients with decompensated disease:</span>", "ID": "b652c88d-6cb0-4db3-b430-aa6de6ed8a1c", "Styles": "None", "Classes": "None", "Text": "Safety in patients with decompensated disease:", "ParentId": "20df9373-9878-498b-aab5-affbfc901015"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Renal toxicity\nis an important feature of the safety profile of adefovir dipivoxil in patients\nwith decompensated liver disease.\u00a0 In clinical studies of wait-listed and\npost-liver transplantation patients, four percent (19/467) of patients\ndiscontinued treatment with adefovir dipivoxil due to renal adverse events.</span></p>", "ID": "f0fd749e-dc1a-469d-8703-a9a37e656049", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Renal toxicity\nis an important feature of the safety profile of adefovir dipivoxil in patients\nwith decompensated liver disease.\u00a0 In clinical studies of wait-listed and\npost-liver transplantation patients, four percent (19/467) of patients\ndiscontinued treatment with adefovir dipivoxil due to renal adverse events.</span>", "ID": "166aa183-bd2b-4a6c-96d0-132d430c1e2d", "Styles": "None", "Classes": "None", "Text": "Renal toxicity is an important feature of the safety profile of adefovir dipivoxil in patients with decompensated liver disease.\u00a0 In clinical studies of wait-listed and post-liver transplantation patients, four percent (19/467) of patients discontinued treatment with adefovir dipivoxil due to renal adverse events.", "ParentId": "f0fd749e-dc1a-469d-8703-a9a37e656049"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f87c5bd5-e3b1-4e0a-9840-51f8c5a7e97e", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7775de0d-ddfa-4740-b47a-b53841248021", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f87c5bd5-e3b1-4e0a-9840-51f8c5a7e97e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><i><span lang=\"EN-GB\">d. Paediatric population</span></i></b></p>", "ID": "4c5ace73-b56a-448d-a49b-8d54efd5ddce", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><i><span lang=\"EN-GB\">d. Paediatric population</span></i></b>", "ID": "5ddb8c27-1f3c-40a0-bf6b-dffa8f7b55e8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4c5ace73-b56a-448d-a49b-8d54efd5ddce"}, {"Element": "<i><span lang=\"EN-GB\">d. Paediatric population</span></i>", "ID": "0608f929-2f45-43ec-9080-3dc850b92e78", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5ddb8c27-1f3c-40a0-bf6b-dffa8f7b55e8"}, {"Element": "<span lang=\"EN-GB\">d. Paediatric population</span>", "ID": "2fd1fece-881d-472e-9f1d-bdc68cf9e994", "Styles": "None", "Classes": "None", "Text": "d. Paediatric population", "ParentId": "0608f929-2f45-43ec-9080-3dc850b92e78"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Because of\ninsufficient data on safety and efficacy, Hepsera should not be used in\nchildren under the age of 18\u00a0years (see Sections\u00a04.2 and 5.1).</span></p>", "ID": "8d9fd0f6-9372-4e5e-9660-38c046ff494f", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Because of\ninsufficient data on safety and efficacy, Hepsera should not be used in\nchildren under the age of 18\u00a0years (see Sections\u00a04.2 and 5.1).</span>", "ID": "c0d7cf01-14ff-490d-9a64-08d0d90a09dd", "Styles": "None", "Classes": "None", "Text": "Because of insufficient data on safety and efficacy, Hepsera should not be used in children under the age of 18\u00a0years (see Sections\u00a04.2 and 5.1).", "ParentId": "8d9fd0f6-9372-4e5e-9660-38c046ff494f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "edea980e-12c4-498a-970b-344b4e92f5d1", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "acaf82cf-8d8b-4f37-853a-bcdb4b035e5b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "edea980e-12c4-498a-970b-344b4e92f5d1"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\nnone\"><u><span lang=\"EN-GB\">Reporting of suspected adverse reactions</span></u></p>", "ID": "78026261-ad85-4492-a086-4fce8df518ed", "Styles": "line-height:normal;page-break-after:avoid;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<u><span lang=\"EN-GB\">Reporting of suspected adverse reactions</span></u>", "ID": "087e7162-fb03-4158-9aab-c6ada4f17448", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "78026261-ad85-4492-a086-4fce8df518ed"}, {"Element": "<span lang=\"EN-GB\">Reporting of suspected adverse reactions</span>", "ID": "2aff0f9a-3df7-4a8d-8a08-7076de6da871", "Styles": "None", "Classes": "None", "Text": "Reporting of suspected adverse reactions", "ParentId": "087e7162-fb03-4158-9aab-c6ada4f17448"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Reporting suspected adverse reactions after authorisation of the\nmedicinal product is important.\u00a0 It allows continued monitoring of the\nbenefit/risk balance of the medicinal product.\u00a0 Healthcare professionals are\nasked to report any suspected adverse reactions via <span style=\"color:black;\nbackground:#D9D9D9\">the national reporting system listed in </span></span><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\"><a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"color:black;text-decoration:none\">Appendix\u00a0V</span></a></span><span lang=\"EN-GB\">.</span></p>", "ID": "3aeed86b-bac6-40cf-b835-fe63d04e6f06", "Styles": "line-height:normal;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Reporting suspected adverse reactions after authorisation of the\nmedicinal product is important.\u00a0 It allows continued monitoring of the\nbenefit/risk balance of the medicinal product.\u00a0 Healthcare professionals are\nasked to report any suspected adverse reactions via <span style=\"color:black;\nbackground:#D9D9D9\">the national reporting system listed in </span></span>", "ID": "a4312e50-2141-4f72-a5eb-a973e179800d", "Styles": "None", "Classes": "None", "Text": "Reporting suspected adverse reactions after authorisation of the medicinal product is important.\u00a0 It allows continued monitoring of the benefit/risk balance of the medicinal product.\u00a0 Healthcare professionals are asked to report any suspected adverse reactions via ", "ParentId": "3aeed86b-bac6-40cf-b835-fe63d04e6f06"}, {"Element": "<span style=\"color:black;\nbackground:#D9D9D9\">the national reporting system listed in </span>", "ID": "076b0cab-1502-4eea-954a-6abc27467407", "Styles": "color:black;\nbackground:#D9D9D9", "Classes": "None", "Text": "the national reporting system listed in ", "ParentId": "a4312e50-2141-4f72-a5eb-a973e179800d"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\"><a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"color:black;text-decoration:none\">Appendix\u00a0V</span></a></span>", "ID": "604cd41f-aca8-4cd4-b523-8d283bb5eaf6", "Styles": "color:black;background:#D9D9D9", "Classes": "None", "Text": "", "ParentId": "3aeed86b-bac6-40cf-b835-fe63d04e6f06"}, {"Element": "<a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"color:black;text-decoration:none\">Appendix\u00a0V</span></a>", "ID": "1c9a766c-2c48-47b2-9ba3-832ce28f0f27", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "604cd41f-aca8-4cd4-b523-8d283bb5eaf6"}, {"Element": "<span style=\"color:black;text-decoration:none\">Appendix\u00a0V</span>", "ID": "e60f98c6-b886-4b67-96b0-ebfb0e541167", "Styles": "color:black;text-decoration:none", "Classes": "None", "Text": "Appendix\u00a0V", "ParentId": "1c9a766c-2c48-47b2-9ba3-832ce28f0f27"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "56ccf65b-b4f9-466a-a946-661706a48db5", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "3aeed86b-bac6-40cf-b835-fe63d04e6f06"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e3740048-cadd-4873-a2ee-4d1b2c08f5b6", "Styles": "line-height:normal;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8533824d-8288-456d-a3dc-afba57faba4c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e3740048-cadd-4873-a2ee-4d1b2c08f5b6"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.9\u00a0\u00a0\u00a0\u00a0 Overdose</span></b></p>", "ID": "3ee1c8f7-edf0-4fa4-9052-d1ef839634da", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">4.9\u00a0\u00a0\u00a0\u00a0 Overdose</span></b>", "ID": "934d0476-5739-40ae-b09a-36c143ac3f61", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3ee1c8f7-edf0-4fa4-9052-d1ef839634da"}, {"Element": "<span lang=\"EN-GB\">4.9\u00a0\u00a0\u00a0\u00a0 Overdose</span>", "ID": "e14b031c-70d5-4801-8647-5ff4f6f53bdc", "Styles": "None", "Classes": "None", "Text": "4.9\u00a0\u00a0\u00a0\u00a0 Overdose", "ParentId": "934d0476-5739-40ae-b09a-36c143ac3f61"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "faa28c38-c9b6-45a9-b285-8503c8bf6ca6", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5b66b2e3-e88e-458b-b0c5-2eeeabc582c4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "faa28c38-c9b6-45a9-b285-8503c8bf6ca6"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Administration\nof 500\u00a0mg adefovir dipivoxil daily for 2\u00a0weeks and 250\u00a0mg daily\nfor 12\u00a0weeks has been associated with the gastrointestinal disorders\nlisted above and anorexia.</span></p>", "ID": "41f2b4aa-0278-4297-a6ee-1242df78f9bf", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Administration\nof 500\u00a0mg adefovir dipivoxil daily for 2\u00a0weeks and 250\u00a0mg daily\nfor 12\u00a0weeks has been associated with the gastrointestinal disorders\nlisted above and anorexia.</span>", "ID": "7548b1fb-ef3d-4f2a-b6e4-8f4b850be7db", "Styles": "None", "Classes": "None", "Text": "Administration of 500\u00a0mg adefovir dipivoxil daily for 2\u00a0weeks and 250\u00a0mg daily for 12\u00a0weeks has been associated with the gastrointestinal disorders listed above and anorexia.", "ParentId": "41f2b4aa-0278-4297-a6ee-1242df78f9bf"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "151478de-efa7-4526-bb75-8366d6aca965", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f4c33f28-36b6-4145-ab6a-d8b2422296a8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "151478de-efa7-4526-bb75-8366d6aca965"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If overdose\noccurs, the patient must be monitored for evidence of toxicity, and standard\nsupportive treatment applied as necessary.</span></p>", "ID": "de9fd5ec-13af-40a7-9e71-aea7c63a7499", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">If overdose\noccurs, the patient must be monitored for evidence of toxicity, and standard\nsupportive treatment applied as necessary.</span>", "ID": "83562a0d-3187-4a5e-b04f-fce4db3df134", "Styles": "None", "Classes": "None", "Text": "If overdose occurs, the patient must be monitored for evidence of toxicity, and standard supportive treatment applied as necessary.", "ParentId": "de9fd5ec-13af-40a7-9e71-aea7c63a7499"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "de5b9d57-766f-4653-841a-0d4482cb2d03", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c7c8130a-732d-4fcf-ab5d-0da5ff081e30", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "de5b9d57-766f-4653-841a-0d4482cb2d03"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adefovir can be\nremoved by haemodialysis; the median haemodialysis clearance of adefovir is\n104\u00a0ml/min.\u00a0 The elimination of adefovir by peritoneal dialysis has not\nbeen studied.</span></p>", "ID": "f10709bf-7b18-4dac-820f-5c7461ebe956", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Adefovir can be\nremoved by haemodialysis; the median haemodialysis clearance of adefovir is\n104\u00a0ml/min.\u00a0 The elimination of adefovir by peritoneal dialysis has not\nbeen studied.</span>", "ID": "9725b8ef-ece5-450e-9218-725b7133caa4", "Styles": "None", "Classes": "None", "Text": "Adefovir can be removed by haemodialysis; the median haemodialysis clearance of adefovir is 104\u00a0ml/min.\u00a0 The elimination of adefovir by peritoneal dialysis has not been studied.", "ParentId": "f10709bf-7b18-4dac-820f-5c7461ebe956"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3324cb0d-5640-4aa4-918a-b36859a24d0f", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6fec1d39-ac85-4d9d-91d6-632201e9804c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3324cb0d-5640-4aa4-918a-b36859a24d0f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0a0a153e-06a1-4453-a36a-5a85f759054e", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "05b45b6c-ac2c-4852-bd2d-8f2ceb4815f6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0a0a153e-06a1-4453-a36a-5a85f759054e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL\nPROPERTIES</span></b></p>", "ID": "ef8a8290-1d6c-4c91-862c-f01778f17158", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL\nPROPERTIES</span></b>", "ID": "675ebf00-85d3-4153-9627-8a0108a34996", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ef8a8290-1d6c-4c91-862c-f01778f17158"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL\nPROPERTIES</span>", "ID": "709aa0da-3e56-4c67-b2e2-34905a718d5c", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL PROPERTIES", "ParentId": "675ebf00-85d3-4153-9627-8a0108a34996"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "18259e55-e007-4da6-bbcb-94858c89a5d6", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "40a3f807-fa70-4817-b6bb-744b91c178f7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "18259e55-e007-4da6-bbcb-94858c89a5d6"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.1\u00a0\u00a0\u00a0\u00a0 Pharmacodynamic\nproperties</span></b></p>", "ID": "29baea86-2f18-4490-a145-e29f11f874f7", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">5.1\u00a0\u00a0\u00a0\u00a0 Pharmacodynamic\nproperties</span></b>", "ID": "c509c368-0278-49f5-803c-47d55ad96c87", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "29baea86-2f18-4490-a145-e29f11f874f7"}, {"Element": "<span lang=\"EN-GB\">5.1\u00a0\u00a0\u00a0\u00a0 Pharmacodynamic\nproperties</span>", "ID": "4306dd51-637a-441f-8f13-265cdd7b4961", "Styles": "None", "Classes": "None", "Text": "5.1\u00a0\u00a0\u00a0\u00a0 Pharmacodynamic properties", "ParentId": "c509c368-0278-49f5-803c-47d55ad96c87"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "00464ab1-a1f8-4ff4-9e03-6938c3eaa098", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "30a54dda-56ba-43a4-a709-aac613b9250a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "00464ab1-a1f8-4ff4-9e03-6938c3eaa098"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Pharmacotherapeutic\ngroup:</span></i><span lang=\"EN-GB\"> Nucleoside and nucleotide reverse\ntranscriptase inhibitors, ATC code: J05AF08.</span></p>", "ID": "d85bcccd-73f4-4c42-bf96-0d98380d8b4d", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Pharmacotherapeutic\ngroup:</span></i>", "ID": "652733cc-7291-40f0-b824-8b5eec876da2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d85bcccd-73f4-4c42-bf96-0d98380d8b4d"}, {"Element": "<span lang=\"EN-GB\">Pharmacotherapeutic\ngroup:</span>", "ID": "f0b118b7-deaf-4753-879e-ac3c26b7aa46", "Styles": "None", "Classes": "None", "Text": "Pharmacotherapeutic group:", "ParentId": "652733cc-7291-40f0-b824-8b5eec876da2"}, {"Element": "<span lang=\"EN-GB\"> Nucleoside and nucleotide reverse\ntranscriptase inhibitors, ATC code: J05AF08.</span>", "ID": "3824d53a-ceb0-4c4f-b842-998f3870e4ce", "Styles": "None", "Classes": "None", "Text": " Nucleoside and nucleotide reverse transcriptase inhibitors, ATC code: J05AF08.", "ParentId": "d85bcccd-73f4-4c42-bf96-0d98380d8b4d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b3d6f20a-6843-4ea3-b329-f96b58c786fe", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "de5f8ac6-ff2a-4e41-8ea9-8f406d489feb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b3d6f20a-6843-4ea3-b329-f96b58c786fe"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><u><span lang=\"EN-GB\">Mechanism\nof action and pharmacodynamic effects:</span></u></i><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">Adefovir dipivoxil is an oral prodrug of adefovir, an acyclic\nnucleotide phosphonate analogue of adenosine monophosphate, which is actively\ntransported into mammalian cells where it is converted by host enzymes to\nadefovir diphosphate.\u00a0 Adefovir diphosphate inhibits viral polymerases by\ncompeting for direct binding with the natural substrate (deoxyadenosine\ntriphosphate) and, after incorporation into viral DNA, causes DNA chain\ntermination.\u00a0 Adefovir diphosphate selectively inhibits HBV\u00a0DNA\npolymerases at concentrations 12\u2011, 700\u2011, and 10\u2011fold lower\nthan those needed to inhibit human DNA polymerases \u03b1, \u03b2, and \u03b3,\nrespectively.\u00a0 Adefovir diphosphate has an intracellular half\u2011life of 12\nto 36\u00a0hours in activated and resting lymphocytes.</span></p>", "ID": "0907c8dd-a8aa-460f-bd2e-d7d261b0e3d6", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><u><span lang=\"EN-GB\">Mechanism\nof action and pharmacodynamic effects:</span></u></i>", "ID": "9dc7c631-a76d-46da-9f15-a46e0b2b00ba", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0907c8dd-a8aa-460f-bd2e-d7d261b0e3d6"}, {"Element": "<u><span lang=\"EN-GB\">Mechanism\nof action and pharmacodynamic effects:</span></u>", "ID": "9efe96de-acd3-419b-954d-ceb277b19860", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9dc7c631-a76d-46da-9f15-a46e0b2b00ba"}, {"Element": "<span lang=\"EN-GB\">Mechanism\nof action and pharmacodynamic effects:</span>", "ID": "fcbaa165-de6b-46db-baa4-cb250bb2a2cb", "Styles": "None", "Classes": "None", "Text": "Mechanism of action and pharmacodynamic effects:", "ParentId": "9efe96de-acd3-419b-954d-ceb277b19860"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "7679a6c0-73f9-4c9c-9994-cdbaed377a7c", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "0907c8dd-a8aa-460f-bd2e-d7d261b0e3d6"}, {"Element": "<span lang=\"EN-GB\">Adefovir dipivoxil is an oral prodrug of adefovir, an acyclic\nnucleotide phosphonate analogue of adenosine monophosphate, which is actively\ntransported into mammalian cells where it is converted by host enzymes to\nadefovir diphosphate.\u00a0 Adefovir diphosphate inhibits viral polymerases by\ncompeting for direct binding with the natural substrate (deoxyadenosine\ntriphosphate) and, after incorporation into viral DNA, causes DNA chain\ntermination.\u00a0 Adefovir diphosphate selectively inhibits HBV\u00a0DNA\npolymerases at concentrations 12\u2011, 700\u2011, and 10\u2011fold lower\nthan those needed to inhibit human DNA polymerases \u03b1, \u03b2, and \u03b3,\nrespectively.\u00a0 Adefovir diphosphate has an intracellular half\u2011life of 12\nto 36\u00a0hours in activated and resting lymphocytes.</span>", "ID": "5a189a91-6e77-454b-a882-f3f66a5224ba", "Styles": "None", "Classes": "None", "Text": "Adefovir dipivoxil is an oral prodrug of adefovir, an acyclic nucleotide phosphonate analogue of adenosine monophosphate, which is actively transported into mammalian cells where it is converted by host enzymes to adefovir diphosphate.\u00a0 Adefovir diphosphate inhibits viral polymerases by competing for direct binding with the natural substrate (deoxyadenosine triphosphate) and, after incorporation into viral DNA, causes DNA chain termination.\u00a0 Adefovir diphosphate selectively inhibits HBV\u00a0DNA polymerases at concentrations 12\u2011, 700\u2011, and 10\u2011fold lower than those needed to inhibit human DNA polymerases \u03b1, \u03b2, and \u03b3, respectively.\u00a0 Adefovir diphosphate has an intracellular half\u2011life of 12 to 36\u00a0hours in activated and resting lymphocytes.", "ParentId": "0907c8dd-a8aa-460f-bd2e-d7d261b0e3d6"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "27492901-3fb8-4c82-b762-60201d3b3020", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b2619058-ae99-4854-986e-eedf8792d33a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "27492901-3fb8-4c82-b762-60201d3b3020"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adefovir is\nactive against hepadnaviruses <i>in\u00a0vitro</i>, including all common forms\nof lamivudine-resistant HBV (rtL180M, rtM204I, rtM204V, rtL180M/rtM204V),\nfamciclovir-associated mutations (rtV173L, rtP177L, rtL180M, rtT184S or\nrtV207I) and hepatitis\u00a0B immunoglobulin escape mutations (rtT128N and\nrtW153Q), and in <i>in\u00a0vivo</i> animal models of hepadnavirus replication.</span></p>", "ID": "ee7199ea-0043-4c83-84e3-699cb4c7e8ae", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Adefovir is\nactive against hepadnaviruses <i>in\u00a0vitro</i>, including all common forms\nof lamivudine-resistant HBV (rtL180M, rtM204I, rtM204V, rtL180M/rtM204V),\nfamciclovir-associated mutations (rtV173L, rtP177L, rtL180M, rtT184S or\nrtV207I) and hepatitis\u00a0B immunoglobulin escape mutations (rtT128N and\nrtW153Q), and in <i>in\u00a0vivo</i> animal models of hepadnavirus replication.</span>", "ID": "9afc34e4-f565-4d49-9cf6-00db20c36997", "Styles": "None", "Classes": "None", "Text": "Adefovir is active against hepadnaviruses , including all common forms of lamivudine-resistant HBV (rtL180M, rtM204I, rtM204V, rtL180M/rtM204V), famciclovir-associated mutations (rtV173L, rtP177L, rtL180M, rtT184S or rtV207I) and hepatitis\u00a0B immunoglobulin escape mutations (rtT128N and rtW153Q), and in  animal models of hepadnavirus replication.", "ParentId": "ee7199ea-0043-4c83-84e3-699cb4c7e8ae"}, {"Element": "<i>in\u00a0vitro</i>", "ID": "5a06601d-b29f-449e-8cbe-e41de0b02fe7", "Styles": "None", "Classes": "None", "Text": "in\u00a0vitro", "ParentId": "9afc34e4-f565-4d49-9cf6-00db20c36997"}, {"Element": "<i>in\u00a0vivo</i>", "ID": "ca0b7f66-482a-4850-84ec-77ec3cc8bfe3", "Styles": "None", "Classes": "None", "Text": "in\u00a0vivo", "ParentId": "9afc34e4-f565-4d49-9cf6-00db20c36997"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3939eaa5-f4d6-44aa-9380-845243516402", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d609fa92-8b13-44c5-8b86-cf8e9a599138", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3939eaa5-f4d6-44aa-9380-845243516402"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Clinical efficacy and safety:</span></u></i></p>", "ID": "40e9ff6a-c471-477b-be54-37565ee5cd5d", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><u><span lang=\"EN-GB\">Clinical efficacy and safety:</span></u></i>", "ID": "8442afe9-b62b-43d4-b3fd-271abec337c5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "40e9ff6a-c471-477b-be54-37565ee5cd5d"}, {"Element": "<u><span lang=\"EN-GB\">Clinical efficacy and safety:</span></u>", "ID": "bdeefb8a-b739-4ff2-aca2-7d46a06633c2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8442afe9-b62b-43d4-b3fd-271abec337c5"}, {"Element": "<span lang=\"EN-GB\">Clinical efficacy and safety:</span>", "ID": "b2416e1a-122d-4d6c-9c4a-6ccd5373a4c3", "Styles": "None", "Classes": "None", "Text": "Clinical efficacy and safety:", "ParentId": "bdeefb8a-b739-4ff2-aca2-7d46a06633c2"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The demonstration of the benefit of adefovir dipivoxil is based on\nhistological, virological, biochemical, and serological responses in adults\nwith:</span></p>", "ID": "64dc8957-ffeb-4ac0-a86b-754a1a02bcaf", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">The demonstration of the benefit of adefovir dipivoxil is based on\nhistological, virological, biochemical, and serological responses in adults\nwith:</span>", "ID": "55e575d6-7f77-4e3d-8a70-1e01478bc860", "Styles": "None", "Classes": "None", "Text": "The demonstration of the benefit of adefovir dipivoxil is based on histological, virological, biochemical, and serological responses in adults with:", "ParentId": "64dc8957-ffeb-4ac0-a86b-754a1a02bcaf"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c61e0168-ee11-4c94-b907-eff12ca7a561", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a411af4d-3c22-46a1-a55f-16d7459def09", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c61e0168-ee11-4c94-b907-eff12ca7a561"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">HBeAg positive and HBeAg negative chronic\nhepatitis\u00a0B with compensated liver disease.</span></p>", "ID": "cc7b4f97-dc42-4217-b5ac-b77204195bd6", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "283aaaa8-dd08-4615-b9e0-816116217dad", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "cc7b4f97-dc42-4217-b5ac-b77204195bd6"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "a0be7230-82bd-4724-aefa-36b16152b7bc", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "283aaaa8-dd08-4615-b9e0-816116217dad"}, {"Element": "<span lang=\"EN-GB\">HBeAg positive and HBeAg negative chronic\nhepatitis\u00a0B with compensated liver disease.</span>", "ID": "2d4ba8bf-7ccc-4918-aa78-1838178d65c7", "Styles": "None", "Classes": "None", "Text": "HBeAg positive and HBeAg negative chronic hepatitis\u00a0B with compensated liver disease.", "ParentId": "cc7b4f97-dc42-4217-b5ac-b77204195bd6"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "82143166-5c9c-410a-90b6-2b3ef6861669", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "72f95672-ac1d-49f1-a1b9-0e156142373c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "82143166-5c9c-410a-90b6-2b3ef6861669"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">lamivudine-resistant HBV with either compensated\nor decompensated liver disease, including patients pre\u2011 and post\u2011liver\ntransplantation or co\u2011infected with HIV.\u00a0 In the majority of these\nstudies adefovir dipivoxil 10\u00a0mg was added to ongoing lamivudine treatment\nin patients failing lamivudine therapy.</span></p>", "ID": "31efad6d-5377-430e-b0b1-e09856f7a707", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "c5870abb-89ba-47d2-bf48-b7fae81bd6ff", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "31efad6d-5377-430e-b0b1-e09856f7a707"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "a0d0de4d-7671-4b3c-abf1-54be353e30d3", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "c5870abb-89ba-47d2-bf48-b7fae81bd6ff"}, {"Element": "<span lang=\"EN-GB\">lamivudine-resistant HBV with either compensated\nor decompensated liver disease, including patients pre\u2011 and post\u2011liver\ntransplantation or co\u2011infected with HIV.\u00a0 In the majority of these\nstudies adefovir dipivoxil 10\u00a0mg was added to ongoing lamivudine treatment\nin patients failing lamivudine therapy.</span>", "ID": "e288a3cf-f151-46bb-8d86-c61517fff532", "Styles": "None", "Classes": "None", "Text": "lamivudine-resistant HBV with either compensated or decompensated liver disease, including patients pre\u2011 and post\u2011liver transplantation or co\u2011infected with HIV.\u00a0 In the majority of these studies adefovir dipivoxil 10\u00a0mg was added to ongoing lamivudine treatment in patients failing lamivudine therapy.", "ParentId": "31efad6d-5377-430e-b0b1-e09856f7a707"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dc66db91-6555-473b-868b-630eb50cef2e", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6943c05f-34e2-4125-ac33-eb3a0fdf86f5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dc66db91-6555-473b-868b-630eb50cef2e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In these\nclinical studies patients had active viral replication (HBV\u00a0DNA \u2265\u00a0100,000\u00a0copies/ml)\nand elevated ALT levels (\u2265\u00a01.2\u00a0x Upper Limit of Normal (ULN)).</span></p>", "ID": "6c1d0421-324c-4956-9541-353e5bf645c4", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">In these\nclinical studies patients had active viral replication (HBV\u00a0DNA \u2265\u00a0100,000\u00a0copies/ml)\nand elevated ALT levels (\u2265\u00a01.2\u00a0x Upper Limit of Normal (ULN)).</span>", "ID": "49e346c2-3e1f-426d-954d-859d1423623c", "Styles": "None", "Classes": "None", "Text": "In these clinical studies patients had active viral replication (HBV\u00a0DNA \u2265\u00a0100,000\u00a0copies/ml) and elevated ALT levels (\u2265\u00a01.2\u00a0x Upper Limit of Normal (ULN)).", "ParentId": "6c1d0421-324c-4956-9541-353e5bf645c4"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5d928fd2-4995-4440-b659-9a62e7ec3642", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d9529b18-3b79-40b2-95c9-50346dc4f96d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5d928fd2-4995-4440-b659-9a62e7ec3642"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Experience in\npatients with compensated liver disease:</span></i><span lang=\"EN-GB\"> In two\nplacebo-controlled studies (total n=522) in HBeAg positive or in HBeAg negative\nchronic hepatitis\u00a0B patients with compensated liver disease, significantly\nmore patients (p\u00a0&lt;\u00a00.001) in the 10\u00a0mg adefovir dipivoxil\ngroups (53 and 64\u00a0%, respectively) had histological improvement from\nbaseline at week\u00a048 than in the placebo groups (25 and 33\u00a0%).\u00a0\nImprovement was defined as a reduction from baseline of two points or more in\nthe Knodell necro-inflammatory score with no concurrent worsening in the\nKnodell fibrosis score.\u00a0 Histological improvement was seen regardless of\nbaseline demographic and hepatitis\u00a0B characteristics, including prior\ninterferon\u2011alpha therapy.\u00a0 High baseline ALT levels\n(\u2265\u00a02\u00a0x\u00a0ULN) and Knodell Histology Activity Index (HAI)\nscores (\u2265\u00a010) and low HBV\u00a0DNA (&lt;\u00a07.6\u00a0log<sub>10</sub>\u00a0copies/ml)\nwere associated with greater histological improvement.\u00a0 Blinded, ranked assessments\nof both necro-inflammatory activity and fibrosis at baseline and week\u00a048,\ndemonstrated that patients treated with 10\u00a0mg adefovir dipivoxil had\nimproved necro-inflammatory and fibrosis scores relative to placebo-treated\npatients.</span></p>", "ID": "3a21b1a8-041c-4c1d-ba65-4cbf88dfe1c5", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Experience in\npatients with compensated liver disease:</span></i>", "ID": "93489c44-30ca-4fea-8dac-17a17abb78ac", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3a21b1a8-041c-4c1d-ba65-4cbf88dfe1c5"}, {"Element": "<span lang=\"EN-GB\">Experience in\npatients with compensated liver disease:</span>", "ID": "4eeced01-43a0-438a-ad5f-cad14ab84cbe", "Styles": "None", "Classes": "None", "Text": "Experience in patients with compensated liver disease:", "ParentId": "93489c44-30ca-4fea-8dac-17a17abb78ac"}, {"Element": "<span lang=\"EN-GB\"> In two\nplacebo-controlled studies (total n=522) in HBeAg positive or in HBeAg negative\nchronic hepatitis\u00a0B patients with compensated liver disease, significantly\nmore patients (p\u00a0&lt;\u00a00.001) in the 10\u00a0mg adefovir dipivoxil\ngroups (53 and 64\u00a0%, respectively) had histological improvement from\nbaseline at week\u00a048 than in the placebo groups (25 and 33\u00a0%).\u00a0\nImprovement was defined as a reduction from baseline of two points or more in\nthe Knodell necro-inflammatory score with no concurrent worsening in the\nKnodell fibrosis score.\u00a0 Histological improvement was seen regardless of\nbaseline demographic and hepatitis\u00a0B characteristics, including prior\ninterferon\u2011alpha therapy.\u00a0 High baseline ALT levels\n(\u2265\u00a02\u00a0x\u00a0ULN) and Knodell Histology Activity Index (HAI)\nscores (\u2265\u00a010) and low HBV\u00a0DNA (&lt;\u00a07.6\u00a0log<sub>10</sub>\u00a0copies/ml)\nwere associated with greater histological improvement.\u00a0 Blinded, ranked assessments\nof both necro-inflammatory activity and fibrosis at baseline and week\u00a048,\ndemonstrated that patients treated with 10\u00a0mg adefovir dipivoxil had\nimproved necro-inflammatory and fibrosis scores relative to placebo-treated\npatients.</span>", "ID": "893e0e85-ac94-4f48-b2cc-8dfd5346190a", "Styles": "None", "Classes": "None", "Text": " In two placebo-controlled studies (total n=522) in HBeAg positive or in HBeAg negative chronic hepatitis\u00a0B patients with compensated liver disease, significantly more patients (p\u00a0<\u00a00.001) in the 10\u00a0mg adefovir dipivoxil groups (53 and 64\u00a0%, respectively) had histological improvement from baseline at week\u00a048 than in the placebo groups (25 and 33\u00a0%).\u00a0 Improvement was defined as a reduction from baseline of two points or more in the Knodell necro-inflammatory score with no concurrent worsening in the Knodell fibrosis score.\u00a0 Histological improvement was seen regardless of baseline demographic and hepatitis\u00a0B characteristics, including prior interferon\u2011alpha therapy.\u00a0 High baseline ALT levels (\u2265\u00a02\u00a0x\u00a0ULN) and Knodell Histology Activity Index (HAI) scores (\u2265\u00a010) and low HBV\u00a0DNA (<\u00a07.6\u00a0log\u00a0copies/ml) were associated with greater histological improvement.\u00a0 Blinded, ranked assessments of both necro-inflammatory activity and fibrosis at baseline and week\u00a048, demonstrated that patients treated with 10\u00a0mg adefovir dipivoxil had improved necro-inflammatory and fibrosis scores relative to placebo-treated patients.", "ParentId": "3a21b1a8-041c-4c1d-ba65-4cbf88dfe1c5"}, {"Element": "<sub>10</sub>", "ID": "5ec62726-8f9f-4c52-8b59-910936768ec3", "Styles": "None", "Classes": "None", "Text": "10", "ParentId": "893e0e85-ac94-4f48-b2cc-8dfd5346190a"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1f582c26-6db7-40fa-addf-b7805f4c5217", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "97737711-ab4d-42cc-892b-878049404eb9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1f582c26-6db7-40fa-addf-b7805f4c5217"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Assessment of\nthe change in fibrosis after 48\u00a0weeks treatment using the Knodell scores\nconfirms that patients treated with adefovir dipivoxil 10\u00a0mg had more\nregression and less progression of fibrosis than patients treated with placebo.</span></p>", "ID": "f6623a2c-e0a9-44c6-8172-53d005abe956", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Assessment of\nthe change in fibrosis after 48\u00a0weeks treatment using the Knodell scores\nconfirms that patients treated with adefovir dipivoxil 10\u00a0mg had more\nregression and less progression of fibrosis than patients treated with placebo.</span>", "ID": "1a6a3c0b-ab23-4533-a67b-dcbbb6e7cbdb", "Styles": "None", "Classes": "None", "Text": "Assessment of the change in fibrosis after 48\u00a0weeks treatment using the Knodell scores confirms that patients treated with adefovir dipivoxil 10\u00a0mg had more regression and less progression of fibrosis than patients treated with placebo.", "ParentId": "f6623a2c-e0a9-44c6-8172-53d005abe956"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "59480003-9dfa-4fce-85f4-48b1c0a63378", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "75db07bc-1b53-4490-94e1-50a106b19384", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "59480003-9dfa-4fce-85f4-48b1c0a63378"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In the two\nstudies mentioned above, treatment with 10\u00a0mg adefovir dipivoxil was\nassociated with significant reductions in serum HBV\u00a0DNA (3.52 and\n3.91\u00a0log<sub>10</sub>\u00a0copies/ml, respectively, <i>versus</i> 0.55 and\n1.35\u00a0log<sub>10</sub>\u00a0copies/ml), increased proportion of patients\nwith normalisation of ALT (48 and 72\u00a0% <i>versus</i> 16 and 29\u00a0%) or\nincreased proportion of patients with serum HBV\u00a0DNA below the limits of\nquantification (&lt;\u00a0400\u00a0copies/ml Roche Amplicor Monitor PCR assay)\n(21 and 51\u00a0% <i>versus</i> 0\u00a0%) when compared with placebo.\u00a0 In the\nstudy in HBeAg positive patients, HBeAg seroconversion (12\u00a0%) and HBeAg\nloss (24\u00a0%) was observed significantly more frequently in patients\nreceiving 10\u00a0mg adefovir dipivoxil than in patients receiving placebo\n(6\u00a0% and 11\u00a0%, respectively) after 48\u00a0weeks of treatment.</span></p>", "ID": "e71e21b8-ea9f-4832-b550-26a4a2156348", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">In the two\nstudies mentioned above, treatment with 10\u00a0mg adefovir dipivoxil was\nassociated with significant reductions in serum HBV\u00a0DNA (3.52 and\n3.91\u00a0log<sub>10</sub>\u00a0copies/ml, respectively, <i>versus</i> 0.55 and\n1.35\u00a0log<sub>10</sub>\u00a0copies/ml), increased proportion of patients\nwith normalisation of ALT (48 and 72\u00a0% <i>versus</i> 16 and 29\u00a0%) or\nincreased proportion of patients with serum HBV\u00a0DNA below the limits of\nquantification (&lt;\u00a0400\u00a0copies/ml Roche Amplicor Monitor PCR assay)\n(21 and 51\u00a0% <i>versus</i> 0\u00a0%) when compared with placebo.\u00a0 In the\nstudy in HBeAg positive patients, HBeAg seroconversion (12\u00a0%) and HBeAg\nloss (24\u00a0%) was observed significantly more frequently in patients\nreceiving 10\u00a0mg adefovir dipivoxil than in patients receiving placebo\n(6\u00a0% and 11\u00a0%, respectively) after 48\u00a0weeks of treatment.</span>", "ID": "ad03aadb-858a-457b-8a34-471523c7e69d", "Styles": "None", "Classes": "None", "Text": "In the two studies mentioned above, treatment with 10\u00a0mg adefovir dipivoxil was associated with significant reductions in serum HBV\u00a0DNA (3.52 and 3.91\u00a0log\u00a0copies/ml, respectively,  0.55 and 1.35\u00a0log\u00a0copies/ml), increased proportion of patients with normalisation of ALT (48 and 72\u00a0%  16 and 29\u00a0%) or increased proportion of patients with serum HBV\u00a0DNA below the limits of quantification (<\u00a0400\u00a0copies/ml Roche Amplicor Monitor PCR assay) (21 and 51\u00a0%  0\u00a0%) when compared with placebo.\u00a0 In the study in HBeAg positive patients, HBeAg seroconversion (12\u00a0%) and HBeAg loss (24\u00a0%) was observed significantly more frequently in patients receiving 10\u00a0mg adefovir dipivoxil than in patients receiving placebo (6\u00a0% and 11\u00a0%, respectively) after 48\u00a0weeks of treatment.", "ParentId": "e71e21b8-ea9f-4832-b550-26a4a2156348"}, {"Element": "<sub>10</sub>", "ID": "d165c259-0dcf-44d4-b98b-5b1848e4568b", "Styles": "None", "Classes": "None", "Text": "10", "ParentId": "ad03aadb-858a-457b-8a34-471523c7e69d"}, {"Element": "<i>versus</i>", "ID": "38fdc334-cd28-4718-ad42-89f99ccefea1", "Styles": "None", "Classes": "None", "Text": "versus", "ParentId": "ad03aadb-858a-457b-8a34-471523c7e69d"}, {"Element": "<sub>10</sub>", "ID": "59cfe117-96f2-410f-89e4-120a2f89dc78", "Styles": "None", "Classes": "None", "Text": "10", "ParentId": "ad03aadb-858a-457b-8a34-471523c7e69d"}, {"Element": "<i>versus</i>", "ID": "6488f217-02c9-4f59-8822-53fdc48f627f", "Styles": "None", "Classes": "None", "Text": "versus", "ParentId": "ad03aadb-858a-457b-8a34-471523c7e69d"}, {"Element": "<i>versus</i>", "ID": "597b9d22-3e0c-40e2-8a9d-ea8ddd7b41fc", "Styles": "None", "Classes": "None", "Text": "versus", "ParentId": "ad03aadb-858a-457b-8a34-471523c7e69d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cc64b776-f33d-4d12-9f85-9f23b710a59e", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f2fd7c68-adb4-4545-9a9c-220a0a4e22af", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cc64b776-f33d-4d12-9f85-9f23b710a59e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In the HBeAg\u00a0positive\nstudy, treatment beyond 48\u00a0weeks resulted in further reductions in serum\nHBV\u00a0DNA levels and increases in the proportion of patients with ALT\nnormalisation, HBeAg loss and seroconversion.</span></p>", "ID": "e9489c31-fd47-4c71-abc4-5f344ee6df6b", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">In the HBeAg\u00a0positive\nstudy, treatment beyond 48\u00a0weeks resulted in further reductions in serum\nHBV\u00a0DNA levels and increases in the proportion of patients with ALT\nnormalisation, HBeAg loss and seroconversion.</span>", "ID": "318a7183-ec54-438e-84eb-aadcd9719f19", "Styles": "None", "Classes": "None", "Text": "In the HBeAg\u00a0positive study, treatment beyond 48\u00a0weeks resulted in further reductions in serum HBV\u00a0DNA levels and increases in the proportion of patients with ALT normalisation, HBeAg loss and seroconversion.", "ParentId": "e9489c31-fd47-4c71-abc4-5f344ee6df6b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "787573d1-e811-4a9f-beb1-c53af8cf112d", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ed049ede-77fc-4b2a-810e-2ffd6490e084", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "787573d1-e811-4a9f-beb1-c53af8cf112d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In the\nHBeAg\u00a0negative study patients on adefovir dipivoxil (0\u201148\u00a0weeks)\nwere re-randomised in a blinded-manner to continue on adefovir dipivoxil or\nreceive placebo for an additional 48\u00a0weeks.\u00a0 At week\u00a096, patients\ncontinuing on adefovir dipivoxil 10\u00a0mg had sustained suppression of serum\nHBV\u00a0with maintenance of the reduction seen at week\u00a048.\u00a0 In over two\nthirds of patients suppression of serum HBV\u00a0DNA was associated with\nnormalisation of ALT levels.\u00a0 In most patients who stopped treatment with\nadefovir dipivoxil, serum HBV\u00a0DNA and ALT levels returned towards\nbaseline.</span></p>", "ID": "d00d61fb-d27e-49a5-b50f-ddc8e52dbc3c", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">In the\nHBeAg\u00a0negative study patients on adefovir dipivoxil (0\u201148\u00a0weeks)\nwere re-randomised in a blinded-manner to continue on adefovir dipivoxil or\nreceive placebo for an additional 48\u00a0weeks.\u00a0 At week\u00a096, patients\ncontinuing on adefovir dipivoxil 10\u00a0mg had sustained suppression of serum\nHBV\u00a0with maintenance of the reduction seen at week\u00a048.\u00a0 In over two\nthirds of patients suppression of serum HBV\u00a0DNA was associated with\nnormalisation of ALT levels.\u00a0 In most patients who stopped treatment with\nadefovir dipivoxil, serum HBV\u00a0DNA and ALT levels returned towards\nbaseline.</span>", "ID": "642a0e8d-29f6-4858-8be4-6022d43d56bf", "Styles": "None", "Classes": "None", "Text": "In the HBeAg\u00a0negative study patients on adefovir dipivoxil (0\u201148\u00a0weeks) were re-randomised in a blinded-manner to continue on adefovir dipivoxil or receive placebo for an additional 48\u00a0weeks.\u00a0 At week\u00a096, patients continuing on adefovir dipivoxil 10\u00a0mg had sustained suppression of serum HBV\u00a0with maintenance of the reduction seen at week\u00a048.\u00a0 In over two thirds of patients suppression of serum HBV\u00a0DNA was associated with normalisation of ALT levels.\u00a0 In most patients who stopped treatment with adefovir dipivoxil, serum HBV\u00a0DNA and ALT levels returned towards baseline.", "ParentId": "d00d61fb-d27e-49a5-b50f-ddc8e52dbc3c"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f548339b-e87f-434a-8458-14893d531e11", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "85c65623-6ca4-4f2d-bf53-0d3c1c865510", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f548339b-e87f-434a-8458-14893d531e11"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Treatment with\nadefovir dipivoxil resulted in improvement in the liver fibrosis from baseline\nto 96\u00a0weeks therapy when analysed using the Ishak score (median change: \u0394=\u00a0\u20111).\u00a0\nNo differences in the median fibrosis score were seen between groups using the\nKnodell fibrosis score.</span></p>", "ID": "97d68533-b170-4eec-85c9-aed554ec1eed", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Treatment with\nadefovir dipivoxil resulted in improvement in the liver fibrosis from baseline\nto 96\u00a0weeks therapy when analysed using the Ishak score (median change: \u0394=\u00a0\u20111).\u00a0\nNo differences in the median fibrosis score were seen between groups using the\nKnodell fibrosis score.</span>", "ID": "3d9e33b9-f817-40fa-aefe-26c1994f980b", "Styles": "None", "Classes": "None", "Text": "Treatment with adefovir dipivoxil resulted in improvement in the liver fibrosis from baseline to 96\u00a0weeks therapy when analysed using the Ishak score (median change: \u0394=\u00a0\u20111).\u00a0 No differences in the median fibrosis score were seen between groups using the Knodell fibrosis score.", "ParentId": "97d68533-b170-4eec-85c9-aed554ec1eed"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1bbbc0bc-9f76-4287-8e21-1c346a0f61d0", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4315af2d-674f-4e0e-8900-61a3ee79ab95", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1bbbc0bc-9f76-4287-8e21-1c346a0f61d0"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Patients who\ncompleted the first 96\u00a0weeks of the HBeAg\u00a0negative study and received\nadefovir dipivoxil treatment during weeks\u00a049 to 96, were offered the\nopportunity to receive open-label treatment with adefovir dipivoxil from study\nweek\u00a097 through to week\u00a0240.\u00a0 Serum HBV\u00a0DNA levels remained\nundetectable and ALT levels normalised in approximately two thirds of patients\nfollowing treatment with adefovir dipivoxil for up to 240\u00a0weeks.\u00a0\nClinically and statistically significant improvement in fibrosis was seen in\nthe changes in Ishak scores from the start of adefovir dipivoxil treatment to\nthe end of the study (week\u00a0240) (median change: \u0394=\u00a0\u20111).\u00a0\nBy the end of the study, 7 of 12\u00a0patients (58\u00a0%) with bridging\nfibrosis or cirrhosis at baseline, had an improved Ishak fibrosis score of\n\u2265\u00a02\u00a0points. \u00a0Five patients achieved and maintained HBsAg\nseroconversion (HBsAg\u00a0negative/HBsAb\u00a0positive).</span></p>", "ID": "f8822c08-0446-42f6-889e-6273c3c023c5", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Patients who\ncompleted the first 96\u00a0weeks of the HBeAg\u00a0negative study and received\nadefovir dipivoxil treatment during weeks\u00a049 to 96, were offered the\nopportunity to receive open-label treatment with adefovir dipivoxil from study\nweek\u00a097 through to week\u00a0240.\u00a0 Serum HBV\u00a0DNA levels remained\nundetectable and ALT levels normalised in approximately two thirds of patients\nfollowing treatment with adefovir dipivoxil for up to 240\u00a0weeks.\u00a0\nClinically and statistically significant improvement in fibrosis was seen in\nthe changes in Ishak scores from the start of adefovir dipivoxil treatment to\nthe end of the study (week\u00a0240) (median change: \u0394=\u00a0\u20111).\u00a0\nBy the end of the study, 7 of 12\u00a0patients (58\u00a0%) with bridging\nfibrosis or cirrhosis at baseline, had an improved Ishak fibrosis score of\n\u2265\u00a02\u00a0points. \u00a0Five patients achieved and maintained HBsAg\nseroconversion (HBsAg\u00a0negative/HBsAb\u00a0positive).</span>", "ID": "6c551cb1-d7ff-4c1e-aa7e-2f698a08a2eb", "Styles": "None", "Classes": "None", "Text": "Patients who completed the first 96\u00a0weeks of the HBeAg\u00a0negative study and received adefovir dipivoxil treatment during weeks\u00a049 to 96, were offered the opportunity to receive open-label treatment with adefovir dipivoxil from study week\u00a097 through to week\u00a0240.\u00a0 Serum HBV\u00a0DNA levels remained undetectable and ALT levels normalised in approximately two thirds of patients following treatment with adefovir dipivoxil for up to 240\u00a0weeks.\u00a0 Clinically and statistically significant improvement in fibrosis was seen in the changes in Ishak scores from the start of adefovir dipivoxil treatment to the end of the study (week\u00a0240) (median change: \u0394=\u00a0\u20111).\u00a0 By the end of the study, 7 of 12\u00a0patients (58\u00a0%) with bridging fibrosis or cirrhosis at baseline, had an improved Ishak fibrosis score of \u2265\u00a02\u00a0points. \u00a0Five patients achieved and maintained HBsAg seroconversion (HBsAg\u00a0negative/HBsAb\u00a0positive).", "ParentId": "f8822c08-0446-42f6-889e-6273c3c023c5"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f82a8dea-1126-41c2-8995-a8e9476abc92", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "40057559-7176-4807-9976-3a31aa9428aa", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f82a8dea-1126-41c2-8995-a8e9476abc92"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Experience in\npatients pre\u2011 and post\u2011liver transplantation with lamivudine\u2011resistant\nHBV:</span></i><span lang=\"EN-GB\"> In a clinical study in 394 chronic\nhepatitis\u00a0B patients with lamivudine-resistant HBV<span style=\"layout-grid-mode:\nline\"> </span>(pre\u2011liver transplantation (n=186) and post\u2011liver\ntransplantation (n=208)), treatment with 10\u00a0mg adefovir dipivoxil resulted\nin a median reduction in serum HBV\u00a0DNA of 4.1 and 4.2\u00a0log<sub>10</sub>\u00a0copies/ml,\nrespectively, at week\u00a048.\u00a0 In the pre\u2011liver transplantation and post\u2011liver\ntransplantation cohorts 77 of 109 (71\u00a0%) patients and 64 of 159\n(40\u00a0%) patients, respectively, achieved undetectable HBV\u00a0DNA levels\nat week\u00a048 (&lt;\u00a01,000\u00a0copies/ml Roche Amplicor Monitor PCR\nassay).\u00a0 Treatment with 10\u00a0mg adefovir dipivoxil showed similar efficacy\nregardless of the patterns of lamivudine-resistant HBV\u00a0DNA polymerase\nmutations at baseline.\u00a0 Improvements or stabilisation were seen in\nChild-Pugh-Turcotte score.\u00a0 Normalisation of ALT, albumin, bilirubin and\nprothrombin time was seen at week\u00a048 in 51\u201185\u00a0% of the\npatients.</span></p>", "ID": "f88477ce-64dd-4e3b-9b68-74d77151ee91", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Experience in\npatients pre\u2011 and post\u2011liver transplantation with lamivudine\u2011resistant\nHBV:</span></i>", "ID": "0c4306b6-7d6a-40ac-8c59-5c5a84899a7d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f88477ce-64dd-4e3b-9b68-74d77151ee91"}, {"Element": "<span lang=\"EN-GB\">Experience in\npatients pre\u2011 and post\u2011liver transplantation with lamivudine\u2011resistant\nHBV:</span>", "ID": "8e08e91f-c93d-49ce-8fcc-9589d40911f6", "Styles": "None", "Classes": "None", "Text": "Experience in patients pre\u2011 and post\u2011liver transplantation with lamivudine\u2011resistant HBV:", "ParentId": "0c4306b6-7d6a-40ac-8c59-5c5a84899a7d"}, {"Element": "<span lang=\"EN-GB\"> In a clinical study in 394 chronic\nhepatitis\u00a0B patients with lamivudine-resistant HBV<span style=\"layout-grid-mode:\nline\"> </span>(pre\u2011liver transplantation (n=186) and post\u2011liver\ntransplantation (n=208)), treatment with 10\u00a0mg adefovir dipivoxil resulted\nin a median reduction in serum HBV\u00a0DNA of 4.1 and 4.2\u00a0log<sub>10</sub>\u00a0copies/ml,\nrespectively, at week\u00a048.\u00a0 In the pre\u2011liver transplantation and post\u2011liver\ntransplantation cohorts 77 of 109 (71\u00a0%) patients and 64 of 159\n(40\u00a0%) patients, respectively, achieved undetectable HBV\u00a0DNA levels\nat week\u00a048 (&lt;\u00a01,000\u00a0copies/ml Roche Amplicor Monitor PCR\nassay).\u00a0 Treatment with 10\u00a0mg adefovir dipivoxil showed similar efficacy\nregardless of the patterns of lamivudine-resistant HBV\u00a0DNA polymerase\nmutations at baseline.\u00a0 Improvements or stabilisation were seen in\nChild-Pugh-Turcotte score.\u00a0 Normalisation of ALT, albumin, bilirubin and\nprothrombin time was seen at week\u00a048 in 51\u201185\u00a0% of the\npatients.</span>", "ID": "65182d36-951e-4a33-8d97-ca07fb381db6", "Styles": "None", "Classes": "None", "Text": " In a clinical study in 394 chronic hepatitis\u00a0B patients with lamivudine-resistant HBV(pre\u2011liver transplantation (n=186) and post\u2011liver transplantation (n=208)), treatment with 10\u00a0mg adefovir dipivoxil resulted in a median reduction in serum HBV\u00a0DNA of 4.1 and 4.2\u00a0log\u00a0copies/ml, respectively, at week\u00a048.\u00a0 In the pre\u2011liver transplantation and post\u2011liver transplantation cohorts 77 of 109 (71\u00a0%) patients and 64 of 159 (40\u00a0%) patients, respectively, achieved undetectable HBV\u00a0DNA levels at week\u00a048 (<\u00a01,000\u00a0copies/ml Roche Amplicor Monitor PCR assay).\u00a0 Treatment with 10\u00a0mg adefovir dipivoxil showed similar efficacy regardless of the patterns of lamivudine-resistant HBV\u00a0DNA polymerase mutations at baseline.\u00a0 Improvements or stabilisation were seen in Child-Pugh-Turcotte score.\u00a0 Normalisation of ALT, albumin, bilirubin and prothrombin time was seen at week\u00a048 in 51\u201185\u00a0% of the patients.", "ParentId": "f88477ce-64dd-4e3b-9b68-74d77151ee91"}, {"Element": "<span style=\"layout-grid-mode:\nline\"> </span>", "ID": "3c90e56e-cf4f-41a6-90b7-9a0817cacc5f", "Styles": "layout-grid-mode:\nline", "Classes": "None", "Text": " ", "ParentId": "65182d36-951e-4a33-8d97-ca07fb381db6"}, {"Element": "<sub>10</sub>", "ID": "6e9e7b76-d869-4fd9-bc3d-3f357a21d6d0", "Styles": "None", "Classes": "None", "Text": "10", "ParentId": "65182d36-951e-4a33-8d97-ca07fb381db6"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c5043c15-2358-45d9-b7e4-90a417dd8c6b", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4943511b-e128-459b-8399-109a48c5e96b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c5043c15-2358-45d9-b7e4-90a417dd8c6b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In the pre\u2011liver\ntransplantation cohort, 25 of 33 (76\u00a0%) patients achieved undetectable\nHBV\u00a0DNA levels and 84\u00a0% of patients had ALT normalisation at\n96\u00a0weeks.\u00a0 In the post\u2011liver transplantation cohort, 61 of 94\n(65\u00a0%) and 35 of 45 (78\u00a0%) of patients achieved undetectable\nHBV\u00a0DNA levels at 96\u00a0and 144\u00a0weeks, respectively, and 70\u00a0%\nand 58\u00a0% of patients had ALT normalisation at these study visits.\u00a0 The\nclinical significance of these findings as they relate to histological\nimprovement is not known.</span></p>", "ID": "9e740645-ceff-4484-9ccc-9c46bf22e8b8", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">In the pre\u2011liver\ntransplantation cohort, 25 of 33 (76\u00a0%) patients achieved undetectable\nHBV\u00a0DNA levels and 84\u00a0% of patients had ALT normalisation at\n96\u00a0weeks.\u00a0 In the post\u2011liver transplantation cohort, 61 of 94\n(65\u00a0%) and 35 of 45 (78\u00a0%) of patients achieved undetectable\nHBV\u00a0DNA levels at 96\u00a0and 144\u00a0weeks, respectively, and 70\u00a0%\nand 58\u00a0% of patients had ALT normalisation at these study visits.\u00a0 The\nclinical significance of these findings as they relate to histological\nimprovement is not known.</span>", "ID": "bedeb62d-4d9e-436e-ab82-53d2ff079bb7", "Styles": "None", "Classes": "None", "Text": "In the pre\u2011liver transplantation cohort, 25 of 33 (76\u00a0%) patients achieved undetectable HBV\u00a0DNA levels and 84\u00a0% of patients had ALT normalisation at 96\u00a0weeks.\u00a0 In the post\u2011liver transplantation cohort, 61 of 94 (65\u00a0%) and 35 of 45 (78\u00a0%) of patients achieved undetectable HBV\u00a0DNA levels at 96\u00a0and 144\u00a0weeks, respectively, and 70\u00a0% and 58\u00a0% of patients had ALT normalisation at these study visits.\u00a0 The clinical significance of these findings as they relate to histological improvement is not known.", "ParentId": "9e740645-ceff-4484-9ccc-9c46bf22e8b8"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a317a482-72b5-4787-a6b5-f16532a335e2", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1c7737d7-76c5-4baf-8215-43e870ff59bd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a317a482-72b5-4787-a6b5-f16532a335e2"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Experience in\npatients with compensated liver disease and lamivudine\u2011resistant HBV:</span></i><span lang=\"EN-GB\"> In a double\u2011blind comparative study in chronic\nhepatitis\u00a0B <span style=\"layout-grid-mode:line\">patients with </span>lamivudine\u2011resistant\nHBV<span style=\"layout-grid-mode:line\"> </span>(n=58),<span style=\"layout-grid-mode:\nline\"> there was no </span>median reduction in HBV\u00a0DNA from baseline<span style=\"layout-grid-mode:line\"> after </span>48\u00a0weeks of treatment with\nlamivudine.\u00a0 Forty-eight weeks of treatment with adefovir dipivoxil 10\u00a0mg\nalone or in combination with lamivudine resulted in a similar significant\ndecrease in median serum HBV\u00a0DNA levels from baseline (4.04\u00a0<span style=\"layout-grid-mode:line\">log<sub>10</sub>\u00a0copies/ml and 3.59\u00a0log<sub>10</sub>\u00a0copies/ml,\nrespectively).\u00a0 The clinical significance of these observed changes in\nHBV\u00a0DNA has </span>not been established.</span></p>", "ID": "2ae115be-b54f-4410-9a1b-8342bed0c134", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Experience in\npatients with compensated liver disease and lamivudine\u2011resistant HBV:</span></i>", "ID": "3ab65778-df5a-4c68-a3fb-64ea1d8d7af8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2ae115be-b54f-4410-9a1b-8342bed0c134"}, {"Element": "<span lang=\"EN-GB\">Experience in\npatients with compensated liver disease and lamivudine\u2011resistant HBV:</span>", "ID": "f7e07798-eac3-446d-8c28-4ce31280c503", "Styles": "None", "Classes": "None", "Text": "Experience in patients with compensated liver disease and lamivudine\u2011resistant HBV:", "ParentId": "3ab65778-df5a-4c68-a3fb-64ea1d8d7af8"}, {"Element": "<span lang=\"EN-GB\"> In a double\u2011blind comparative study in chronic\nhepatitis\u00a0B <span style=\"layout-grid-mode:line\">patients with </span>lamivudine\u2011resistant\nHBV<span style=\"layout-grid-mode:line\"> </span>(n=58),<span style=\"layout-grid-mode:\nline\"> there was no </span>median reduction in HBV\u00a0DNA from baseline<span style=\"layout-grid-mode:line\"> after </span>48\u00a0weeks of treatment with\nlamivudine.\u00a0 Forty-eight weeks of treatment with adefovir dipivoxil 10\u00a0mg\nalone or in combination with lamivudine resulted in a similar significant\ndecrease in median serum HBV\u00a0DNA levels from baseline (4.04\u00a0<span style=\"layout-grid-mode:line\">log<sub>10</sub>\u00a0copies/ml and 3.59\u00a0log<sub>10</sub>\u00a0copies/ml,\nrespectively).\u00a0 The clinical significance of these observed changes in\nHBV\u00a0DNA has </span>not been established.</span>", "ID": "b2e29204-e7cd-40d5-8669-a05b06b8fd68", "Styles": "None", "Classes": "None", "Text": " In a double\u2011blind comparative study in chronic hepatitis\u00a0B lamivudine\u2011resistant HBV(n=58),median reduction in HBV\u00a0DNA from baseline48\u00a0weeks of treatment with lamivudine.\u00a0 Forty-eight weeks of treatment with adefovir dipivoxil 10\u00a0mg alone or in combination with lamivudine resulted in a similar significant decrease in median serum HBV\u00a0DNA levels from baseline (4.04\u00a0not been established.", "ParentId": "2ae115be-b54f-4410-9a1b-8342bed0c134"}, {"Element": "<span style=\"layout-grid-mode:line\">patients with </span>", "ID": "cdfacdf5-df18-44ea-ad11-bca5aa80ed9a", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "patients with ", "ParentId": "b2e29204-e7cd-40d5-8669-a05b06b8fd68"}, {"Element": "<span style=\"layout-grid-mode:line\"> </span>", "ID": "91024bb9-a849-4fe5-89e4-73f0bf92fe8b", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": " ", "ParentId": "b2e29204-e7cd-40d5-8669-a05b06b8fd68"}, {"Element": "<span style=\"layout-grid-mode:\nline\"> there was no </span>", "ID": "4a182bd1-d6f0-4ef8-bdf4-997e7f685091", "Styles": "layout-grid-mode:\nline", "Classes": "None", "Text": " there was no ", "ParentId": "b2e29204-e7cd-40d5-8669-a05b06b8fd68"}, {"Element": "<span style=\"layout-grid-mode:line\"> after </span>", "ID": "53f7ff65-054f-4f91-ab2a-c7a5bff90076", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": " after ", "ParentId": "b2e29204-e7cd-40d5-8669-a05b06b8fd68"}, {"Element": "<span style=\"layout-grid-mode:line\">log<sub>10</sub>\u00a0copies/ml and 3.59\u00a0log<sub>10</sub>\u00a0copies/ml,\nrespectively).\u00a0 The clinical significance of these observed changes in\nHBV\u00a0DNA has </span>", "ID": "c5ca46be-9bcc-42d6-9557-7d51e75596b4", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "log\u00a0copies/ml and 3.59\u00a0log\u00a0copies/ml, respectively).\u00a0 The clinical significance of these observed changes in HBV\u00a0DNA has ", "ParentId": "b2e29204-e7cd-40d5-8669-a05b06b8fd68"}, {"Element": "<sub>10</sub>", "ID": "55920c50-9db6-427a-83ec-2b6a35d59fb4", "Styles": "None", "Classes": "None", "Text": "10", "ParentId": "c5ca46be-9bcc-42d6-9557-7d51e75596b4"}, {"Element": "<sub>10</sub>", "ID": "2faacf16-b649-47f7-ba15-4a63eb533987", "Styles": "None", "Classes": "None", "Text": "10", "ParentId": "c5ca46be-9bcc-42d6-9557-7d51e75596b4"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "676025db-0b24-4c56-86e8-808c7b613c6b", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "17e12985-7528-43da-b2b6-4bc2e57c6515", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "676025db-0b24-4c56-86e8-808c7b613c6b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Experience in\npatients with decompensated liver disease and lamivudine\u2011resistant HBV:</span></i><span lang=\"EN-GB\"> In 40 HBeAg positive or HBeAg negative patients with\nlamivudine-resistant HBV and decompensated liver disease receiving treatment\nwith 100\u00a0mg lamivudine, addition of 10\u00a0mg adefovir dipivoxil\ntreatment for 52\u00a0weeks resulted in a median reduction in HBV\u00a0DNA of\n4.6\u00a0log<sub>10</sub>\u00a0copies/ml.\u00a0 Improvement in liver function was\nalso seen after one year of therapy.</span></p>", "ID": "6a7d3cb7-c5f9-4b29-af41-8e6fa5038061", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Experience in\npatients with decompensated liver disease and lamivudine\u2011resistant HBV:</span></i>", "ID": "24edd6ee-66f3-42f8-99ac-edb3b9198415", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6a7d3cb7-c5f9-4b29-af41-8e6fa5038061"}, {"Element": "<span lang=\"EN-GB\">Experience in\npatients with decompensated liver disease and lamivudine\u2011resistant HBV:</span>", "ID": "247052fc-cf9a-417e-9652-0efc1db76114", "Styles": "None", "Classes": "None", "Text": "Experience in patients with decompensated liver disease and lamivudine\u2011resistant HBV:", "ParentId": "24edd6ee-66f3-42f8-99ac-edb3b9198415"}, {"Element": "<span lang=\"EN-GB\"> In 40 HBeAg positive or HBeAg negative patients with\nlamivudine-resistant HBV and decompensated liver disease receiving treatment\nwith 100\u00a0mg lamivudine, addition of 10\u00a0mg adefovir dipivoxil\ntreatment for 52\u00a0weeks resulted in a median reduction in HBV\u00a0DNA of\n4.6\u00a0log<sub>10</sub>\u00a0copies/ml.\u00a0 Improvement in liver function was\nalso seen after one year of therapy.</span>", "ID": "6e417cfc-3d05-4022-84dc-0c96a8b740ae", "Styles": "None", "Classes": "None", "Text": " In 40 HBeAg positive or HBeAg negative patients with lamivudine-resistant HBV and decompensated liver disease receiving treatment with 100\u00a0mg lamivudine, addition of 10\u00a0mg adefovir dipivoxil treatment for 52\u00a0weeks resulted in a median reduction in HBV\u00a0DNA of 4.6\u00a0log\u00a0copies/ml.\u00a0 Improvement in liver function was also seen after one year of therapy.", "ParentId": "6a7d3cb7-c5f9-4b29-af41-8e6fa5038061"}, {"Element": "<sub>10</sub>", "ID": "b5708cc2-1605-4f74-9bb1-3798db5c12d1", "Styles": "None", "Classes": "None", "Text": "10", "ParentId": "6e417cfc-3d05-4022-84dc-0c96a8b740ae"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "59ef6f85-f80e-4e72-8494-f745ae1775e9", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0f3d395b-a6fb-438d-9fd6-aceed9a0a04d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "59ef6f85-f80e-4e72-8494-f745ae1775e9"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Experience in\npatients with HIV co\u2011infection and lamivudine\u2011resistant HBV:</span></i><span lang=\"EN-GB\"> In an open-label investigator study in 35 chronic hepatitis\u00a0B\npatients with lamivudine-resistant HBV and co\u2011infected with HIV,\ncontinued treatment with 10\u00a0mg adefovir dipivoxil resulted in progressive\nreductions in serum HBV\u00a0DNA levels and ALT levels throughout the course of\ntreatment up to 144\u00a0weeks.</span></p>", "ID": "2c2a3ffe-54c4-4cda-841e-6c3faaa4f90d", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Experience in\npatients with HIV co\u2011infection and lamivudine\u2011resistant HBV:</span></i>", "ID": "dee9ba79-4510-41a9-b0c1-3f7e7c82cbcf", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2c2a3ffe-54c4-4cda-841e-6c3faaa4f90d"}, {"Element": "<span lang=\"EN-GB\">Experience in\npatients with HIV co\u2011infection and lamivudine\u2011resistant HBV:</span>", "ID": "26a1d52a-5876-46b9-a654-a6a78d285f7a", "Styles": "None", "Classes": "None", "Text": "Experience in patients with HIV co\u2011infection and lamivudine\u2011resistant HBV:", "ParentId": "dee9ba79-4510-41a9-b0c1-3f7e7c82cbcf"}, {"Element": "<span lang=\"EN-GB\"> In an open-label investigator study in 35 chronic hepatitis\u00a0B\npatients with lamivudine-resistant HBV and co\u2011infected with HIV,\ncontinued treatment with 10\u00a0mg adefovir dipivoxil resulted in progressive\nreductions in serum HBV\u00a0DNA levels and ALT levels throughout the course of\ntreatment up to 144\u00a0weeks.</span>", "ID": "4a3ae75f-1d2e-49ef-820d-9d06c5ac19d7", "Styles": "None", "Classes": "None", "Text": " In an open-label investigator study in 35 chronic hepatitis\u00a0B patients with lamivudine-resistant HBV and co\u2011infected with HIV, continued treatment with 10\u00a0mg adefovir dipivoxil resulted in progressive reductions in serum HBV\u00a0DNA levels and ALT levels throughout the course of treatment up to 144\u00a0weeks.", "ParentId": "2c2a3ffe-54c4-4cda-841e-6c3faaa4f90d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0b28ad01-f312-4e0b-a37a-dc737910a900", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "eabcc556-8887-4a8f-b5f1-ec416d65c937", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0b28ad01-f312-4e0b-a37a-dc737910a900"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In a second open\u2011label,\none\u2011arm study, 10\u00a0mg adefovir dipivoxil and pegylated interferon\nalpha\u20112a were added to ongoing lamivudine therapy in 18 HIV/HBV co\u2011infected\npatients with lamivudine\u2011resistant HBV.\u00a0 Patients were all HBeAg\u00a0positive\nand had median CD4 cell count of 441\u00a0cells/mm<sup>3</sup> (no patient had\nCD4 count &lt;\u00a0200\u00a0cells/mm<sup>3</sup>).\u00a0 During therapy, serum HBV\u00a0DNA\nlevels were significantly lower compared to baseline for up to 48\u00a0weeks of\ntreatment while ALT levels declined progressively from week\u00a012.\u00a0 However,\non\u2011treatment HBV\u00a0DNA response was not maintained off\u2011therapy\nsince all the patients had a rebound in HBV\u00a0DNA after adefovir dipivoxil\nand pegylated interferon alpha\u20112a discontinuation.\u00a0 No patients became\nHBsAg\u2011 or HBeAg\u2011negative during the study.\u00a0 Due to the small sample\nsize and the study design, in particular the lack of treatment arms with\npegylated interferon alpha\u20112a monotherapy and with adefovir monotherapy, it\nis not possible to draw formal conclusions on the best therapeutic management\nof HIV co\u2011infected patients with lamivudine\u2011resistant HBV.</span></p>", "ID": "571095bf-c44b-4da4-b873-ffbd84328f8d", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">In a second open\u2011label,\none\u2011arm study, 10\u00a0mg adefovir dipivoxil and pegylated interferon\nalpha\u20112a were added to ongoing lamivudine therapy in 18 HIV/HBV co\u2011infected\npatients with lamivudine\u2011resistant HBV.\u00a0 Patients were all HBeAg\u00a0positive\nand had median CD4 cell count of 441\u00a0cells/mm<sup>3</sup> (no patient had\nCD4 count &lt;\u00a0200\u00a0cells/mm<sup>3</sup>).\u00a0 During therapy, serum HBV\u00a0DNA\nlevels were significantly lower compared to baseline for up to 48\u00a0weeks of\ntreatment while ALT levels declined progressively from week\u00a012.\u00a0 However,\non\u2011treatment HBV\u00a0DNA response was not maintained off\u2011therapy\nsince all the patients had a rebound in HBV\u00a0DNA after adefovir dipivoxil\nand pegylated interferon alpha\u20112a discontinuation.\u00a0 No patients became\nHBsAg\u2011 or HBeAg\u2011negative during the study.\u00a0 Due to the small sample\nsize and the study design, in particular the lack of treatment arms with\npegylated interferon alpha\u20112a monotherapy and with adefovir monotherapy, it\nis not possible to draw formal conclusions on the best therapeutic management\nof HIV co\u2011infected patients with lamivudine\u2011resistant HBV.</span>", "ID": "672ec16b-b9df-435a-9117-d6f1619e3a8d", "Styles": "None", "Classes": "None", "Text": "In a second open\u2011label, one\u2011arm study, 10\u00a0mg adefovir dipivoxil and pegylated interferon alpha\u20112a were added to ongoing lamivudine therapy in 18 HIV/HBV co\u2011infected patients with lamivudine\u2011resistant HBV.\u00a0 Patients were all HBeAg\u00a0positive and had median CD4 cell count of 441\u00a0cells/mm (no patient had CD4 count <\u00a0200\u00a0cells/mm).\u00a0 During therapy, serum HBV\u00a0DNA levels were significantly lower compared to baseline for up to 48\u00a0weeks of treatment while ALT levels declined progressively from week\u00a012.\u00a0 However, on\u2011treatment HBV\u00a0DNA response was not maintained off\u2011therapy since all the patients had a rebound in HBV\u00a0DNA after adefovir dipivoxil and pegylated interferon alpha\u20112a discontinuation.\u00a0 No patients became HBsAg\u2011 or HBeAg\u2011negative during the study.\u00a0 Due to the small sample size and the study design, in particular the lack of treatment arms with pegylated interferon alpha\u20112a monotherapy and with adefovir monotherapy, it is not possible to draw formal conclusions on the best therapeutic management of HIV co\u2011infected patients with lamivudine\u2011resistant HBV.", "ParentId": "571095bf-c44b-4da4-b873-ffbd84328f8d"}, {"Element": "<sup>3</sup>", "ID": "177a4eb5-3216-4c18-b7dd-b0215ed50f83", "Styles": "None", "Classes": "None", "Text": "3", "ParentId": "672ec16b-b9df-435a-9117-d6f1619e3a8d"}, {"Element": "<sup>3</sup>", "ID": "cdcebffe-f0ad-4d2d-9676-da19c526c2a6", "Styles": "None", "Classes": "None", "Text": "3", "ParentId": "672ec16b-b9df-435a-9117-d6f1619e3a8d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d23aca31-70df-4d92-8db3-db809a24d0e8", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "eee168cd-c7c5-4c29-8105-b1e149edf8f9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d23aca31-70df-4d92-8db3-db809a24d0e8"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:8.1pt;line-height:normal;text-autospace:\nnone\"><i><span lang=\"EN-GB\">Clinical resistance in patients receiving adefovir\ndipivoxil as monotherapy and in combination with lamivudine:</span></i><span lang=\"EN-GB\"> In several clinical studies (HBeAg\u00a0positive,\nHBeAg\u00a0negative, pre\u2011 and post-liver transplantation with\nlamivudine-resistant HBV and lamivudine-resistant HBV co\u2011infected with\nHIV patients), genotypic analyses were conducted on HBV isolates from 379 of a\ntotal of 629\u00a0patients, treated with adefovir dipivoxil for 48\u00a0weeks.\u00a0\nNo HBV\u00a0DNA polymerase mutations associated with resistance to adefovir\nwere identified when patients were genotyped at baseline and at week\u00a048.\u00a0\nAfter 96, 144, 192 and 240\u00a0weeks of treatment with adefovir dipivoxil,\nresistance surveillance was performed for 293, 221, 116 and 64\u00a0patients,\nrespectively.\u00a0 Two novel conserved site mutations were identified in the HBV\npolymerase gene (rtN236T and rtA181V), which conferred clinical resistance to\nadefovir dipivoxil.\u00a0 The cumulative probabilities of developing these\nadefovir-associated resistance mutations in all patients treated with adefovir\ndipivoxil were 0\u00a0% at 48\u00a0weeks and approximately 2\u00a0%, 7\u00a0%, 14\u00a0%\nand 25\u00a0% after 96, 144, 192 and 240\u00a0weeks, respectively.</span></p>", "ID": "356d44d5-a891-489f-9964-312512feb73f", "Styles": "margin-right:8.1pt;line-height:normal;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Clinical resistance in patients receiving adefovir\ndipivoxil as monotherapy and in combination with lamivudine:</span></i>", "ID": "713a3ce1-7254-4212-9186-e83ceb13d7be", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "356d44d5-a891-489f-9964-312512feb73f"}, {"Element": "<span lang=\"EN-GB\">Clinical resistance in patients receiving adefovir\ndipivoxil as monotherapy and in combination with lamivudine:</span>", "ID": "777fc61b-bed3-417c-8404-5966d1cecf0a", "Styles": "None", "Classes": "None", "Text": "Clinical resistance in patients receiving adefovir dipivoxil as monotherapy and in combination with lamivudine:", "ParentId": "713a3ce1-7254-4212-9186-e83ceb13d7be"}, {"Element": "<span lang=\"EN-GB\"> In several clinical studies (HBeAg\u00a0positive,\nHBeAg\u00a0negative, pre\u2011 and post-liver transplantation with\nlamivudine-resistant HBV and lamivudine-resistant HBV co\u2011infected with\nHIV patients), genotypic analyses were conducted on HBV isolates from 379 of a\ntotal of 629\u00a0patients, treated with adefovir dipivoxil for 48\u00a0weeks.\u00a0\nNo HBV\u00a0DNA polymerase mutations associated with resistance to adefovir\nwere identified when patients were genotyped at baseline and at week\u00a048.\u00a0\nAfter 96, 144, 192 and 240\u00a0weeks of treatment with adefovir dipivoxil,\nresistance surveillance was performed for 293, 221, 116 and 64\u00a0patients,\nrespectively.\u00a0 Two novel conserved site mutations were identified in the HBV\npolymerase gene (rtN236T and rtA181V), which conferred clinical resistance to\nadefovir dipivoxil.\u00a0 The cumulative probabilities of developing these\nadefovir-associated resistance mutations in all patients treated with adefovir\ndipivoxil were 0\u00a0% at 48\u00a0weeks and approximately 2\u00a0%, 7\u00a0%, 14\u00a0%\nand 25\u00a0% after 96, 144, 192 and 240\u00a0weeks, respectively.</span>", "ID": "bdc76305-1ecf-4f76-8726-a4a3b7cb3c21", "Styles": "None", "Classes": "None", "Text": " In several clinical studies (HBeAg\u00a0positive, HBeAg\u00a0negative, pre\u2011 and post-liver transplantation with lamivudine-resistant HBV and lamivudine-resistant HBV co\u2011infected with HIV patients), genotypic analyses were conducted on HBV isolates from 379 of a total of 629\u00a0patients, treated with adefovir dipivoxil for 48\u00a0weeks.\u00a0 No HBV\u00a0DNA polymerase mutations associated with resistance to adefovir were identified when patients were genotyped at baseline and at week\u00a048.\u00a0 After 96, 144, 192 and 240\u00a0weeks of treatment with adefovir dipivoxil, resistance surveillance was performed for 293, 221, 116 and 64\u00a0patients, respectively.\u00a0 Two novel conserved site mutations were identified in the HBV polymerase gene (rtN236T and rtA181V), which conferred clinical resistance to adefovir dipivoxil.\u00a0 The cumulative probabilities of developing these adefovir-associated resistance mutations in all patients treated with adefovir dipivoxil were 0\u00a0% at 48\u00a0weeks and approximately 2\u00a0%, 7\u00a0%, 14\u00a0% and 25\u00a0% after 96, 144, 192 and 240\u00a0weeks, respectively.", "ParentId": "356d44d5-a891-489f-9964-312512feb73f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:8.1pt;line-height:normal;text-autospace:\nnone\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f8c8161c-64d9-4777-9de9-2cb21febde75", "Styles": "margin-right:8.1pt;line-height:normal;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c35280cb-30c8-46ec-8bf7-edb2cc2f7a83", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f8c8161c-64d9-4777-9de9-2cb21febde75"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:8.1pt;line-height:normal;text-autospace:\nnone\"><i><span lang=\"EN-GB\">Clinical resistance in monotherapy studies in\nnucleoside na\u00efve patients:</span></i><span lang=\"EN-GB\"> In patients receiving\nadefovir dipivoxil monotherapy (HBeAg\u00a0negative study) the cumulative\nprobability of developing adefovir\u2011associated resistance mutations was\n0\u00a0%, 3\u00a0%, 11\u00a0%, 18\u00a0% and 29\u00a0% at 48, 96, 144, 192 and\n240\u00a0weeks respectively.\u00a0 In addition, the long\u2011term (4 to\n5\u00a0years) development of resistance to adefovir dipivoxil was significantly\nlower in patients who had serum HBV\u00a0DNA below the limit of quantification\n(&lt;\u00a01,000\u00a0copies/ml) at week\u00a048 as compared to patients with\nserum HBV\u00a0DNA above 1,000\u00a0copies/ml at week\u00a048.\u00a0 In HBeAg\u00a0positive\npatients, the incidence of adefovir-associated resistance mutations was\n3\u00a0% (2/65), 17\u00a0% (11/65) and 20\u00a0% (13/65) after a median\nduration exposure of 135, 189 and 235\u00a0weeks respectively.</span></p>", "ID": "f8a84edf-d28b-4c36-8361-9c4764f81c00", "Styles": "margin-right:8.1pt;line-height:normal;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Clinical resistance in monotherapy studies in\nnucleoside na\u00efve patients:</span></i>", "ID": "387e7a5f-0147-4d66-a5e2-0766131cc09a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f8a84edf-d28b-4c36-8361-9c4764f81c00"}, {"Element": "<span lang=\"EN-GB\">Clinical resistance in monotherapy studies in\nnucleoside na\u00efve patients:</span>", "ID": "4ad43b87-590f-4fa2-875f-4a18d9619946", "Styles": "None", "Classes": "None", "Text": "Clinical resistance in monotherapy studies in nucleoside na\u00efve patients:", "ParentId": "387e7a5f-0147-4d66-a5e2-0766131cc09a"}, {"Element": "<span lang=\"EN-GB\"> In patients receiving\nadefovir dipivoxil monotherapy (HBeAg\u00a0negative study) the cumulative\nprobability of developing adefovir\u2011associated resistance mutations was\n0\u00a0%, 3\u00a0%, 11\u00a0%, 18\u00a0% and 29\u00a0% at 48, 96, 144, 192 and\n240\u00a0weeks respectively.\u00a0 In addition, the long\u2011term (4 to\n5\u00a0years) development of resistance to adefovir dipivoxil was significantly\nlower in patients who had serum HBV\u00a0DNA below the limit of quantification\n(&lt;\u00a01,000\u00a0copies/ml) at week\u00a048 as compared to patients with\nserum HBV\u00a0DNA above 1,000\u00a0copies/ml at week\u00a048.\u00a0 In HBeAg\u00a0positive\npatients, the incidence of adefovir-associated resistance mutations was\n3\u00a0% (2/65), 17\u00a0% (11/65) and 20\u00a0% (13/65) after a median\nduration exposure of 135, 189 and 235\u00a0weeks respectively.</span>", "ID": "344bddf1-13fe-46a2-90b3-ba520e17a7de", "Styles": "None", "Classes": "None", "Text": " In patients receiving adefovir dipivoxil monotherapy (HBeAg\u00a0negative study) the cumulative probability of developing adefovir\u2011associated resistance mutations was 0\u00a0%, 3\u00a0%, 11\u00a0%, 18\u00a0% and 29\u00a0% at 48, 96, 144, 192 and 240\u00a0weeks respectively.\u00a0 In addition, the long\u2011term (4 to 5\u00a0years) development of resistance to adefovir dipivoxil was significantly lower in patients who had serum HBV\u00a0DNA below the limit of quantification (<\u00a01,000\u00a0copies/ml) at week\u00a048 as compared to patients with serum HBV\u00a0DNA above 1,000\u00a0copies/ml at week\u00a048.\u00a0 In HBeAg\u00a0positive patients, the incidence of adefovir-associated resistance mutations was 3\u00a0% (2/65), 17\u00a0% (11/65) and 20\u00a0% (13/65) after a median duration exposure of 135, 189 and 235\u00a0weeks respectively.", "ParentId": "f8a84edf-d28b-4c36-8361-9c4764f81c00"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:8.1pt;line-height:normal;text-autospace:\nnone\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c956209b-92d1-4e38-9a35-14c363474ebe", "Styles": "margin-right:8.1pt;line-height:normal;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6ef8e107-1115-4640-b82d-12bd0237e5c9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c956209b-92d1-4e38-9a35-14c363474ebe"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:8.1pt;line-height:normal;text-autospace:\nnone\"><i><span lang=\"EN-GB\">Clinical resistance in studies where adefovir\ndipivoxil was added to ongoing lamivudine in patients with\nlamivudine-resistance:</span></i><span lang=\"EN-GB\"> In an open-label study of\npre\u2011 and post\u2011liver transplantation patients with clinical evidence\nof lamivudine-resistant HBV, no adefovir-associated resistance mutations were\nobserved at week\u00a048.\u00a0 With up to 3\u00a0years of exposure, no patients\nreceiving both adefovir dipivoxil and lamivudine developed resistance to\nadefovir dipivoxil. \u00a0However, 4\u00a0patients who discontinued lamivudine\ntreatment developed the rtN236T mutation while receiving adefovir dipivoxil\nmonotherapy and all experienced serum HBV rebound.</span></p>", "ID": "432fc318-e357-4117-8f84-43c8ba240a45", "Styles": "margin-right:8.1pt;line-height:normal;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Clinical resistance in studies where adefovir\ndipivoxil was added to ongoing lamivudine in patients with\nlamivudine-resistance:</span></i>", "ID": "30222a99-8892-487b-8d6b-173710f55261", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "432fc318-e357-4117-8f84-43c8ba240a45"}, {"Element": "<span lang=\"EN-GB\">Clinical resistance in studies where adefovir\ndipivoxil was added to ongoing lamivudine in patients with\nlamivudine-resistance:</span>", "ID": "dc92ec06-c036-4f39-b457-b4802f3691bd", "Styles": "None", "Classes": "None", "Text": "Clinical resistance in studies where adefovir dipivoxil was added to ongoing lamivudine in patients with lamivudine-resistance:", "ParentId": "30222a99-8892-487b-8d6b-173710f55261"}, {"Element": "<span lang=\"EN-GB\"> In an open-label study of\npre\u2011 and post\u2011liver transplantation patients with clinical evidence\nof lamivudine-resistant HBV, no adefovir-associated resistance mutations were\nobserved at week\u00a048.\u00a0 With up to 3\u00a0years of exposure, no patients\nreceiving both adefovir dipivoxil and lamivudine developed resistance to\nadefovir dipivoxil. \u00a0However, 4\u00a0patients who discontinued lamivudine\ntreatment developed the rtN236T mutation while receiving adefovir dipivoxil\nmonotherapy and all experienced serum HBV rebound.</span>", "ID": "45448f95-90cf-4748-9482-20cee849e78f", "Styles": "None", "Classes": "None", "Text": " In an open-label study of pre\u2011 and post\u2011liver transplantation patients with clinical evidence of lamivudine-resistant HBV, no adefovir-associated resistance mutations were observed at week\u00a048.\u00a0 With up to 3\u00a0years of exposure, no patients receiving both adefovir dipivoxil and lamivudine developed resistance to adefovir dipivoxil. \u00a0However, 4\u00a0patients who discontinued lamivudine treatment developed the rtN236T mutation while receiving adefovir dipivoxil monotherapy and all experienced serum HBV rebound.", "ParentId": "432fc318-e357-4117-8f84-43c8ba240a45"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:8.1pt;line-height:normal;text-autospace:\nnone\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "51abb313-d26b-438e-b11a-8757b6ede2c0", "Styles": "margin-right:8.1pt;line-height:normal;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "da4601c5-3921-41fe-9044-bb855ce8a4e9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "51abb313-d26b-438e-b11a-8757b6ede2c0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:8.1pt;line-height:normal;text-autospace:\nnone\"><span lang=\"EN-GB\">The currently available data both <i>in\u00a0vitro</i>\nand in patients suggest that HBV expressing the adefovir-associated resistance\nmutation rtN236T is susceptible to lamivudine.\u00a0 Preliminary clinical data\nsuggest the adefovir-associated resistance mutation rtA181V may confer a\nreduced susceptibility to lamivudine, and the lamivudine\u2011associated\nmutation rtA181T may confer a reduced susceptibility to adefovir dipivoxil.</span></p>", "ID": "3d4ceb97-5b85-4443-b678-755b245273db", "Styles": "margin-right:8.1pt;line-height:normal;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">The currently available data both <i>in\u00a0vitro</i>\nand in patients suggest that HBV expressing the adefovir-associated resistance\nmutation rtN236T is susceptible to lamivudine.\u00a0 Preliminary clinical data\nsuggest the adefovir-associated resistance mutation rtA181V may confer a\nreduced susceptibility to lamivudine, and the lamivudine\u2011associated\nmutation rtA181T may confer a reduced susceptibility to adefovir dipivoxil.</span>", "ID": "f10674d8-a517-4252-85c7-4ab0d22f19a2", "Styles": "None", "Classes": "None", "Text": "The currently available data both  and in patients suggest that HBV expressing the adefovir-associated resistance mutation rtN236T is susceptible to lamivudine.\u00a0 Preliminary clinical data suggest the adefovir-associated resistance mutation rtA181V may confer a reduced susceptibility to lamivudine, and the lamivudine\u2011associated mutation rtA181T may confer a reduced susceptibility to adefovir dipivoxil.", "ParentId": "3d4ceb97-5b85-4443-b678-755b245273db"}, {"Element": "<i>in\u00a0vitro</i>", "ID": "f80a5a39-165f-47ec-a61f-5c94f67adef8", "Styles": "None", "Classes": "None", "Text": "in\u00a0vitro", "ParentId": "f10674d8-a517-4252-85c7-4ab0d22f19a2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:8.1pt;line-height:normal;text-autospace:\nnone\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "92a16078-1392-499a-b01b-0e4f2b2287b2", "Styles": "margin-right:8.1pt;line-height:normal;text-autospace:\nnone", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "70241891-1155-48d3-9956-1c75a18f07ff", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "92a16078-1392-499a-b01b-0e4f2b2287b2"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Paediatric population:</span></u></i></p>", "ID": "98cd3136-fab2-4da3-a38e-cf93373fd04b", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><u><span lang=\"EN-GB\">Paediatric population:</span></u></i>", "ID": "89c74207-bb54-42e2-9f86-38d028707712", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "98cd3136-fab2-4da3-a38e-cf93373fd04b"}, {"Element": "<u><span lang=\"EN-GB\">Paediatric population:</span></u>", "ID": "bf0f67ba-0008-4e5f-98d8-2ba034085348", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "89c74207-bb54-42e2-9f86-38d028707712"}, {"Element": "<span lang=\"EN-GB\">Paediatric population:</span>", "ID": "22898b0d-b553-44cc-999f-7ef62d4c7c06", "Styles": "None", "Classes": "None", "Text": "Paediatric population:", "ParentId": "bf0f67ba-0008-4e5f-98d8-2ba034085348"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The efficacy and\nsafety of a daily dose of 0.25\u00a0mg/kg to 10\u00a0mg adefovir dipivoxil in\nchildren (aged from 2 to\u00a0&lt;\u00a018\u00a0years) were examined in a\ndouble\u2011blind, randomised, placebo\u2011controlled study in 173\npaediatric patients (115 on adefovir dipivoxil, 58 on placebo) who had\nHBeAg\u00a0positive chronic hepatitis\u00a0B, serum ALT levels\n\u2265\u00a01.5\u00a0x upper limit of normal (ULN) and compensated liver\ndisease.\u00a0 At week\u00a048, in children aged 2 to 11\u00a0years old, no\nstatistically significant difference was observed in the proportions of\npatients that achieved the primary endpoint of serum HBV<span style=\"color:\nblack;background:white\">\u00a0</span>DNA<span style=\"color:black;background:\nwhite\"> </span>&lt;\u00a01,000\u00a0copies/ml and normal ALT levels between the\nplacebo arm and the adefovir dipivoxil arm.\u00a0 In the adolescent population\n(n=83) (aged from 12 to &lt;\u00a018\u00a0years), significantly more patients\ntreated with adefovir dipivoxil achieved the primary efficacy endpoint and\nobtained significant reductions in serum HBV<span style=\"color:black;\nbackground:white\">\u00a0</span>DNA<span style=\"color:black;background:white\"> </span>(23\u00a0%)\ncompared to placebo\u2011treated patients (0\u00a0%).\u00a0 However, the\nproportions of subjects who achieved HBeAg seroconversion at week\u00a048 were\nsimilar (11\u00a0%) between the placebo arm and the adefovir dipivoxil\n10\u00a0mg arm in adolescent patients.</span></p>", "ID": "77400347-39f2-4030-85f3-55d0d232f0d8", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">The efficacy and\nsafety of a daily dose of 0.25\u00a0mg/kg to 10\u00a0mg adefovir dipivoxil in\nchildren (aged from 2 to\u00a0&lt;\u00a018\u00a0years) were examined in a\ndouble\u2011blind, randomised, placebo\u2011controlled study in 173\npaediatric patients (115 on adefovir dipivoxil, 58 on placebo) who had\nHBeAg\u00a0positive chronic hepatitis\u00a0B, serum ALT levels\n\u2265\u00a01.5\u00a0x upper limit of normal (ULN) and compensated liver\ndisease.\u00a0 At week\u00a048, in children aged 2 to 11\u00a0years old, no\nstatistically significant difference was observed in the proportions of\npatients that achieved the primary endpoint of serum HBV<span style=\"color:\nblack;background:white\">\u00a0</span>DNA<span style=\"color:black;background:\nwhite\"> </span>&lt;\u00a01,000\u00a0copies/ml and normal ALT levels between the\nplacebo arm and the adefovir dipivoxil arm.\u00a0 In the adolescent population\n(n=83) (aged from 12 to &lt;\u00a018\u00a0years), significantly more patients\ntreated with adefovir dipivoxil achieved the primary efficacy endpoint and\nobtained significant reductions in serum HBV<span style=\"color:black;\nbackground:white\">\u00a0</span>DNA<span style=\"color:black;background:white\"> </span>(23\u00a0%)\ncompared to placebo\u2011treated patients (0\u00a0%).\u00a0 However, the\nproportions of subjects who achieved HBeAg seroconversion at week\u00a048 were\nsimilar (11\u00a0%) between the placebo arm and the adefovir dipivoxil\n10\u00a0mg arm in adolescent patients.</span>", "ID": "314d6bc9-29e5-4f45-bff1-f9518946aa08", "Styles": "None", "Classes": "None", "Text": "The efficacy and safety of a daily dose of 0.25\u00a0mg/kg to 10\u00a0mg adefovir dipivoxil in children (aged from 2 to\u00a0<\u00a018\u00a0years) were examined in a double\u2011blind, randomised, placebo\u2011controlled study in 173 paediatric patients (115 on adefovir dipivoxil, 58 on placebo) who had HBeAg\u00a0positive chronic hepatitis\u00a0B, serum ALT levels \u2265\u00a01.5\u00a0x upper limit of normal (ULN) and compensated liver disease.\u00a0 At week\u00a048, in children aged 2 to 11\u00a0years old, no statistically significant difference was observed in the proportions of patients that achieved the primary endpoint of serum HBVDNA<\u00a01,000\u00a0copies/ml and normal ALT levels between the placebo arm and the adefovir dipivoxil arm.\u00a0 In the adolescent population (n=83) (aged from 12 to <\u00a018\u00a0years), significantly more patients treated with adefovir dipivoxil achieved the primary efficacy endpoint and obtained significant reductions in serum HBVDNA(23\u00a0%) compared to placebo\u2011treated patients (0\u00a0%).\u00a0 However, the proportions of subjects who achieved HBeAg seroconversion at week\u00a048 were similar (11\u00a0%) between the placebo arm and the adefovir dipivoxil 10\u00a0mg arm in adolescent patients.", "ParentId": "77400347-39f2-4030-85f3-55d0d232f0d8"}, {"Element": "<span style=\"color:\nblack;background:white\">\u00a0</span>", "ID": "20326af3-53c1-4284-b741-c829cce87193", "Styles": "color:\nblack;background:white", "Classes": "None", "Text": "\u00a0", "ParentId": "314d6bc9-29e5-4f45-bff1-f9518946aa08"}, {"Element": "<span style=\"color:black;background:\nwhite\"> </span>", "ID": "dbd5e22f-612f-4694-9c43-0f1616c75067", "Styles": "color:black;background:\nwhite", "Classes": "None", "Text": " ", "ParentId": "314d6bc9-29e5-4f45-bff1-f9518946aa08"}, {"Element": "<span style=\"color:black;\nbackground:white\">\u00a0</span>", "ID": "f9b71176-2fdc-499e-b72c-ff80ae605901", "Styles": "color:black;\nbackground:white", "Classes": "None", "Text": "\u00a0", "ParentId": "314d6bc9-29e5-4f45-bff1-f9518946aa08"}, {"Element": "<span style=\"color:black;background:white\"> </span>", "ID": "5e71a59e-798e-4a48-a561-ea2fda8f7285", "Styles": "color:black;background:white", "Classes": "None", "Text": " ", "ParentId": "314d6bc9-29e5-4f45-bff1-f9518946aa08"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a8691014-cf88-4965-93af-4ca1b780f18d", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5d1ba90d-0dda-4850-8a75-6e1308203360", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a8691014-cf88-4965-93af-4ca1b780f18d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Overall, the\nsafety profile of adefovir dipivoxil in children was consistent with the known\nsafety profile in adult patients.\u00a0 However, a signal towards a higher rate of\ndecreased appetite and/or food intake was observed in the adefovir arm as\ncompared to the placebo arm.\u00a0 At week\u00a048 and 96, mean changes from\nbaseline in weight and BMI\u00a0Z\u00a0scores tended to decrease in adefovir\ndipivoxil\u2011treated patients.\u00a0 \u00a0At week\u00a048, all placebo-treated\nsubjects who did not exhibit HBeAg or HBsAg seroconversion, plus all adefovir\ndipivoxil\u2011treated subjects, were offered the opportunity to receive\nopen-label adefovir dipivoxil from study week\u00a049 through to week\u00a0240.\u00a0\nA high rate (30%) of hepatic flares was reported following discontinuation of\nadefovir dipivoxil during the 3\u00a0years open\u2011label phase of the\nstudy.\u00a0 Furthermore, for the few patients who remained on drug at week\u00a0240\n(n=12) BMI\u00a0Z\u00a0score was lower than typical for their age and gender.\u00a0\nVery few patients developed adefovir-associated mutations up to 5\u00a0years;\nhowever, the number of patients who remained on drugs above week 96\u00a0was\nlimited.\u00a0 Due to their limitations, the clinical data available do not allow to\ndraw definitive conclusions on the benefit/risk ratio of the adefovir treatment\nin children with chronic hepatitis\u00a0B (see section\u00a04.2).</span></p>", "ID": "6dcfde50-9856-44b9-8b8c-f97119031ed5", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Overall, the\nsafety profile of adefovir dipivoxil in children was consistent with the known\nsafety profile in adult patients.\u00a0 However, a signal towards a higher rate of\ndecreased appetite and/or food intake was observed in the adefovir arm as\ncompared to the placebo arm.\u00a0 At week\u00a048 and 96, mean changes from\nbaseline in weight and BMI\u00a0Z\u00a0scores tended to decrease in adefovir\ndipivoxil\u2011treated patients.\u00a0 \u00a0At week\u00a048, all placebo-treated\nsubjects who did not exhibit HBeAg or HBsAg seroconversion, plus all adefovir\ndipivoxil\u2011treated subjects, were offered the opportunity to receive\nopen-label adefovir dipivoxil from study week\u00a049 through to week\u00a0240.\u00a0\nA high rate (30%) of hepatic flares was reported following discontinuation of\nadefovir dipivoxil during the 3\u00a0years open\u2011label phase of the\nstudy.\u00a0 Furthermore, for the few patients who remained on drug at week\u00a0240\n(n=12) BMI\u00a0Z\u00a0score was lower than typical for their age and gender.\u00a0\nVery few patients developed adefovir-associated mutations up to 5\u00a0years;\nhowever, the number of patients who remained on drugs above week 96\u00a0was\nlimited.\u00a0 Due to their limitations, the clinical data available do not allow to\ndraw definitive conclusions on the benefit/risk ratio of the adefovir treatment\nin children with chronic hepatitis\u00a0B (see section\u00a04.2).</span>", "ID": "e7df3f43-e9ea-40d5-b7d6-2fdf94d73cde", "Styles": "None", "Classes": "None", "Text": "Overall, the safety profile of adefovir dipivoxil in children was consistent with the known safety profile in adult patients.\u00a0 However, a signal towards a higher rate of decreased appetite and/or food intake was observed in the adefovir arm as compared to the placebo arm.\u00a0 At week\u00a048 and 96, mean changes from baseline in weight and BMI\u00a0Z\u00a0scores tended to decrease in adefovir dipivoxil\u2011treated patients.\u00a0 \u00a0At week\u00a048, all placebo-treated subjects who did not exhibit HBeAg or HBsAg seroconversion, plus all adefovir dipivoxil\u2011treated subjects, were offered the opportunity to receive open-label adefovir dipivoxil from study week\u00a049 through to week\u00a0240.\u00a0 A high rate (30%) of hepatic flares was reported following discontinuation of adefovir dipivoxil during the 3\u00a0years open\u2011label phase of the study.\u00a0 Furthermore, for the few patients who remained on drug at week\u00a0240 (n=12) BMI\u00a0Z\u00a0score was lower than typical for their age and gender.\u00a0 Very few patients developed adefovir-associated mutations up to 5\u00a0years; however, the number of patients who remained on drugs above week 96\u00a0was limited.\u00a0 Due to their limitations, the clinical data available do not allow to draw definitive conclusions on the benefit/risk ratio of the adefovir treatment in children with chronic hepatitis\u00a0B (see section\u00a04.2).", "ParentId": "6dcfde50-9856-44b9-8b8c-f97119031ed5"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5783e822-35ba-4eb9-acf9-a24de753b05e", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "49d74e43-992f-41b7-b6d7-66282147741e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5783e822-35ba-4eb9-acf9-a24de753b05e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic properties</span></b></p>", "ID": "aed1c3ab-e513-47c7-a7fb-bb340184e91e", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic properties</span></b>", "ID": "8e18c5bf-f097-4d0c-a542-849f0c42b246", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "aed1c3ab-e513-47c7-a7fb-bb340184e91e"}, {"Element": "<span lang=\"EN-GB\">5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic properties</span>", "ID": "9af0a32f-0406-4448-a8bc-24d983a98a3e", "Styles": "None", "Classes": "None", "Text": "5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic properties", "ParentId": "8e18c5bf-f097-4d0c-a542-849f0c42b246"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e591c478-e1d1-4e65-ab60-3c0a1dd221e5", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9a2ac8b2-6590-4328-9354-145b83ce60ed", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e591c478-e1d1-4e65-ab60-3c0a1dd221e5"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adefovir\ndipivoxil is a dipivaloyloxymethyl ester prodrug of the active substance\nadefovir, an acyclic nucleotide analogue which is actively transported into\ncells where it is converted by host enzymes to adefovir diphosphate.</span></p>", "ID": "1d4a6b26-f591-4c35-825b-4703629b0cbc", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Adefovir\ndipivoxil is a dipivaloyloxymethyl ester prodrug of the active substance\nadefovir, an acyclic nucleotide analogue which is actively transported into\ncells where it is converted by host enzymes to adefovir diphosphate.</span>", "ID": "e5f5deed-ad61-4f78-aafb-33674b072e55", "Styles": "None", "Classes": "None", "Text": "Adefovir dipivoxil is a dipivaloyloxymethyl ester prodrug of the active substance adefovir, an acyclic nucleotide analogue which is actively transported into cells where it is converted by host enzymes to adefovir diphosphate.", "ParentId": "1d4a6b26-f591-4c35-825b-4703629b0cbc"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "965a7c1e-6e3c-430b-9d5f-6284b53f58c1", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "04df31d9-fb8d-4410-9c89-995f1618cd29", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "965a7c1e-6e3c-430b-9d5f-6284b53f58c1"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Absorption:</span></i><span lang=\"EN-GB\"> The oral bioavailability of adefovir from 10\u00a0mg adefovir\ndipivoxil is 59\u00a0%.\u00a0 Following oral administration of a single dose of\n10\u00a0mg adefovir dipivoxil to chronic hepatitis\u00a0B patients, the median\n(range) peak serum concentration (C<sub>max</sub>) was achieved after\n1.75\u00a0h (0.58\u20114.0\u00a0h).\u00a0 Median C<sub>max</sub> and AUC<sub>0\u2011\u221e</sub>\nvalues were 16.70\u00a0(9.66\u201130.56)\u00a0ng/ml and 204.40\u00a0(109.75\u2011356.05)\u00a0ng<b>\u00b7</b>h/ml,\nrespectively.\u00a0 Systemic exposure to adefovir was not affected when 10\u00a0mg\nadefovir dipivoxil was taken with a high fat meal.\u00a0 The t<sub>max</sub> was\ndelayed by two hours.</span></p>", "ID": "f1706790-7a3f-4b03-9712-6081ae98c1cb", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Absorption:</span></i>", "ID": "61d5d271-c3dc-462f-a0c7-685665ebfa83", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f1706790-7a3f-4b03-9712-6081ae98c1cb"}, {"Element": "<span lang=\"EN-GB\">Absorption:</span>", "ID": "674222af-10f0-4f75-91a0-0c506cb854c1", "Styles": "None", "Classes": "None", "Text": "Absorption:", "ParentId": "61d5d271-c3dc-462f-a0c7-685665ebfa83"}, {"Element": "<span lang=\"EN-GB\"> The oral bioavailability of adefovir from 10\u00a0mg adefovir\ndipivoxil is 59\u00a0%.\u00a0 Following oral administration of a single dose of\n10\u00a0mg adefovir dipivoxil to chronic hepatitis\u00a0B patients, the median\n(range) peak serum concentration (C<sub>max</sub>) was achieved after\n1.75\u00a0h (0.58\u20114.0\u00a0h).\u00a0 Median C<sub>max</sub> and AUC<sub>0\u2011\u221e</sub>\nvalues were 16.70\u00a0(9.66\u201130.56)\u00a0ng/ml and 204.40\u00a0(109.75\u2011356.05)\u00a0ng<b>\u00b7</b>h/ml,\nrespectively.\u00a0 Systemic exposure to adefovir was not affected when 10\u00a0mg\nadefovir dipivoxil was taken with a high fat meal.\u00a0 The t<sub>max</sub> was\ndelayed by two hours.</span>", "ID": "6e29b29f-cb92-4dff-8d75-eb45c9bec61b", "Styles": "None", "Classes": "None", "Text": " The oral bioavailability of adefovir from 10\u00a0mg adefovir dipivoxil is 59\u00a0%.\u00a0 Following oral administration of a single dose of 10\u00a0mg adefovir dipivoxil to chronic hepatitis\u00a0B patients, the median (range) peak serum concentration (C) was achieved after 1.75\u00a0h (0.58\u20114.0\u00a0h).\u00a0 Median C and AUC values were 16.70\u00a0(9.66\u201130.56)\u00a0ng/ml and 204.40\u00a0(109.75\u2011356.05)\u00a0ngh/ml, respectively.\u00a0 Systemic exposure to adefovir was not affected when 10\u00a0mg adefovir dipivoxil was taken with a high fat meal.\u00a0 The t was delayed by two hours.", "ParentId": "f1706790-7a3f-4b03-9712-6081ae98c1cb"}, {"Element": "<sub>max</sub>", "ID": "bb69a430-f515-42f0-9bbe-f7ed85470099", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "6e29b29f-cb92-4dff-8d75-eb45c9bec61b"}, {"Element": "<sub>max</sub>", "ID": "5046affc-8901-4b5f-a5b5-cfe053aecb05", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "6e29b29f-cb92-4dff-8d75-eb45c9bec61b"}, {"Element": "<sub>0\u2011\u221e</sub>", "ID": "8f15b056-6af1-48be-b820-f2f9e7397161", "Styles": "None", "Classes": "None", "Text": "0\u2011\u221e", "ParentId": "6e29b29f-cb92-4dff-8d75-eb45c9bec61b"}, {"Element": "<b>\u00b7</b>", "ID": "3c5cf948-9dcb-4d1a-bbe8-e46b7e38e1c8", "Styles": "None", "Classes": "None", "Text": "\u00b7", "ParentId": "6e29b29f-cb92-4dff-8d75-eb45c9bec61b"}, {"Element": "<sub>max</sub>", "ID": "e0ce148a-bd1e-4a3a-beba-1ffecb9bb66d", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "6e29b29f-cb92-4dff-8d75-eb45c9bec61b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "da9821b9-faff-466f-8324-2b5094c4a5c8", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3d626889-b095-47b7-b23a-71f9b0959fc4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "da9821b9-faff-466f-8324-2b5094c4a5c8"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Distribution:</span></i><span lang=\"EN-GB\"> Preclinical studies show that after oral administration of adefovir\ndipivoxil, adefovir is distributed to most tissues with the highest\nconcentrations occurring in kidney, liver and intestinal tissues.\u00a0 <i>In\u00a0vitro</i>\nbinding of adefovir to human plasma or human serum proteins is \u2264\u00a04\u00a0%,\nover the adefovir concentration range of 0.1 to 25\u00a0\u03bcg/ml.\u00a0 The volume\nof distribution at steady\u2011state following intravenous administration of\n1.0 or 3.0\u00a0mg/kg/day is 392\u00b175 and 352\u00b19\u00a0ml/kg, respectively.</span></p>", "ID": "c87d6c7f-caf9-48cb-a179-7c12785c5ecf", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Distribution:</span></i>", "ID": "75b0eada-de09-4ddb-99a5-53df84c0b770", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c87d6c7f-caf9-48cb-a179-7c12785c5ecf"}, {"Element": "<span lang=\"EN-GB\">Distribution:</span>", "ID": "f3df0791-f6ac-4f95-8a60-387e5d33d071", "Styles": "None", "Classes": "None", "Text": "Distribution:", "ParentId": "75b0eada-de09-4ddb-99a5-53df84c0b770"}, {"Element": "<span lang=\"EN-GB\"> Preclinical studies show that after oral administration of adefovir\ndipivoxil, adefovir is distributed to most tissues with the highest\nconcentrations occurring in kidney, liver and intestinal tissues.\u00a0 <i>In\u00a0vitro</i>\nbinding of adefovir to human plasma or human serum proteins is \u2264\u00a04\u00a0%,\nover the adefovir concentration range of 0.1 to 25\u00a0\u03bcg/ml.\u00a0 The volume\nof distribution at steady\u2011state following intravenous administration of\n1.0 or 3.0\u00a0mg/kg/day is 392\u00b175 and 352\u00b19\u00a0ml/kg, respectively.</span>", "ID": "fc52047c-f117-4da7-8b5a-40e94429add9", "Styles": "None", "Classes": "None", "Text": " Preclinical studies show that after oral administration of adefovir dipivoxil, adefovir is distributed to most tissues with the highest concentrations occurring in kidney, liver and intestinal tissues.\u00a0  binding of adefovir to human plasma or human serum proteins is \u2264\u00a04\u00a0%, over the adefovir concentration range of 0.1 to 25\u00a0\u03bcg/ml.\u00a0 The volume of distribution at steady\u2011state following intravenous administration of 1.0 or 3.0\u00a0mg/kg/day is 392\u00b175 and 352\u00b19\u00a0ml/kg, respectively.", "ParentId": "c87d6c7f-caf9-48cb-a179-7c12785c5ecf"}, {"Element": "<i>In\u00a0vitro</i>", "ID": "22748cf1-575d-48fe-aade-adaa183ba72f", "Styles": "None", "Classes": "None", "Text": "In\u00a0vitro", "ParentId": "fc52047c-f117-4da7-8b5a-40e94429add9"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5c2359c7-e05f-4bb8-932f-377404167646", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "62b814d1-2cca-420d-8846-45c5af82738a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5c2359c7-e05f-4bb8-932f-377404167646"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Biotransformation:</span></i><span lang=\"EN-GB\"> Following oral administration, adefovir dipivoxil is rapidly\nconverted to adefovir.\u00a0 At concentrations substantially higher (&gt;\u00a04,000\u2011fold)\nthan those observed <i>in\u00a0vivo</i>, adefovir did not inhibit any of the\nfollowing human CYP450 isoforms, CYP1A2, CYP2D6, CYP2C9, CYP2C19, CYP3A4.\u00a0 Based\non the results of these <i>in\u00a0vitro</i> experiments and the known\nelimination pathway of adefovir, the potential for CYP450 mediated interactions\ninvolving adefovir with other medicinal products is low.</span></p>", "ID": "a20cc264-a324-4a5b-8eb4-f90aa297b720", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Biotransformation:</span></i>", "ID": "0755e3d1-adda-40f8-80bf-97b52a5f47db", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a20cc264-a324-4a5b-8eb4-f90aa297b720"}, {"Element": "<span lang=\"EN-GB\">Biotransformation:</span>", "ID": "e65ea170-3944-4c83-8b79-45e6d59f9659", "Styles": "None", "Classes": "None", "Text": "Biotransformation:", "ParentId": "0755e3d1-adda-40f8-80bf-97b52a5f47db"}, {"Element": "<span lang=\"EN-GB\"> Following oral administration, adefovir dipivoxil is rapidly\nconverted to adefovir.\u00a0 At concentrations substantially higher (&gt;\u00a04,000\u2011fold)\nthan those observed <i>in\u00a0vivo</i>, adefovir did not inhibit any of the\nfollowing human CYP450 isoforms, CYP1A2, CYP2D6, CYP2C9, CYP2C19, CYP3A4.\u00a0 Based\non the results of these <i>in\u00a0vitro</i> experiments and the known\nelimination pathway of adefovir, the potential for CYP450 mediated interactions\ninvolving adefovir with other medicinal products is low.</span>", "ID": "62614af0-bc39-47aa-a020-0b7dc6420dd4", "Styles": "None", "Classes": "None", "Text": " Following oral administration, adefovir dipivoxil is rapidly converted to adefovir.\u00a0 At concentrations substantially higher (>\u00a04,000\u2011fold) than those observed , adefovir did not inhibit any of the following human CYP450 isoforms, CYP1A2, CYP2D6, CYP2C9, CYP2C19, CYP3A4.\u00a0 Based on the results of these  experiments and the known elimination pathway of adefovir, the potential for CYP450 mediated interactions involving adefovir with other medicinal products is low.", "ParentId": "a20cc264-a324-4a5b-8eb4-f90aa297b720"}, {"Element": "<i>in\u00a0vivo</i>", "ID": "e08de699-8327-4525-9442-85c5b0d8d0ef", "Styles": "None", "Classes": "None", "Text": "in\u00a0vivo", "ParentId": "62614af0-bc39-47aa-a020-0b7dc6420dd4"}, {"Element": "<i>in\u00a0vitro</i>", "ID": "99e98e01-e7a5-4896-a2b1-1e50ffaa3a9a", "Styles": "None", "Classes": "None", "Text": "in\u00a0vitro", "ParentId": "62614af0-bc39-47aa-a020-0b7dc6420dd4"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "359a20e0-1306-481a-a7b0-45c5c2a230e8", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2b3297b7-a9df-4be0-8545-71f682a8a3f8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "359a20e0-1306-481a-a7b0-45c5c2a230e8"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Elimination:</span></i><span lang=\"EN-GB\"> Adefovir is excreted renally by a combination of glomerular\nfiltration and active tubular secretion.\u00a0 The median (min\u2011max) renal\nclearance of adefovir in subjects with normal renal function (Cl<sub>cr</sub>\u00a0&gt;\u00a080\u00a0ml/min)\nis 211\u2002ml/min (172\u2011316\u00a0ml/min), approximately twice calculated\ncreatinine clearance (Cockroft\u2011Gault method).<u>\u00a0 </u>After repeated\nadministration of 10\u00a0mg adefovir dipivoxil, 45\u00a0% of the dose is\nrecovered as adefovir in the urine over 24\u00a0hours.\u00a0 Plasma adefovir\nconcentrations declined in a biexponential manner with a median terminal\nelimination half\u2011life of 7.22\u00a0h (4.72\u201110.70\u00a0h).</span></p>", "ID": "3d1d068d-dd98-4a59-b174-fa0b90949bfb", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Elimination:</span></i>", "ID": "8b025bce-a892-4905-a327-e1d25e7d98be", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3d1d068d-dd98-4a59-b174-fa0b90949bfb"}, {"Element": "<span lang=\"EN-GB\">Elimination:</span>", "ID": "cff55e3e-7a3f-44fb-bc87-1a016d7c1e79", "Styles": "None", "Classes": "None", "Text": "Elimination:", "ParentId": "8b025bce-a892-4905-a327-e1d25e7d98be"}, {"Element": "<span lang=\"EN-GB\"> Adefovir is excreted renally by a combination of glomerular\nfiltration and active tubular secretion.\u00a0 The median (min\u2011max) renal\nclearance of adefovir in subjects with normal renal function (Cl<sub>cr</sub>\u00a0&gt;\u00a080\u00a0ml/min)\nis 211\u2002ml/min (172\u2011316\u00a0ml/min), approximately twice calculated\ncreatinine clearance (Cockroft\u2011Gault method).<u>\u00a0 </u>After repeated\nadministration of 10\u00a0mg adefovir dipivoxil, 45\u00a0% of the dose is\nrecovered as adefovir in the urine over 24\u00a0hours.\u00a0 Plasma adefovir\nconcentrations declined in a biexponential manner with a median terminal\nelimination half\u2011life of 7.22\u00a0h (4.72\u201110.70\u00a0h).</span>", "ID": "10394720-794d-4610-a2e1-1f7902114aed", "Styles": "None", "Classes": "None", "Text": " Adefovir is excreted renally by a combination of glomerular filtration and active tubular secretion.\u00a0 The median (min\u2011max) renal clearance of adefovir in subjects with normal renal function (Cl\u00a0>\u00a080\u00a0ml/min) is 211\u2002ml/min (172\u2011316\u00a0ml/min), approximately twice calculated creatinine clearance (Cockroft\u2011Gault method).After repeated administration of 10\u00a0mg adefovir dipivoxil, 45\u00a0% of the dose is recovered as adefovir in the urine over 24\u00a0hours.\u00a0 Plasma adefovir concentrations declined in a biexponential manner with a median terminal elimination half\u2011life of 7.22\u00a0h (4.72\u201110.70\u00a0h).", "ParentId": "3d1d068d-dd98-4a59-b174-fa0b90949bfb"}, {"Element": "<sub>cr</sub>", "ID": "8e6c94e1-cf10-41ab-a1c2-921d6e111708", "Styles": "None", "Classes": "None", "Text": "cr", "ParentId": "10394720-794d-4610-a2e1-1f7902114aed"}, {"Element": "<u>\u00a0 </u>", "ID": "2dd911dd-556a-4cd7-9b3d-bda83d8259d6", "Styles": "None", "Classes": "None", "Text": "\u00a0 ", "ParentId": "10394720-794d-4610-a2e1-1f7902114aed"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e598c441-ddb7-4d3f-8527-9e6a2f9ea591", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "717799fd-c881-4ec5-b3d1-be447a08aeb2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e598c441-ddb7-4d3f-8527-9e6a2f9ea591"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Linearity/non\u2011linearity:</span></i><span lang=\"EN-GB\"> The pharmacokinetics of adefovir are proportional to dose when\ngiven as adefovir dipivoxil over the dose range of 10 to 60\u00a0mg.\u00a0 Repeated\ndosing of adefovir dipivoxil 10\u00a0mg daily did not influence the\npharmacokinetics of adefovir.</span></p>", "ID": "8f9f4c7f-6f7a-499c-a140-876f876c094a", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Linearity/non\u2011linearity:</span></i>", "ID": "0c620764-278f-4659-b319-25466848d341", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8f9f4c7f-6f7a-499c-a140-876f876c094a"}, {"Element": "<span lang=\"EN-GB\">Linearity/non\u2011linearity:</span>", "ID": "194c75c0-bfe6-45d9-9cac-faf324d3c80f", "Styles": "None", "Classes": "None", "Text": "Linearity/non\u2011linearity:", "ParentId": "0c620764-278f-4659-b319-25466848d341"}, {"Element": "<span lang=\"EN-GB\"> The pharmacokinetics of adefovir are proportional to dose when\ngiven as adefovir dipivoxil over the dose range of 10 to 60\u00a0mg.\u00a0 Repeated\ndosing of adefovir dipivoxil 10\u00a0mg daily did not influence the\npharmacokinetics of adefovir.</span>", "ID": "261b01d0-3725-4843-84f6-bb449de839ce", "Styles": "None", "Classes": "None", "Text": " The pharmacokinetics of adefovir are proportional to dose when given as adefovir dipivoxil over the dose range of 10 to 60\u00a0mg.\u00a0 Repeated dosing of adefovir dipivoxil 10\u00a0mg daily did not influence the pharmacokinetics of adefovir.", "ParentId": "8f9f4c7f-6f7a-499c-a140-876f876c094a"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c4f53c3d-7773-476f-ae6d-efb274b45b5d", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1dfd3e19-6db3-490c-8e91-605c2651f465", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c4f53c3d-7773-476f-ae6d-efb274b45b5d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Gender, age\nand ethnicity:</span></i><span lang=\"EN-GB\"> The pharmacokinetics of adefovir\nwere similar in male and female patients.\u00a0 Pharmacokinetic studies have not\nbeen conducted in the elderly.\u00a0 Pharmacokinetic studies were principally\nconducted in Caucasian patients.\u00a0 The available data do not appear to indicate\nany difference in pharmacokinetics with regard to race.</span></p>", "ID": "b93f5ce4-1fec-4b76-bc4d-bb083bb0f0d1", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Gender, age\nand ethnicity:</span></i>", "ID": "fa4031ac-fd20-4b7f-899c-c7ee2c5da01e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b93f5ce4-1fec-4b76-bc4d-bb083bb0f0d1"}, {"Element": "<span lang=\"EN-GB\">Gender, age\nand ethnicity:</span>", "ID": "2e115852-f442-46ec-9138-a7d0902cc0ce", "Styles": "None", "Classes": "None", "Text": "Gender, age and ethnicity:", "ParentId": "fa4031ac-fd20-4b7f-899c-c7ee2c5da01e"}, {"Element": "<span lang=\"EN-GB\"> The pharmacokinetics of adefovir\nwere similar in male and female patients.\u00a0 Pharmacokinetic studies have not\nbeen conducted in the elderly.\u00a0 Pharmacokinetic studies were principally\nconducted in Caucasian patients.\u00a0 The available data do not appear to indicate\nany difference in pharmacokinetics with regard to race.</span>", "ID": "2e1e45d1-bd5d-49c4-979c-e90c056a0eaa", "Styles": "None", "Classes": "None", "Text": " The pharmacokinetics of adefovir were similar in male and female patients.\u00a0 Pharmacokinetic studies have not been conducted in the elderly.\u00a0 Pharmacokinetic studies were principally conducted in Caucasian patients.\u00a0 The available data do not appear to indicate any difference in pharmacokinetics with regard to race.", "ParentId": "b93f5ce4-1fec-4b76-bc4d-bb083bb0f0d1"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "591b1315-9869-4824-8811-bd961c11e785", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e4a02419-cda5-4d6f-bc61-058a310770cc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "591b1315-9869-4824-8811-bd961c11e785"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Renal impairment:</span></i><span lang=\"EN-GB\"> The mean (\u00b1 SD)\npharmacokinetic parameters of adefovir following administration of a single\ndose of 10\u00a0mg adefovir dipivoxil to patients with varying degrees of renal\nimpairment are described in the table below:</span></p>", "ID": "34852985-0281-4c38-81f5-0cdcaedb3a7e", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Renal impairment:</span></i>", "ID": "761a1f8a-4072-43db-9c85-2fd474ae0f52", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "34852985-0281-4c38-81f5-0cdcaedb3a7e"}, {"Element": "<span lang=\"EN-GB\">Renal impairment:</span>", "ID": "b0a83600-2c90-49c3-9ea2-267d62bee1aa", "Styles": "None", "Classes": "None", "Text": "Renal impairment:", "ParentId": "761a1f8a-4072-43db-9c85-2fd474ae0f52"}, {"Element": "<span lang=\"EN-GB\"> The mean (\u00b1 SD)\npharmacokinetic parameters of adefovir following administration of a single\ndose of 10\u00a0mg adefovir dipivoxil to patients with varying degrees of renal\nimpairment are described in the table below:</span>", "ID": "f37dc19b-ac77-4c4c-a5cf-c4ee3887407a", "Styles": "None", "Classes": "None", "Text": " The mean (\u00b1 SD) pharmacokinetic parameters of adefovir following administration of a single dose of 10\u00a0mg adefovir dipivoxil to patients with varying degrees of renal impairment are described in the table below:", "ParentId": "34852985-0281-4c38-81f5-0cdcaedb3a7e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5bf9b3d1-6644-46ec-b34e-3f99fb149a62", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "261288c9-4cd8-40b4-a466-0912d732a89d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5bf9b3d1-6644-46ec-b34e-3f99fb149a62"}, {"Element": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:.9pt;border-collapse:collapse\" width=\"639\">\n<tr style=\"page-break-inside:avoid;height:7.5pt\">\n<td style=\"width:117.9pt;border:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"157\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Renal Function\n  Group</span></b></p>\n</td>\n<td style=\"width:161.1pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"215\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Unimpaired</span></b></p>\n</td>\n<td style=\"width:72.8pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"97\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Mild</span></b></p>\n</td>\n<td style=\"width:63.8pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Moderate</span></b></p>\n</td>\n<td style=\"width:63.8pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Severe</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:7.5pt\">\n<td style=\"width:117.9pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"157\">\n<p class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Baseline Creatinine Clearance (ml/min)</span></b></p>\n</td>\n<td style=\"width:161.1pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"215\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">&gt;\u00a080</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">(n=7)</span></b></p>\n</td>\n<td style=\"width:72.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"97\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">50\u201180</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">(n=8)</span></b></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">30\u201149</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">(n=7)</span></b></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">10\u201129</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">(n=10)</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:7.5pt\">\n<td style=\"width:117.9pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"157\">\n<p class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:\n  avoid\"><span lang=\"EN-GB\">C<sub>max</sub> (ng/ml)</span></p>\n</td>\n<td style=\"width:161.1pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"215\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">17.8\u00b13.2</span></p>\n</td>\n<td style=\"width:72.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"97\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">22.4\u00b14.0</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">28.5\u00b18.6</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">51.6\u00b110.3</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:7.5pt\">\n<td style=\"width:117.9pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"157\">\n<p class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:\n  avoid\"><span lang=\"EN-GB\">AUC<sub>0\u2011\u221e</sub> (ng<b>\u00b7</b>h/ml)</span></p>\n</td>\n<td style=\"width:161.1pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"215\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">201\u00b140.8</span></p>\n</td>\n<td style=\"width:72.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"97\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">266\u00b155.7</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">455\u00b1176</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">1240\u00b1629</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:7.5pt\">\n<td style=\"width:117.9pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"157\">\n<p class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:\n  avoid\"><span lang=\"EN-GB\">CL/F (ml/min)</span></p>\n</td>\n<td style=\"width:161.1pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"215\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">469\u00b199.0</span></p>\n</td>\n<td style=\"width:72.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"97\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">356\u00b185.6</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">237\u00b1118</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">91.7\u00b151.3</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid;height:7.5pt\">\n<td style=\"width:117.9pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"157\">\n<p class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal\"><span lang=\"EN-GB\">CL<sub>renal</sub> (ml/min)</span></p>\n</td>\n<td style=\"width:161.1pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"215\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">231\u00b148.9</span></p>\n</td>\n<td style=\"width:72.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"97\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">148\u00b139.3</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">83.9\u00b127.5</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">37.0\u00b118.4</span></p>\n</td>\n</tr>\n</table>", "ID": "2fa697b3-404a-4d26-8a8e-59170cbe7c47", "Styles": "margin-left:.9pt;border-collapse:collapse", "Classes": "['MsoNormalTable']", "Text": "       ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<tr style=\"page-break-inside:avoid;height:7.5pt\">\n<td style=\"width:117.9pt;border:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"157\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Renal Function\n  Group</span></b></p>\n</td>\n<td style=\"width:161.1pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"215\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Unimpaired</span></b></p>\n</td>\n<td style=\"width:72.8pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"97\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Mild</span></b></p>\n</td>\n<td style=\"width:63.8pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Moderate</span></b></p>\n</td>\n<td style=\"width:63.8pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Severe</span></b></p>\n</td>\n</tr>", "ID": "46005dad-043d-4803-b1d7-754ec7b8f791", "Styles": "page-break-inside:avoid;height:7.5pt", "Classes": "None", "Text": "      ", "ParentId": "2fa697b3-404a-4d26-8a8e-59170cbe7c47"}, {"Element": "<td style=\"width:117.9pt;border:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"157\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Renal Function\n  Group</span></b></p>\n</td>", "ID": "9e97ce05-98e3-4945-892b-8ac9e6b8d769", "Styles": "width:117.9pt;border:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt", "Classes": "None", "Text": "   ", "ParentId": "46005dad-043d-4803-b1d7-754ec7b8f791"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "7287daf8-3d1a-4041-8ba5-b7ab9bc596bf", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9e97ce05-98e3-4945-892b-8ac9e6b8d769"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "637485e5-c3c1-4346-87d9-1ca1f6df67cf", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7287daf8-3d1a-4041-8ba5-b7ab9bc596bf"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "67da7d4d-d721-4c5b-946a-4e88c162ae8b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "637485e5-c3c1-4346-87d9-1ca1f6df67cf"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "b7c3487c-a09e-4612-9769-352bc0356bbe", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "67da7d4d-d721-4c5b-946a-4e88c162ae8b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Renal Function\n  Group</span></b></p>", "ID": "3722cad3-b1a4-470c-b18c-4f441f1b5dc8", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9e97ce05-98e3-4945-892b-8ac9e6b8d769"}, {"Element": "<b><span lang=\"EN-GB\">Renal Function\n  Group</span></b>", "ID": "309cd0f5-99c0-46bf-a93b-bc337d4e6510", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3722cad3-b1a4-470c-b18c-4f441f1b5dc8"}, {"Element": "<span lang=\"EN-GB\">Renal Function\n  Group</span>", "ID": "5ed6ac8f-132e-4367-94b6-62501a747c97", "Styles": "None", "Classes": "None", "Text": "Renal Function   Group", "ParentId": "309cd0f5-99c0-46bf-a93b-bc337d4e6510"}, {"Element": "<td style=\"width:161.1pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"215\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Unimpaired</span></b></p>\n</td>", "ID": "d59117d8-400c-402a-a2a8-5fa5c1838225", "Styles": "width:161.1pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt", "Classes": "None", "Text": "  ", "ParentId": "46005dad-043d-4803-b1d7-754ec7b8f791"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Unimpaired</span></b></p>", "ID": "59933fd5-d346-439a-8683-d2b0dda8b58f", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d59117d8-400c-402a-a2a8-5fa5c1838225"}, {"Element": "<b><span lang=\"EN-GB\">Unimpaired</span></b>", "ID": "fe49bc3a-6fd6-41d0-a07b-064fc72edb8f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "59933fd5-d346-439a-8683-d2b0dda8b58f"}, {"Element": "<span lang=\"EN-GB\">Unimpaired</span>", "ID": "d848d11b-52e0-4c6a-8d73-012467118acf", "Styles": "None", "Classes": "None", "Text": "Unimpaired", "ParentId": "fe49bc3a-6fd6-41d0-a07b-064fc72edb8f"}, {"Element": "<td style=\"width:72.8pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"97\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Mild</span></b></p>\n</td>", "ID": "aa9282a6-14bc-4bdb-ba10-0d6fef320b99", "Styles": "width:72.8pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt", "Classes": "None", "Text": "  ", "ParentId": "46005dad-043d-4803-b1d7-754ec7b8f791"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Mild</span></b></p>", "ID": "b6b4eb90-f418-4377-8caa-308960acc305", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "aa9282a6-14bc-4bdb-ba10-0d6fef320b99"}, {"Element": "<b><span lang=\"EN-GB\">Mild</span></b>", "ID": "d658df42-ceaa-4b93-8dd8-a22b1041cfff", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b6b4eb90-f418-4377-8caa-308960acc305"}, {"Element": "<span lang=\"EN-GB\">Mild</span>", "ID": "b660d876-4b7f-48cf-b52f-f80eea62f552", "Styles": "None", "Classes": "None", "Text": "Mild", "ParentId": "d658df42-ceaa-4b93-8dd8-a22b1041cfff"}, {"Element": "<td style=\"width:63.8pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Moderate</span></b></p>\n</td>", "ID": "fa3bb85b-5409-44ff-8001-7a9f70701639", "Styles": "width:63.8pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt", "Classes": "None", "Text": "  ", "ParentId": "46005dad-043d-4803-b1d7-754ec7b8f791"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Moderate</span></b></p>", "ID": "c070f756-ac44-4ba4-90e7-cd0a08b3ad54", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fa3bb85b-5409-44ff-8001-7a9f70701639"}, {"Element": "<b><span lang=\"EN-GB\">Moderate</span></b>", "ID": "46e0b8e1-183c-4255-be47-7ff8bce45f80", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c070f756-ac44-4ba4-90e7-cd0a08b3ad54"}, {"Element": "<span lang=\"EN-GB\">Moderate</span>", "ID": "467e2398-495c-4098-8e19-fce67111f6e4", "Styles": "None", "Classes": "None", "Text": "Moderate", "ParentId": "46e0b8e1-183c-4255-be47-7ff8bce45f80"}, {"Element": "<td style=\"width:63.8pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Severe</span></b></p>\n</td>", "ID": "f5ab87ff-a05f-480e-9362-7c089451c55e", "Styles": "width:63.8pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt", "Classes": "None", "Text": "  ", "ParentId": "46005dad-043d-4803-b1d7-754ec7b8f791"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Severe</span></b></p>", "ID": "d849a679-807e-407d-be69-7a39bfe9fdde", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f5ab87ff-a05f-480e-9362-7c089451c55e"}, {"Element": "<b><span lang=\"EN-GB\">Severe</span></b>", "ID": "3ed7255d-9ef4-40dc-b270-8aa36af60315", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d849a679-807e-407d-be69-7a39bfe9fdde"}, {"Element": "<span lang=\"EN-GB\">Severe</span>", "ID": "7ff43aa1-090a-42b8-a4e4-b9fcd7c1b51c", "Styles": "None", "Classes": "None", "Text": "Severe", "ParentId": "3ed7255d-9ef4-40dc-b270-8aa36af60315"}, {"Element": "<tr style=\"page-break-inside:avoid;height:7.5pt\">\n<td style=\"width:117.9pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"157\">\n<p class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Baseline Creatinine Clearance (ml/min)</span></b></p>\n</td>\n<td style=\"width:161.1pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"215\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">&gt;\u00a080</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">(n=7)</span></b></p>\n</td>\n<td style=\"width:72.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"97\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">50\u201180</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">(n=8)</span></b></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">30\u201149</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">(n=7)</span></b></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">10\u201129</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">(n=10)</span></b></p>\n</td>\n</tr>", "ID": "7e95140f-5ec9-4515-9571-195c5210cff5", "Styles": "page-break-inside:avoid;height:7.5pt", "Classes": "None", "Text": "      ", "ParentId": "2fa697b3-404a-4d26-8a8e-59170cbe7c47"}, {"Element": "<td style=\"width:117.9pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"157\">\n<p class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Baseline Creatinine Clearance (ml/min)</span></b></p>\n</td>", "ID": "9c0d6e17-9f0b-434f-a06e-01a190e2c417", "Styles": "width:117.9pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt", "Classes": "None", "Text": "  ", "ParentId": "7e95140f-5ec9-4515-9571-195c5210cff5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Baseline Creatinine Clearance (ml/min)</span></b></p>", "ID": "7e04317f-7b64-4f33-906a-56acfe060cf3", "Styles": "margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9c0d6e17-9f0b-434f-a06e-01a190e2c417"}, {"Element": "<b><span lang=\"EN-GB\">Baseline Creatinine Clearance (ml/min)</span></b>", "ID": "7bd598c6-927b-49fb-b35c-debf5ea79abc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7e04317f-7b64-4f33-906a-56acfe060cf3"}, {"Element": "<span lang=\"EN-GB\">Baseline Creatinine Clearance (ml/min)</span>", "ID": "95abd58a-d5d0-41d4-81e3-5ff52fbd9bb3", "Styles": "None", "Classes": "None", "Text": "Baseline Creatinine Clearance (ml/min)", "ParentId": "7bd598c6-927b-49fb-b35c-debf5ea79abc"}, {"Element": "<td style=\"width:161.1pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"215\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">&gt;\u00a080</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">(n=7)</span></b></p>\n</td>", "ID": "017e7c50-d292-4164-bf63-5ab66951cbb6", "Styles": "width:161.1pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt", "Classes": "None", "Text": "   ", "ParentId": "7e95140f-5ec9-4515-9571-195c5210cff5"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">&gt;\u00a080</span></b></p>", "ID": "da3cc983-45b3-4d5f-9921-fe58316a8374", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "017e7c50-d292-4164-bf63-5ab66951cbb6"}, {"Element": "<b><span lang=\"EN-GB\">&gt;\u00a080</span></b>", "ID": "e5eb6e93-5cdd-4d83-b2db-5ac53a3ed567", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "da3cc983-45b3-4d5f-9921-fe58316a8374"}, {"Element": "<span lang=\"EN-GB\">&gt;\u00a080</span>", "ID": "dd458fc7-43c9-48e0-a889-ae52b2bfd8a7", "Styles": "None", "Classes": "None", "Text": ">\u00a080", "ParentId": "e5eb6e93-5cdd-4d83-b2db-5ac53a3ed567"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">(n=7)</span></b></p>", "ID": "197e7550-ff3a-4aa8-91f8-6234df2d8ad0", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "017e7c50-d292-4164-bf63-5ab66951cbb6"}, {"Element": "<b><span lang=\"EN-GB\">(n=7)</span></b>", "ID": "b0557862-0861-4207-9ec9-7bafb92b0bfc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "197e7550-ff3a-4aa8-91f8-6234df2d8ad0"}, {"Element": "<span lang=\"EN-GB\">(n=7)</span>", "ID": "33430973-cbc1-4190-9171-383f1f6f584a", "Styles": "None", "Classes": "None", "Text": "(n=7)", "ParentId": "b0557862-0861-4207-9ec9-7bafb92b0bfc"}, {"Element": "<td style=\"width:72.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"97\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">50\u201180</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">(n=8)</span></b></p>\n</td>", "ID": "fd50ac0d-1c72-4680-9cbd-872662eba9c8", "Styles": "width:72.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt", "Classes": "None", "Text": "   ", "ParentId": "7e95140f-5ec9-4515-9571-195c5210cff5"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">50\u201180</span></b></p>", "ID": "e5474030-ee5f-4885-a776-cc47dca32c75", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fd50ac0d-1c72-4680-9cbd-872662eba9c8"}, {"Element": "<b><span lang=\"EN-GB\">50\u201180</span></b>", "ID": "5a80303f-0e4b-46fa-a0c9-0e4f3b269b86", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e5474030-ee5f-4885-a776-cc47dca32c75"}, {"Element": "<span lang=\"EN-GB\">50\u201180</span>", "ID": "c304ced1-9323-4335-aabb-023b771efa98", "Styles": "None", "Classes": "None", "Text": "50\u201180", "ParentId": "5a80303f-0e4b-46fa-a0c9-0e4f3b269b86"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">(n=8)</span></b></p>", "ID": "bdb8e51e-6000-4585-b922-2bc50c004116", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fd50ac0d-1c72-4680-9cbd-872662eba9c8"}, {"Element": "<b><span lang=\"EN-GB\">(n=8)</span></b>", "ID": "a5bea84f-a052-42b8-abb7-dfd024f8e139", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bdb8e51e-6000-4585-b922-2bc50c004116"}, {"Element": "<span lang=\"EN-GB\">(n=8)</span>", "ID": "a0e0e046-0eb0-4d4f-9d4f-a36e795db6ed", "Styles": "None", "Classes": "None", "Text": "(n=8)", "ParentId": "a5bea84f-a052-42b8-abb7-dfd024f8e139"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">30\u201149</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">(n=7)</span></b></p>\n</td>", "ID": "1719343a-43a8-4226-acab-31a08cc4f66d", "Styles": "width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt", "Classes": "None", "Text": "   ", "ParentId": "7e95140f-5ec9-4515-9571-195c5210cff5"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">30\u201149</span></b></p>", "ID": "8b33672a-8bdd-4719-b59b-4d28360387cd", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1719343a-43a8-4226-acab-31a08cc4f66d"}, {"Element": "<b><span lang=\"EN-GB\">30\u201149</span></b>", "ID": "2ce098e2-cccb-4e9d-b2cc-f6bca7a92f0e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8b33672a-8bdd-4719-b59b-4d28360387cd"}, {"Element": "<span lang=\"EN-GB\">30\u201149</span>", "ID": "986effb9-b570-4720-98c7-6f3977d3f5a8", "Styles": "None", "Classes": "None", "Text": "30\u201149", "ParentId": "2ce098e2-cccb-4e9d-b2cc-f6bca7a92f0e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">(n=7)</span></b></p>", "ID": "4e2aff1f-ec4d-4958-b409-5ed0e1a7d8fe", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1719343a-43a8-4226-acab-31a08cc4f66d"}, {"Element": "<b><span lang=\"EN-GB\">(n=7)</span></b>", "ID": "c5be22f4-09eb-4ac9-979d-1fc7ba8e0cbc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4e2aff1f-ec4d-4958-b409-5ed0e1a7d8fe"}, {"Element": "<span lang=\"EN-GB\">(n=7)</span>", "ID": "6c7102f3-442f-4cbd-a930-cc78c3752ebf", "Styles": "None", "Classes": "None", "Text": "(n=7)", "ParentId": "c5be22f4-09eb-4ac9-979d-1fc7ba8e0cbc"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">10\u201129</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">(n=10)</span></b></p>\n</td>", "ID": "a0c79a85-8f29-4a9a-bddd-23c3b07fd6ed", "Styles": "width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt", "Classes": "None", "Text": "   ", "ParentId": "7e95140f-5ec9-4515-9571-195c5210cff5"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">10\u201129</span></b></p>", "ID": "48e89d2f-fcd4-4bee-9eb6-cc29da4eb2f3", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a0c79a85-8f29-4a9a-bddd-23c3b07fd6ed"}, {"Element": "<b><span lang=\"EN-GB\">10\u201129</span></b>", "ID": "261eafab-a4ee-44b7-898c-ec7263c18155", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "48e89d2f-fcd4-4bee-9eb6-cc29da4eb2f3"}, {"Element": "<span lang=\"EN-GB\">10\u201129</span>", "ID": "2fabca6e-5ac7-41b5-a675-11597463aa14", "Styles": "None", "Classes": "None", "Text": "10\u201129", "ParentId": "261eafab-a4ee-44b7-898c-ec7263c18155"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">(n=10)</span></b></p>", "ID": "862d30ec-9efe-4801-a9af-e0a9595b82f4", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a0c79a85-8f29-4a9a-bddd-23c3b07fd6ed"}, {"Element": "<b><span lang=\"EN-GB\">(n=10)</span></b>", "ID": "3c42fc72-05a6-4105-8390-775b10f5a940", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "862d30ec-9efe-4801-a9af-e0a9595b82f4"}, {"Element": "<span lang=\"EN-GB\">(n=10)</span>", "ID": "8c823d47-23ba-40c0-9432-915864854f82", "Styles": "None", "Classes": "None", "Text": "(n=10)", "ParentId": "3c42fc72-05a6-4105-8390-775b10f5a940"}, {"Element": "<tr style=\"page-break-inside:avoid;height:7.5pt\">\n<td style=\"width:117.9pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"157\">\n<p class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:\n  avoid\"><span lang=\"EN-GB\">C<sub>max</sub> (ng/ml)</span></p>\n</td>\n<td style=\"width:161.1pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"215\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">17.8\u00b13.2</span></p>\n</td>\n<td style=\"width:72.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"97\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">22.4\u00b14.0</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">28.5\u00b18.6</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">51.6\u00b110.3</span></p>\n</td>\n</tr>", "ID": "cac81d43-a4d0-400f-9086-0b2f91e9251b", "Styles": "page-break-inside:avoid;height:7.5pt", "Classes": "None", "Text": "      ", "ParentId": "2fa697b3-404a-4d26-8a8e-59170cbe7c47"}, {"Element": "<td style=\"width:117.9pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"157\">\n<p class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:\n  avoid\"><span lang=\"EN-GB\">C<sub>max</sub> (ng/ml)</span></p>\n</td>", "ID": "5b852ccc-a79e-4a81-941a-0d1e8e8a9245", "Styles": "width:117.9pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt", "Classes": "None", "Text": "  ", "ParentId": "cac81d43-a4d0-400f-9086-0b2f91e9251b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:\n  avoid\"><span lang=\"EN-GB\">C<sub>max</sub> (ng/ml)</span></p>", "ID": "216c7b8b-dfd3-46f4-ac5b-3b3e0c954b2c", "Styles": "margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5b852ccc-a79e-4a81-941a-0d1e8e8a9245"}, {"Element": "<span lang=\"EN-GB\">C<sub>max</sub> (ng/ml)</span>", "ID": "37623f30-5bd4-4f17-9ca7-1ea309135423", "Styles": "None", "Classes": "None", "Text": "C (ng/ml)", "ParentId": "216c7b8b-dfd3-46f4-ac5b-3b3e0c954b2c"}, {"Element": "<sub>max</sub>", "ID": "5b538c96-c64d-464d-94d8-36127a0b7196", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "37623f30-5bd4-4f17-9ca7-1ea309135423"}, {"Element": "<td style=\"width:161.1pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"215\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">17.8\u00b13.2</span></p>\n</td>", "ID": "c9250cf5-d2f4-40af-a0f3-75752f5a894a", "Styles": "width:161.1pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt", "Classes": "None", "Text": "  ", "ParentId": "cac81d43-a4d0-400f-9086-0b2f91e9251b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">17.8\u00b13.2</span></p>", "ID": "f646973d-1a34-4d38-ac8b-6dbe3119ba8d", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c9250cf5-d2f4-40af-a0f3-75752f5a894a"}, {"Element": "<span lang=\"EN-GB\">17.8\u00b13.2</span>", "ID": "15c4f943-011f-4f6d-80c3-f6b5ccb1eca1", "Styles": "None", "Classes": "None", "Text": "17.8\u00b13.2", "ParentId": "f646973d-1a34-4d38-ac8b-6dbe3119ba8d"}, {"Element": "<td style=\"width:72.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"97\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">22.4\u00b14.0</span></p>\n</td>", "ID": "e21db9d5-c898-4f8f-af4a-c421aa0433fc", "Styles": "width:72.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt", "Classes": "None", "Text": "  ", "ParentId": "cac81d43-a4d0-400f-9086-0b2f91e9251b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">22.4\u00b14.0</span></p>", "ID": "07ec62af-2fa5-4fcf-8bf0-1aa87f6474b6", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e21db9d5-c898-4f8f-af4a-c421aa0433fc"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">22.4\u00b14.0</span>", "ID": "26d5da30-62a5-4a66-9914-247ab584cea1", "Styles": "layout-grid-mode:\n  line", "Classes": "None", "Text": "22.4\u00b14.0", "ParentId": "07ec62af-2fa5-4fcf-8bf0-1aa87f6474b6"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">28.5\u00b18.6</span></p>\n</td>", "ID": "d5bc11ca-19e3-4a15-aeca-ee5c678958f7", "Styles": "width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt", "Classes": "None", "Text": "  ", "ParentId": "cac81d43-a4d0-400f-9086-0b2f91e9251b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">28.5\u00b18.6</span></p>", "ID": "a1a10353-1057-4af5-bea9-a817dfedde53", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d5bc11ca-19e3-4a15-aeca-ee5c678958f7"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">28.5\u00b18.6</span>", "ID": "a7ac5aab-5233-4e78-a0a7-55fc39991791", "Styles": "layout-grid-mode:\n  line", "Classes": "None", "Text": "28.5\u00b18.6", "ParentId": "a1a10353-1057-4af5-bea9-a817dfedde53"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">51.6\u00b110.3</span></p>\n</td>", "ID": "be708b7e-6797-4236-9126-158b10868da2", "Styles": "width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt", "Classes": "None", "Text": "  ", "ParentId": "cac81d43-a4d0-400f-9086-0b2f91e9251b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">51.6\u00b110.3</span></p>", "ID": "c510c3a7-089d-4bd6-8e84-b328dbd364bd", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "be708b7e-6797-4236-9126-158b10868da2"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">51.6\u00b110.3</span>", "ID": "f5b73459-2a8f-4c9d-b122-1c7a0c68c0df", "Styles": "layout-grid-mode:\n  line", "Classes": "None", "Text": "51.6\u00b110.3", "ParentId": "c510c3a7-089d-4bd6-8e84-b328dbd364bd"}, {"Element": "<tr style=\"page-break-inside:avoid;height:7.5pt\">\n<td style=\"width:117.9pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"157\">\n<p class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:\n  avoid\"><span lang=\"EN-GB\">AUC<sub>0\u2011\u221e</sub> (ng<b>\u00b7</b>h/ml)</span></p>\n</td>\n<td style=\"width:161.1pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"215\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">201\u00b140.8</span></p>\n</td>\n<td style=\"width:72.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"97\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">266\u00b155.7</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">455\u00b1176</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">1240\u00b1629</span></p>\n</td>\n</tr>", "ID": "60204c40-9430-41f7-b1a9-5beb835d1adc", "Styles": "page-break-inside:avoid;height:7.5pt", "Classes": "None", "Text": "      ", "ParentId": "2fa697b3-404a-4d26-8a8e-59170cbe7c47"}, {"Element": "<td style=\"width:117.9pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"157\">\n<p class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:\n  avoid\"><span lang=\"EN-GB\">AUC<sub>0\u2011\u221e</sub> (ng<b>\u00b7</b>h/ml)</span></p>\n</td>", "ID": "04aef06d-6a5a-4d5d-91dd-6f4002ece968", "Styles": "width:117.9pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt", "Classes": "None", "Text": "  ", "ParentId": "60204c40-9430-41f7-b1a9-5beb835d1adc"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:\n  avoid\"><span lang=\"EN-GB\">AUC<sub>0\u2011\u221e</sub> (ng<b>\u00b7</b>h/ml)</span></p>", "ID": "0a39ad25-fb9c-42ae-9d3a-85a078157268", "Styles": "margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "04aef06d-6a5a-4d5d-91dd-6f4002ece968"}, {"Element": "<span lang=\"EN-GB\">AUC<sub>0\u2011\u221e</sub> (ng<b>\u00b7</b>h/ml)</span>", "ID": "44388aa0-ee5d-421d-9f35-6406bae666ed", "Styles": "None", "Classes": "None", "Text": "AUC (ngh/ml)", "ParentId": "0a39ad25-fb9c-42ae-9d3a-85a078157268"}, {"Element": "<sub>0\u2011\u221e</sub>", "ID": "c003e3be-2042-484a-9539-130e2fb1830d", "Styles": "None", "Classes": "None", "Text": "0\u2011\u221e", "ParentId": "44388aa0-ee5d-421d-9f35-6406bae666ed"}, {"Element": "<b>\u00b7</b>", "ID": "c6d79eaf-4f04-422e-a180-b33071cb99c6", "Styles": "None", "Classes": "None", "Text": "\u00b7", "ParentId": "44388aa0-ee5d-421d-9f35-6406bae666ed"}, {"Element": "<td style=\"width:161.1pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"215\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">201\u00b140.8</span></p>\n</td>", "ID": "6e36042f-20f0-4923-a8d8-a585697f5fc6", "Styles": "width:161.1pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt", "Classes": "None", "Text": "  ", "ParentId": "60204c40-9430-41f7-b1a9-5beb835d1adc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">201\u00b140.8</span></p>", "ID": "488c96c3-13d8-417c-b2f9-241719729b5b", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6e36042f-20f0-4923-a8d8-a585697f5fc6"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">201\u00b140.8</span>", "ID": "7528deea-7dad-4b25-8493-a3961f6f8b16", "Styles": "layout-grid-mode:\n  line", "Classes": "None", "Text": "201\u00b140.8", "ParentId": "488c96c3-13d8-417c-b2f9-241719729b5b"}, {"Element": "<td style=\"width:72.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"97\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">266\u00b155.7</span></p>\n</td>", "ID": "0a4e9baf-f11d-4bfd-b3b0-c375b1241de6", "Styles": "width:72.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt", "Classes": "None", "Text": "  ", "ParentId": "60204c40-9430-41f7-b1a9-5beb835d1adc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">266\u00b155.7</span></p>", "ID": "bbc8f9e6-54eb-4d40-91a6-2435587e8560", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0a4e9baf-f11d-4bfd-b3b0-c375b1241de6"}, {"Element": "<span lang=\"EN-GB\">266\u00b155.7</span>", "ID": "c3165f9b-1e71-4bdb-b7d4-a8d3d56cb3d2", "Styles": "None", "Classes": "None", "Text": "266\u00b155.7", "ParentId": "bbc8f9e6-54eb-4d40-91a6-2435587e8560"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">455\u00b1176</span></p>\n</td>", "ID": "9e493c2d-19cb-4baa-92a3-813499464325", "Styles": "width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt", "Classes": "None", "Text": "  ", "ParentId": "60204c40-9430-41f7-b1a9-5beb835d1adc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">455\u00b1176</span></p>", "ID": "94faf8be-89e7-4f0a-ad5d-cdd2bf333757", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9e493c2d-19cb-4baa-92a3-813499464325"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">455\u00b1176</span>", "ID": "fb411470-a428-43c9-9fd0-7f6e0e4479de", "Styles": "layout-grid-mode:\n  line", "Classes": "None", "Text": "455\u00b1176", "ParentId": "94faf8be-89e7-4f0a-ad5d-cdd2bf333757"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">1240\u00b1629</span></p>\n</td>", "ID": "58f3e4bd-55b1-4f36-a148-4beab84be499", "Styles": "width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt", "Classes": "None", "Text": "  ", "ParentId": "60204c40-9430-41f7-b1a9-5beb835d1adc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">1240\u00b1629</span></p>", "ID": "50d9f994-4183-4b88-8f43-fcb348d019f6", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "58f3e4bd-55b1-4f36-a148-4beab84be499"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">1240\u00b1629</span>", "ID": "8c8818af-e46e-4a40-9202-75e3f6e718f2", "Styles": "layout-grid-mode:\n  line", "Classes": "None", "Text": "1240\u00b1629", "ParentId": "50d9f994-4183-4b88-8f43-fcb348d019f6"}, {"Element": "<tr style=\"page-break-inside:avoid;height:7.5pt\">\n<td style=\"width:117.9pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"157\">\n<p class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:\n  avoid\"><span lang=\"EN-GB\">CL/F (ml/min)</span></p>\n</td>\n<td style=\"width:161.1pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"215\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">469\u00b199.0</span></p>\n</td>\n<td style=\"width:72.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"97\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">356\u00b185.6</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">237\u00b1118</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">91.7\u00b151.3</span></p>\n</td>\n</tr>", "ID": "1e4fe82b-2904-4517-9f5a-ccdddb3052e6", "Styles": "page-break-inside:avoid;height:7.5pt", "Classes": "None", "Text": "      ", "ParentId": "2fa697b3-404a-4d26-8a8e-59170cbe7c47"}, {"Element": "<td style=\"width:117.9pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"157\">\n<p class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:\n  avoid\"><span lang=\"EN-GB\">CL/F (ml/min)</span></p>\n</td>", "ID": "85717941-d0e8-479d-a68c-21985bb9501a", "Styles": "width:117.9pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt", "Classes": "None", "Text": "  ", "ParentId": "1e4fe82b-2904-4517-9f5a-ccdddb3052e6"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:\n  avoid\"><span lang=\"EN-GB\">CL/F (ml/min)</span></p>", "ID": "0b1251b8-1570-4fd8-9fca-c1a866ff8c1a", "Styles": "margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "85717941-d0e8-479d-a68c-21985bb9501a"}, {"Element": "<span lang=\"EN-GB\">CL/F (ml/min)</span>", "ID": "a565a5b1-460b-4342-86d2-fb944e047b9a", "Styles": "None", "Classes": "None", "Text": "CL/F (ml/min)", "ParentId": "0b1251b8-1570-4fd8-9fca-c1a866ff8c1a"}, {"Element": "<td style=\"width:161.1pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"215\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">469\u00b199.0</span></p>\n</td>", "ID": "c96bf24a-13f4-497f-8751-98ab6241c0a9", "Styles": "width:161.1pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt", "Classes": "None", "Text": "  ", "ParentId": "1e4fe82b-2904-4517-9f5a-ccdddb3052e6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">469\u00b199.0</span></p>", "ID": "159d44ae-652c-47ee-b835-5eb77964f7c3", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c96bf24a-13f4-497f-8751-98ab6241c0a9"}, {"Element": "<span lang=\"EN-GB\">469\u00b199.0</span>", "ID": "e36f2602-4b12-4631-a69a-b76dc5b06ed9", "Styles": "None", "Classes": "None", "Text": "469\u00b199.0", "ParentId": "159d44ae-652c-47ee-b835-5eb77964f7c3"}, {"Element": "<td style=\"width:72.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"97\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">356\u00b185.6</span></p>\n</td>", "ID": "7b855e18-43c7-4ec5-ac51-ad3b19ca47a1", "Styles": "width:72.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt", "Classes": "None", "Text": "  ", "ParentId": "1e4fe82b-2904-4517-9f5a-ccdddb3052e6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">356\u00b185.6</span></p>", "ID": "6715b4b6-4a78-4a23-b14d-d2fbace2b031", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7b855e18-43c7-4ec5-ac51-ad3b19ca47a1"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">356\u00b185.6</span>", "ID": "25f858a6-5ed9-4127-88d2-3104286d643d", "Styles": "layout-grid-mode:\n  line", "Classes": "None", "Text": "356\u00b185.6", "ParentId": "6715b4b6-4a78-4a23-b14d-d2fbace2b031"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">237\u00b1118</span></p>\n</td>", "ID": "e5de4b1b-531f-4876-85f7-5ee6bfc2cfff", "Styles": "width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt", "Classes": "None", "Text": "  ", "ParentId": "1e4fe82b-2904-4517-9f5a-ccdddb3052e6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">237\u00b1118</span></p>", "ID": "45170461-8f66-44c4-b9f9-be723490cd95", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e5de4b1b-531f-4876-85f7-5ee6bfc2cfff"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">237\u00b1118</span>", "ID": "373bb151-fb58-4581-9d93-50ae62a32fbf", "Styles": "layout-grid-mode:\n  line", "Classes": "None", "Text": "237\u00b1118", "ParentId": "45170461-8f66-44c4-b9f9-be723490cd95"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">91.7\u00b151.3</span></p>\n</td>", "ID": "d8786f13-f858-4e75-b101-2e23842ea440", "Styles": "width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt", "Classes": "None", "Text": "  ", "ParentId": "1e4fe82b-2904-4517-9f5a-ccdddb3052e6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">91.7\u00b151.3</span></p>", "ID": "0b7380f2-ed8f-4608-945f-51acd63ea1bc", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d8786f13-f858-4e75-b101-2e23842ea440"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:\n  line\">91.7\u00b151.3</span>", "ID": "faa2ac44-64fc-4352-b84e-2b6b2f320a7b", "Styles": "layout-grid-mode:\n  line", "Classes": "None", "Text": "91.7\u00b151.3", "ParentId": "0b7380f2-ed8f-4608-945f-51acd63ea1bc"}, {"Element": "<tr style=\"page-break-inside:avoid;height:7.5pt\">\n<td style=\"width:117.9pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"157\">\n<p class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal\"><span lang=\"EN-GB\">CL<sub>renal</sub> (ml/min)</span></p>\n</td>\n<td style=\"width:161.1pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"215\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">231\u00b148.9</span></p>\n</td>\n<td style=\"width:72.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"97\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">148\u00b139.3</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">83.9\u00b127.5</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">37.0\u00b118.4</span></p>\n</td>\n</tr>", "ID": "0853ed12-9768-4dce-b8f8-e39be3bfc059", "Styles": "page-break-inside:avoid;height:7.5pt", "Classes": "None", "Text": "      ", "ParentId": "2fa697b3-404a-4d26-8a8e-59170cbe7c47"}, {"Element": "<td style=\"width:117.9pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"157\">\n<p class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal\"><span lang=\"EN-GB\">CL<sub>renal</sub> (ml/min)</span></p>\n</td>", "ID": "ad980b8c-c0ca-4d78-9a55-4dc674042308", "Styles": "width:117.9pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt", "Classes": "None", "Text": "  ", "ParentId": "0853ed12-9768-4dce-b8f8-e39be3bfc059"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal\"><span lang=\"EN-GB\">CL<sub>renal</sub> (ml/min)</span></p>", "ID": "df2d0f15-7363-4703-9c94-a025ec8e65c9", "Styles": "margin-top:3.0pt;margin-right:-.1pt;margin-bottom:\n  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ad980b8c-c0ca-4d78-9a55-4dc674042308"}, {"Element": "<span lang=\"EN-GB\">CL<sub>renal</sub> (ml/min)</span>", "ID": "b37a75f5-718b-4bbc-bc99-e7338b4ca1dc", "Styles": "None", "Classes": "None", "Text": "CL (ml/min)", "ParentId": "df2d0f15-7363-4703-9c94-a025ec8e65c9"}, {"Element": "<sub>renal</sub>", "ID": "99eecbcf-d9cb-41df-923a-631503d7b4ea", "Styles": "None", "Classes": "None", "Text": "renal", "ParentId": "b37a75f5-718b-4bbc-bc99-e7338b4ca1dc"}, {"Element": "<td style=\"width:161.1pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt\" valign=\"top\" width=\"215\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">231\u00b148.9</span></p>\n</td>", "ID": "38638437-940d-46db-910d-1a79dc974572", "Styles": "width:161.1pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;height:7.5pt", "Classes": "None", "Text": "  ", "ParentId": "0853ed12-9768-4dce-b8f8-e39be3bfc059"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">231\u00b148.9</span></p>", "ID": "c2cb738f-64c4-4e61-a3a1-6a567f62b29d", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "38638437-940d-46db-910d-1a79dc974572"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">231\u00b148.9</span>", "ID": "f83fe482-b624-4157-9aa5-1cd5c11ca717", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "231\u00b148.9", "ParentId": "c2cb738f-64c4-4e61-a3a1-6a567f62b29d"}, {"Element": "<td style=\"width:72.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"97\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">148\u00b139.3</span></p>\n</td>", "ID": "e4968e75-cfb2-41fb-9d40-f10fc9e59e42", "Styles": "width:72.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt", "Classes": "None", "Text": "  ", "ParentId": "0853ed12-9768-4dce-b8f8-e39be3bfc059"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">148\u00b139.3</span></p>", "ID": "7375d368-7656-4d0a-861c-a7a00bc49616", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e4968e75-cfb2-41fb-9d40-f10fc9e59e42"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">148\u00b139.3</span>", "ID": "bd81ddfd-999f-4d02-aaea-06ba695cb8a7", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "148\u00b139.3", "ParentId": "7375d368-7656-4d0a-861c-a7a00bc49616"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">83.9\u00b127.5</span></p>\n</td>", "ID": "1989dbba-9808-44c8-8530-f4a567dcdfba", "Styles": "width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt", "Classes": "None", "Text": "  ", "ParentId": "0853ed12-9768-4dce-b8f8-e39be3bfc059"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">83.9\u00b127.5</span></p>", "ID": "aaa37ebe-5bba-4cd7-b157-d51bfe210704", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1989dbba-9808-44c8-8530-f4a567dcdfba"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">83.9\u00b127.5</span>", "ID": "1edda621-db90-472b-84e0-be6a7bc78720", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "83.9\u00b127.5", "ParentId": "aaa37ebe-5bba-4cd7-b157-d51bfe210704"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt\" valign=\"top\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">37.0\u00b118.4</span></p>\n</td>", "ID": "408ae0e1-6ebe-43b1-9cee-114fb7da4dcb", "Styles": "width:63.8pt;border-top:none;border-left:none;\n  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;\n  height:7.5pt", "Classes": "None", "Text": "  ", "ParentId": "0853ed12-9768-4dce-b8f8-e39be3bfc059"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">37.0\u00b118.4</span></p>", "ID": "884fd52f-facb-40be-97ef-379fbc3c8f73", "Styles": "margin-top:3.0pt;margin-right:-.1pt;\n  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;\n  line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "408ae0e1-6ebe-43b1-9cee-114fb7da4dcb"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">37.0\u00b118.4</span>", "ID": "266dcd3b-9540-47e0-8f7a-fc9b7c2bee3e", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "37.0\u00b118.4", "ParentId": "884fd52f-facb-40be-97ef-379fbc3c8f73"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0406f61d-ec06-43b8-93af-3709148bec4b", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e9ccce09-1ae6-4f1e-a3a4-e5b87d47985e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0406f61d-ec06-43b8-93af-3709148bec4b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">A four-hour\nperiod of haemodialysis removed approximately 35\u00a0% of the adefovir dose.\u00a0\nThe effect of peritoneal dialysis on adefovir removal has not been evaluated.</span></p>", "ID": "4f065982-af1f-47b5-aede-355d6848bba0", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">A four-hour\nperiod of haemodialysis removed approximately 35\u00a0% of the adefovir dose.\u00a0\nThe effect of peritoneal dialysis on adefovir removal has not been evaluated.</span>", "ID": "e247a062-19d2-45b1-8c92-8e19606453ae", "Styles": "None", "Classes": "None", "Text": "A four-hour period of haemodialysis removed approximately 35\u00a0% of the adefovir dose.\u00a0 The effect of peritoneal dialysis on adefovir removal has not been evaluated.", "ParentId": "4f065982-af1f-47b5-aede-355d6848bba0"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "55d173f5-762d-45c6-ae16-eb0e4908366b", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8f6ca5ee-33ff-4a9b-9ac6-1c4c99621eba", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "55d173f5-762d-45c6-ae16-eb0e4908366b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">It is\nrecommended that the dosing interval of 10\u00a0mg adefovir dipivoxil is\nmodified in patients with creatinine clearance between 30 and\u00a049\u00a0ml/min.\n\u00a0Adefovir dipivoxil is not recommended in patients with creatinine clearance of\n&lt;\u00a030\u00a0ml/min or in patients on dialysis (see\u00a0section\u00a04.2\nand 4.4).</span></p>", "ID": "7fdfbe0c-a228-4b85-b130-f14bd1256f25", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">It is\nrecommended that the dosing interval of 10\u00a0mg adefovir dipivoxil is\nmodified in patients with creatinine clearance between 30 and\u00a049\u00a0ml/min.\n\u00a0Adefovir dipivoxil is not recommended in patients with creatinine clearance of\n&lt;\u00a030\u00a0ml/min or in patients on dialysis (see\u00a0section\u00a04.2\nand 4.4).</span>", "ID": "0ee87617-0b67-4347-a8b9-a6c569af3333", "Styles": "None", "Classes": "None", "Text": "It is recommended that the dosing interval of 10\u00a0mg adefovir dipivoxil is modified in patients with creatinine clearance between 30 and\u00a049\u00a0ml/min. \u00a0Adefovir dipivoxil is not recommended in patients with creatinine clearance of <\u00a030\u00a0ml/min or in patients on dialysis (see\u00a0section\u00a04.2 and 4.4).", "ParentId": "7fdfbe0c-a228-4b85-b130-f14bd1256f25"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f2eb1200-c806-4b69-aabd-a9055cd6f21d", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9ec7c0b1-c409-4595-a307-4db514ccc7ac", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f2eb1200-c806-4b69-aabd-a9055cd6f21d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Hepatic\nimpairment:</span></i><span lang=\"EN-GB\"> Pharmacokinetic properties were similar\nin patients with moderate and severe hepatic impairment compared to healthy\nvolunteers (see\u00a0section\u00a04.2).</span></p>", "ID": "ceea9e32-8c17-4b18-9686-1bd68f76bd70", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Hepatic\nimpairment:</span></i>", "ID": "4bb08b1a-2727-46d0-8e5d-4986b71660f3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ceea9e32-8c17-4b18-9686-1bd68f76bd70"}, {"Element": "<span lang=\"EN-GB\">Hepatic\nimpairment:</span>", "ID": "88de35ea-c6ac-48a5-b6ad-bcc95faff583", "Styles": "None", "Classes": "None", "Text": "Hepatic impairment:", "ParentId": "4bb08b1a-2727-46d0-8e5d-4986b71660f3"}, {"Element": "<span lang=\"EN-GB\"> Pharmacokinetic properties were similar\nin patients with moderate and severe hepatic impairment compared to healthy\nvolunteers (see\u00a0section\u00a04.2).</span>", "ID": "bdf0fca2-31f0-4576-a0d0-6a6bc93377d2", "Styles": "None", "Classes": "None", "Text": " Pharmacokinetic properties were similar in patients with moderate and severe hepatic impairment compared to healthy volunteers (see\u00a0section\u00a04.2).", "ParentId": "ceea9e32-8c17-4b18-9686-1bd68f76bd70"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "022da015-244f-494b-b0c2-5a8faa7573a3", "Styles": "margin-right:-.1pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6ee8015a-6b07-4d51-b23b-89aef47796c5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "022da015-244f-494b-b0c2-5a8faa7573a3"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">Paediatric\npopulation: </span></i><span lang=\"EN-GB\">The pharmacokinetics of adefovir\ndipivoxil were studied in an efficacy and safety study of a daily dose of\n0.25\u00a0mg/kg to 10\u00a0mg adefovir dipivoxil in children (aged 2 to\n&lt;\u00a018\u00a0years).\u00a0 Pharmacokinetic analysis revealed that adefovir\nexposure was comparable among 3 age groups, 2 to 6\u00a0years (0.3\u00a0mg/kg),\n7 to 11\u00a0years (0.25\u00a0mg/kg) and 12 to 17\u00a0years (10\u00a0mg) and\nall age groups achieved adefovir exposure in the target range (for efficacy\nresults see\u00a0section\u00a05.1), which was based on adefovir plasma\nconcentrations in adult patients with chronic hepatitis\u00a0B with established\nsafety and efficacy profiles.</span></p>", "ID": "d8e26af0-4e17-4728-9ddb-439308575ead", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">Paediatric\npopulation: </span></i>", "ID": "004aeecb-da79-49b0-9941-600a76b565bd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d8e26af0-4e17-4728-9ddb-439308575ead"}, {"Element": "<span lang=\"EN-GB\">Paediatric\npopulation: </span>", "ID": "cffa6a0e-965a-4e9f-9592-c090fdb2d953", "Styles": "None", "Classes": "None", "Text": "Paediatric population: ", "ParentId": "004aeecb-da79-49b0-9941-600a76b565bd"}, {"Element": "<span lang=\"EN-GB\">The pharmacokinetics of adefovir\ndipivoxil were studied in an efficacy and safety study of a daily dose of\n0.25\u00a0mg/kg to 10\u00a0mg adefovir dipivoxil in children (aged 2 to\n&lt;\u00a018\u00a0years).\u00a0 Pharmacokinetic analysis revealed that adefovir\nexposure was comparable among 3 age groups, 2 to 6\u00a0years (0.3\u00a0mg/kg),\n7 to 11\u00a0years (0.25\u00a0mg/kg) and 12 to 17\u00a0years (10\u00a0mg) and\nall age groups achieved adefovir exposure in the target range (for efficacy\nresults see\u00a0section\u00a05.1), which was based on adefovir plasma\nconcentrations in adult patients with chronic hepatitis\u00a0B with established\nsafety and efficacy profiles.</span>", "ID": "254183fc-2768-4140-9a68-cc3118384cb6", "Styles": "None", "Classes": "None", "Text": "The pharmacokinetics of adefovir dipivoxil were studied in an efficacy and safety study of a daily dose of 0.25\u00a0mg/kg to 10\u00a0mg adefovir dipivoxil in children (aged 2 to <\u00a018\u00a0years).\u00a0 Pharmacokinetic analysis revealed that adefovir exposure was comparable among 3 age groups, 2 to 6\u00a0years (0.3\u00a0mg/kg), 7 to 11\u00a0years (0.25\u00a0mg/kg) and 12 to 17\u00a0years (10\u00a0mg) and all age groups achieved adefovir exposure in the target range (for efficacy results see\u00a0section\u00a05.1), which was based on adefovir plasma concentrations in adult patients with chronic hepatitis\u00a0B with established safety and efficacy profiles.", "ParentId": "d8e26af0-4e17-4728-9ddb-439308575ead"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b15cbea9-54b0-4e54-8ccf-6ce482529b0f", "Styles": "margin-right:-.1pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dba177b4-61f4-42ca-830d-c2b277f93200", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b15cbea9-54b0-4e54-8ccf-6ce482529b0f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.3\u00a0\u00a0\u00a0\u00a0 Preclinical safety\ndata</span></b></p>", "ID": "abb05886-0227-4278-8df7-417756d9abd3", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">5.3\u00a0\u00a0\u00a0\u00a0 Preclinical safety\ndata</span></b>", "ID": "72290aa3-2ecb-4bfc-ab02-8dd1b0e1433a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "abb05886-0227-4278-8df7-417756d9abd3"}, {"Element": "<span lang=\"EN-GB\">5.3\u00a0\u00a0\u00a0\u00a0 Preclinical safety\ndata</span>", "ID": "ab95cc5f-24ef-4ad8-81ed-02bf6ca25c8e", "Styles": "None", "Classes": "None", "Text": "5.3\u00a0\u00a0\u00a0\u00a0 Preclinical safety data", "ParentId": "72290aa3-2ecb-4bfc-ab02-8dd1b0e1433a"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "66fd2b55-6066-42eb-8978-868768ee4453", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3271252f-0ef7-49f8-a69b-a48f4b3cadc7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "66fd2b55-6066-42eb-8978-868768ee4453"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The primary dose\u2011limiting\ntoxic effect associated with administration of adefovir dipivoxil in animals\n(mice, rats and monkeys) was renal tubular nephropathy characterised by\nhistological alterations and/or increases in blood urea nitrogen and serum\ncreatinine.\u00a0 Nephrotoxicity was observed in animals at systemic exposures at\nleast 3\u201110\u00a0times higher than those achieved in humans at the\nrecommended therapeutic dose of 10\u00a0mg/day.</span></p>", "ID": "a7e0207d-7ed7-47b2-958d-429a861ee84d", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">The primary dose\u2011limiting\ntoxic effect associated with administration of adefovir dipivoxil in animals\n(mice, rats and monkeys) was renal tubular nephropathy characterised by\nhistological alterations and/or increases in blood urea nitrogen and serum\ncreatinine.\u00a0 Nephrotoxicity was observed in animals at systemic exposures at\nleast 3\u201110\u00a0times higher than those achieved in humans at the\nrecommended therapeutic dose of 10\u00a0mg/day.</span>", "ID": "37e13bf6-df16-4cc2-9f8f-dac9acb9348b", "Styles": "None", "Classes": "None", "Text": "The primary dose\u2011limiting toxic effect associated with administration of adefovir dipivoxil in animals (mice, rats and monkeys) was renal tubular nephropathy characterised by histological alterations and/or increases in blood urea nitrogen and serum creatinine.\u00a0 Nephrotoxicity was observed in animals at systemic exposures at least 3\u201110\u00a0times higher than those achieved in humans at the recommended therapeutic dose of 10\u00a0mg/day.", "ParentId": "a7e0207d-7ed7-47b2-958d-429a861ee84d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "075b646d-198e-4fdb-a375-fd1a336afbf6", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7e98d4f6-fa0f-46eb-b561-799444cd00e0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "075b646d-198e-4fdb-a375-fd1a336afbf6"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">No effects on\nmale or female fertility, or reproductive performance, occurred in rats and\nthere was no embryotoxicity or teratogenicity in rats or rabbits administered\nadefovir dipivoxil orally.</span></p>", "ID": "a8c74bce-dcc0-4740-a91c-fc72c8b0e94b", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">No effects on\nmale or female fertility, or reproductive performance, occurred in rats and\nthere was no embryotoxicity or teratogenicity in rats or rabbits administered\nadefovir dipivoxil orally.</span>", "ID": "a8ddf295-ac36-4d2f-b010-623503133da6", "Styles": "None", "Classes": "None", "Text": "No effects on male or female fertility, or reproductive performance, occurred in rats and there was no embryotoxicity or teratogenicity in rats or rabbits administered adefovir dipivoxil orally.", "ParentId": "a8c74bce-dcc0-4740-a91c-fc72c8b0e94b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3ffc73d5-5055-4716-9868-1bf995acca09", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "72e69258-d99a-4981-b153-ae5692f90ba4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3ffc73d5-5055-4716-9868-1bf995acca09"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">When adefovir\nwas administered intravenously to pregnant rats at doses associated with\nnotable maternal toxicity (systemic exposure 38\u00a0times that achieved in\nhumans at the therapeutic dose) embryotoxicity and an increased incidence of\nfoetal malformations (anasarca, depressed eye bulge, umbilical hernia and\nkinked tail) were observed.\u00a0 No adverse effects on development were seen at\nsystemic exposures approximately 12\u00a0times that achieved in humans at the\ntherapeutic dose.</span></p>", "ID": "4e1b6e41-141d-402e-9a72-517ca98b10ce", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">When adefovir\nwas administered intravenously to pregnant rats at doses associated with\nnotable maternal toxicity (systemic exposure 38\u00a0times that achieved in\nhumans at the therapeutic dose) embryotoxicity and an increased incidence of\nfoetal malformations (anasarca, depressed eye bulge, umbilical hernia and\nkinked tail) were observed.\u00a0 No adverse effects on development were seen at\nsystemic exposures approximately 12\u00a0times that achieved in humans at the\ntherapeutic dose.</span>", "ID": "4c1b7268-17d2-4445-a0fc-c3bfa98c4d36", "Styles": "None", "Classes": "None", "Text": "When adefovir was administered intravenously to pregnant rats at doses associated with notable maternal toxicity (systemic exposure 38\u00a0times that achieved in humans at the therapeutic dose) embryotoxicity and an increased incidence of foetal malformations (anasarca, depressed eye bulge, umbilical hernia and kinked tail) were observed.\u00a0 No adverse effects on development were seen at systemic exposures approximately 12\u00a0times that achieved in humans at the therapeutic dose.", "ParentId": "4e1b6e41-141d-402e-9a72-517ca98b10ce"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dc766cdf-9dec-47e8-966e-5de1e5a7ae61", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "075cd621-2613-4a24-9a2b-c99531069fa8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dc766cdf-9dec-47e8-966e-5de1e5a7ae61"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adefovir\ndipivoxil was mutagenic in the <i>in\u00a0vitro</i> mouse lymphoma cell assay\n(with or without metabolic activation), but was not clastogenic in the <i>in\u00a0vivo</i>\nmouse micronucleus assay.</span></p>", "ID": "f4f68370-092a-42a1-9734-9d89a8d9f6ce", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Adefovir\ndipivoxil was mutagenic in the <i>in\u00a0vitro</i> mouse lymphoma cell assay\n(with or without metabolic activation), but was not clastogenic in the <i>in\u00a0vivo</i>\nmouse micronucleus assay.</span>", "ID": "c6aac41a-7037-4806-8a54-0ecdfc070e66", "Styles": "None", "Classes": "None", "Text": "Adefovir dipivoxil was mutagenic in the  mouse lymphoma cell assay (with or without metabolic activation), but was not clastogenic in the  mouse micronucleus assay.", "ParentId": "f4f68370-092a-42a1-9734-9d89a8d9f6ce"}, {"Element": "<i>in\u00a0vitro</i>", "ID": "101ad36a-a661-45f5-b65e-b9b409bff635", "Styles": "None", "Classes": "None", "Text": "in\u00a0vitro", "ParentId": "c6aac41a-7037-4806-8a54-0ecdfc070e66"}, {"Element": "<i>in\u00a0vivo</i>", "ID": "1e0d1678-2f38-497b-9c0b-ed16042b0458", "Styles": "None", "Classes": "None", "Text": "in\u00a0vivo", "ParentId": "c6aac41a-7037-4806-8a54-0ecdfc070e66"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "eb6db3ba-295d-40f2-b81f-8cb74bb10c80", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9ac682b2-e997-4544-922e-fedd5b6beb8b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "eb6db3ba-295d-40f2-b81f-8cb74bb10c80"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adefovir was not\nmutagenic in microbial mutagenicity assays involving <i>Salmonella typhimurium</i>\n(Ames) and <i>Escherichia coli</i> in the presence and absence of metabolic\nactivation.\u00a0 Adefovir induced chromosomal aberrations in the <i>in\u00a0vitro</i>\nhuman peripheral blood lymphocyte assay without metabolic activation.</span></p>", "ID": "2a806820-707d-4148-8808-49783081db01", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Adefovir was not\nmutagenic in microbial mutagenicity assays involving <i>Salmonella typhimurium</i>\n(Ames) and <i>Escherichia coli</i> in the presence and absence of metabolic\nactivation.\u00a0 Adefovir induced chromosomal aberrations in the <i>in\u00a0vitro</i>\nhuman peripheral blood lymphocyte assay without metabolic activation.</span>", "ID": "ed68e4ad-e9a8-4225-9aef-8a1fd55c2c6d", "Styles": "None", "Classes": "None", "Text": "Adefovir was not mutagenic in microbial mutagenicity assays involving  (Ames) and  in the presence and absence of metabolic activation.\u00a0 Adefovir induced chromosomal aberrations in the  human peripheral blood lymphocyte assay without metabolic activation.", "ParentId": "2a806820-707d-4148-8808-49783081db01"}, {"Element": "<i>Salmonella typhimurium</i>", "ID": "54a3d18e-b4de-4fe5-8cfd-134d646110ff", "Styles": "None", "Classes": "None", "Text": "Salmonella typhimurium", "ParentId": "ed68e4ad-e9a8-4225-9aef-8a1fd55c2c6d"}, {"Element": "<i>Escherichia coli</i>", "ID": "9b64ad6b-d767-4d5c-a596-5731365fccb6", "Styles": "None", "Classes": "None", "Text": "Escherichia coli", "ParentId": "ed68e4ad-e9a8-4225-9aef-8a1fd55c2c6d"}, {"Element": "<i>in\u00a0vitro</i>", "ID": "412cb724-51a4-4bb0-aa2e-7235f0abc782", "Styles": "None", "Classes": "None", "Text": "in\u00a0vitro", "ParentId": "ed68e4ad-e9a8-4225-9aef-8a1fd55c2c6d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1566ed98-a567-4a23-950f-f12490ecf333", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dea5514c-c6c8-4459-9c3f-3e07ffbeaba6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1566ed98-a567-4a23-950f-f12490ecf333"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In long\u2011term\ncarcinogenicity studies in rats and mice with adefovir dipivoxil, no\ntreatment-related increase in tumour incidence was found in mice or rats\n(systemic exposures approximately 10 and 4\u00a0times those achieved in humans\nat the therapeutic dose of 10\u00a0mg/day, respectively).</span></p>", "ID": "6b69123a-3f4a-41a4-bb66-5390b8829bae", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">In long\u2011term\ncarcinogenicity studies in rats and mice with adefovir dipivoxil, no\ntreatment-related increase in tumour incidence was found in mice or rats\n(systemic exposures approximately 10 and 4\u00a0times those achieved in humans\nat the therapeutic dose of 10\u00a0mg/day, respectively).</span>", "ID": "35e58ba9-4aae-4f7b-a9f9-7dc16fcdf1d6", "Styles": "None", "Classes": "None", "Text": "In long\u2011term carcinogenicity studies in rats and mice with adefovir dipivoxil, no treatment-related increase in tumour incidence was found in mice or rats (systemic exposures approximately 10 and 4\u00a0times those achieved in humans at the therapeutic dose of 10\u00a0mg/day, respectively).", "ParentId": "6b69123a-3f4a-41a4-bb66-5390b8829bae"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c76db8ae-ac5a-46bc-b4c7-ef984422c5ac", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9f583eea-f456-4738-a7f7-14c8a6fed203", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c76db8ae-ac5a-46bc-b4c7-ef984422c5ac"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e67194b9-6448-4e6f-a8e6-af09c2af5cf9", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d47c0bb3-cfe3-46ed-8066-65f4a28bed0a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e67194b9-6448-4e6f-a8e6-af09c2af5cf9"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL PARTICULARS</span></b></p>", "ID": "331186fc-93e2-42cb-ab2f-9e5d57b1dbef", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL PARTICULARS</span></b>", "ID": "e5f921cb-111d-45c0-bb56-4a6122bdd80b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "331186fc-93e2-42cb-ab2f-9e5d57b1dbef"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL PARTICULARS</span>", "ID": "88417914-b4f3-4f2c-85d5-2d01a3f68a6c", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL PARTICULARS", "ParentId": "e5f921cb-111d-45c0-bb56-4a6122bdd80b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4078b843-172f-495d-b009-e15f97e8bf8f", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e572d442-0585-45a5-a402-f52366275552", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4078b843-172f-495d-b009-e15f97e8bf8f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.1\u00a0\u00a0\u00a0\u00a0 List of excipients</span></b></p>", "ID": "9f195dee-ad1a-4b7c-8683-ed63cc9187de", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">6.1\u00a0\u00a0\u00a0\u00a0 List of excipients</span></b>", "ID": "a669b4b4-d1b0-41eb-afc9-ec070700e3ad", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9f195dee-ad1a-4b7c-8683-ed63cc9187de"}, {"Element": "<span lang=\"EN-GB\">6.1\u00a0\u00a0\u00a0\u00a0 List of excipients</span>", "ID": "378c8a73-9395-4108-8de4-828407b21664", "Styles": "None", "Classes": "None", "Text": "6.1\u00a0\u00a0\u00a0\u00a0 List of excipients", "ParentId": "a669b4b4-d1b0-41eb-afc9-ec070700e3ad"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fe381128-56f3-44ed-971d-21cfc9a318c3", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c0ed8281-73b6-485f-bd58-1f0a2447f270", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fe381128-56f3-44ed-971d-21cfc9a318c3"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Pregelatinised starch</span></p>", "ID": "0e7ad565-4566-4cca-b1f7-34f1c94549f4", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Pregelatinised starch</span>", "ID": "062a52e1-374c-42b0-bd8f-d61e2175d7f2", "Styles": "None", "Classes": "None", "Text": "Pregelatinised starch", "ParentId": "0e7ad565-4566-4cca-b1f7-34f1c94549f4"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Croscarmellose sodium</span></p>", "ID": "8bc5a644-0562-4447-919b-3e2b6ded14dd", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Croscarmellose sodium</span>", "ID": "bfa683b5-3456-49a7-a355-d23590c73d5b", "Styles": "None", "Classes": "None", "Text": "Croscarmellose sodium", "ParentId": "8bc5a644-0562-4447-919b-3e2b6ded14dd"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Lactose monohydrate</span></p>", "ID": "17abf5e5-40c3-4edd-abaf-ac39010c7ca7", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Lactose monohydrate</span>", "ID": "32d7a015-c117-41ec-8cc1-af6fae36fa73", "Styles": "None", "Classes": "None", "Text": "Lactose monohydrate", "ParentId": "17abf5e5-40c3-4edd-abaf-ac39010c7ca7"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Talc</span></p>", "ID": "35832ab8-e881-4587-a3d3-bcfcdb557525", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Talc</span>", "ID": "ef8766ec-7c31-44d6-b79a-78b002f94e05", "Styles": "None", "Classes": "None", "Text": "Talc", "ParentId": "35832ab8-e881-4587-a3d3-bcfcdb557525"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Magnesium\nstearate</span></p>", "ID": "20631016-1f3c-4c0c-abff-1b4b9c8564d1", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Magnesium\nstearate</span>", "ID": "aa2c6259-ba50-47d1-94ec-b65dd8440143", "Styles": "None", "Classes": "None", "Text": "Magnesium stearate", "ParentId": "20631016-1f3c-4c0c-abff-1b4b9c8564d1"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6ae8af73-77b3-4290-b404-b39492948e9c", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "30efeec8-4ecb-4e3f-b941-bfa86bef18b1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6ae8af73-77b3-4290-b404-b39492948e9c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities</span></b></p>", "ID": "c4bed926-61a8-4648-b8e3-df30f1f536c5", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities</span></b>", "ID": "ba285c0f-db0a-4a1d-8397-3528165f5139", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c4bed926-61a8-4648-b8e3-df30f1f536c5"}, {"Element": "<span lang=\"EN-GB\">6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities</span>", "ID": "1cc74e8b-8f0f-4869-8d65-b8553edaef90", "Styles": "None", "Classes": "None", "Text": "6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities", "ParentId": "ba285c0f-db0a-4a1d-8397-3528165f5139"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4464b27c-f4dc-467c-9e1f-2bc62af5fe5c", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "264af95f-8319-43d9-add6-e6425c726033", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4464b27c-f4dc-467c-9e1f-2bc62af5fe5c"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Not applicable.</span></p>", "ID": "6604a711-465b-425e-b094-479ed98ab635", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Not applicable.</span>", "ID": "3ece43c9-dec5-4db8-984a-fc9be402185e", "Styles": "None", "Classes": "None", "Text": "Not applicable.", "ParentId": "6604a711-465b-425e-b094-479ed98ab635"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "48c20946-24aa-4fa4-8de3-84967b51dbf3", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2d200e94-d52c-4567-99b1-a794a7ca7599", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "48c20946-24aa-4fa4-8de3-84967b51dbf3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.3\u00a0\u00a0\u00a0\u00a0 Shelf life</span></b></p>", "ID": "3f8c8e64-909c-467e-bdd6-49b0ddcd67ee", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">6.3\u00a0\u00a0\u00a0\u00a0 Shelf life</span></b>", "ID": "47327fcb-4b17-449a-aef6-0abb1781ed22", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3f8c8e64-909c-467e-bdd6-49b0ddcd67ee"}, {"Element": "<span lang=\"EN-GB\">6.3\u00a0\u00a0\u00a0\u00a0 Shelf life</span>", "ID": "1f15a6e3-b7b6-41ed-a422-6d35c43de917", "Styles": "None", "Classes": "None", "Text": "6.3\u00a0\u00a0\u00a0\u00a0 Shelf life", "ParentId": "47327fcb-4b17-449a-aef6-0abb1781ed22"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "93b848c5-303a-479a-98a0-df19ccd6ce42", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "01f752b2-4264-4660-8197-fa82070fb038", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "93b848c5-303a-479a-98a0-df19ccd6ce42"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">2\u00a0years.</span></p>", "ID": "0cbe7687-ff5e-47e0-a5b6-5f1c106ca1c0", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">2\u00a0years.</span>", "ID": "2c0dc91c-137f-431c-a2dc-0a56ccba796f", "Styles": "None", "Classes": "None", "Text": "2\u00a0years.", "ParentId": "0cbe7687-ff5e-47e0-a5b6-5f1c106ca1c0"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a9392074-6bbd-4574-86d8-eadc1ff3975f", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e5c34f93-e43e-4f44-b3a2-bded4e96a806", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a9392074-6bbd-4574-86d8-eadc1ff3975f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.4\u00a0\u00a0\u00a0\u00a0 Special precautions\nfor storage</span></b></p>", "ID": "dcd854d8-6ccf-4dbd-9caa-5eb0cd639bcc", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">6.4\u00a0\u00a0\u00a0\u00a0 Special precautions\nfor storage</span></b>", "ID": "811c4370-e427-44d5-9e9a-31514d3b4597", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dcd854d8-6ccf-4dbd-9caa-5eb0cd639bcc"}, {"Element": "<span lang=\"EN-GB\">6.4\u00a0\u00a0\u00a0\u00a0 Special precautions\nfor storage</span>", "ID": "cafc7b87-fdef-42d4-85a4-74a098271a5a", "Styles": "None", "Classes": "None", "Text": "6.4\u00a0\u00a0\u00a0\u00a0 Special precautions for storage", "ParentId": "811c4370-e427-44d5-9e9a-31514d3b4597"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "995d11bb-ba80-4d5c-bfa5-97186c6b69bf", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3103221c-dec8-4e91-93da-49883ac5abc5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "995d11bb-ba80-4d5c-bfa5-97186c6b69bf"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Do not store\nabove 30\u00baC.\u00a0 Store in the original package in order to protect from moisture. \u00a0Keep\nthe bottle tightly closed.</span></p>", "ID": "6c564abd-2033-4aee-954d-04b39273ba6a", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Do not store\nabove 30\u00baC.\u00a0 Store in the original package in order to protect from moisture. \u00a0Keep\nthe bottle tightly closed.</span>", "ID": "2a030202-861b-4cfd-bd9d-c8919f14bfdc", "Styles": "None", "Classes": "None", "Text": "Do not store above 30\u00baC.\u00a0 Store in the original package in order to protect from moisture. \u00a0Keep the bottle tightly closed.", "ParentId": "6c564abd-2033-4aee-954d-04b39273ba6a"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ea2232d3-d312-4789-ba73-88b49c283362", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b02e9c8b-ea21-41c3-832c-395db86887e9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ea2232d3-d312-4789-ba73-88b49c283362"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.5\u00a0\u00a0\u00a0\u00a0 Nature and contents\nof container</span></b></p>", "ID": "56cc1b9e-5c64-4ec5-ba0c-e6e8ebd27a88", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">6.5\u00a0\u00a0\u00a0\u00a0 Nature and contents\nof container</span></b>", "ID": "1b927e7f-103c-4cf6-a439-0431558b69bb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "56cc1b9e-5c64-4ec5-ba0c-e6e8ebd27a88"}, {"Element": "<span lang=\"EN-GB\">6.5\u00a0\u00a0\u00a0\u00a0 Nature and contents\nof container</span>", "ID": "b0f30a86-1928-40ec-a14e-bb5a044d3291", "Styles": "None", "Classes": "None", "Text": "6.5\u00a0\u00a0\u00a0\u00a0 Nature and contents of container", "ParentId": "1b927e7f-103c-4cf6-a439-0431558b69bb"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "63493acd-c014-4676-b0bb-36356f883c57", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "291122be-37a4-4ee5-b4fd-ffa0f023b576", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "63493acd-c014-4676-b0bb-36356f883c57"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Hepsera is\nsupplied in high-density polyethylene (HDPE) bottles with a child\u2011resistant\nclosure.\u00a0 Each bottle contains 30\u00a0tablets, silica gel desiccant and fibre\npacking material.</span></p>", "ID": "cf2a9949-4c53-42b1-b396-0328b280438f", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Hepsera is\nsupplied in high-density polyethylene (HDPE) bottles with a child\u2011resistant\nclosure.\u00a0 Each bottle contains 30\u00a0tablets, silica gel desiccant and fibre\npacking material.</span>", "ID": "5a35f5db-d33a-46cc-bd9e-ee824c397853", "Styles": "None", "Classes": "None", "Text": "Hepsera is supplied in high-density polyethylene (HDPE) bottles with a child\u2011resistant closure.\u00a0 Each bottle contains 30\u00a0tablets, silica gel desiccant and fibre packing material.", "ParentId": "cf2a9949-4c53-42b1-b396-0328b280438f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "191b7b6a-054c-4ed3-94f1-0ce1c9354bfe", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1b68721b-384f-48a6-a27c-5e25c368e8e0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "191b7b6a-054c-4ed3-94f1-0ce1c9354bfe"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The following\npack sizes are available: outer cartons containing 1\u00a0bottle of\n30\u00a0tablets and outer cartons containing 90\u00a0(3\u00a0bottles of\n30)\u00a0tablets. \u00a0Not all pack sizes may be marketed.</span></p>", "ID": "b40095fa-2a04-45b7-84f2-5bc45ec463f4", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">The following\npack sizes are available: outer cartons containing 1\u00a0bottle of\n30\u00a0tablets and outer cartons containing 90\u00a0(3\u00a0bottles of\n30)\u00a0tablets. \u00a0Not all pack sizes may be marketed.</span>", "ID": "04f28f1a-ebd3-4639-9da1-2ad8e148cae8", "Styles": "None", "Classes": "None", "Text": "The following pack sizes are available: outer cartons containing 1\u00a0bottle of 30\u00a0tablets and outer cartons containing 90\u00a0(3\u00a0bottles of 30)\u00a0tablets. \u00a0Not all pack sizes may be marketed.", "ParentId": "b40095fa-2a04-45b7-84f2-5bc45ec463f4"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2806f497-f39a-4a18-a9e4-39a23f7d135d", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "940a51a7-0873-4c43-9af2-84d31346e314", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2806f497-f39a-4a18-a9e4-39a23f7d135d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.6\u00a0\u00a0\u00a0\u00a0 Special precautions\nfor disposal</span></b></p>", "ID": "34d37d11-e996-4104-95fd-b84958e9b9c8", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">6.6\u00a0\u00a0\u00a0\u00a0 Special precautions\nfor disposal</span></b>", "ID": "bddaf40a-152b-43e3-8610-d30f2cc8d19e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "34d37d11-e996-4104-95fd-b84958e9b9c8"}, {"Element": "<span lang=\"EN-GB\">6.6\u00a0\u00a0\u00a0\u00a0 Special precautions\nfor disposal</span>", "ID": "727d4fe8-5e86-4215-96c9-ae3dffcd0749", "Styles": "None", "Classes": "None", "Text": "6.6\u00a0\u00a0\u00a0\u00a0 Special precautions for disposal", "ParentId": "bddaf40a-152b-43e3-8610-d30f2cc8d19e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "58f65442-bf74-4764-b8c4-061eaf76dcc7", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fbc3405f-7c9f-42ed-97d6-8e1871c511fb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "58f65442-bf74-4764-b8c4-061eaf76dcc7"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Any unused medicinal\nproduct or waste material should be disposed of in accordance with local\nrequirements.</span></p>", "ID": "d2200b63-569f-4b2c-9796-e5dcbb96ea39", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Any unused medicinal\nproduct or waste material should be disposed of in accordance with local\nrequirements.</span>", "ID": "45508abe-fc2b-40f6-8159-c7b476f3a004", "Styles": "None", "Classes": "None", "Text": "Any unused medicinal product or waste material should be disposed of in accordance with local requirements.", "ParentId": "d2200b63-569f-4b2c-9796-e5dcbb96ea39"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3ff860f9-f17e-4d8d-93d3-d7550fefb1fc", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "67d14e5f-8666-4ebe-9e36-9bf0ce3f748a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3ff860f9-f17e-4d8d-93d3-d7550fefb1fc"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "603b2b30-4efd-4565-a260-3c877021737b", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fb7fc568-540f-4a7a-9ed2-d9ffdea54edc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "603b2b30-4efd-4565-a260-3c877021737b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION HOLDER</span></b></p>", "ID": "63771ee5-d434-492f-9696-0be4e44e67f0", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION HOLDER</span></b>", "ID": "1736128d-4ae3-45d1-9260-575e2741457e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "63771ee5-d434-492f-9696-0be4e44e67f0"}, {"Element": "<span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION HOLDER</span>", "ID": "479e1725-2284-41e1-8d35-5bbae9d740c1", "Styles": "None", "Classes": "None", "Text": "7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION HOLDER", "ParentId": "1736128d-4ae3-45d1-9260-575e2741457e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "64aac067-5ef4-4a43-be66-79c83d63dd2f", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8d01aa29-3300-4c21-8e30-04463b9bd488", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "64aac067-5ef4-4a43-be66-79c83d63dd2f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead Sciences\nIreland UC</span></p>", "ID": "5852cd41-14bc-4004-b02a-921c6a089296", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Gilead Sciences\nIreland UC</span>", "ID": "41c8efd3-ae14-4ea5-a283-5d9fed74abb3", "Styles": "None", "Classes": "None", "Text": "Gilead Sciences Ireland UC", "ParentId": "5852cd41-14bc-4004-b02a-921c6a089296"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Carrigtohill</span></p>", "ID": "b0656534-1c69-4ea0-9dbe-2468d02df29c", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Carrigtohill</span>", "ID": "7129443a-6574-407c-ad4f-a1e1aa312a35", "Styles": "None", "Classes": "None", "Text": "Carrigtohill", "ParentId": "b0656534-1c69-4ea0-9dbe-2468d02df29c"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">County Cork, T45\nDP77</span></p>", "ID": "5282a734-7779-42d8-a48d-fbb87aace492", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">County Cork, T45\nDP77</span>", "ID": "8cae1733-a016-4b23-a6cf-d258d247776a", "Styles": "None", "Classes": "None", "Text": "County Cork, T45 DP77", "ParentId": "5282a734-7779-42d8-a48d-fbb87aace492"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Ireland</span></p>", "ID": "31e000ba-d420-4368-99e4-e04161e05864", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Ireland</span>", "ID": "dfa0dc4e-f541-47f2-af7f-97d0a434ace6", "Styles": "None", "Classes": "None", "Text": "Ireland", "ParentId": "31e000ba-d420-4368-99e4-e04161e05864"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8dfc0677-7fff-471f-bbdc-f8df94640c5a", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8059f5bf-b275-4649-b09f-b27247220fee", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8dfc0677-7fff-471f-bbdc-f8df94640c5a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION\nNUMBER(S)</span></b></p>", "ID": "dc5b0032-2fb1-4129-b68c-226e57ad1201", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION\nNUMBER(S)</span></b>", "ID": "f2b7c4e8-0f62-4a4f-bd25-9f32a4a80c34", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dc5b0032-2fb1-4129-b68c-226e57ad1201"}, {"Element": "<span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION\nNUMBER(S)</span>", "ID": "e4d10b4f-08ec-44b5-8c9d-d8ff1609939b", "Styles": "None", "Classes": "None", "Text": "8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION NUMBER(S)", "ParentId": "f2b7c4e8-0f62-4a4f-bd25-9f32a4a80c34"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c284909f-0e91-4e19-9574-c8d8d2cb43d3", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6664950c-dcda-4268-8ed4-d688487e9b38", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c284909f-0e91-4e19-9574-c8d8d2cb43d3"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">EU/1/03/251/001</span></p>", "ID": "235ccfcd-b3a8-4913-b60e-234fae1a0d47", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">EU/1/03/251/001</span>", "ID": "989ce148-3aea-4798-ac6d-be8f8d06a8e3", "Styles": "None", "Classes": "None", "Text": "EU/1/03/251/001", "ParentId": "235ccfcd-b3a8-4913-b60e-234fae1a0d47"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EU/1/03/251/002</span></p>", "ID": "bc564e12-171f-4710-bd4a-12d6a5229277", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">EU/1/03/251/002</span>", "ID": "b54eb047-618d-4b18-8785-5ed757e53d06", "Styles": "None", "Classes": "None", "Text": "EU/1/03/251/002", "ParentId": "bc564e12-171f-4710-bd4a-12d6a5229277"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4b82cd23-6d7c-4a8d-901f-9b64037fa557", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7fad1b44-e84e-4625-9b92-5267f9e7b355", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4b82cd23-6d7c-4a8d-901f-9b64037fa557"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "038389a4-b17e-4870-a00e-2f5e0111543c", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5c96af01-28c4-48dc-a62a-0e639354e468", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "038389a4-b17e-4870-a00e-2f5e0111543c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF FIRST\nAUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>", "ID": "2054d0e9-b0ba-46b6-8b72-d19417a59a31", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF FIRST\nAUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b>", "ID": "f99f0423-a529-42be-9972-c714feb8f500", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2054d0e9-b0ba-46b6-8b72-d19417a59a31"}, {"Element": "<span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF FIRST\nAUTHORISATION/RENEWAL OF THE AUTHORISATION</span>", "ID": "39b989ce-5379-4122-94a4-8197956b95ad", "Styles": "None", "Classes": "None", "Text": "9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION", "ParentId": "f99f0423-a529-42be-9972-c714feb8f500"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ca05386b-16d0-46f3-acee-600076e347e7", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dd052003-9ffb-4260-a169-70a7ab113a11", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ca05386b-16d0-46f3-acee-600076e347e7"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Date of first authorisation: 06 March 2003</span></p>", "ID": "73ae370f-20af-4ddd-9a63-0ddb4d614d10", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Date of first authorisation: 06 March 2003</span>", "ID": "7cedaf20-eecc-4eb1-beb4-105696447b3a", "Styles": "None", "Classes": "None", "Text": "Date of first authorisation: 06 March 2003", "ParentId": "73ae370f-20af-4ddd-9a63-0ddb4d614d10"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Date of latest\nrenewal: 06 March 2008</span></p>", "ID": "0fed2be0-f398-4a4d-a167-bda443807e1d", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Date of latest\nrenewal: 06 March 2008</span>", "ID": "14629df3-5220-411b-bbd0-55d64ee1432f", "Styles": "None", "Classes": "None", "Text": "Date of latest renewal: 06 March 2008", "ParentId": "0fed2be0-f398-4a4d-a167-bda443807e1d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bcb78002-ea45-4e57-b24b-c5d5c5564156", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6fdfe1b2-b86f-4abd-9e07-ca1373d999b0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bcb78002-ea45-4e57-b24b-c5d5c5564156"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7376e25c-657f-4b03-9098-0079e55226bb", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6359c59d-a8c7-46cd-ac18-7e66a32aafa2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7376e25c-657f-4b03-9098-0079e55226bb"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 DATE OF REVISION OF\nTHE TEXT</span></b></p>", "ID": "af994d19-403d-4efb-b821-230775880365", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 DATE OF REVISION OF\nTHE TEXT</span></b>", "ID": "1eabbc05-15dd-4192-a139-bab0007b054e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "af994d19-403d-4efb-b821-230775880365"}, {"Element": "<span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 DATE OF REVISION OF\nTHE TEXT</span>", "ID": "4610d3c1-d6cf-4ebe-8a68-8d2c7b8791fa", "Styles": "None", "Classes": "None", "Text": "10.\u00a0\u00a0\u00a0\u00a0 DATE OF REVISION OF THE TEXT", "ParentId": "1eabbc05-15dd-4192-a139-bab0007b054e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1a42eef5-f3be-4b90-8576-d0f2de8537a4", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d50d5cc5-d3b1-44cc-8b27-774eb73fdeb3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1a42eef5-f3be-4b90-8576-d0f2de8537a4"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">{MM/YYYY}</span></p>", "ID": "48fb6f5a-f43c-4544-a830-d105c818ff69", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">{MM/YYYY}</span>", "ID": "c5ce5b07-8d7c-4cab-a3e0-cfe47427fdc2", "Styles": "None", "Classes": "None", "Text": "{MM/YYYY}", "ParentId": "48fb6f5a-f43c-4544-a830-d105c818ff69"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ae7f15ac-654a-43d5-a794-97065f5a4bb9", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ae06dd5e-a01a-456c-bdc8-8020dc6105c7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ae7f15ac-654a-43d5-a794-97065f5a4bb9"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Detailed information\non this medicinal product is available on the website of the European Medicines\nAgency http://www.ema.europa.eu</span></p>", "ID": "94ec3db4-dcee-4022-9f80-977bbbd086df", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Detailed information\non this medicinal product is available on the website of the European Medicines\nAgency http://www.ema.europa.eu</span>", "ID": "64a48137-886f-464b-a85d-e4ec716da051", "Styles": "None", "Classes": "None", "Text": "Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu", "ParentId": "94ec3db4-dcee-4022-9f80-977bbbd086df"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ccf8fcf2-396e-43ff-8445-84d24e348cc5", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b9cb7cc6-dfb0-4b72-b76d-06d44a02e220", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ccf8fcf2-396e-43ff-8445-84d24e348cc5"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "266d9df4-bea8-4b59-80d8-50b0549589bd", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ee765085-09c2-4ec0-b4cb-3ad817922363", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "266d9df4-bea8-4b59-80d8-50b0549589bd"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "2f655040-8cd6-4044-b177-a0cf1e74d17a", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "19a3a16f-c2b5-49cf-8dc1-116f1dbfe918", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "2f655040-8cd6-4044-b177-a0cf1e74d17a"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c8ee144f-796d-4f0c-a34d-6a134e33e2b8", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "822c2059-580c-4baa-a5e1-22c2e4a33fb5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c8ee144f-796d-4f0c-a34d-6a134e33e2b8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "afbc0b2a-3f44-4f27-b0ff-2ffec05c9d2b", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dee95d97-931d-4f5c-b48a-d4e31f9e698d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "afbc0b2a-3f44-4f27-b0ff-2ffec05c9d2b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "97b24228-f24c-423a-b987-871017479593", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "16ba0aa1-651e-49e7-a580-920fb4d35c8b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "97b24228-f24c-423a-b987-871017479593"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4c4b378e-a724-447c-8213-bbd6a56dabbe", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7554826d-cbab-4b51-b73b-d5c9c3e01d37", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4c4b378e-a724-447c-8213-bbd6a56dabbe"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f430e284-e7cf-46ca-bb3b-5f8d56cb3e1b", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b7327837-adaf-46df-8663-d7c4c60be229", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f430e284-e7cf-46ca-bb3b-5f8d56cb3e1b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4a2184ff-5924-4749-86a4-a57674b64b4a", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "830ad410-fc81-48c2-b35a-0aa9d2c3a1d4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4a2184ff-5924-4749-86a4-a57674b64b4a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fefb38b5-c824-43a8-8535-a6b08ae64bd0", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bac6ebdc-0d85-4f40-9040-8d78f83f68e7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fefb38b5-c824-43a8-8535-a6b08ae64bd0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a3facab9-5dde-4ad5-b8dc-4a1a9340cb0b", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f76e7f90-729c-40ce-8a1a-dd343b33ad94", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a3facab9-5dde-4ad5-b8dc-4a1a9340cb0b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "20884573-4d67-4046-9bb1-839a0d49191e", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "33a2dc9f-92ff-4f41-9b88-335000d1d276", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "20884573-4d67-4046-9bb1-839a0d49191e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "aa688415-2aa3-499e-b7c6-87f85602ccf4", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4c3090bf-e067-4203-a6d0-4d4d2592a4e7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "aa688415-2aa3-499e-b7c6-87f85602ccf4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "224b1067-6783-40bb-8ee5-00bc0aa88e7a", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "82dba01d-e364-4cce-84f7-15acce41b003", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "224b1067-6783-40bb-8ee5-00bc0aa88e7a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a6e31c97-e759-4b0d-beba-708d0e99e42b", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bf529e04-5220-4e15-ab59-2ad209119a19", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a6e31c97-e759-4b0d-beba-708d0e99e42b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2fdd80a0-9262-40c8-b102-d2d59614f81c", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "850e3081-2f0b-4594-8712-01de29c76ed8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2fdd80a0-9262-40c8-b102-d2d59614f81c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "82b3c187-59a9-4567-86d1-85936b2514c2", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "59a511fe-5afe-485e-922e-ce9d6ebb933f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "82b3c187-59a9-4567-86d1-85936b2514c2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "376fcc78-7aa4-47a7-9512-448eccc44d6a", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3a8fa0af-cc74-487e-ae91-e44b3e188ab1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "376fcc78-7aa4-47a7-9512-448eccc44d6a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "56f3b785-1542-4803-8dcb-4fb3b663e72e", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "88e83125-f251-4b07-a185-6732bb2b25f8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "56f3b785-1542-4803-8dcb-4fb3b663e72e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "51e99975-15d1-43a2-a8fa-24d38857aae9", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3b7eadcb-6eea-4cfa-9c93-b29f94fabf48", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "51e99975-15d1-43a2-a8fa-24d38857aae9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "909d23dc-1f30-4d09-9721-0e3f4ca03cd7", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e019e68b-b613-4c51-975b-3eb3df2cc72c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "909d23dc-1f30-4d09-9721-0e3f4ca03cd7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "06991a7e-4c03-4add-bf09-b24ddf8aba1b", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f3d6e0b8-3a00-4814-847d-be4323f46e79", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "06991a7e-4c03-4add-bf09-b24ddf8aba1b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4ef9ab3f-95b1-4145-8412-22b75cdeb089", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "298bc7da-5ba0-474f-baaa-a32e90bfe5db", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4ef9ab3f-95b1-4145-8412-22b75cdeb089"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "eb0eed2d-22a6-4865-b715-c1f3b52d7c73", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "846cf614-977b-4a83-a441-e49c90b0911d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "eb0eed2d-22a6-4865-b715-c1f3b52d7c73"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "42413722-d278-4aea-8988-7ea7baaa3a70", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b1070874-0474-4166-bcad-06243c724dc4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "42413722-d278-4aea-8988-7ea7baaa3a70"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1ecb0f31-9d7a-4786-a90f-b0feefcd30d5", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dcaf1482-0698-4887-9119-863429bdbbbb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1ecb0f31-9d7a-4786-a90f-b0feefcd30d5"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">ANNEX II</span></b></p>", "ID": "297d6e46-b6f4-4318-a5ea-7ee93231e10e", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">ANNEX II</span></b>", "ID": "5ed6b6c1-3370-412c-a091-404206a8016a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "297d6e46-b6f4-4318-a5ea-7ee93231e10e"}, {"Element": "<span lang=\"EN-GB\">ANNEX II</span>", "ID": "ae143247-fe54-4790-bd41-08f8c6ab915b", "Styles": "None", "Classes": "None", "Text": "ANNEX II", "ParentId": "5ed6b6c1-3370-412c-a091-404206a8016a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9be48e50-19c6-44ea-a1dd-63b3e0e86289", "Styles": "margin-top:0in;margin-right:70.8pt;margin-bottom:\n0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "df2d1384-4cbc-4c37-bed4-659aeb79753a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9be48e50-19c6-44ea-a1dd-63b3e0e86289"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-28.35pt;line-height:\nnormal\"><b><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S) RESPONSIBLE FOR BATCH\nRELEASE</span></b></p>", "ID": "09ffccfb-d484-43c3-94fb-78d618ef2a36", "Styles": "margin-left:85.05pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S) RESPONSIBLE FOR BATCH\nRELEASE</span></b>", "ID": "17986731-7756-4942-a710-aad05dda5cec", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "09ffccfb-d484-43c3-94fb-78d618ef2a36"}, {"Element": "<span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S) RESPONSIBLE FOR BATCH\nRELEASE</span>", "ID": "d0e6603d-0d99-4420-8a57-97f742fb27d6", "Styles": "None", "Classes": "None", "Text": "A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE", "ParentId": "17986731-7756-4942-a710-aad05dda5cec"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ce6c65d8-fee4-4d8a-868b-52fcda43ac60", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9f356d9c-2025-470f-ba55-0f12696bb4c1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ce6c65d8-fee4-4d8a-868b-52fcda43ac60"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-28.35pt;line-height:\nnormal\"><b><span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING SUPPLY\nAND USE</span></b></p>", "ID": "d3fa57eb-af3a-4b88-a8cd-1ec61f8d1fbb", "Styles": "margin-left:85.05pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING SUPPLY\nAND USE</span></b>", "ID": "d25e3cf2-8e77-4880-b0eb-afdaa856fbf7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d3fa57eb-af3a-4b88-a8cd-1ec61f8d1fbb"}, {"Element": "<span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING SUPPLY\nAND USE</span>", "ID": "b94be8a2-3515-4b8d-bde4-6db1d7e6b822", "Styles": "None", "Classes": "None", "Text": "B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE", "ParentId": "d25e3cf2-8e77-4880-b0eb-afdaa856fbf7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-28.35pt;line-height:\nnormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "09172f8c-1b10-4e61-bc6d-295668c126fe", "Styles": "margin-left:85.05pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "83d99a44-d47a-492a-9153-165598800f84", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "09172f8c-1b10-4e61-bc6d-295668c126fe"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a7c0faee-4b7a-4976-8f40-f34d9e43b5eb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "83d99a44-d47a-492a-9153-165598800f84"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-28.35pt;line-height:\nnormal\"><b><span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS OF THE\nMARKETING AUTHORISATION</span></b></p>", "ID": "adcfab50-30f5-4075-b524-2a5a4660eaad", "Styles": "margin-left:85.05pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS OF THE\nMARKETING AUTHORISATION</span></b>", "ID": "846ae053-6136-4ebd-b05b-c5b82eb4383f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "adcfab50-30f5-4075-b524-2a5a4660eaad"}, {"Element": "<span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS OF THE\nMARKETING AUTHORISATION</span>", "ID": "b585a5c8-6af7-4eb8-9dee-2ec7cc99cede", "Styles": "None", "Classes": "None", "Text": "C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION", "ParentId": "846ae053-6136-4ebd-b05b-c5b82eb4383f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-28.35pt;line-height:\nnormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "522ba181-7187-4762-ad0f-ace702329870", "Styles": "margin-left:85.05pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "1cc2c074-0f45-408f-b431-bdd5a65695c6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "522ba181-7187-4762-ad0f-ace702329870"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e452f3c3-48fb-4afd-8047-f486d0ef308a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1cc2c074-0f45-408f-b431-bdd5a65695c6"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:85.05pt;text-indent:-28.35pt;line-height:\nnormal\"><b><span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS WITH REGARD TO\nTHE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>", "ID": "1486a9a7-74de-4394-bb0b-b768ece53da9", "Styles": "margin-left:85.05pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS WITH REGARD TO\nTHE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b>", "ID": "9fe2eb32-d04f-48c3-92e7-c09b7acd622e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1486a9a7-74de-4394-bb0b-b768ece53da9"}, {"Element": "<span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS WITH REGARD TO\nTHE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span>", "ID": "110f7e09-7812-49aa-b705-77b4ecd55af4", "Styles": "None", "Classes": "None", "Text": "D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT", "ParentId": "9fe2eb32-d04f-48c3-92e7-c09b7acd622e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fe97d905-886a-4884-b4c5-66f80e9295db", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b6fde527-5d37-436f-a7e0-b7a40a69c56a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fe97d905-886a-4884-b4c5-66f80e9295db"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:77.9pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "212e8abc-0588-4562-9d6b-e95a6cd62a1b", "Styles": "margin-right:77.9pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "29932178-16cb-4532-95c8-c4f07238314a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "212e8abc-0588-4562-9d6b-e95a6cd62a1b"}, {"Element": "<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>", "ID": "c0ff52c2-6033-4f4c-ab0e-82665ebc8430", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "15052bfb-4bce-4c53-b83b-6aa0894519cd", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "c0ff52c2-6033-4f4c-ab0e-82665ebc8430"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "f29211c0-c618-4662-94c5-1cf8449fb5a7", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "15052bfb-4bce-4c53-b83b-6aa0894519cd"}, {"Element": "<p class=\"TitleB\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S)\nRESPONSIBLE FOR BATCH RELEASE</span></p>", "ID": "4c79533d-88f3-4f9e-ac25-f3d95a2e100e", "Styles": "page-break-after:avoid", "Classes": "['TitleB']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S)\nRESPONSIBLE FOR BATCH RELEASE</span>", "ID": "1e9f63c8-8e79-4afa-9289-d54e9b1446cf", "Styles": "None", "Classes": "None", "Text": "A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE", "ParentId": "4c79533d-88f3-4f9e-ac25-f3d95a2e100e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8d69a78f-b5f5-4637-a204-7188f6319342", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cbc4e9c9-4aff-4b3c-a97f-713cbf4079d6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8d69a78f-b5f5-4637-a204-7188f6319342"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Name and address of the manufacturer(s) responsible for batch\nrelease</span></u></p>", "ID": "b6fe7038-4278-444c-9794-ea116fd319b6", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<u><span lang=\"EN-GB\">Name and address of the manufacturer(s) responsible for batch\nrelease</span></u>", "ID": "1ee334c4-e8d2-4551-8e4b-82bb9b286ae9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b6fe7038-4278-444c-9794-ea116fd319b6"}, {"Element": "<span lang=\"EN-GB\">Name and address of the manufacturer(s) responsible for batch\nrelease</span>", "ID": "715d8718-4b48-42fb-8b42-a8cb4a061490", "Styles": "None", "Classes": "None", "Text": "Name and address of the manufacturer(s) responsible for batch release", "ParentId": "1ee334c4-e8d2-4551-8e4b-82bb9b286ae9"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7d000d75-4f7f-44e1-a1ba-4649a1a0a179", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ecea0d12-a8e5-43d7-9ca9-63aa87bb5a83", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7d000d75-4f7f-44e1-a1ba-4649a1a0a179"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Gilead Sciences Ireland UC</span></p>", "ID": "ee808a2b-6ed4-4cc8-b336-fc24e1264c51", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Gilead Sciences Ireland UC</span>", "ID": "340222e4-e219-4e60-b9da-f63f57a8262d", "Styles": "None", "Classes": "None", "Text": "Gilead Sciences Ireland UC", "ParentId": "ee808a2b-6ed4-4cc8-b336-fc24e1264c51"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">IDA Business &amp; Technology Park</span></p>", "ID": "becf4abe-9c99-435a-b2a5-2689e7f49006", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">IDA Business &amp; Technology Park</span>", "ID": "1ba93512-359f-4b1b-9032-b4140b468553", "Styles": "None", "Classes": "None", "Text": "IDA Business & Technology Park", "ParentId": "becf4abe-9c99-435a-b2a5-2689e7f49006"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Carrigtohill Co. Cork</span></p>", "ID": "3256dacf-63e0-41e9-b3d9-f5fc6863fcd7", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Carrigtohill Co. Cork</span>", "ID": "3cae12c0-52d1-4ea0-a72e-a5915ea23a8e", "Styles": "None", "Classes": "None", "Text": "Carrigtohill Co. Cork", "ParentId": "3256dacf-63e0-41e9-b3d9-f5fc6863fcd7"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Ireland</span></p>", "ID": "03d8ad4e-f917-48dc-8108-8954386221bd", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Ireland</span>", "ID": "f0db38f6-d22c-4383-93b9-882f42e34777", "Styles": "None", "Classes": "None", "Text": "Ireland", "ParentId": "03d8ad4e-f917-48dc-8108-8954386221bd"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "de8aebf8-12cf-4d1b-9c86-855af49bf600", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1baf8e54-0945-40c6-8ff7-388d9c69fe20", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "de8aebf8-12cf-4d1b-9c86-855af49bf600"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e18199df-1a8f-4877-a407-8f81a2e3f502", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9228e899-468c-40c0-9040-022be1ef08f6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e18199df-1a8f-4877-a407-8f81a2e3f502"}, {"Element": "<p class=\"TitleB\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS\nOR RESTRICTIONS REGARDING SUPPLY AND USE</span></p>", "ID": "7379b0a7-f5e3-4923-a3a4-136914efb6f1", "Styles": "page-break-after:avoid", "Classes": "['TitleB']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS\nOR RESTRICTIONS REGARDING SUPPLY AND USE</span>", "ID": "e0cc03cb-679c-4667-9f01-0f5107a4b06b", "Styles": "None", "Classes": "None", "Text": "B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE", "ParentId": "7379b0a7-f5e3-4923-a3a4-136914efb6f1"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e57d1d5e-9d20-48b0-b16f-f8876eacaae6", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fb3ec5de-0c01-40fe-a761-531b3cd450df", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e57d1d5e-9d20-48b0-b16f-f8876eacaae6"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Medicinal\nproduct subject to restricted medical prescription (see Annex\u00a0I: Summary\nof Product Characteristics, section\u00a04.2).</span></p>", "ID": "471dd508-009d-4dcc-9f4d-556838fc2b00", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Medicinal\nproduct subject to restricted medical prescription (see Annex\u00a0I: Summary\nof Product Characteristics, section\u00a04.2).</span>", "ID": "0a2afe0f-9fb2-4471-8efb-380f58144281", "Styles": "None", "Classes": "None", "Text": "Medicinal product subject to restricted medical prescription (see Annex\u00a0I: Summary of Product Characteristics, section\u00a04.2).", "ParentId": "471dd508-009d-4dcc-9f4d-556838fc2b00"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "62a1daa5-1e5d-48fc-8309-3a4e50df7b52", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3723f4cc-2bb6-4555-8e48-c153bf0f7e2b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "62a1daa5-1e5d-48fc-8309-3a4e50df7b52"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "abcb4220-4cc4-4f87-843e-e9b1ae9d1708", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7dc1ad3e-4826-4eee-973f-f8486d56b7a1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "abcb4220-4cc4-4f87-843e-e9b1ae9d1708"}, {"Element": "<p class=\"TitleB\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nCONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></p>", "ID": "0cc46ee6-6d1f-406e-bf40-401f979e9c1d", "Styles": "page-break-after:avoid", "Classes": "['TitleB']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nCONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span>", "ID": "35179953-b291-41a7-983d-e7407632f94c", "Styles": "None", "Classes": "None", "Text": "C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION", "ParentId": "0cc46ee6-6d1f-406e-bf40-401f979e9c1d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d070e292-a589-4972-9968-247d80545461", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0457a19c-fd28-4ffe-94cb-72803f67ec7d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d070e292-a589-4972-9968-247d80545461"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Periodic Safety Update Reports</span></b></p>", "ID": "4a4e8f5c-493f-4844-9427-25e8a9c3fe41", "Styles": "margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "025f5483-76ec-4971-a26f-64a03236d22f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "4a4e8f5c-493f-4844-9427-25e8a9c3fe41"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "0ad83074-dd52-4a94-92f4-96155c76f0b4", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "025f5483-76ec-4971-a26f-64a03236d22f"}, {"Element": "<b><span lang=\"EN-GB\">Periodic Safety Update Reports</span></b>", "ID": "135e8a43-a253-4932-9508-0ae01868d55b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4a4e8f5c-493f-4844-9427-25e8a9c3fe41"}, {"Element": "<span lang=\"EN-GB\">Periodic Safety Update Reports</span>", "ID": "f205313d-0a8c-4ee6-a6e6-3e763e9ee9b8", "Styles": "None", "Classes": "None", "Text": "Periodic Safety Update Reports", "ParentId": "135e8a43-a253-4932-9508-0ae01868d55b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:normal;page-break-after:\navoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "71bd442e-8287-4c1b-a493-563d6b11834f", "Styles": "margin-right:28.35pt;line-height:normal;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "41a4ab00-969a-4eaf-a015-467cea7ed485", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "71bd442e-8287-4c1b-a493-563d6b11834f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:normal\"><span lang=\"EN-GB\">The marketing authorisation holder shall submit periodic safety\nupdate reports for this product in accordance with the requirements set out in\nthe list of Union reference dates (EURD list) provided for under Article\n107c(7) of Directive 2001/83</span><span lang=\"EN-GB\">/EC</span><span lang=\"EN-GB\">\nand published on the European medicines web-portal.</span></p>", "ID": "edcd08dd-c8f8-4666-9876-1ac8799b9291", "Styles": "margin-right:28.35pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">The marketing authorisation holder shall submit periodic safety\nupdate reports for this product in accordance with the requirements set out in\nthe list of Union reference dates (EURD list) provided for under Article\n107c(7) of Directive 2001/83</span>", "ID": "98765d7c-b94a-4377-b7fe-68915527ce68", "Styles": "None", "Classes": "None", "Text": "The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83", "ParentId": "edcd08dd-c8f8-4666-9876-1ac8799b9291"}, {"Element": "<span lang=\"EN-GB\">/EC</span>", "ID": "fab6bcc2-54e0-4abe-a996-9f2674ced555", "Styles": "None", "Classes": "None", "Text": "/EC", "ParentId": "edcd08dd-c8f8-4666-9876-1ac8799b9291"}, {"Element": "<span lang=\"EN-GB\">\nand published on the European medicines web-portal.</span>", "ID": "68ab6d54-f904-4003-a9c1-cc6c9cac1148", "Styles": "None", "Classes": "None", "Text": " and published on the European medicines web-portal.", "ParentId": "edcd08dd-c8f8-4666-9876-1ac8799b9291"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5542356d-0c13-4b74-81c1-deaad5e636f2", "Styles": "margin-right:28.35pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "348e5f34-61c2-475b-bd80-dad6243c75bf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5542356d-0c13-4b74-81c1-deaad5e636f2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6c9b6e12-2569-4403-9b85-5f09a9dc694c", "Styles": "margin-right:28.35pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "121f3212-587a-45b1-aa8a-d1d40dcc5a2a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6c9b6e12-2569-4403-9b85-5f09a9dc694c"}, {"Element": "<p class=\"TitleB\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS\nOR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL\nPRODUCT</span></p>", "ID": "51673d3f-530d-4d42-a724-f3d1b9736d22", "Styles": "page-break-after:avoid", "Classes": "['TitleB']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS\nOR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL\nPRODUCT</span>", "ID": "e4946032-a5e2-4d5d-8dba-f8547bac4a65", "Styles": "None", "Classes": "None", "Text": "D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT", "ParentId": "51673d3f-530d-4d42-a724-f3d1b9736d22"}, {"Element": "<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\npage-break-after:avoid;background:white\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "1d259b86-f671-4bc0-b7d1-897c238aa86e", "Styles": "margin-left:0in;text-indent:0in;line-height:normal;\npage-break-after:avoid;background:white", "Classes": "['SPCList']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "d50ee235-048b-4a9f-87f1-c3335d5ccb5c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1d259b86-f671-4bc0-b7d1-897c238aa86e"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b3908f6c-03d6-48ec-ba86-76c4261bf89e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d50ee235-048b-4a9f-87f1-c3335d5ccb5c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in;line-height:normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Risk Management Plan (RMP)</span></b></p>", "ID": "0f496b98-c061-4851-ac4d-b599e2271ea4", "Styles": "margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "ed9dea02-ef60-4a8e-a66d-90efeeffc6f9", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "0f496b98-c061-4851-ac4d-b599e2271ea4"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "07fde130-4018-424e-a7b8-dcdbd992bdd1", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "ed9dea02-ef60-4a8e-a66d-90efeeffc6f9"}, {"Element": "<b><span lang=\"EN-GB\">Risk Management Plan (RMP)</span></b>", "ID": "79a947d4-e7a1-4e9e-8175-533dc7e05ca9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0f496b98-c061-4851-ac4d-b599e2271ea4"}, {"Element": "<span lang=\"EN-GB\">Risk Management Plan (RMP)</span>", "ID": "7179f044-fdd3-49af-945c-5429701d8e23", "Styles": "None", "Classes": "None", "Text": "Risk Management Plan (RMP)", "ParentId": "79a947d4-e7a1-4e9e-8175-533dc7e05ca9"}, {"Element": "<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\npage-break-after:avoid;background:white\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "70e2cfde-51a6-4f4e-9fec-6276c123f05d", "Styles": "margin-left:0in;text-indent:0in;line-height:normal;\npage-break-after:avoid;background:white", "Classes": "['SPCList']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f2caf09c-6261-4908-b09c-1e29af6fe534", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "70e2cfde-51a6-4f4e-9fec-6276c123f05d"}, {"Element": "<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\nbackground:white\"><span lang=\"EN-GB\" style=\"color:black\">The MAH shall perform\nthe required pharmacovigilance activities and interventions detailed in the\nagreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any\nagreed subsequent updates of the RMP.</span></p>", "ID": "0301219a-01bb-461a-a808-8bfaf25e048c", "Styles": "margin-left:0in;text-indent:0in;line-height:normal;\nbackground:white", "Classes": "['SPCList']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">The MAH shall perform\nthe required pharmacovigilance activities and interventions detailed in the\nagreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any\nagreed subsequent updates of the RMP.</span>", "ID": "38bb66ff-277e-4f74-ab5b-ddda90d176e7", "Styles": "color:black", "Classes": "None", "Text": "The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.", "ParentId": "0301219a-01bb-461a-a808-8bfaf25e048c"}, {"Element": "<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\nbackground:white\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "634d92ab-9b38-4559-b3af-bdba8b1207c1", "Styles": "margin-left:0in;text-indent:0in;line-height:normal;\nbackground:white", "Classes": "['SPCList']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f13839e2-4ccd-43b4-854f-044eeae5d566", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "634d92ab-9b38-4559-b3af-bdba8b1207c1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:normal\"><span lang=\"EN-GB\">An updated RMP should be submitted:</span></p>", "ID": "733075af-a9da-48ff-b45c-ce8905d5973f", "Styles": "margin-right:-.05pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">An updated RMP should be submitted:</span>", "ID": "19a0e681-8f74-41fc-85bb-7e5fa7d85e7d", "Styles": "None", "Classes": "None", "Text": "An updated RMP should be submitted:", "ParentId": "733075af-a9da-48ff-b45c-ce8905d5973f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">At the request of the European Medicines Agency;</span></p>", "ID": "3f33d82e-869a-4973-a031-880d141b9662", "Styles": "margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "7669b78f-032e-45a6-b3f7-6504e50fd10e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "3f33d82e-869a-4973-a031-880d141b9662"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "69d2fcd0-a7af-41ab-bce0-5e04e5595878", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "7669b78f-032e-45a6-b3f7-6504e50fd10e"}, {"Element": "<span lang=\"EN-GB\">At the request of the European Medicines Agency;</span>", "ID": "598f65bf-94d8-40bd-8002-be74b0e82c36", "Styles": "None", "Classes": "None", "Text": "At the request of the European Medicines Agency;", "ParentId": "3f33d82e-869a-4973-a031-880d141b9662"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Whenever the risk management system is modified,\nespecially as the result of new information being received that may lead to a\nsignificant change to the benefit/risk profile or as the result of an important\n(pharmacovigilance or risk minimisation) milestone being reached.</span></p>", "ID": "83108c72-bce1-4ac8-9890-fd0477cbc4d3", "Styles": "margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "c27dc0b0-6afe-44be-a911-a7a93b1092c3", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "83108c72-bce1-4ac8-9890-fd0477cbc4d3"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "06bb3544-5493-4be7-9947-2f7275cc6945", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "c27dc0b0-6afe-44be-a911-a7a93b1092c3"}, {"Element": "<span lang=\"EN-GB\">Whenever the risk management system is modified,\nespecially as the result of new information being received that may lead to a\nsignificant change to the benefit/risk profile or as the result of an important\n(pharmacovigilance or risk minimisation) milestone being reached.</span>", "ID": "23371f46-7e3c-402a-9cdf-fe8ec91fb304", "Styles": "None", "Classes": "None", "Text": "Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.", "ParentId": "83108c72-bce1-4ac8-9890-fd0477cbc4d3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b3174007-6969-4f4b-b4fe-8d3d09e585c9", "Styles": "margin-right:-.05pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5cac2e29-2d71-42d4-94b6-2f0e9cc03df3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b3174007-6969-4f4b-b4fe-8d3d09e585c9"}, {"Element": "<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\nbackground:white\"><span lang=\"EN-GB\" style=\"color:black\">If the dates for\nsubmission of a PSUR and the update of a RMP coincide, they can be submitted at\nthe same time.</span></p>", "ID": "53dfd6c1-73ac-43f1-b5c4-d9653352cded", "Styles": "margin-left:0in;text-indent:0in;line-height:normal;\nbackground:white", "Classes": "['SPCList']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">If the dates for\nsubmission of a PSUR and the update of a RMP coincide, they can be submitted at\nthe same time.</span>", "ID": "60384b5c-c044-48f8-b848-6c6f07f867ba", "Styles": "color:black", "Classes": "None", "Text": "If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time.", "ParentId": "53dfd6c1-73ac-43f1-b5c4-d9653352cded"}, {"Element": "<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\nbackground:white\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e886d529-36e9-441d-a38c-e443c0f89b23", "Styles": "margin-left:0in;text-indent:0in;line-height:normal;\nbackground:white", "Classes": "['SPCList']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "09abf52a-5137-40c2-9400-77edee88f260", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e886d529-36e9-441d-a38c-e443c0f89b23"}, {"Element": "<p class=\"SPCList\" style=\"line-height:normal;page-break-after:avoid;background:\nwhite\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\" style=\"color:black\">Obligation to conduct\npost-authorisation measures</span></b></p>", "ID": "8f095133-8a7f-433d-b673-929613f370fc", "Styles": "line-height:normal;page-break-after:avoid;background:\nwhite", "Classes": "['SPCList']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "442459ac-fe39-426d-8ca2-c3f77854cd12", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "8f095133-8a7f-433d-b673-929613f370fc"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "dc518454-94f8-4d05-a9c4-5972a57de4ed", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "442459ac-fe39-426d-8ca2-c3f77854cd12"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">Obligation to conduct\npost-authorisation measures</span></b>", "ID": "d8b85992-7089-4f06-b9b6-26c31dde5a52", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8f095133-8a7f-433d-b673-929613f370fc"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Obligation to conduct\npost-authorisation measures</span>", "ID": "55219f2e-db6c-4dda-bd51-0be138398e6c", "Styles": "color:black", "Classes": "None", "Text": "Obligation to conduct post-authorisation measures", "ParentId": "d8b85992-7089-4f06-b9b6-26c31dde5a52"}, {"Element": "<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\npage-break-after:avoid;background:white\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f4ec373d-c396-4baa-83d1-64f9c9723210", "Styles": "margin-left:0in;text-indent:0in;line-height:normal;\npage-break-after:avoid;background:white", "Classes": "['SPCList']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "939502b5-6a43-4151-95cd-24a0bdceba68", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f4ec373d-c396-4baa-83d1-64f9c9723210"}, {"Element": "<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\npage-break-after:avoid;background:white\"><span lang=\"EN-GB\" style=\"color:black\">The\nMAH shall complete, within the stated timeframe, the following measures:</span></p>", "ID": "f5883f76-a1ea-4175-be2e-3e3504b0ad73", "Styles": "margin-left:0in;text-indent:0in;line-height:normal;\npage-break-after:avoid;background:white", "Classes": "['SPCList']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">The\nMAH shall complete, within the stated timeframe, the following measures:</span>", "ID": "add3bff9-50c5-4dd3-9f51-4e03a0ad72c7", "Styles": "color:black", "Classes": "None", "Text": "The MAH shall complete, within the stated timeframe, the following measures:", "ParentId": "f5883f76-a1ea-4175-be2e-3e3504b0ad73"}, {"Element": "<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\npage-break-after:avoid;background:white\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e4a59122-63f3-42ce-a450-4322a4227191", "Styles": "margin-left:0in;text-indent:0in;line-height:normal;\npage-break-after:avoid;background:white", "Classes": "['SPCList']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "96672b9c-6465-435e-a8ff-90b464c1bf26", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e4a59122-63f3-42ce-a450-4322a4227191"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr>\n<td style=\"width:388.15pt;border:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 1.4pt 5.4pt\" valign=\"top\" width=\"518\">\n<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\n  page-break-after:avoid;background:white\"><b><span lang=\"EN-GB\" style=\"color:black\">Description</span></b></p>\n</td>\n<td style=\"width:76.2pt;border:solid windowtext 1.0pt;\n  border-left:none;background:white;padding:0in 5.4pt 1.4pt 5.4pt\" valign=\"top\" width=\"102\">\n<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\n  page-break-after:avoid;background:white\"><b><span lang=\"EN-GB\" style=\"color:black\">Due date</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:388.15pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 1.4pt 5.4pt\" valign=\"top\" width=\"518\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">The MAH commits to ensure continuous assessment of\n  cross-resistance of adefovir to established and new nucleos(t)ide analogues,\n  and provide reviews of these assessments as new data becomes available. The\n  role of adefovir and add-on lamivudine+adefovir in HBV therapy strategy\n  should be regularly discussed in the light of emerging data.</span></p>\n</td>\n<td style=\"width:76.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 1.4pt 5.4pt\" valign=\"top\" width=\"102\">\n<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\n  page-break-after:avoid;background:white\"><span lang=\"EN-GB\" style=\"color:black\">As\n  data becomes available</span></p>\n</td>\n</tr>\n</table>", "ID": "d7f16c45-e90d-4ccf-bbe6-e11b950c87b9", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "   ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<tr>\n<td style=\"width:388.15pt;border:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 1.4pt 5.4pt\" valign=\"top\" width=\"518\">\n<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\n  page-break-after:avoid;background:white\"><b><span lang=\"EN-GB\" style=\"color:black\">Description</span></b></p>\n</td>\n<td style=\"width:76.2pt;border:solid windowtext 1.0pt;\n  border-left:none;background:white;padding:0in 5.4pt 1.4pt 5.4pt\" valign=\"top\" width=\"102\">\n<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\n  page-break-after:avoid;background:white\"><b><span lang=\"EN-GB\" style=\"color:black\">Due date</span></b></p>\n</td>\n</tr>", "ID": "bd176106-b2c8-4e22-873f-5811c525787e", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "d7f16c45-e90d-4ccf-bbe6-e11b950c87b9"}, {"Element": "<td style=\"width:388.15pt;border:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 1.4pt 5.4pt\" valign=\"top\" width=\"518\">\n<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\n  page-break-after:avoid;background:white\"><b><span lang=\"EN-GB\" style=\"color:black\">Description</span></b></p>\n</td>", "ID": "417d1237-d317-4a55-a784-079bbe7ae787", "Styles": "width:388.15pt;border:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 1.4pt 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "bd176106-b2c8-4e22-873f-5811c525787e"}, {"Element": "<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\n  page-break-after:avoid;background:white\"><b><span lang=\"EN-GB\" style=\"color:black\">Description</span></b></p>", "ID": "e4eee888-8006-4f30-9e36-d12d098f5bca", "Styles": "margin-left:0in;text-indent:0in;line-height:normal;\n  page-break-after:avoid;background:white", "Classes": "['SPCList']", "Text": "", "ParentId": "417d1237-d317-4a55-a784-079bbe7ae787"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">Description</span></b>", "ID": "7a0c6f5e-91a5-473e-996d-2cd55b971a1e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e4eee888-8006-4f30-9e36-d12d098f5bca"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Description</span>", "ID": "10660a65-eed1-4ead-b8f0-20cdee45e320", "Styles": "color:black", "Classes": "None", "Text": "Description", "ParentId": "7a0c6f5e-91a5-473e-996d-2cd55b971a1e"}, {"Element": "<td style=\"width:76.2pt;border:solid windowtext 1.0pt;\n  border-left:none;background:white;padding:0in 5.4pt 1.4pt 5.4pt\" valign=\"top\" width=\"102\">\n<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\n  page-break-after:avoid;background:white\"><b><span lang=\"EN-GB\" style=\"color:black\">Due date</span></b></p>\n</td>", "ID": "5debf0a4-0d5d-4b57-be18-d6aab5ba88a4", "Styles": "width:76.2pt;border:solid windowtext 1.0pt;\n  border-left:none;background:white;padding:0in 5.4pt 1.4pt 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "bd176106-b2c8-4e22-873f-5811c525787e"}, {"Element": "<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\n  page-break-after:avoid;background:white\"><b><span lang=\"EN-GB\" style=\"color:black\">Due date</span></b></p>", "ID": "fac6a42e-21d5-49a9-a63f-c3a6db390a16", "Styles": "margin-left:0in;text-indent:0in;line-height:normal;\n  page-break-after:avoid;background:white", "Classes": "['SPCList']", "Text": "", "ParentId": "5debf0a4-0d5d-4b57-be18-d6aab5ba88a4"}, {"Element": "<b><span lang=\"EN-GB\" style=\"color:black\">Due date</span></b>", "ID": "46af299d-e8b7-41bc-aa30-ed6a7720f320", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fac6a42e-21d5-49a9-a63f-c3a6db390a16"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">Due date</span>", "ID": "5271b7e3-5eac-44f3-9cc0-7c1101c3f39a", "Styles": "color:black", "Classes": "None", "Text": "Due date", "ParentId": "46af299d-e8b7-41bc-aa30-ed6a7720f320"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:388.15pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 1.4pt 5.4pt\" valign=\"top\" width=\"518\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">The MAH commits to ensure continuous assessment of\n  cross-resistance of adefovir to established and new nucleos(t)ide analogues,\n  and provide reviews of these assessments as new data becomes available. The\n  role of adefovir and add-on lamivudine+adefovir in HBV therapy strategy\n  should be regularly discussed in the light of emerging data.</span></p>\n</td>\n<td style=\"width:76.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 1.4pt 5.4pt\" valign=\"top\" width=\"102\">\n<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\n  page-break-after:avoid;background:white\"><span lang=\"EN-GB\" style=\"color:black\">As\n  data becomes available</span></p>\n</td>\n</tr>", "ID": "7a6a7600-2744-4444-a04d-15e59b8ca2c9", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "d7f16c45-e90d-4ccf-bbe6-e11b950c87b9"}, {"Element": "<td style=\"width:388.15pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 1.4pt 5.4pt\" valign=\"top\" width=\"518\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">The MAH commits to ensure continuous assessment of\n  cross-resistance of adefovir to established and new nucleos(t)ide analogues,\n  and provide reviews of these assessments as new data becomes available. The\n  role of adefovir and add-on lamivudine+adefovir in HBV therapy strategy\n  should be regularly discussed in the light of emerging data.</span></p>\n</td>", "ID": "0f5787db-0a88-4e68-8be3-9a1a32f2cfba", "Styles": "width:388.15pt;border:solid windowtext 1.0pt;\n  border-top:none;background:white;padding:0in 5.4pt 1.4pt 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7a6a7600-2744-4444-a04d-15e59b8ca2c9"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">The MAH commits to ensure continuous assessment of\n  cross-resistance of adefovir to established and new nucleos(t)ide analogues,\n  and provide reviews of these assessments as new data becomes available. The\n  role of adefovir and add-on lamivudine+adefovir in HBV therapy strategy\n  should be regularly discussed in the light of emerging data.</span></p>", "ID": "e9ab5cb2-5c6b-4641-b1f3-cc0e463b205d", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0f5787db-0a88-4e68-8be3-9a1a32f2cfba"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">The MAH commits to ensure continuous assessment of\n  cross-resistance of adefovir to established and new nucleos(t)ide analogues,\n  and provide reviews of these assessments as new data becomes available. The\n  role of adefovir and add-on lamivudine+adefovir in HBV therapy strategy\n  should be regularly discussed in the light of emerging data.</span>", "ID": "eb4e3fab-11a6-467f-88a2-8da7d308d006", "Styles": "color:black", "Classes": "None", "Text": "The MAH commits to ensure continuous assessment of   cross-resistance of adefovir to established and new nucleos(t)ide analogues,   and provide reviews of these assessments as new data becomes available. The   role of adefovir and add-on lamivudine+adefovir in HBV therapy strategy   should be regularly discussed in the light of emerging data.", "ParentId": "e9ab5cb2-5c6b-4641-b1f3-cc0e463b205d"}, {"Element": "<td style=\"width:76.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 1.4pt 5.4pt\" valign=\"top\" width=\"102\">\n<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\n  page-break-after:avoid;background:white\"><span lang=\"EN-GB\" style=\"color:black\">As\n  data becomes available</span></p>\n</td>", "ID": "eba508d7-6510-457a-b7af-a60c916fe20b", "Styles": "width:76.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  background:white;padding:0in 5.4pt 1.4pt 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7a6a7600-2744-4444-a04d-15e59b8ca2c9"}, {"Element": "<p class=\"SPCList\" style=\"margin-left:0in;text-indent:0in;line-height:normal;\n  page-break-after:avoid;background:white\"><span lang=\"EN-GB\" style=\"color:black\">As\n  data becomes available</span></p>", "ID": "633f5e8e-2fc5-4fe3-a8f9-e622323fbf09", "Styles": "margin-left:0in;text-indent:0in;line-height:normal;\n  page-break-after:avoid;background:white", "Classes": "['SPCList']", "Text": "", "ParentId": "eba508d7-6510-457a-b7af-a60c916fe20b"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black\">As\n  data becomes available</span>", "ID": "84ea2645-e863-44aa-9b08-6eb775240d72", "Styles": "color:black", "Classes": "None", "Text": "As   data becomes available", "ParentId": "633f5e8e-2fc5-4fe3-a8f9-e622323fbf09"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "8ab75d9c-7b9a-4261-bb6c-558d5160b2e6", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black", "Classes": "None", "Text": " ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "66f4d682-5a71-4e3e-ba14-b19c14017c64", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "8ab75d9c-7b9a-4261-bb6c-558d5160b2e6"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:28.3pt;line-height:normal;background:\nwhite\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fe72105b-a4a5-4f84-96d6-b5810132d04f", "Styles": "margin-right:28.3pt;line-height:normal;background:\nwhite", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a23f15c7-047f-4656-aec9-5cbbab2e1683", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fe72105b-a4a5-4f84-96d6-b5810132d04f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f4ea9649-6466-43f5-adac-6070e2747c07", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9d6837f9-6466-4fa9-9327-1b2a55e44331", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f4ea9649-6466-43f5-adac-6070e2747c07"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "99c88230-8d68-4237-8d96-70e20f3e5210", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fe22f9a5-a47b-4268-914d-7318e3979ef7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "99c88230-8d68-4237-8d96-70e20f3e5210"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7fe11922-6d27-4317-aca5-8f1304d53f3b", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "61903159-0f5d-434f-bb77-11f2c5d10129", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7fe11922-6d27-4317-aca5-8f1304d53f3b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "639c3097-cd21-496c-883d-5ea5eb5d492d", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c732cf34-21d6-44b6-9adf-a27e0a197a12", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "639c3097-cd21-496c-883d-5ea5eb5d492d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b6c094d8-e25e-4a13-be7b-6b30870503f7", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0cda7b0c-388f-474d-99a5-de2c3ddde97e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b6c094d8-e25e-4a13-be7b-6b30870503f7"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "639ef907-f10c-4bfb-9cb5-e4e9ad8b1f87", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "eb46e9a4-3386-442c-9804-ef57a2c1113a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "639ef907-f10c-4bfb-9cb5-e4e9ad8b1f87"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3a73e5c3-1106-4e45-8d52-b1023df899d9", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "499d971f-887b-4c1d-b192-0cff52dd6edb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3a73e5c3-1106-4e45-8d52-b1023df899d9"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d38954a4-4d44-401f-aae0-2317e1507118", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e40a876b-4bb8-4353-b3a3-8c132fa11e4c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d38954a4-4d44-401f-aae0-2317e1507118"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7fe702ac-51d8-4726-949d-52b359ade0ef", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4cb3ecf9-aeb9-47e9-9667-fed562b1c7b3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7fe702ac-51d8-4726-949d-52b359ade0ef"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1a745758-ccb7-44aa-87dc-210fc1a24ec2", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b420d222-4fb4-4efa-b115-31eecd6cf58c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1a745758-ccb7-44aa-87dc-210fc1a24ec2"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "98a07b65-1529-469d-a91f-c546baa98290", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "35679202-2969-48d5-8959-bd57dbc7dbc3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "98a07b65-1529-469d-a91f-c546baa98290"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "11da998f-9ae3-48b6-963e-561a718de939", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a61d1057-9ca8-4724-8547-2b7745df570e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "11da998f-9ae3-48b6-963e-561a718de939"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d3e1d9bd-19ee-44a5-88f7-a9557aebd45b", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f2f741f1-f4c3-40a8-9ef4-34fbfc7de859", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d3e1d9bd-19ee-44a5-88f7-a9557aebd45b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "82aa61c2-707e-4509-a52c-e7e2adc6cdb4", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dd246455-80c3-4350-a1e6-f14c9f7de450", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "82aa61c2-707e-4509-a52c-e7e2adc6cdb4"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "17bb79fe-60da-463b-9fb9-a71cdf312d5e", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d092723f-7c5d-436c-8ef6-0e498ed3a2a6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "17bb79fe-60da-463b-9fb9-a71cdf312d5e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0f327f8b-553e-45a6-b61a-cf1240b2492e", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "392c12cc-b422-484d-8cba-7134d1bfc38d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0f327f8b-553e-45a6-b61a-cf1240b2492e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9bad4dcb-6a6a-405d-8013-c8b9c49261b4", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "52316f98-12bd-4162-96ac-727a3fd044ad", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9bad4dcb-6a6a-405d-8013-c8b9c49261b4"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ecc84616-f3a3-4fd4-bc20-26fed66f5dd7", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0277cca9-c34e-40f2-a9b7-2b1785d24347", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ecc84616-f3a3-4fd4-bc20-26fed66f5dd7"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4ccfd240-5c98-46b2-9e48-37214b8423de", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cbf4a215-1b3b-45dc-a7a2-893f054697c8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4ccfd240-5c98-46b2-9e48-37214b8423de"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "99530a5a-eb8e-46e0-9527-3053588ba35c", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d17403b2-abbe-4a40-b949-67d6aea8647f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "99530a5a-eb8e-46e0-9527-3053588ba35c"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3cac9ea6-913b-4772-9a70-c13b966d8cb5", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4c919742-7ada-4aa6-b664-abfc56e636c0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3cac9ea6-913b-4772-9a70-c13b966d8cb5"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0f1ae729-1879-4760-89db-84c094b1b62e", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5ffc57c0-9962-4083-8fff-72f65fcc0eee", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0f1ae729-1879-4760-89db-84c094b1b62e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">ANNEX III</span></b></p>", "ID": "1cac59ac-a1fd-434d-9632-559270e42081", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">ANNEX III</span></b>", "ID": "0d2f90f0-66f5-44f7-b899-db380bd93203", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1cac59ac-a1fd-434d-9632-559270e42081"}, {"Element": "<span lang=\"EN-GB\">ANNEX III</span>", "ID": "ddae0f2b-9932-45b5-bb70-90b1dff1a6ee", "Styles": "None", "Classes": "None", "Text": "ANNEX III", "ParentId": "0d2f90f0-66f5-44f7-b899-db380bd93203"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "6580c8f7-42d0-41d3-87d3-9d83bbef3bb2", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "52bcfd7d-1869-4b6a-9c5c-0dc464f816e3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6580c8f7-42d0-41d3-87d3-9d83bbef3bb2"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "affa44f4-e517-4257-ace5-e2c4f379e0b5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "52bcfd7d-1869-4b6a-9c5c-0dc464f816e3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">LABELLING AND PACKAGE LEAFLET</span></b></p>", "ID": "0d3e1811-1f4c-4bd7-9f78-bb662bb384cb", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">LABELLING AND PACKAGE LEAFLET</span></b>", "ID": "d46ff47b-0ef7-405a-875b-3c976c75d38f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0d3e1811-1f4c-4bd7-9f78-bb662bb384cb"}, {"Element": "<span lang=\"EN-GB\">LABELLING AND PACKAGE LEAFLET</span>", "ID": "d8eef9c5-fb0a-438e-a3a3-99b6961acb4e", "Styles": "None", "Classes": "None", "Text": "LABELLING AND PACKAGE LEAFLET", "ParentId": "d46ff47b-0ef7-405a-875b-3c976c75d38f"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "434ec251-dfbe-467d-bdb2-1ab21ba2e6c5", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "15c4171d-6b14-481b-8404-8c3541a11153", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "434ec251-dfbe-467d-bdb2-1ab21ba2e6c5"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3a1ef175-892c-4997-85c1-cb5b7051ac9f", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bcbdccfc-05f9-4c5a-9aab-ee9d932b5751", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3a1ef175-892c-4997-85c1-cb5b7051ac9f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8254c94d-40f7-4896-84e9-d8835025ac50", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e54d360f-710a-49e9-98f7-c10f5f16f966", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8254c94d-40f7-4896-84e9-d8835025ac50"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0447674c-19e5-4e4b-b497-84dbed075c25", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fa3dcdaf-7e1c-4121-b436-37a2b26b3e53", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0447674c-19e5-4e4b-b497-84dbed075c25"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "827f38e9-e743-4cc9-aebc-457eca870b5b", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a3bceff6-b845-4a91-8272-2918faf0c3b3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "827f38e9-e743-4cc9-aebc-457eca870b5b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7a9abf18-bdc4-468e-b757-28e03327ba8a", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dc3a5940-aae1-4167-ae0b-feb18f488af7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7a9abf18-bdc4-468e-b757-28e03327ba8a"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "03289138-2449-4048-9e4f-12b9e2f21bd2", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8f2d7060-8f75-4d1a-8df7-ab761149a488", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "03289138-2449-4048-9e4f-12b9e2f21bd2"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e020b834-fba3-4a96-9097-a8f49f14e209", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4922f74e-0060-4469-bfe8-5dcb4e8b63a6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e020b834-fba3-4a96-9097-a8f49f14e209"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ec2be200-11d7-4983-aade-86146b6dfa06", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1c858689-2df9-45c1-8da2-0e612d3b8834", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ec2be200-11d7-4983-aade-86146b6dfa06"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bb3dea53-6cd3-44ef-a896-9ae6518030e6", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dd528345-eeba-4ddd-9b94-e86e49794cbf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bb3dea53-6cd3-44ef-a896-9ae6518030e6"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "75559edf-aa38-46f7-b7ad-9d26e0617ab4", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e90ce392-4f9a-4f99-8624-66aef221d798", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "75559edf-aa38-46f7-b7ad-9d26e0617ab4"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9a3c3de5-0c7f-4401-b9db-61a046080c96", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4eb7f4e7-29cc-46c6-8fb5-1f01544882a0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9a3c3de5-0c7f-4401-b9db-61a046080c96"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c496a2cf-5320-41d3-b853-844a4490368a", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7a86fd82-faa8-4760-8692-64b146f10eed", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c496a2cf-5320-41d3-b853-844a4490368a"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8f5456f2-db85-47f4-9311-7d8c0d17d8a6", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0725b3fe-ae3d-45fd-85b6-ed09f6202bef", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8f5456f2-db85-47f4-9311-7d8c0d17d8a6"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2377f0d5-a35b-45ed-8b37-63e3a21ae6e7", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "811ab4f0-d4ce-4a0f-b549-85df153ea516", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2377f0d5-a35b-45ed-8b37-63e3a21ae6e7"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "49fe923e-8d49-4b00-b772-4396b15d988c", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d1c309ae-c09f-47f9-b424-38d07ce11e1e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "49fe923e-8d49-4b00-b772-4396b15d988c"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d61aac4f-dc4c-4af4-94ec-1a5b10864b08", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "04036e5d-d40b-425f-9f71-d5af54986f79", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d61aac4f-dc4c-4af4-94ec-1a5b10864b08"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "594dec7b-3662-44cb-ac49-9d53f9ae88e3", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d1b2829b-3c62-4bd7-8308-b535540168ba", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "594dec7b-3662-44cb-ac49-9d53f9ae88e3"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4b266ee5-2c1b-49ca-baf2-34d35efcba1c", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c7009012-cdac-4c72-9605-6d811dcfb76a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4b266ee5-2c1b-49ca-baf2-34d35efcba1c"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "165be1fe-aced-4626-aa43-35a4de5d148b", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "759c6113-f403-4196-bead-02474de94fa5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "165be1fe-aced-4626-aa43-35a4de5d148b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d267bb29-f4cd-47e6-93e3-5e28c5fd79ab", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "120998bf-0988-4848-925c-b93d3e9eccf2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d267bb29-f4cd-47e6-93e3-5e28c5fd79ab"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1bcafcda-465d-4db5-8fa2-d11354e6c430", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5e45493e-2ee9-49a5-b098-3ffe65408899", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1bcafcda-465d-4db5-8fa2-d11354e6c430"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7c8aeb93-01eb-4b88-9deb-1e7dbfa7ec97", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f001829a-de14-4c30-907c-c975811fa24b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7c8aeb93-01eb-4b88-9deb-1e7dbfa7ec97"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9fda4310-8484-4447-9017-7c4212750516", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1214c649-9ef1-425e-8971-42f4c7a634c7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9fda4310-8484-4447-9017-7c4212750516"}, {"Element": "<p class=\"TitleA\"><span lang=\"EN-GB\">A. LABELLING</span></p>", "ID": "c5679868-a347-4e75-bb98-4ea6bcd3b955", "Styles": "None", "Classes": "['TitleA']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">A. LABELLING</span>", "ID": "8e375d6d-f1e3-4fa6-9337-986794272af7", "Styles": "None", "Classes": "None", "Text": "A. LABELLING", "ParentId": "c5679868-a347-4e75-bb98-4ea6bcd3b955"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "78378abb-c991-449b-86d0-00371774e732", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif;\ncolor:black", "Classes": "None", "Text": " ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "91b7d8f6-2256-4c88-850c-60282678272c", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "78378abb-c991-449b-86d0-00371774e732"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;background:white\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fbefb51a-ff64-4718-8c0a-e3fe8cdff60d", "Styles": "line-height:normal;background:white", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f3f0055d-aebf-49cb-9b46-449692a63198", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fbefb51a-ff64-4718-8c0a-e3fe8cdff60d"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE\nPACKAGING</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;border:none;padding:0in\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">CARTON AND BOTTLE LABELLING</span></b></p>\n</div>", "ID": "6a6d1fa4-3b90-40c9-a82c-3b1909180d3f", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "    ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE\nPACKAGING</span></b></p>", "ID": "a7fb80d3-1f00-4edd-b118-34f83df5bde9", "Styles": "line-height:normal;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6a6d1fa4-3b90-40c9-a82c-3b1909180d3f"}, {"Element": "<b><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE\nPACKAGING</span></b>", "ID": "d4c0b6af-1ba9-448e-a124-30e120a5b771", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a7fb80d3-1f00-4edd-b118-34f83df5bde9"}, {"Element": "<span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE\nPACKAGING</span>", "ID": "fcaa573b-fd23-4432-b3f9-9324eadff30a", "Styles": "None", "Classes": "None", "Text": "PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING", "ParentId": "d4c0b6af-1ba9-448e-a124-30e120a5b771"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;border:none;padding:0in\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7de350b6-32cb-4ea8-b7fd-ea80a4f4780f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6a6d1fa4-3b90-40c9-a82c-3b1909180d3f"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "566dd329-00a9-47e6-a3fa-c5f5032a5b81", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7de350b6-32cb-4ea8-b7fd-ea80a4f4780f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">CARTON AND BOTTLE LABELLING</span></b></p>", "ID": "de895e37-2caa-46da-8ac3-4754b15a993f", "Styles": "line-height:normal;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6a6d1fa4-3b90-40c9-a82c-3b1909180d3f"}, {"Element": "<b><span lang=\"EN-GB\">CARTON AND BOTTLE LABELLING</span></b>", "ID": "1b4f511b-ea62-43de-a863-a8f59b0576e5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "de895e37-2caa-46da-8ac3-4754b15a993f"}, {"Element": "<span lang=\"EN-GB\">CARTON AND BOTTLE LABELLING</span>", "ID": "7deb7469-6e48-4cbd-a8b5-013aba9def09", "Styles": "None", "Classes": "None", "Text": "CARTON AND BOTTLE LABELLING", "ParentId": "1b4f511b-ea62-43de-a863-a8f59b0576e5"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c21b1cc5-1e2d-4022-8c37-8a6bc0556ab6", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fe031712-2b71-47fd-b26b-df3842bac42d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c21b1cc5-1e2d-4022-8c37-8a6bc0556ab6"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1a60c64f-5bb8-4434-9cf1-c0d43acce11f", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e5936a14-651c-406a-8375-d5bca529e176", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1a60c64f-5bb8-4434-9cf1-c0d43acce11f"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span></b></p>\n</div>", "ID": "bc8f3349-e73a-4637-9119-55581a39bd11", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span></b></p>", "ID": "2552e2d3-a8a5-4aa0-ba7a-ed962c50e1c1", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bc8f3349-e73a-4637-9119-55581a39bd11"}, {"Element": "<b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span></b>", "ID": "cf5e2104-4952-4fbc-8303-2c8ed3d1f73f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2552e2d3-a8a5-4aa0-ba7a-ed962c50e1c1"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span>", "ID": "79a5be5e-fb9a-4513-8baa-3ce87a9d7d70", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT", "ParentId": "cf5e2104-4952-4fbc-8303-2c8ed3d1f73f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "02a8518b-e633-433e-bace-e75d81ddd6ec", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6b3d1c47-4137-47f0-a0f6-b84d9dbf9ec8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "02a8518b-e633-433e-bace-e75d81ddd6ec"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Hepsera 10\u00a0mg tablets</span></p>", "ID": "f9ec1f83-954a-4667-902a-ad43103efffa", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Hepsera 10\u00a0mg tablets</span>", "ID": "33c51fe3-9dbf-4bd5-b9a2-3ef5e6a67aea", "Styles": "None", "Classes": "None", "Text": "Hepsera 10\u00a0mg tablets", "ParentId": "f9ec1f83-954a-4667-902a-ad43103efffa"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adefovir\ndipivoxil</span></p>", "ID": "d49d7abe-5ce1-44cf-b46f-42624c5d1299", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Adefovir\ndipivoxil</span>", "ID": "340067bf-d82c-4bf9-be87-ccb24ff3b88c", "Styles": "None", "Classes": "None", "Text": "Adefovir dipivoxil", "ParentId": "d49d7abe-5ce1-44cf-b46f-42624c5d1299"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2254a492-2b70-44b4-87dc-efc6f1b07274", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "99bdecc1-d97c-4652-860f-3bf62387389c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2254a492-2b70-44b4-87dc-efc6f1b07274"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2fa947e4-0db7-4334-8a16-47c5578abc3e", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a1c0677c-6f59-41c6-a445-3dd0b2ef9d46", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2fa947e4-0db7-4334-8a16-47c5578abc3e"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span></b></p>\n</div>", "ID": "8aa0d473-c3bf-4f51-8420-b6d526662ad0", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span></b></p>", "ID": "56660956-9c0c-4472-afa8-009470601c43", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8aa0d473-c3bf-4f51-8420-b6d526662ad0"}, {"Element": "<b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span></b>", "ID": "6d41fcbd-0a72-4c63-ae9b-91416e9d2f46", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "56660956-9c0c-4472-afa8-009470601c43"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span>", "ID": "9c2c722d-4689-468a-88dc-dbd77483d37c", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT OF ACTIVE SUBSTANCE(S)", "ParentId": "6d41fcbd-0a72-4c63-ae9b-91416e9d2f46"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b6e9b947-2d45-4121-9ff8-c4772fbd4fd4", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "64463ae1-1d60-404c-8312-ad675801073e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b6e9b947-2d45-4121-9ff8-c4772fbd4fd4"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Each tablet\ncontains 10\u00a0mg adefovir dipivoxil.</span></p>", "ID": "a405f672-4f34-40f7-be38-9104320d1740", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Each tablet\ncontains 10\u00a0mg adefovir dipivoxil.</span>", "ID": "1ac27ef4-3379-4474-a773-3454fd870b1a", "Styles": "None", "Classes": "None", "Text": "Each tablet contains 10\u00a0mg adefovir dipivoxil.", "ParentId": "a405f672-4f34-40f7-be38-9104320d1740"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cbf2702c-1d4f-4c3d-b176-ae7a30cf7bb3", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b299cf0a-bd3f-44b9-87f7-a549689b404b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cbf2702c-1d4f-4c3d-b176-ae7a30cf7bb3"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c29527e7-b735-4193-aa63-f395d38666f6", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "49c6f287-1504-431c-b8c0-96fbe4d4574c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c29527e7-b735-4193-aa63-f395d38666f6"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span></b></p>\n</div>", "ID": "33f76312-18ff-4a10-b759-0a1265ccdeb5", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span></b></p>", "ID": "21e82d57-314d-4f38-b23f-e021178871b7", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "33f76312-18ff-4a10-b759-0a1265ccdeb5"}, {"Element": "<b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span></b>", "ID": "79db7777-e8d6-4602-b51a-da613111e21f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "21e82d57-314d-4f38-b23f-e021178871b7"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span>", "ID": "05280e51-e134-4a82-9724-a321852537a4", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST OF EXCIPIENTS", "ParentId": "79db7777-e8d6-4602-b51a-da613111e21f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8d725a17-efc1-4a44-8a3e-04fe76507009", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a148acfb-5a71-4831-8558-d99059ab1a4b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8d725a17-efc1-4a44-8a3e-04fe76507009"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Contains lactose\nmonohydrate, see package leaflet for further information.</span></p>", "ID": "80b60b14-daf3-4c12-979c-781759df5984", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Contains lactose\nmonohydrate, see package leaflet for further information.</span>", "ID": "b5d53ffd-fd79-44c4-9762-bef9a3595794", "Styles": "None", "Classes": "None", "Text": "Contains lactose monohydrate, see package leaflet for further information.", "ParentId": "80b60b14-daf3-4c12-979c-781759df5984"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ec867642-7c6d-420a-a260-42537053355c", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bac9aa5e-cdf9-4aeb-8b90-a207645f3a42", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ec867642-7c6d-420a-a260-42537053355c"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d7c14874-41ee-4d82-9b74-b134c4914f8c", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d77b9bfd-7775-4c6b-a1ee-d48a0fb91046", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d7c14874-41ee-4d82-9b74-b134c4914f8c"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span></b></p>\n</div>", "ID": "144e5340-5b3d-439b-ad9c-040735e0b633", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span></b></p>", "ID": "b2f4e7c8-6737-4d7f-a689-1a10b5bf60eb", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "144e5340-5b3d-439b-ad9c-040735e0b633"}, {"Element": "<b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span></b>", "ID": "5ab2a213-3321-4057-bf3a-a3f4d1f03d0a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b2f4e7c8-6737-4d7f-a689-1a10b5bf60eb"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span>", "ID": "431b7d85-0e3c-48ac-bbe6-bed29dd21580", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM AND CONTENTS", "ParentId": "5ab2a213-3321-4057-bf3a-a3f4d1f03d0a"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7a0574d5-4d28-4fe2-ac21-c4ced07894cf", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "adbe4a91-a3c3-4ef2-a59c-dc99ac38126c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7a0574d5-4d28-4fe2-ac21-c4ced07894cf"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">30\u00a0tablets.</span></p>", "ID": "27c8d230-37ad-4fb2-a21d-479067510df8", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">30\u00a0tablets.</span>", "ID": "cf6e62ed-4fa5-4917-a0cf-7b5dd8d2636c", "Styles": "None", "Classes": "None", "Text": "30\u00a0tablets.", "ParentId": "27c8d230-37ad-4fb2-a21d-479067510df8"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">90 (3\u00a0bottles of 30)\u00a0tablets.</span></p>", "ID": "ca4e88db-3d09-44a6-ad98-b2704efa2733", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">90 (3\u00a0bottles of 30)\u00a0tablets.</span>", "ID": "8ff37ece-a7f0-48d3-9e06-a04f0acf8dd2", "Styles": "color:black;background:#D9D9D9", "Classes": "None", "Text": "90 (3\u00a0bottles of 30)\u00a0tablets.", "ParentId": "ca4e88db-3d09-44a6-ad98-b2704efa2733"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b7c50d4a-589b-4c4f-828d-1ded16271e86", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b9c6ba08-bc2f-4ee9-b98c-4c64408b23b7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b7c50d4a-589b-4c4f-828d-1ded16271e86"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ed38bfd5-434e-4b40-88f2-68ab084d3b2d", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1b870c8a-0256-46d7-bec1-74693f8be2ee", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ed38bfd5-434e-4b40-88f2-68ab084d3b2d"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span></b></p>\n</div>", "ID": "b51b42f7-de6b-4319-a13d-aec2c8f14944", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span></b></p>", "ID": "4ec3da3a-3ebc-4c51-acc9-c755f7b52bdf", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b51b42f7-de6b-4319-a13d-aec2c8f14944"}, {"Element": "<b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span></b>", "ID": "bf76c540-2c14-40fb-9dba-e719b133d433", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4ec3da3a-3ebc-4c51-acc9-c755f7b52bdf"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span>", "ID": "b0670f3f-237c-444b-a09a-8bab5dae9dca", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD AND ROUTE(S) OF ADMINISTRATION", "ParentId": "bf76c540-2c14-40fb-9dba-e719b133d433"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5c8a2ec0-8231-4cad-95e1-c553c8eacf91", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5e6b9629-4a6a-478a-8270-8106eed3eecf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5c8a2ec0-8231-4cad-95e1-c553c8eacf91"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Oral use.</span></p>", "ID": "9df5aeaf-80b1-47c8-9b1f-42720384b91c", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Oral use.</span>", "ID": "4df77bd1-45fd-42bb-b157-e33c1f332e06", "Styles": "None", "Classes": "None", "Text": "Oral use.", "ParentId": "9df5aeaf-80b1-47c8-9b1f-42720384b91c"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Read the package\nleaflet before use.</span></p>", "ID": "8ed80ce9-dc07-4f63-82e0-58c5b5831997", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Read the package\nleaflet before use.</span>", "ID": "4f9fba38-6afd-4c55-ba57-4a0e8dfbf73a", "Styles": "None", "Classes": "None", "Text": "Read the package leaflet before use.", "ParentId": "8ed80ce9-dc07-4f63-82e0-58c5b5831997"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5950a975-95ce-4777-9479-edf4debd207d", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e21dc584-c0ac-4842-910a-17014345b6d6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5950a975-95ce-4777-9479-edf4debd207d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f22927f4-0f56-478b-aad9-57192e4fb1e8", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c26d5063-2692-4766-aac3-57c9da6b5943", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f22927f4-0f56-478b-aad9-57192e4fb1e8"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nWARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\nCHILDREN</span></b></p>\n</div>", "ID": "39ad5052-ab8f-489a-b289-a23c4974b0bd", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nWARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\nCHILDREN</span></b></p>", "ID": "53f07082-933e-4c76-a083-a9759a1fa88a", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "39ad5052-ab8f-489a-b289-a23c4974b0bd"}, {"Element": "<b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nWARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\nCHILDREN</span></b>", "ID": "89bb147a-f91d-4e55-b35b-27ae2f868b2e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "53f07082-933e-4c76-a083-a9759a1fa88a"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nWARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\nCHILDREN</span>", "ID": "dfc055ed-0188-46b6-9d4b-37ee1071912a", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN", "ParentId": "89bb147a-f91d-4e55-b35b-27ae2f868b2e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "13d8ef87-74ed-465d-ae87-b49ee536e987", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fd9aa37d-4574-42c8-b95d-c1d9724cde91", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "13d8ef87-74ed-465d-ae87-b49ee536e987"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Keep out of the\nsight and reach of children.</span></p>", "ID": "e899d738-c0b8-4020-8c05-f9e7867fe5ef", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Keep out of the\nsight and reach of children.</span>", "ID": "88b4db18-e69a-42c2-867d-a9dae70e9eee", "Styles": "None", "Classes": "None", "Text": "Keep out of the sight and reach of children.", "ParentId": "e899d738-c0b8-4020-8c05-f9e7867fe5ef"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f129c156-55a7-4104-84e2-a0687685b1a5", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4abcf1a0-f335-4363-945b-51762c90eb38", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f129c156-55a7-4104-84e2-a0687685b1a5"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b1c5dc14-bffe-4ab7-847c-2dc053e9a9da", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5873b808-1e96-4712-87ca-9857972e3068", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b1c5dc14-bffe-4ab7-847c-2dc053e9a9da"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span></b></p>\n</div>", "ID": "36d8fc6f-ee60-4f73-a841-6d7312621455", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span></b></p>", "ID": "f678b1ca-905d-4d3d-b331-6a0fedb41fc7", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "36d8fc6f-ee60-4f73-a841-6d7312621455"}, {"Element": "<b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span></b>", "ID": "18d79aa1-3c59-445d-bd5a-d99c1a671ee8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f678b1ca-905d-4d3d-b331-6a0fedb41fc7"}, {"Element": "<span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span>", "ID": "3bb24470-b689-4b03-85b8-711e90247808", "Styles": "None", "Classes": "None", "Text": "7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER SPECIAL WARNING(S), IF NECESSARY", "ParentId": "18d79aa1-3c59-445d-bd5a-d99c1a671ee8"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "aea7ea3d-889b-4db3-8806-e23fb608f3e7", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "171aec76-1d5d-4077-9d67-f5c60a8ddbb4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "aea7ea3d-889b-4db3-8806-e23fb608f3e7"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "77dca2a9-9099-4484-a2d1-94ff41582416", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "030d0392-55d9-4ed7-b24a-729ef297dd95", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "77dca2a9-9099-4484-a2d1-94ff41582416"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b></p>\n</div>", "ID": "bb55475d-e558-479e-a42f-02eea78922e6", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b></p>", "ID": "109c8b80-0015-440c-99a3-191f01e79a1d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bb55475d-e558-479e-a42f-02eea78922e6"}, {"Element": "<b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b>", "ID": "4eb1006e-9e93-447b-a786-ad98a542972d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "109c8b80-0015-440c-99a3-191f01e79a1d"}, {"Element": "<span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span>", "ID": "c260c578-b95a-4a47-986d-0d701db047e3", "Styles": "None", "Classes": "None", "Text": "8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE", "ParentId": "4eb1006e-9e93-447b-a786-ad98a542972d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "491352be-ace0-4e8c-96a8-fe293c4966f6", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b5899947-1128-463d-a668-9fd611eea191", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "491352be-ace0-4e8c-96a8-fe293c4966f6"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EXP</span></p>", "ID": "47b456ad-bebb-43f7-91a9-35f8b2d01c08", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">EXP</span>", "ID": "35988d2b-1ef8-4f2d-b252-72c6f1fc6840", "Styles": "None", "Classes": "None", "Text": "EXP", "ParentId": "47b456ad-bebb-43f7-91a9-35f8b2d01c08"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0d971dee-4990-4d11-a0c0-4b18699e852d", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4e96c458-f9ce-475a-b60b-97bc6ac75cc9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0d971dee-4990-4d11-a0c0-4b18699e852d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "03bc7fab-85ed-405a-9366-e63c203cc965", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b083e241-4ab8-4a1f-b0fe-0949a65b9013", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "03bc7fab-85ed-405a-9366-e63c203cc965"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nSTORAGE CONDITIONS</span></b></p>\n</div>", "ID": "3f1b1254-9384-4a73-a2c4-4c71fdec6122", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nSTORAGE CONDITIONS</span></b></p>", "ID": "b11bae52-107b-4d41-a865-c23ad6ac2702", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3f1b1254-9384-4a73-a2c4-4c71fdec6122"}, {"Element": "<b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nSTORAGE CONDITIONS</span></b>", "ID": "332f9e46-412b-4bed-b276-794ae712db60", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b11bae52-107b-4d41-a865-c23ad6ac2702"}, {"Element": "<span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nSTORAGE CONDITIONS</span>", "ID": "693dc63a-0b52-4d0d-a1be-f26ca7ab798c", "Styles": "None", "Classes": "None", "Text": "9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE CONDITIONS", "ParentId": "332f9e46-412b-4bed-b276-794ae712db60"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b9005afb-35af-46fc-ab2b-a81341b0cc73", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6e14b798-7a9c-4d65-95fb-ff19b10f9831", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b9005afb-35af-46fc-ab2b-a81341b0cc73"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Do not store\nabove 30\u00baC.\u00a0 Store in the original package in order to protect from moisture.\u00a0\nKeep the bottle tightly closed.</span></p>", "ID": "ca4db71c-2284-415a-8125-6297a0eba617", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Do not store\nabove 30\u00baC.\u00a0 Store in the original package in order to protect from moisture.\u00a0\nKeep the bottle tightly closed.</span>", "ID": "cc04ac3a-8506-42f0-b4f1-51f07e187196", "Styles": "None", "Classes": "None", "Text": "Do not store above 30\u00baC.\u00a0 Store in the original package in order to protect from moisture.\u00a0 Keep the bottle tightly closed.", "ParentId": "ca4db71c-2284-415a-8125-6297a0eba617"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a3f1db42-28f6-4a63-a60f-a6e3ed55dc83", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ba78c284-6c83-4a1c-b53e-3aa47f77f4a0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a3f1db42-28f6-4a63-a60f-a6e3ed55dc83"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5a5cb11d-0090-49af-9252-de98e322ce06", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a9b5f74f-bf65-4cbc-a3e3-26f12a333211", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5a5cb11d-0090-49af-9252-de98e322ce06"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL\nPRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\nDERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>\n</div>", "ID": "734f0db7-27c0-4165-b9a5-39f0c86b909d", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL\nPRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\nDERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>", "ID": "521aab1b-7e5b-4a77-812f-6092bf269576", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "734f0db7-27c0-4165-b9a5-39f0c86b909d"}, {"Element": "<b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL\nPRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\nDERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b>", "ID": "24678dd3-d459-4cdd-8031-d09b0742e71a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "521aab1b-7e5b-4a77-812f-6092bf269576"}, {"Element": "<span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL\nPRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\nDERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span>", "ID": "51bbe125-15dc-481b-ae7c-15f961d456dc", "Styles": "None", "Classes": "None", "Text": "10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE", "ParentId": "24678dd3-d459-4cdd-8031-d09b0742e71a"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0e3d3571-8860-4424-b10c-4271173e1124", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dd7cb448-022a-4e8c-a4ab-ecc34677e3a5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0e3d3571-8860-4424-b10c-4271173e1124"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "750e7578-c7b9-47d7-a722-3615fed66512", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "95e6a265-3e71-4742-9c6b-d497a3663491", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "750e7578-c7b9-47d7-a722-3615fed66512"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0 NAME\nAND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>\n</div>", "ID": "62fde46f-d8b8-4076-97ba-c40aab5c5787", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0 NAME\nAND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>", "ID": "5effabb5-cd2c-46b4-a127-437e675e55b2", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "62fde46f-d8b8-4076-97ba-c40aab5c5787"}, {"Element": "<b><span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0 NAME\nAND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b>", "ID": "e4fdada7-0842-44ee-ad82-f638a540fe2a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5effabb5-cd2c-46b4-a127-437e675e55b2"}, {"Element": "<span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0 NAME\nAND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span>", "ID": "81c32cbe-37f9-4cf2-95ae-f235174b6b06", "Styles": "None", "Classes": "None", "Text": "11.\u00a0\u00a0\u00a0\u00a0 NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER", "ParentId": "e4fdada7-0842-44ee-ad82-f638a540fe2a"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ac3d7606-c644-4582-bb10-1b8f8c56f760", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7808752f-40ca-48f3-af6d-f674c31061f0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ac3d7606-c644-4582-bb10-1b8f8c56f760"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Gilead Sciences Ireland UC</span></p>", "ID": "5f2e8f18-2aa1-49f2-9638-cc05d5579d83", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Gilead Sciences Ireland UC</span>", "ID": "4f48b9b2-1453-4c0e-a7d6-e6653552105f", "Styles": "None", "Classes": "None", "Text": "Gilead Sciences Ireland UC", "ParentId": "5f2e8f18-2aa1-49f2-9638-cc05d5579d83"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Carrigtohill</span></p>", "ID": "5297b2bb-471b-4193-8962-7afd37473772", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Carrigtohill</span>", "ID": "add3270a-5e71-4a62-b952-fb3a6c691217", "Styles": "None", "Classes": "None", "Text": "Carrigtohill", "ParentId": "5297b2bb-471b-4193-8962-7afd37473772"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">County Cork, T45 DP77</span></p>", "ID": "a49a5028-e1e9-424f-8ba6-99d4edf6f2ba", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">County Cork, T45 DP77</span>", "ID": "f2fd1c3b-4ba5-4afe-b7de-f5edaf1890bf", "Styles": "None", "Classes": "None", "Text": "County Cork, T45 DP77", "ParentId": "a49a5028-e1e9-424f-8ba6-99d4edf6f2ba"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Ireland</span></p>", "ID": "5deebcfc-c9c4-4dcc-9acd-80e97429b24c", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Ireland</span>", "ID": "64f59721-c487-4ec1-9fc7-8beab1610958", "Styles": "None", "Classes": "None", "Text": "Ireland", "ParentId": "5deebcfc-c9c4-4dcc-9acd-80e97429b24c"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a06a94cb-bd91-4312-838c-6b45c47c48e5", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6f1a4446-e7e7-4a9c-bb01-7fa4060ae1d1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a06a94cb-bd91-4312-838c-6b45c47c48e5"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a644d750-a6e2-4b72-9874-ed4508bac2a0", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1ff6ac89-a1bb-4252-b780-5c4d6c79e8f4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a644d750-a6e2-4b72-9874-ed4508bac2a0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span></b></p>\n</div>", "ID": "ad4ac358-c9b2-432f-9399-b0217e74c737", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span></b></p>", "ID": "388730cc-6940-430d-afd0-08b6ac0a81f1", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ad4ac358-c9b2-432f-9399-b0217e74c737"}, {"Element": "<b><span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span></b>", "ID": "9944320f-59d2-47c6-b8cf-96c3f18d6124", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "388730cc-6940-430d-afd0-08b6ac0a81f1"}, {"Element": "<span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span>", "ID": "3ee950a9-c44e-45a6-a8a6-33da43ae0a39", "Styles": "None", "Classes": "None", "Text": "12.\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION NUMBER(S)", "ParentId": "9944320f-59d2-47c6-b8cf-96c3f18d6124"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "434fb07f-be98-4abd-95bf-ddb52cd2cd22", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "57eae996-ca22-452f-94d1-d6e85f328c6e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "434fb07f-be98-4abd-95bf-ddb52cd2cd22"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">EU/1/03/251/001 <span style=\"color:black;background:#D9D9D9\">30\u00a0tablets</span></span></p>", "ID": "3063a23b-c200-47b6-b9a6-f977f39846f9", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">EU/1/03/251/001 <span style=\"color:black;background:#D9D9D9\">30\u00a0tablets</span></span>", "ID": "fa5025d2-8637-4da9-9be2-72503f2859e7", "Styles": "None", "Classes": "None", "Text": "EU/1/03/251/001 ", "ParentId": "3063a23b-c200-47b6-b9a6-f977f39846f9"}, {"Element": "<span style=\"color:black;background:#D9D9D9\">30\u00a0tablets</span>", "ID": "5f7d2366-66fb-463f-9f03-d5c4d557a963", "Styles": "color:black;background:#D9D9D9", "Classes": "None", "Text": "30\u00a0tablets", "ParentId": "fa5025d2-8637-4da9-9be2-72503f2859e7"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">EU/1/03/251/002 90 (3\u00a0bottles of 30)\u00a0tablets</span></p>", "ID": "933fc6de-89e1-49c2-9108-46d3aaeda832", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">EU/1/03/251/002 90 (3\u00a0bottles of 30)\u00a0tablets</span>", "ID": "5652799a-f9d4-461d-9d2b-b3c6ca225155", "Styles": "color:black;background:#D9D9D9", "Classes": "None", "Text": "EU/1/03/251/002 90 (3\u00a0bottles of 30)\u00a0tablets", "ParentId": "933fc6de-89e1-49c2-9108-46d3aaeda832"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cef277c0-0d52-4624-9a32-7a22f8850229", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cb04f91a-c4b5-4760-b69d-67d73897e99b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cef277c0-0d52-4624-9a32-7a22f8850229"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9b55f84d-e5a8-43bb-9f6c-4ee1099c2440", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "370a89d4-32ff-45b0-a716-f469c4aed55f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9b55f84d-e5a8-43bb-9f6c-4ee1099c2440"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b></p>\n</div>", "ID": "2fd86ab5-a5ff-4a03-a2d1-c8d2a8042b97", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b></p>", "ID": "af90c3ff-8e36-4f79-a12d-b69ca619050d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2fd86ab5-a5ff-4a03-a2d1-c8d2a8042b97"}, {"Element": "<b><span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span></b>", "ID": "c5fa17e8-3caf-4d54-8502-8e7770531d05", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "af90c3ff-8e36-4f79-a12d-b69ca619050d"}, {"Element": "<span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0 BATCH\nNUMBER</span>", "ID": "9557a5eb-5c38-4d15-a495-45dd99b8a888", "Styles": "None", "Classes": "None", "Text": "13.\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER", "ParentId": "c5fa17e8-3caf-4d54-8502-8e7770531d05"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "969bf59a-01bb-431b-ba93-6f0a6a471304", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2861e0d3-fbdd-4a4b-a779-31ce0a59ab71", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "969bf59a-01bb-431b-ba93-6f0a6a471304"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Lot</span></p>", "ID": "a4944392-7486-4efc-8d58-13c5c742afc7", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Lot</span>", "ID": "a8ebfb1e-d503-4673-b3fd-ae5c5d4e1c4d", "Styles": "None", "Classes": "None", "Text": "Lot", "ParentId": "a4944392-7486-4efc-8d58-13c5c742afc7"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9f0a4828-71de-4b14-9a76-5eca4f1f8784", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "67b030d4-1301-4105-b6b6-77667122ce19", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9f0a4828-71de-4b14-9a76-5eca4f1f8784"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "30851685-6647-46de-a688-b7c4e55dee12", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8d3d802b-f2cb-4772-a5ec-b6e498178cf8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "30851685-6647-46de-a688-b7c4e55dee12"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL\nCLASSIFICATION FOR SUPPLY</span></b></p>\n</div>", "ID": "92753472-bbca-4c85-8a5e-487b12fab745", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL\nCLASSIFICATION FOR SUPPLY</span></b></p>", "ID": "b68a9445-e71b-4964-b8d8-48fa54361947", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "92753472-bbca-4c85-8a5e-487b12fab745"}, {"Element": "<b><span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL\nCLASSIFICATION FOR SUPPLY</span></b>", "ID": "6a254ce2-865e-4a4c-908f-41358768eba8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b68a9445-e71b-4964-b8d8-48fa54361947"}, {"Element": "<span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL\nCLASSIFICATION FOR SUPPLY</span>", "ID": "280bbc58-af44-4257-b6e8-11707a6576fb", "Styles": "None", "Classes": "None", "Text": "14.\u00a0\u00a0\u00a0\u00a0 GENERAL CLASSIFICATION FOR SUPPLY", "ParentId": "6a254ce2-865e-4a4c-908f-41358768eba8"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bab2c744-6839-4f2b-b103-2460ba48e954", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d2101298-c77f-4e54-815f-d60f664b979c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bab2c744-6839-4f2b-b103-2460ba48e954"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "55e65ba0-7627-4690-8eb5-0228448ec479", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bc8e4cc7-9f9b-4aae-9e12-3ff365d1c2d4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "55e65ba0-7627-4690-8eb5-0228448ec479"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "318da270-fc96-4e1d-a179-aa0b7ff0092b", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ae912057-c6ba-4aa5-ae05-2dcb8dd23e5c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "318da270-fc96-4e1d-a179-aa0b7ff0092b"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span></b></p>\n</div>", "ID": "ad7d8527-b2d0-46e3-ab79-e17282647c95", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span></b></p>", "ID": "eb97fbed-0703-4112-ae0f-95cc896a697a", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ad7d8527-b2d0-46e3-ab79-e17282647c95"}, {"Element": "<b><span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span></b>", "ID": "97c61837-7092-4a2c-ab7b-67091247b3f5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "eb97fbed-0703-4112-ae0f-95cc896a697a"}, {"Element": "<span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS\nON USE</span>", "ID": "33529542-2a8c-487a-9869-48d53ed75a76", "Styles": "None", "Classes": "None", "Text": "15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS ON USE", "ParentId": "97c61837-7092-4a2c-ab7b-67091247b3f5"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0df9a95b-f344-4f59-9c7a-0b319133e251", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3c1a94fc-074a-47aa-85d3-964cc9c46e93", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0df9a95b-f344-4f59-9c7a-0b319133e251"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c4c79d59-63c7-468d-8a1f-f5d83648e399", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2cc17fa5-987f-4940-89d1-542a0ee19b7f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c4c79d59-63c7-468d-8a1f-f5d83648e399"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION\nIN BRAILLE</span></b></p>\n</div>", "ID": "cf7bd56c-5f85-4feb-a8e3-0ede0a15271b", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION\nIN BRAILLE</span></b></p>", "ID": "36e561db-fd31-445f-9446-ed5f30d1c141", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cf7bd56c-5f85-4feb-a8e3-0ede0a15271b"}, {"Element": "<b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION\nIN BRAILLE</span></b>", "ID": "af87495d-2a28-4f31-88fb-a1bf0563a0da", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "36e561db-fd31-445f-9446-ed5f30d1c141"}, {"Element": "<span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION\nIN BRAILLE</span>", "ID": "4424e2c1-755a-4667-9256-6d294b873b42", "Styles": "None", "Classes": "None", "Text": "16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN BRAILLE", "ParentId": "af87495d-2a28-4f31-88fb-a1bf0563a0da"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "96a8c22e-2ea7-4801-888c-7bd7a0acb120", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8088e132-7c3b-4233-932d-a15aedec6cbd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "96a8c22e-2ea7-4801-888c-7bd7a0acb120"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Hepsera</span></p>", "ID": "4336469f-96b7-4691-a356-633854b21665", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Hepsera</span>", "ID": "4a48d118-1180-476b-a4b0-572467aa2a14", "Styles": "None", "Classes": "None", "Text": "Hepsera", "ParentId": "4336469f-96b7-4691-a356-633854b21665"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">[</span><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">outer packaging only</span><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">]</span></p>", "ID": "bf766510-3cfb-4216-9cc8-a15a14bfeec9", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">[</span>", "ID": "b840f741-b9df-4725-bc9e-66832870c251", "Styles": "color:black;background:#D9D9D9", "Classes": "None", "Text": "[", "ParentId": "bf766510-3cfb-4216-9cc8-a15a14bfeec9"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">outer packaging only</span>", "ID": "3687ffc9-dc24-4992-8731-df5e77cc1b07", "Styles": "color:black;background:#D9D9D9", "Classes": "None", "Text": "outer packaging only", "ParentId": "bf766510-3cfb-4216-9cc8-a15a14bfeec9"}, {"Element": "<span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">]</span>", "ID": "20d90ded-945e-44a9-9ffb-1840972260a7", "Styles": "color:black;background:#D9D9D9", "Classes": "None", "Text": "]", "ParentId": "bf766510-3cfb-4216-9cc8-a15a14bfeec9"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:#CCCCCC\">\u00a0</span></p>", "ID": "3531c576-86a1-4cdd-ae3f-e3d9a47b52a6", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"background:#CCCCCC\">\u00a0</span>", "ID": "c30f8160-e111-4597-8a18-ad99f6a547dc", "Styles": "background:#CCCCCC", "Classes": "None", "Text": "\u00a0", "ParentId": "3531c576-86a1-4cdd-ae3f-e3d9a47b52a6"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:#CCCCCC\">\u00a0</span></p>", "ID": "b616f5f2-47b5-41ed-90b2-865b22192728", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"background:#CCCCCC\">\u00a0</span>", "ID": "9589a84e-8128-42c2-b300-092f88a1f6a4", "Styles": "background:#CCCCCC", "Classes": "None", "Text": "\u00a0", "ParentId": "b616f5f2-47b5-41ed-90b2-865b22192728"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE</span></b></p>\n</div>", "ID": "ce9b0a63-4d7a-4774-980d-61312a76ec78", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE</span></b></p>", "ID": "0479952f-863e-4b93-a9b2-5616dc9e4d03", "Styles": "line-height:normal;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ce9b0a63-4d7a-4774-980d-61312a76ec78"}, {"Element": "<b><span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE</span></b>", "ID": "bc8122fe-0d63-463f-8770-eae8a56d0b36", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0479952f-863e-4b93-a9b2-5616dc9e4d03"}, {"Element": "<span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE</span>", "ID": "3aed125a-634b-4251-a721-797929ab2ecc", "Styles": "None", "Classes": "None", "Text": "17.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE", "ParentId": "bc8122fe-0d63-463f-8770-eae8a56d0b36"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6b0e777a-f775-4f9a-8cab-94ed606b8996", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9b47392f-b9ef-422d-aa72-e3cb69d172c1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6b0e777a-f775-4f9a-8cab-94ed606b8996"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:silver\">2D barcode carrying the unique identifier included.</span></p>", "ID": "5d52455c-a517-44c2-86b3-34ce669bbd67", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"background:silver\">2D barcode carrying the unique identifier included.</span>", "ID": "d8fb7fce-a951-4602-b244-161ad88bff44", "Styles": "background:silver", "Classes": "None", "Text": "2D barcode carrying the unique identifier included.", "ParentId": "5d52455c-a517-44c2-86b3-34ce669bbd67"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b7c1629b-38cc-4502-b6d6-720a786b9675", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3540af7a-fa8c-4b9b-a5a2-c3fe931ab217", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b7c1629b-38cc-4502-b6d6-720a786b9675"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "893308cd-6257-4bf8-b341-90d9833555f0", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c8d1c3c1-fde7-4733-bcea-f6368c7a91d1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "893308cd-6257-4bf8-b341-90d9833555f0"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\">\n<p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>\n</div>", "ID": "5927e2d3-c8a3-4382-9a56-6860ef74fadb", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>", "ID": "cdad5c8f-f7df-4c75-86b4-7125dd05ef4a", "Styles": "line-height:normal;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5927e2d3-c8a3-4382-9a56-6860ef74fadb"}, {"Element": "<b><span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b>", "ID": "a09f485e-ddcb-481f-a6d4-ace0f74b584b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cdad5c8f-f7df-4c75-86b4-7125dd05ef4a"}, {"Element": "<span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER - HUMAN READABLE DATA</span>", "ID": "e910fc61-0afc-424b-bf85-ca76e683c91e", "Styles": "None", "Classes": "None", "Text": "18.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER - HUMAN READABLE DATA", "ParentId": "a09f485e-ddcb-481f-a6d4-ace0f74b584b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "df1b285b-4487-41e4-ad4e-fe74a7e4c7b5", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5f5b595c-5162-4323-9e50-35086a177622", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "df1b285b-4487-41e4-ad4e-fe74a7e4c7b5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">PC: {number} </span></p>", "ID": "9f0db862-49f5-4d9c-ad58-0e3e540a0bbc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">PC: {number} </span>", "ID": "6bcd78df-ea12-4dd4-bd0c-b6ea5ed4f30b", "Styles": "None", "Classes": "None", "Text": "PC: {number} ", "ParentId": "9f0db862-49f5-4d9c-ad58-0e3e540a0bbc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">SN: {number}</span></p>", "ID": "71ab326e-2202-4edd-8029-44b5f5d02de1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">SN: {number}</span>", "ID": "1e19adbe-634e-4b87-82c3-c5bc84dfa274", "Styles": "None", "Classes": "None", "Text": "SN: {number}", "ParentId": "71ab326e-2202-4edd-8029-44b5f5d02de1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">NN: {number}</span></p>", "ID": "fc7e0fda-38e6-4049-a29e-ad1ec0c46a6c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">NN: {number}</span>", "ID": "6d7ccbd7-be29-4658-9340-29b05d16490a", "Styles": "None", "Classes": "None", "Text": "NN: {number}", "ParentId": "fc7e0fda-38e6-4049-a29e-ad1ec0c46a6c"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "2415d28f-985f-442c-b75a-604a5a2de7b8", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "423581c9-210e-4f6b-add8-24d9cbe3a0b1", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "2415d28f-985f-442c-b75a-604a5a2de7b8"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "30a385a5-14ef-4592-a245-3c726ea65b2e", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d07c80f1-dc7b-438d-83b4-2cedb8922d24", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "30a385a5-14ef-4592-a245-3c726ea65b2e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7fb7eb45-0ba0-4da8-b3ec-85b9f334e745", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "976e60d6-afd4-41ab-9b3a-c48610126f5f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7fb7eb45-0ba0-4da8-b3ec-85b9f334e745"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ce75f007-046b-4250-b446-9469af1e9fc6", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ae7b27b6-d3e5-487f-98e9-a61437c337f6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ce75f007-046b-4250-b446-9469af1e9fc6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "acfb6030-5a62-4d46-87b3-5a687d913603", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "261e4f69-e32a-42f1-afaa-7430f4172681", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "acfb6030-5a62-4d46-87b3-5a687d913603"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "59dbb83c-51c1-400e-a9b8-562d56de8908", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "62aea8b6-1814-4ec7-ae7b-c0e6c1bffd7a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "59dbb83c-51c1-400e-a9b8-562d56de8908"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "55a7167c-de0a-4388-9f5c-849e5eb5e492", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "aa10aaf4-b026-4292-9c2d-89fc29786035", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "55a7167c-de0a-4388-9f5c-849e5eb5e492"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "17ca15c7-bcb3-4dca-847d-46271535c90f", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ef6505a0-3713-409b-95f5-7a4cd83a13cc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "17ca15c7-bcb3-4dca-847d-46271535c90f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4e086642-c0be-4ae8-a601-4a4f74983020", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cfe3e0b2-3040-4c6b-8158-3a6fe2395db3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4e086642-c0be-4ae8-a601-4a4f74983020"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "511eb310-b897-4d06-b4b8-912351ad072e", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4a73f822-6713-4c2c-a6b7-71606aafe247", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "511eb310-b897-4d06-b4b8-912351ad072e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a69c792e-5e65-40c6-9dc6-e0fa5fc66875", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6cbe4325-dd58-4d20-b669-0956d502254b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a69c792e-5e65-40c6-9dc6-e0fa5fc66875"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ebda4960-da2f-4cb0-ac79-7dfdfc563a9e", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b9ba1234-8524-4e3a-af7f-4df324243372", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ebda4960-da2f-4cb0-ac79-7dfdfc563a9e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5078b2ab-7091-48aa-88e4-536cc811d390", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f684732e-1b35-41f7-b1fa-a19b0021e3b1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5078b2ab-7091-48aa-88e4-536cc811d390"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "de0ab88a-b99e-4154-b69a-3b1ee4383766", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bcc5eb1c-33da-4dc2-905a-351392294d6b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "de0ab88a-b99e-4154-b69a-3b1ee4383766"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "afcdafe0-d4bf-45cf-9ffc-24f706ccecfd", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f7d32984-7141-452a-86c9-40f31354032b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "afcdafe0-d4bf-45cf-9ffc-24f706ccecfd"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b04dfe0c-92b4-426b-acdf-5765a3f6e0b3", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a25c6828-86dd-4ade-b3ea-996c15789c3f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b04dfe0c-92b4-426b-acdf-5765a3f6e0b3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "91d02048-acb2-4da1-955b-01909e816b0a", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "66281289-aa85-4154-8714-5d32e3407d6d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "91d02048-acb2-4da1-955b-01909e816b0a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2622a20f-eda3-406d-bbb0-92e96e5e5a86", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "11313f18-34d8-425c-8cda-f9b1089a2ea2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2622a20f-eda3-406d-bbb0-92e96e5e5a86"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a5dacf0e-835a-488c-9571-0ae2e9f7ac50", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "606ec20a-7b08-4101-aa33-9cf7e2afcc10", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a5dacf0e-835a-488c-9571-0ae2e9f7ac50"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0d8998b2-1e85-438f-a9eb-a857330b05ff", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5b410daa-46c1-4ac7-9faf-99a14b2cae49", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0d8998b2-1e85-438f-a9eb-a857330b05ff"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "052a45d5-3971-47be-be72-3bb9298f7ae2", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1266e8c0-c9c7-47ce-99f3-8e4d699e6cad", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "052a45d5-3971-47be-be72-3bb9298f7ae2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1bd4c6ca-251c-4f19-9278-d07b41a7b2dd", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "10d3f879-1df3-4c62-abaf-5cf6839ed356", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1bd4c6ca-251c-4f19-9278-d07b41a7b2dd"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c7a2c735-79f9-496d-a872-a192c44c6222", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "428d37ea-3e5c-4528-a544-d0d567b42718", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c7a2c735-79f9-496d-a872-a192c44c6222"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5f514b52-e3b5-4c36-b15d-3c9911dcb9de", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "541388c6-676f-4200-80f4-8826bd091e5f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5f514b52-e3b5-4c36-b15d-3c9911dcb9de"}, {"Element": "<p class=\"TitleA\"><span lang=\"EN-GB\">B. PACKAGE LEAFLET</span></p>", "ID": "e0c34cdc-8dc8-421f-8b33-93c7f0031004", "Styles": "None", "Classes": "['TitleA']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">B. PACKAGE LEAFLET</span>", "ID": "ea8f996a-e5ca-430a-99d5-1cb45c0a2a43", "Styles": "None", "Classes": "None", "Text": "B. PACKAGE LEAFLET", "ParentId": "e0c34cdc-8dc8-421f-8b33-93c7f0031004"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2a501274-88be-4b70-9020-d56bf8bc8aff", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fa774341-3468-4cd3-ada4-191688f85edc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2a501274-88be-4b70-9020-d56bf8bc8aff"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "0a26aadf-78f8-46d1-b9e6-2f5e9b7574f9", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "357fa93b-f576-4cff-ad51-94018e2918ac", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "0a26aadf-78f8-46d1-b9e6-2f5e9b7574f9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Package leaflet: Information for the user</span></b></p>", "ID": "e2cf0243-4a3d-478e-ad08-0f1d48e4fcd8", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">Package leaflet: Information for the user</span></b>", "ID": "561c0de8-2697-47d7-ae2b-3fe9632d1594", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e2cf0243-4a3d-478e-ad08-0f1d48e4fcd8"}, {"Element": "<span lang=\"EN-GB\">Package leaflet: Information for the user</span>", "ID": "19a6f000-f84b-44fa-a4ae-a31f2913bbb7", "Styles": "None", "Classes": "None", "Text": "Package leaflet: Information for the user", "ParentId": "561c0de8-2697-47d7-ae2b-3fe9632d1594"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "828e72aa-2e22-4398-8dac-161edf8251b0", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "5f8ff1d4-28e2-4325-b186-00a8fef04945", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "828e72aa-2e22-4398-8dac-161edf8251b0"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "509a9133-eb97-4681-a3ac-e3f43bd878df", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5f8ff1d4-28e2-4325-b186-00a8fef04945"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Hepsera 10\u00a0mg tablets</span></b></p>", "ID": "1b8d218a-1b6d-41e7-a3ce-d11136df8a70", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">Hepsera 10\u00a0mg tablets</span></b>", "ID": "e32b2258-4449-4376-9d72-21afc8e841cd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1b8d218a-1b6d-41e7-a3ce-d11136df8a70"}, {"Element": "<span lang=\"EN-GB\">Hepsera 10\u00a0mg tablets</span>", "ID": "77d1d708-ec42-421c-b359-80eb737d834d", "Styles": "None", "Classes": "None", "Text": "Hepsera 10\u00a0mg tablets", "ParentId": "e32b2258-4449-4376-9d72-21afc8e841cd"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">Adefovir dipivoxil</span></p>", "ID": "383be80c-5d61-4656-ada9-4a20f628c1fc", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Adefovir dipivoxil</span>", "ID": "901ce436-9f67-4a34-8ba4-b15351dff21c", "Styles": "None", "Classes": "None", "Text": "Adefovir dipivoxil", "ParentId": "383be80c-5d61-4656-ada9-4a20f628c1fc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ae57e0fc-1915-4e4c-9eef-162c0238e446", "Styles": "text-align:center;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c9822929-881c-43ad-8aa1-6b0a23bb518e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ae57e0fc-1915-4e4c-9eef-162c0238e446"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Read all of\nthis leaflet carefully before you start taking this medicine because it\ncontains important information for you.</span></b></p>", "ID": "95702162-4b54-4716-9a0b-c85d38230301", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">Read all of\nthis leaflet carefully before you start taking this medicine because it\ncontains important information for you.</span></b>", "ID": "5a2e6161-b7e6-4eb9-9e62-40e5bb2dcb18", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "95702162-4b54-4716-9a0b-c85d38230301"}, {"Element": "<span lang=\"EN-GB\">Read all of\nthis leaflet carefully before you start taking this medicine because it\ncontains important information for you.</span>", "ID": "58ee4623-401f-42ed-bbf8-e981ab59792b", "Styles": "None", "Classes": "None", "Text": "Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.", "ParentId": "5a2e6161-b7e6-4eb9-9e62-40e5bb2dcb18"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Keep this leaflet. \u00a0You may need to read it\nagain.</span></p>", "ID": "b1b69c15-5c8b-447d-9491-f1264c5e4dd1", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Keep this leaflet. \u00a0You may need to read it\nagain.</span>", "ID": "62150a85-a6af-40b7-bbda-9996285578ca", "Styles": "None", "Classes": "None", "Text": "-\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Keep this leaflet. \u00a0You may need to read it again.", "ParentId": "b1b69c15-5c8b-447d-9491-f1264c5e4dd1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you have any further questions, ask your\ndoctor or pharmacist.</span></p>", "ID": "3a7a312f-ed08-475e-b6fa-9e26ef16b6ae", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you have any further questions, ask your\ndoctor or pharmacist.</span>", "ID": "4ed56382-db36-4ecf-81bf-d9be0b5cfc85", "Styles": "None", "Classes": "None", "Text": "-\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you have any further questions, ask your doctor or pharmacist.", "ParentId": "3a7a312f-ed08-475e-b6fa-9e26ef16b6ae"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 This medicine has been prescribed for you\nonly.\u00a0 Do not pass it on to others.\u00a0 It may harm them, even if their signs of\nillness are the same as yours.</span></p>", "ID": "2dcd0e6c-d08e-44d3-8b00-9b4fda6d1536", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 This medicine has been prescribed for you\nonly.\u00a0 Do not pass it on to others.\u00a0 It may harm them, even if their signs of\nillness are the same as yours.</span>", "ID": "9307a818-58d8-4085-a23e-0e63c4d70f0e", "Styles": "None", "Classes": "None", "Text": "-\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 This medicine has been prescribed for you only.\u00a0 Do not pass it on to others.\u00a0 It may harm them, even if their signs of illness are the same as yours.", "ParentId": "2dcd0e6c-d08e-44d3-8b00-9b4fda6d1536"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you get any side effects, talk to your\ndoctor or pharmacist.\u00a0 This includes any possible side effects not listed in\nthis leaflet. \u00a0See section\u00a04.</span></p>", "ID": "5682dc44-61c9-482d-84de-5cd29db4dfd0", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">-\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you get any side effects, talk to your\ndoctor or pharmacist.\u00a0 This includes any possible side effects not listed in\nthis leaflet. \u00a0See section\u00a04.</span>", "ID": "8c6a2582-a5f4-4635-82f5-2fc3f0d4a98b", "Styles": "None", "Classes": "None", "Text": "-\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 If you get any side effects, talk to your doctor or pharmacist.\u00a0 This includes any possible side effects not listed in this leaflet. \u00a0See section\u00a04.", "ParentId": "5682dc44-61c9-482d-84de-5cd29db4dfd0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a711eb7d-02aa-43be-a770-212698bc9a1e", "Styles": "margin-right:-.1pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c6774cdd-5bc7-48d2-9a64-54de2405e5c8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a711eb7d-02aa-43be-a770-212698bc9a1e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "79d3dbea-de65-45bc-9344-c601d85cffb8", "Styles": "margin-right:-.1pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "edabcb4e-529c-4bfc-a479-0e74d0499920", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "79d3dbea-de65-45bc-9344-c601d85cffb8"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">What is in this leaflet</span></b></p>", "ID": "f55a5218-c835-4aca-b92a-e9575bf53b9d", "Styles": "margin-right:-.1pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">What is in this leaflet</span></b>", "ID": "35461551-f72f-478b-bfde-b23285bcf226", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f55a5218-c835-4aca-b92a-e9575bf53b9d"}, {"Element": "<span lang=\"EN-GB\">What is in this leaflet</span>", "ID": "484018d3-ccad-479f-b1c3-e995dc06db52", "Styles": "None", "Classes": "None", "Text": "What is in this leaflet", "ParentId": "35461551-f72f-478b-bfde-b23285bcf226"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Hepsera is and what it is used for</span></p>", "ID": "b0654685-cb53-4449-8fbe-71edef45790c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Hepsera is and what it is used for</span>", "ID": "12c0017d-d315-45f7-94a5-45f8be1944eb", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Hepsera is and what it is used for", "ParentId": "b0654685-cb53-4449-8fbe-71edef45790c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to know before you take Hepsera</span></p>", "ID": "72f6337b-0a7f-4cc9-826e-3bd58f55f95d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to know before you take Hepsera</span>", "ID": "61faac26-be8e-4637-bd41-37ad6faa7abf", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to know before you take Hepsera", "ParentId": "72f6337b-0a7f-4cc9-826e-3bd58f55f95d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to take Hepsera</span></p>", "ID": "c008f34e-cd17-4a99-8d6b-32b7c292c4ca", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to take Hepsera</span>", "ID": "04f98970-6985-4183-8bff-e3f3b12b08a0", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to take Hepsera", "ParentId": "c008f34e-cd17-4a99-8d6b-32b7c292c4ca"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side effects</span></p>", "ID": "55f0692f-e78b-40d1-bdba-650df7bb3ffb", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side effects</span>", "ID": "082b9058-c207-4adc-bb83-bc6287a2f097", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side effects", "ParentId": "55f0692f-e78b-40d1-bdba-650df7bb3ffb"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store Hepsera</span></p>", "ID": "7a7fc23b-91ee-43e1-ac9c-68199da401f7", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store Hepsera</span>", "ID": "3ce362e8-3c4c-4772-8ccd-aa1b27841a4b", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store Hepsera", "ParentId": "7a7fc23b-91ee-43e1-ac9c-68199da401f7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the pack and other information</span></p>", "ID": "5bf214bf-24ff-4b4d-955d-16b4ef304f48", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the pack and other information</span>", "ID": "29e659a9-243e-4085-b784-6c20f95e383e", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the pack and other information", "ParentId": "5bf214bf-24ff-4b4d-955d-16b4ef304f48"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "47236248-6de8-422a-bee6-8ec54a7d1ca1", "Styles": "margin-right:-1.45pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b5f036b0-af06-413f-817e-66f39a586d4f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "47236248-6de8-422a-bee6-8ec54a7d1ca1"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "99d95b3e-999c-4246-bcd8-c272f6075767", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d11ac17a-75ad-4b01-9cfc-ab5f91e3ec29", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "99d95b3e-999c-4246-bcd8-c272f6075767"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Hepsera is and\nwhat it is used for</span></b></p>", "ID": "bd7e3e31-8a03-464b-9902-f68a937aa55e", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Hepsera is and\nwhat it is used for</span></b>", "ID": "934f4b9d-0caf-491b-82fc-abc7e0bdad5e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bd7e3e31-8a03-464b-9902-f68a937aa55e"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Hepsera is and\nwhat it is used for</span>", "ID": "6a1980bf-5832-414b-91e4-0d269dc79dd1", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Hepsera is and what it is used for", "ParentId": "934f4b9d-0caf-491b-82fc-abc7e0bdad5e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6247228a-83a4-4c77-83ae-3529d610e889", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d872f791-14f1-4c84-b7a7-caff52fb48ec", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6247228a-83a4-4c77-83ae-3529d610e889"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">What Hepsera is</span></b></p>", "ID": "9c9f478e-a369-4a7a-bfcc-a2b0b98c5a61", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">What Hepsera is</span></b>", "ID": "79e58776-0e6b-40a1-97d3-0313de82a0d2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9c9f478e-a369-4a7a-bfcc-a2b0b98c5a61"}, {"Element": "<span lang=\"EN-GB\">What Hepsera is</span>", "ID": "45736c0c-0030-4266-9b5b-465b7025bc23", "Styles": "None", "Classes": "None", "Text": "What Hepsera is", "ParentId": "79e58776-0e6b-40a1-97d3-0313de82a0d2"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Hepsera belongs\nto a group of medicines called antiviral medicines.</span></p>", "ID": "24e67e99-d4dc-4d9c-a2f6-ee89fde5e364", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Hepsera belongs\nto a group of medicines called antiviral medicines.</span>", "ID": "734c2390-402a-4514-bc11-72c5434b23d0", "Styles": "None", "Classes": "None", "Text": "Hepsera belongs to a group of medicines called antiviral medicines.", "ParentId": "24e67e99-d4dc-4d9c-a2f6-ee89fde5e364"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2ff4ea0c-6815-41c1-984d-b3ece7c89bee", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ee10a8e4-5c35-4f04-8719-9f05ab633de7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2ff4ea0c-6815-41c1-984d-b3ece7c89bee"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">What it is used for</span></b></p>", "ID": "813984b9-880c-4d03-b18e-4b1e5e41045c", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">What it is used for</span></b>", "ID": "93fcf245-3b9f-429d-9996-aff5a6ac6657", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "813984b9-880c-4d03-b18e-4b1e5e41045c"}, {"Element": "<span lang=\"EN-GB\">What it is used for</span>", "ID": "b9b1c7dd-cdca-4355-b5ea-6ca18fac3a3f", "Styles": "None", "Classes": "None", "Text": "What it is used for", "ParentId": "93fcf245-3b9f-429d-9996-aff5a6ac6657"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Hepsera is used\nto treat chronic hepatitis\u00a0B, an infection with hepatitis\u00a0B virus\n(HBV), in adults.</span></p>", "ID": "627447f2-e69b-4da3-8d23-e75d903cc941", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Hepsera is used\nto treat chronic hepatitis\u00a0B, an infection with hepatitis\u00a0B virus\n(HBV), in adults.</span>", "ID": "da7ab440-1950-44c4-9592-3b350ad5cac0", "Styles": "None", "Classes": "None", "Text": "Hepsera is used to treat chronic hepatitis\u00a0B, an infection with hepatitis\u00a0B virus (HBV), in adults.", "ParentId": "627447f2-e69b-4da3-8d23-e75d903cc941"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Infection with\nthe hepatitis\u00a0B virus leads to damage to the liver.\u00a0 Hepsera reduces the\namount of the virus in your body, and has been shown to reduce liver damage.</span></p>", "ID": "daab4394-c77b-4177-953c-e08595fd0a01", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Infection with\nthe hepatitis\u00a0B virus leads to damage to the liver.\u00a0 Hepsera reduces the\namount of the virus in your body, and has been shown to reduce liver damage.</span>", "ID": "f16b3b7c-31f6-40f1-a192-da9a930feaa8", "Styles": "None", "Classes": "None", "Text": "Infection with the hepatitis\u00a0B virus leads to damage to the liver.\u00a0 Hepsera reduces the amount of the virus in your body, and has been shown to reduce liver damage.", "ParentId": "daab4394-c77b-4177-953c-e08595fd0a01"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b2f5b8a0-10bc-4306-97c5-60992053b847", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "80194149-a2c5-4cc5-9d33-5ad892f303da", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b2f5b8a0-10bc-4306-97c5-60992053b847"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d6bb247d-bcd5-4428-9a72-faf4b37fbbf8", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4a716c8a-8766-4d0f-9dd8-8059e6a2c8fd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d6bb247d-bcd5-4428-9a72-faf4b37fbbf8"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to\nknow before you take Hepsera</span></b></p>", "ID": "fdc0ac4d-0931-4955-ade4-464c20122b17", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to\nknow before you take Hepsera</span></b>", "ID": "0395fa0d-3280-4a7a-b2b7-9c804778ffdb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fdc0ac4d-0931-4955-ade4-464c20122b17"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to\nknow before you take Hepsera</span>", "ID": "12b0bfa6-9d30-4d25-b20a-608a60585cc6", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to know before you take Hepsera", "ParentId": "0395fa0d-3280-4a7a-b2b7-9c804778ffdb"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3b409495-afca-4f30-a145-bd99a940bf32", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c815a7cd-1697-4d0e-8a43-f9a6dbce23dc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3b409495-afca-4f30-a145-bd99a940bf32"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Do not take Hepsera</span></b></p>", "ID": "d330d0ef-b279-4f07-a544-44bba67d6f21", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">Do not take Hepsera</span></b>", "ID": "16e4e3cf-8dac-49b0-8a1f-b0a7adc60ec0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d330d0ef-b279-4f07-a544-44bba67d6f21"}, {"Element": "<span lang=\"EN-GB\">Do not take Hepsera</span>", "ID": "dd4cd724-7908-4b1b-b35f-317f37006e89", "Styles": "None", "Classes": "None", "Text": "Do not take Hepsera", "ParentId": "16e4e3cf-8dac-49b0-8a1f-b0a7adc60ec0"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1e2f08f4-518b-417b-91c3-15036d298cbf", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cac2da15-4166-44b0-aaac-81f35d3d003f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1e2f08f4-518b-417b-91c3-15036d298cbf"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">If you are allergic</span></b><span lang=\"EN-GB\"> to adefovir, adefovir dipivoxil or any of the other ingredients of\nthis medicine (listed in section\u00a06).</span></p>", "ID": "0ec96feb-bd4a-43c8-ba89-de8a57c87e0f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "5ac8b682-c932-4699-a551-eb93cda14a55", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "0ec96feb-bd4a-43c8-ba89-de8a57c87e0f"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "7dd7e5e5-5e04-43a8-b50d-2f7d5d60c9a6", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "5ac8b682-c932-4699-a551-eb93cda14a55"}, {"Element": "<b><span lang=\"EN-GB\">If you are allergic</span></b>", "ID": "4a25c0b3-4b28-4925-9c52-33d28a042bb7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0ec96feb-bd4a-43c8-ba89-de8a57c87e0f"}, {"Element": "<span lang=\"EN-GB\">If you are allergic</span>", "ID": "3284a8f2-2785-4bf9-af0c-1e254b3cfdc7", "Styles": "None", "Classes": "None", "Text": "If you are allergic", "ParentId": "4a25c0b3-4b28-4925-9c52-33d28a042bb7"}, {"Element": "<span lang=\"EN-GB\"> to adefovir, adefovir dipivoxil or any of the other ingredients of\nthis medicine (listed in section\u00a06).</span>", "ID": "94943aa4-4ab4-4f95-ae7a-ff3276bf1448", "Styles": "None", "Classes": "None", "Text": " to adefovir, adefovir dipivoxil or any of the other ingredients of this medicine (listed in section\u00a06).", "ParentId": "0ec96feb-bd4a-43c8-ba89-de8a57c87e0f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a91ef3dd-977c-4664-976e-df3284937068", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3a38bece-1abb-4d4f-bbea-e0e7280baf57", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a91ef3dd-977c-4664-976e-df3284937068"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Tell your doctor at once </span></b><span lang=\"EN-GB\">if you could be allergic to adefovir, adefovir dipivoxil or any of\nthe other ingredients of Hepsera.</span></p>", "ID": "4efb2e95-3bf2-4eb4-a658-e3134acfae09", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "27bfad63-2f16-4259-8686-e3f1791aff5f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "4efb2e95-3bf2-4eb4-a658-e3134acfae09"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "ef4186fe-0475-4ffe-8b4a-cf84e54ba787", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "27bfad63-2f16-4259-8686-e3f1791aff5f"}, {"Element": "<b><span lang=\"EN-GB\">Tell your doctor at once </span></b>", "ID": "b790358c-8d93-46fa-95f2-f97d53ce92c7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4efb2e95-3bf2-4eb4-a658-e3134acfae09"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor at once </span>", "ID": "79a6f4d2-de5b-4f39-a40d-2ed583d5a7a6", "Styles": "None", "Classes": "None", "Text": "Tell your doctor at once ", "ParentId": "b790358c-8d93-46fa-95f2-f97d53ce92c7"}, {"Element": "<span lang=\"EN-GB\">if you could be allergic to adefovir, adefovir dipivoxil or any of\nthe other ingredients of Hepsera.</span>", "ID": "ae91c618-efb8-4159-8649-73b3c4b90d73", "Styles": "None", "Classes": "None", "Text": "if you could be allergic to adefovir, adefovir dipivoxil or any of the other ingredients of Hepsera.", "ParentId": "4efb2e95-3bf2-4eb4-a658-e3134acfae09"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "eaf85473-0f2e-4ed1-b916-3c55d0a50708", "Styles": "margin-right:-.1pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "15bbbdd0-e775-47c3-a027-3dbccde2581a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "eaf85473-0f2e-4ed1-b916-3c55d0a50708"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Warnings and precautions</span></b></p>", "ID": "ff93ae55-2a28-4b3d-85c3-d442608c19f4", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">Warnings and precautions</span></b>", "ID": "2407585e-8c7d-4c8e-b2e8-cd64d436a7e3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ff93ae55-2a28-4b3d-85c3-d442608c19f4"}, {"Element": "<span lang=\"EN-GB\">Warnings and precautions</span>", "ID": "ceefe655-a7ef-4d2c-b3c5-0522aa072264", "Styles": "None", "Classes": "None", "Text": "Warnings and precautions", "ParentId": "2407585e-8c7d-4c8e-b2e8-cd64d436a7e3"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Talk to your doctor before using Hepsera.</span></p>", "ID": "4f810e54-7365-4bfa-b7d5-bf49cf3a3f02", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Talk to your doctor before using Hepsera.</span>", "ID": "c743ff7d-d124-4c70-ac6b-783e0f9d0a53", "Styles": "None", "Classes": "None", "Text": "Talk to your doctor before using Hepsera.", "ParentId": "4f810e54-7365-4bfa-b7d5-bf49cf3a3f02"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d39ad99d-a7c3-4638-9b09-7d38684f5634", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6f2ebba3-1cce-468a-904e-a09aa85eed3b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d39ad99d-a7c3-4638-9b09-7d38684f5634"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Tell your doctor if you have had kidney\ndisease</span></b><span lang=\"EN-GB\">, or if tests have shown problems with your\nkidneys. \u00a0Hepsera can affect the way your kidneys work. \u00a0The risk of this\noccurring is increased with long-term use of Hepsera.\u00a0 Your doctor should run\ntests to check your kidneys and liver are working properly, before and during\nyour treatment.\u00a0 Depending on the results, your doctor may change how often you\ntake Hepsera.</span></p>", "ID": "0d7dc29a-b9b0-4a6c-849d-34e9e4046faf", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "953dbc28-d492-436e-8701-3d9423a1d6d2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "0d7dc29a-b9b0-4a6c-849d-34e9e4046faf"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "d329a05d-aea1-4c94-86f6-b1fc96eeccd0", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "953dbc28-d492-436e-8701-3d9423a1d6d2"}, {"Element": "<b><span lang=\"EN-GB\">Tell your doctor if you have had kidney\ndisease</span></b>", "ID": "ec622346-c8cd-486c-a22e-6f40446ce5d0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0d7dc29a-b9b0-4a6c-849d-34e9e4046faf"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor if you have had kidney\ndisease</span>", "ID": "d479f417-9110-41bb-a15e-9d040f94876f", "Styles": "None", "Classes": "None", "Text": "Tell your doctor if you have had kidney disease", "ParentId": "ec622346-c8cd-486c-a22e-6f40446ce5d0"}, {"Element": "<span lang=\"EN-GB\">, or if tests have shown problems with your\nkidneys. \u00a0Hepsera can affect the way your kidneys work. \u00a0The risk of this\noccurring is increased with long-term use of Hepsera.\u00a0 Your doctor should run\ntests to check your kidneys and liver are working properly, before and during\nyour treatment.\u00a0 Depending on the results, your doctor may change how often you\ntake Hepsera.</span>", "ID": "bba0a4b5-7a88-4a55-8331-d7fb8f7c0866", "Styles": "None", "Classes": "None", "Text": ", or if tests have shown problems with your kidneys. \u00a0Hepsera can affect the way your kidneys work. \u00a0The risk of this occurring is increased with long-term use of Hepsera.\u00a0 Your doctor should run tests to check your kidneys and liver are working properly, before and during your treatment.\u00a0 Depending on the results, your doctor may change how often you take Hepsera.", "ParentId": "0d7dc29a-b9b0-4a6c-849d-34e9e4046faf"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "092fc72d-cb8b-4211-9c9d-dc8f985469e1", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ba4c7604-d00d-4182-ad37-6cac492b5cef", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "092fc72d-cb8b-4211-9c9d-dc8f985469e1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">If you are over 65\u00a0years of age your doctor\nmay monitor your health more closely.</span></p>", "ID": "741bd1ec-7511-4e7c-a6c9-ca124a531b6f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "7d42f488-102a-4f7b-a023-02f67602cef9", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "741bd1ec-7511-4e7c-a6c9-ca124a531b6f"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "8d332a18-f0cb-4185-b16c-d9a3ba8182f4", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "7d42f488-102a-4f7b-a023-02f67602cef9"}, {"Element": "<span lang=\"EN-GB\">If you are over 65\u00a0years of age your doctor\nmay monitor your health more closely.</span>", "ID": "480fc56f-8bd8-470c-a008-74c79aa9367f", "Styles": "None", "Classes": "None", "Text": "If you are over 65\u00a0years of age your doctor may monitor your health more closely.", "ParentId": "741bd1ec-7511-4e7c-a6c9-ca124a531b6f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7be4009b-8f92-4b9a-8659-10305abe60d0", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5eedf948-c760-40c6-ac12-9ea603fd08b2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7be4009b-8f92-4b9a-8659-10305abe60d0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Don\u2019t stop taking Hepsera</span></b><span lang=\"EN-GB\"> without your doctor\u2019s advice.</span></p>", "ID": "b3654b8f-797e-46a0-bfc9-7609e5b1e42d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "06cbe1a7-cb18-40bd-b2bf-22730db8fb7b", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "b3654b8f-797e-46a0-bfc9-7609e5b1e42d"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "bd62cc61-4312-4242-b3d5-6f3343d1ec65", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "06cbe1a7-cb18-40bd-b2bf-22730db8fb7b"}, {"Element": "<b><span lang=\"EN-GB\">Don\u2019t stop taking Hepsera</span></b>", "ID": "12429cfc-7863-4d6b-8bdb-ff48e6ed37f9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b3654b8f-797e-46a0-bfc9-7609e5b1e42d"}, {"Element": "<span lang=\"EN-GB\">Don\u2019t stop taking Hepsera</span>", "ID": "9f96a882-c94f-4ee6-8a45-1b1f5998032e", "Styles": "None", "Classes": "None", "Text": "Don\u2019t stop taking Hepsera", "ParentId": "12429cfc-7863-4d6b-8bdb-ff48e6ed37f9"}, {"Element": "<span lang=\"EN-GB\"> without your doctor\u2019s advice.</span>", "ID": "ae79cb28-cc9d-42d8-b10d-41c1b6b7309d", "Styles": "None", "Classes": "None", "Text": " without your doctor\u2019s advice.", "ParentId": "b3654b8f-797e-46a0-bfc9-7609e5b1e42d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fdc4e3a5-2c83-466b-8843-1bb1722cbbf9", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b578ad95-1a0d-4c0a-a921-fe1a9c10e1c1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fdc4e3a5-2c83-466b-8843-1bb1722cbbf9"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">After stopping Hepsera tell your doctor\nimmediately</span></b><span lang=\"EN-GB\"> about any new, unusual or worsening\nsymptoms that you notice after stopping treatment.\u00a0 Some patients have had\nsymptoms or blood tests indicating that their hepatitis has worsened after\nstopping treatment with Hepsera.\u00a0 It\u2019s best for your doctor to monitor your\nhealth after stopping treatment with Hepsera.\u00a0 You may need blood tests for\nseveral months after treatment.</span></p>", "ID": "a38e9b91-e3fe-4bd2-a1e3-ff8874ad3b86", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "51b04ae0-4cfc-44c8-9a15-9dcbbebce39f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "a38e9b91-e3fe-4bd2-a1e3-ff8874ad3b86"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "455172ec-8586-47cd-a405-ca907f0beb8d", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "51b04ae0-4cfc-44c8-9a15-9dcbbebce39f"}, {"Element": "<b><span lang=\"EN-GB\">After stopping Hepsera tell your doctor\nimmediately</span></b>", "ID": "c2e604a6-8e5b-4b23-bfe8-6717278257a1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a38e9b91-e3fe-4bd2-a1e3-ff8874ad3b86"}, {"Element": "<span lang=\"EN-GB\">After stopping Hepsera tell your doctor\nimmediately</span>", "ID": "e18bf195-f317-4920-b070-db1402570c07", "Styles": "None", "Classes": "None", "Text": "After stopping Hepsera tell your doctor immediately", "ParentId": "c2e604a6-8e5b-4b23-bfe8-6717278257a1"}, {"Element": "<span lang=\"EN-GB\"> about any new, unusual or worsening\nsymptoms that you notice after stopping treatment.\u00a0 Some patients have had\nsymptoms or blood tests indicating that their hepatitis has worsened after\nstopping treatment with Hepsera.\u00a0 It\u2019s best for your doctor to monitor your\nhealth after stopping treatment with Hepsera.\u00a0 You may need blood tests for\nseveral months after treatment.</span>", "ID": "2d66077e-83c3-44f0-9183-97633acdf138", "Styles": "None", "Classes": "None", "Text": " about any new, unusual or worsening symptoms that you notice after stopping treatment.\u00a0 Some patients have had symptoms or blood tests indicating that their hepatitis has worsened after stopping treatment with Hepsera.\u00a0 It\u2019s best for your doctor to monitor your health after stopping treatment with Hepsera.\u00a0 You may need blood tests for several months after treatment.", "ParentId": "a38e9b91-e3fe-4bd2-a1e3-ff8874ad3b86"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "46e5a7b6-c990-45e2-b241-dbb0535cb8db", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "febc262e-14c3-4f3b-be9c-fc1d0b42acbc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "46e5a7b6-c990-45e2-b241-dbb0535cb8db"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Once you start taking Hepsera:</span></b></p>", "ID": "c4f8f0ec-2d62-4f22-9b7f-fbc16eb6d6a4", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "9d392d98-c976-4e6c-b1fc-4b8800ba103d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "c4f8f0ec-2d62-4f22-9b7f-fbc16eb6d6a4"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "995612c3-f2ac-4b89-9d36-f5e35414eccc", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "9d392d98-c976-4e6c-b1fc-4b8800ba103d"}, {"Element": "<b><span lang=\"EN-GB\">Once you start taking Hepsera:</span></b>", "ID": "c4d096a0-a74d-47bd-8b49-1e1c7d4bf4f4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c4f8f0ec-2d62-4f22-9b7f-fbc16eb6d6a4"}, {"Element": "<span lang=\"EN-GB\">Once you start taking Hepsera:</span>", "ID": "0078dce1-ac47-4133-bbba-cb332efc87cb", "Styles": "None", "Classes": "None", "Text": "Once you start taking Hepsera:", "ParentId": "c4d096a0-a74d-47bd-8b49-1e1c7d4bf4f4"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "43d05977-761f-4682-b25f-fe066171e1a3", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6a160bce-f9e4-44f8-b531-fdc689f39f2e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "43d05977-761f-4682-b25f-fe066171e1a3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">look out for possible signs of lactic\nacidosis</span></b><span lang=\"EN-GB\"> \u2013 see\u00a0section\u00a04, Possible side\neffects.</span></p>", "ID": "9b65aa84-d7c6-483b-9659-81be33e0c0a3", "Styles": "margin-left:56.7pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "3dc353b5-1b66-4a15-81ad-dfa0825b87d3", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "9b65aa84-d7c6-483b-9659-81be33e0c0a3"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "910e3574-3da2-4db5-816d-8b6f19e9bdff", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "3dc353b5-1b66-4a15-81ad-dfa0825b87d3"}, {"Element": "<b><span lang=\"EN-GB\">look out for possible signs of lactic\nacidosis</span></b>", "ID": "b8952983-955c-4478-aec2-679c45fbd77c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9b65aa84-d7c6-483b-9659-81be33e0c0a3"}, {"Element": "<span lang=\"EN-GB\">look out for possible signs of lactic\nacidosis</span>", "ID": "7c015c19-f49a-40be-b003-7a460d396390", "Styles": "None", "Classes": "None", "Text": "look out for possible signs of lactic acidosis", "ParentId": "b8952983-955c-4478-aec2-679c45fbd77c"}, {"Element": "<span lang=\"EN-GB\"> \u2013 see\u00a0section\u00a04, Possible side\neffects.</span>", "ID": "5df095ca-ce51-4861-927b-7c257d958378", "Styles": "None", "Classes": "None", "Text": " \u2013 see\u00a0section\u00a04, Possible side effects.", "ParentId": "9b65aa84-d7c6-483b-9659-81be33e0c0a3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">your doctor should order blood tests every\nthree months</span></b><span lang=\"EN-GB\"> to check your medicine is keeping your\nchronic hepatitis\u00a0B infection under control.</span></p>", "ID": "336b393f-7041-4f3a-af6d-70beaf33d7af", "Styles": "margin-left:56.7pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "1560652b-79a6-4a9a-a8ba-63d35b3f06aa", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "336b393f-7041-4f3a-af6d-70beaf33d7af"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "f92d24e5-e40e-4184-bfb8-9ac6f1f24167", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "1560652b-79a6-4a9a-a8ba-63d35b3f06aa"}, {"Element": "<b><span lang=\"EN-GB\">your doctor should order blood tests every\nthree months</span></b>", "ID": "18525438-f84c-4ae6-a98b-160ffd20913e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "336b393f-7041-4f3a-af6d-70beaf33d7af"}, {"Element": "<span lang=\"EN-GB\">your doctor should order blood tests every\nthree months</span>", "ID": "0098590b-f261-4111-b318-38e4022e0387", "Styles": "None", "Classes": "None", "Text": "your doctor should order blood tests every three months", "ParentId": "18525438-f84c-4ae6-a98b-160ffd20913e"}, {"Element": "<span lang=\"EN-GB\"> to check your medicine is keeping your\nchronic hepatitis\u00a0B infection under control.</span>", "ID": "5328c985-78e0-41bc-a4a3-2d73ac935bb2", "Styles": "None", "Classes": "None", "Text": " to check your medicine is keeping your chronic hepatitis\u00a0B infection under control.", "ParentId": "336b393f-7041-4f3a-af6d-70beaf33d7af"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e2cf7a8e-3474-4a1f-8b59-80c6a3ddfe31", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "652e47e2-f2d2-414c-8288-b4c74dde4751", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e2cf7a8e-3474-4a1f-8b59-80c6a3ddfe31"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Take care not to infect other people.</span></b><span lang=\"EN-GB\"> \u00a0Hepsera does not reduce the risk of passing on HBV to others\nthrough sexual contact or blood contamination. \u00a0You must continue to take precautions\nto avoid this.\u00a0 A vaccine is available to protect those at risk from becoming\ninfected with HBV.</span></p>", "ID": "b8eab9ab-aa87-41c9-8103-5283cceb8965", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "60031b8e-fa56-40b8-8453-ffb76429d242", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "b8eab9ab-aa87-41c9-8103-5283cceb8965"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "8fe46430-c565-42a7-8a02-30a9d4ef8a53", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "60031b8e-fa56-40b8-8453-ffb76429d242"}, {"Element": "<b><span lang=\"EN-GB\">Take care not to infect other people.</span></b>", "ID": "a8fb1bd1-ffe4-416a-9103-5475c9522991", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b8eab9ab-aa87-41c9-8103-5283cceb8965"}, {"Element": "<span lang=\"EN-GB\">Take care not to infect other people.</span>", "ID": "12a009b7-eee6-4fab-adfe-2e7723bfb672", "Styles": "None", "Classes": "None", "Text": "Take care not to infect other people.", "ParentId": "a8fb1bd1-ffe4-416a-9103-5475c9522991"}, {"Element": "<span lang=\"EN-GB\"> \u00a0Hepsera does not reduce the risk of passing on HBV to others\nthrough sexual contact or blood contamination. \u00a0You must continue to take precautions\nto avoid this.\u00a0 A vaccine is available to protect those at risk from becoming\ninfected with HBV.</span>", "ID": "0856caae-45f6-40e0-baeb-ed516b0cc282", "Styles": "None", "Classes": "None", "Text": " \u00a0Hepsera does not reduce the risk of passing on HBV to others through sexual contact or blood contamination. \u00a0You must continue to take precautions to avoid this.\u00a0 A vaccine is available to protect those at risk from becoming infected with HBV.", "ParentId": "b8eab9ab-aa87-41c9-8103-5283cceb8965"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5f2545dd-0551-4d1f-a906-4f72e30f7449", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "99f77714-d70e-4f80-a74b-256242327a2e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5f2545dd-0551-4d1f-a906-4f72e30f7449"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">If you are HIV\u00a0positive this medicine will\nnot control your HIV\u00a0infection.</span></p>", "ID": "f43fa0b5-abc7-4776-b035-cce24bf97e1b", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "2858e081-9597-4c7e-ba02-39c8d1fdd82c", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "f43fa0b5-abc7-4776-b035-cce24bf97e1b"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "327037bc-5216-48ef-82e8-034b87bd33f7", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "2858e081-9597-4c7e-ba02-39c8d1fdd82c"}, {"Element": "<span lang=\"EN-GB\">If you are HIV\u00a0positive this medicine will\nnot control your HIV\u00a0infection.</span>", "ID": "de0bfbee-2e33-4969-91ab-9218a8b1a94d", "Styles": "None", "Classes": "None", "Text": "If you are HIV\u00a0positive this medicine will not control your HIV\u00a0infection.", "ParentId": "f43fa0b5-abc7-4776-b035-cce24bf97e1b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e8868149-929f-4d2f-8c75-fcf162aac102", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bdc2d776-7420-4975-8d29-fb2b998f7e2e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e8868149-929f-4d2f-8c75-fcf162aac102"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Children and adolescents</span></b></p>", "ID": "22592445-452d-4415-b746-75fc6f9387fe", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">Children and adolescents</span></b>", "ID": "e022593f-8c41-4d3a-926b-a28b453c461f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "22592445-452d-4415-b746-75fc6f9387fe"}, {"Element": "<span lang=\"EN-GB\">Children and adolescents</span>", "ID": "7a378566-a9d7-4f50-be5b-e738b352feb0", "Styles": "None", "Classes": "None", "Text": "Children and adolescents", "ParentId": "e022593f-8c41-4d3a-926b-a28b453c461f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "374e9325-39e0-439d-9107-2b3824ceccbc", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "c9272c9f-d0c5-452f-a602-593d1fe77e12", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "374e9325-39e0-439d-9107-2b3824ceccbc"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0d7f3ab3-4571-4e2f-912d-34b9be6a4cef", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c9272c9f-d0c5-452f-a602-593d1fe77e12"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Do not use Hepsera in children</span></b><span lang=\"EN-GB\"> or adolescents under 18\u00a0years of age.</span></p>", "ID": "5f891a92-b266-4e04-933a-7dd3a625a4e2", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "3d78e8fe-185b-4b3e-aa61-77820baf4807", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "5f891a92-b266-4e04-933a-7dd3a625a4e2"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "5a5eac7f-fa4a-4cee-9f86-a8c88c26e692", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "3d78e8fe-185b-4b3e-aa61-77820baf4807"}, {"Element": "<b><span lang=\"EN-GB\">Do not use Hepsera in children</span></b>", "ID": "9916466b-5018-4856-a7a7-9bd99abd5591", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5f891a92-b266-4e04-933a-7dd3a625a4e2"}, {"Element": "<span lang=\"EN-GB\">Do not use Hepsera in children</span>", "ID": "b707a954-10a4-441a-bf4e-58f177ba40c7", "Styles": "None", "Classes": "None", "Text": "Do not use Hepsera in children", "ParentId": "9916466b-5018-4856-a7a7-9bd99abd5591"}, {"Element": "<span lang=\"EN-GB\"> or adolescents under 18\u00a0years of age.</span>", "ID": "6c26ec51-55c8-44e3-9606-6c138b89c9ce", "Styles": "None", "Classes": "None", "Text": " or adolescents under 18\u00a0years of age.", "ParentId": "5f891a92-b266-4e04-933a-7dd3a625a4e2"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "09b9c961-eaa2-422a-82e7-4c84efa069c2", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2a626c7e-1525-40d1-a10e-958e1fd98646", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "09b9c961-eaa2-422a-82e7-4c84efa069c2"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Other medicines and Hepsera</span></b></p>", "ID": "152e8813-5854-4e01-bc8d-0f05535e7c9d", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">Other medicines and Hepsera</span></b>", "ID": "0d15b8ee-1604-46fb-8fc0-970ac1193f13", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "152e8813-5854-4e01-bc8d-0f05535e7c9d"}, {"Element": "<span lang=\"EN-GB\">Other medicines and Hepsera</span>", "ID": "32a12483-bf76-4ca3-a845-ef2b595207a0", "Styles": "None", "Classes": "None", "Text": "Other medicines and Hepsera", "ParentId": "0d15b8ee-1604-46fb-8fc0-970ac1193f13"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "12362bb3-388c-4a3a-be71-fa1426a1fa74", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ce370967-2b2f-4cee-abf9-af1b9659a8f0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "12362bb3-388c-4a3a-be71-fa1426a1fa74"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Do not take Hepsera if you are taking any\nmedicines containing tenofovir.</span></p>", "ID": "d305ef77-cd4f-45f6-9452-4a4ade8cf69b", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "494cbb27-9016-465f-9ec0-84d852375f6d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d305ef77-cd4f-45f6-9452-4a4ade8cf69b"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "da071831-8d62-4107-8056-912662259015", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "494cbb27-9016-465f-9ec0-84d852375f6d"}, {"Element": "<span lang=\"EN-GB\">Do not take Hepsera if you are taking any\nmedicines containing tenofovir.</span>", "ID": "39e036cc-d3e8-49d5-92c7-9d58480a2276", "Styles": "None", "Classes": "None", "Text": "Do not take Hepsera if you are taking any medicines containing tenofovir.", "ParentId": "d305ef77-cd4f-45f6-9452-4a4ade8cf69b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "943c8f4f-5569-4c9c-ae23-bd290f6ace18", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0e213473-0dff-4665-b86f-43e720c53b18", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "943c8f4f-5569-4c9c-ae23-bd290f6ace18"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Tell your doctor or pharmacist</span></b><span lang=\"EN-GB\"> if you are taking, have recently taken or might take any other medicines,\nincluding medicines and herbal products obtained without a prescription.</span></p>", "ID": "62710afc-4128-4510-b3d1-13bc25658b22", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "1fcc68da-1040-4b14-87c8-c815d6d424d4", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "62710afc-4128-4510-b3d1-13bc25658b22"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "0b183659-5d12-4d12-95a8-860d81071cc8", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "1fcc68da-1040-4b14-87c8-c815d6d424d4"}, {"Element": "<b><span lang=\"EN-GB\">Tell your doctor or pharmacist</span></b>", "ID": "fa19cf4d-ae72-4b12-ae17-356ed219e138", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "62710afc-4128-4510-b3d1-13bc25658b22"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor or pharmacist</span>", "ID": "59536c23-c935-4702-b268-3358c367acbd", "Styles": "None", "Classes": "None", "Text": "Tell your doctor or pharmacist", "ParentId": "fa19cf4d-ae72-4b12-ae17-356ed219e138"}, {"Element": "<span lang=\"EN-GB\"> if you are taking, have recently taken or might take any other medicines,\nincluding medicines and herbal products obtained without a prescription.</span>", "ID": "1a263049-26ba-4340-a8fd-6c09e3c09ffb", "Styles": "None", "Classes": "None", "Text": " if you are taking, have recently taken or might take any other medicines, including medicines and herbal products obtained without a prescription.", "ParentId": "62710afc-4128-4510-b3d1-13bc25658b22"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cff48074-5c9b-45bd-9125-a0552fcc5f0c", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2ced7d01-a813-466b-b7ac-597a0839047b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cff48074-5c9b-45bd-9125-a0552fcc5f0c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">It is especially important to tell your\ndoctor</span></b><span lang=\"EN-GB\"> if you are taking or have recently taken any\nof the following medicines which may damage your kidneys, or interact with\nHepsera:</span></p>", "ID": "4b38a049-774f-49d3-a2d7-3c75ffad4c7f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "953b4f20-c2d9-42ec-8534-10ac06860340", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "4b38a049-774f-49d3-a2d7-3c75ffad4c7f"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "a3775b1a-cf3f-499b-b29f-da626282f291", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "953b4f20-c2d9-42ec-8534-10ac06860340"}, {"Element": "<b><span lang=\"EN-GB\">It is especially important to tell your\ndoctor</span></b>", "ID": "893d51d6-90c2-457a-a6d7-df964a537806", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4b38a049-774f-49d3-a2d7-3c75ffad4c7f"}, {"Element": "<span lang=\"EN-GB\">It is especially important to tell your\ndoctor</span>", "ID": "ef151e30-ed66-4d51-9485-8791ed02ea9b", "Styles": "None", "Classes": "None", "Text": "It is especially important to tell your doctor", "ParentId": "893d51d6-90c2-457a-a6d7-df964a537806"}, {"Element": "<span lang=\"EN-GB\"> if you are taking or have recently taken any\nof the following medicines which may damage your kidneys, or interact with\nHepsera:</span>", "ID": "e4ea64f8-9bb6-4c82-a76e-cc3ab1f05491", "Styles": "None", "Classes": "None", "Text": " if you are taking or have recently taken any of the following medicines which may damage your kidneys, or interact with Hepsera:", "ParentId": "4b38a049-774f-49d3-a2d7-3c75ffad4c7f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4e3bebe5-ecd4-4389-b3a6-4b5a92d99b42", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e7ff3563-2365-4ead-9b5a-808e38f4aedd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4e3bebe5-ecd4-4389-b3a6-4b5a92d99b42"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">vancomycin and aminoglycosides, used for\nbacterial infections</span></p>", "ID": "498ac322-8485-4598-903b-69a7d945db4d", "Styles": "margin-left:56.7pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "bd1168d5-b521-4585-85ea-d57d05d67b11", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "498ac322-8485-4598-903b-69a7d945db4d"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "8fb8a613-83a4-4558-8748-ae827fdd19b7", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "bd1168d5-b521-4585-85ea-d57d05d67b11"}, {"Element": "<span lang=\"EN-GB\">vancomycin and aminoglycosides, used for\nbacterial infections</span>", "ID": "35042a4a-d92a-4a3e-8e7d-78faf643134c", "Styles": "None", "Classes": "None", "Text": "vancomycin and aminoglycosides, used for bacterial infections", "ParentId": "498ac322-8485-4598-903b-69a7d945db4d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">amphotericin\u00a0B, for fungal infections</span></p>", "ID": "493ade59-dc09-41b2-9bca-d31f7339630b", "Styles": "margin-left:56.7pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "936cc75c-c152-4410-9477-1558debc944e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "493ade59-dc09-41b2-9bca-d31f7339630b"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "499fd9eb-4418-460d-b468-caa44cb62280", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "936cc75c-c152-4410-9477-1558debc944e"}, {"Element": "<span lang=\"EN-GB\">amphotericin\u00a0B, for fungal infections</span>", "ID": "2675b3ed-b0e7-4073-9b34-48efc1e5b6ad", "Styles": "None", "Classes": "None", "Text": "amphotericin\u00a0B, for fungal infections", "ParentId": "493ade59-dc09-41b2-9bca-d31f7339630b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">foscarnet, cidofovir or tenofovir disoproxil\nfumarate, for viral infections</span></p>", "ID": "d643ed86-cbc0-4e52-882a-9fd9352e538e", "Styles": "margin-left:56.7pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "2bc7ce12-9551-44d0-954b-4a237dae6a9d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d643ed86-cbc0-4e52-882a-9fd9352e538e"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "44df7a00-8609-4988-904f-4d55a3b6fa0d", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "2bc7ce12-9551-44d0-954b-4a237dae6a9d"}, {"Element": "<span lang=\"EN-GB\">foscarnet, cidofovir or tenofovir disoproxil\nfumarate, for viral infections</span>", "ID": "6fdecc0b-c776-40c1-88bd-7d39c9bd5f65", "Styles": "None", "Classes": "None", "Text": "foscarnet, cidofovir or tenofovir disoproxil fumarate, for viral infections", "ParentId": "d643ed86-cbc0-4e52-882a-9fd9352e538e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\nmargin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">pentamidine, for other types of infection.</span></p>", "ID": "6b7127b5-16d0-450b-b511-03f1bc6ae3f7", "Styles": "margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\nmargin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "29c871b4-3772-43a8-a77b-5ae13a737271", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "6b7127b5-16d0-450b-b511-03f1bc6ae3f7"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "7d3d83b0-b6dc-4f0a-975b-7135d88abc85", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "29c871b4-3772-43a8-a77b-5ae13a737271"}, {"Element": "<span lang=\"EN-GB\">pentamidine, for other types of infection.</span>", "ID": "25a019e0-30e4-453d-bf43-5bbcab95399b", "Styles": "None", "Classes": "None", "Text": "pentamidine, for other types of infection.", "ParentId": "6b7127b5-16d0-450b-b511-03f1bc6ae3f7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0fa4d2e6-74d8-4479-b092-ec34873d659d", "Styles": "margin-right:-.1pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "989c78e0-c024-4802-bc7e-2df2cfd389e0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0fa4d2e6-74d8-4479-b092-ec34873d659d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Hepsera with food and drink</span></b></p>", "ID": "e7620256-f7c1-49f6-93a1-2f9e8fb3a6f1", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">Hepsera with food and drink</span></b>", "ID": "9f3d2370-ff4c-4fb1-8bc7-954b9130e37a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e7620256-f7c1-49f6-93a1-2f9e8fb3a6f1"}, {"Element": "<span lang=\"EN-GB\">Hepsera with food and drink</span>", "ID": "dc767e4b-54dd-4496-a794-b43a54873401", "Styles": "None", "Classes": "None", "Text": "Hepsera with food and drink", "ParentId": "9f3d2370-ff4c-4fb1-8bc7-954b9130e37a"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d487fbe7-31ef-4c8f-bada-c458cf34e136", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "43069ebe-2d1d-4c79-a74d-4ab6f41208bc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d487fbe7-31ef-4c8f-bada-c458cf34e136"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Hepsera can be taken with or without food.</span></p>", "ID": "b9790ce3-639d-4eba-baa0-8a5c2040fe31", "Styles": "margin-right:-.1pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Hepsera can be taken with or without food.</span>", "ID": "ed17479b-13db-4551-a173-84499e607950", "Styles": "None", "Classes": "None", "Text": "Hepsera can be taken with or without food.", "ParentId": "b9790ce3-639d-4eba-baa0-8a5c2040fe31"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0c2868b4-2b04-4ee8-ae37-fd6670664e58", "Styles": "margin-right:-.1pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "20319638-1616-49e0-9ca4-8cfe4817bb58", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0c2868b4-2b04-4ee8-ae37-fd6670664e58"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Pregnancy and breast-feeding</span></b></p>", "ID": "59437085-3177-4082-99ca-0bb0a995ae79", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">Pregnancy and breast-feeding</span></b>", "ID": "ebbba049-800a-40f9-adf0-47b8b101f5a8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "59437085-3177-4082-99ca-0bb0a995ae79"}, {"Element": "<span lang=\"EN-GB\">Pregnancy and breast-feeding</span>", "ID": "a8b38bf1-25cf-46c9-9187-d821ea6ee6c6", "Styles": "None", "Classes": "None", "Text": "Pregnancy and breast-feeding", "ParentId": "ebbba049-800a-40f9-adf0-47b8b101f5a8"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e6983256-b711-41ae-97b4-b91e46b8eaa1", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "59ce7a44-a40c-4766-9309-0ed8ef4d9e9a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e6983256-b711-41ae-97b4-b91e46b8eaa1"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If you are\npregnant or breast-feeding, think you may be pregnant or are planning to have a\nbaby, ask your doctor or pharmacist for advice before taking this medicine.</span></p>", "ID": "662d910e-7056-4701-855a-a9e9748ca89d", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">If you are\npregnant or breast-feeding, think you may be pregnant or are planning to have a\nbaby, ask your doctor or pharmacist for advice before taking this medicine.</span>", "ID": "ccc757af-ae11-439c-b6a2-fe8b46fe4da1", "Styles": "None", "Classes": "None", "Text": "If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.", "ParentId": "662d910e-7056-4701-855a-a9e9748ca89d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "54334803-d028-48df-8527-4305b552a4b3", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3162b67d-a195-4bc6-a27d-3f246caf72b7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "54334803-d028-48df-8527-4305b552a4b3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Tell your doctor immediately if you are\npregnant</span></b><span lang=\"EN-GB\"> or planning to become pregnant. \u00a0It is not\nknown whether Hepsera is safe to use during human pregnancy.</span></p>", "ID": "c1a70d1e-3738-4f0c-823e-b7a4cd13395d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "b6ffd36b-4500-4203-ad09-1037a8e4d972", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "c1a70d1e-3738-4f0c-823e-b7a4cd13395d"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "00fbdb62-2194-4300-b000-530e0a144002", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "b6ffd36b-4500-4203-ad09-1037a8e4d972"}, {"Element": "<b><span lang=\"EN-GB\">Tell your doctor immediately if you are\npregnant</span></b>", "ID": "a431b113-8826-4dff-9021-3aa5610b2c73", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c1a70d1e-3738-4f0c-823e-b7a4cd13395d"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor immediately if you are\npregnant</span>", "ID": "d7661ce9-5fb8-4483-b096-7981e63a26f1", "Styles": "None", "Classes": "None", "Text": "Tell your doctor immediately if you are pregnant", "ParentId": "a431b113-8826-4dff-9021-3aa5610b2c73"}, {"Element": "<span lang=\"EN-GB\"> or planning to become pregnant. \u00a0It is not\nknown whether Hepsera is safe to use during human pregnancy.</span>", "ID": "0f1d4778-e140-4370-a234-4e48b72c127f", "Styles": "None", "Classes": "None", "Text": " or planning to become pregnant. \u00a0It is not known whether Hepsera is safe to use during human pregnancy.", "ParentId": "c1a70d1e-3738-4f0c-823e-b7a4cd13395d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e5ecf0ec-a089-44be-9877-ea472e1780a9", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9611add4-f7a6-4c38-8263-29a03df198d8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e5ecf0ec-a089-44be-9877-ea472e1780a9"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Use an effective method of contraception</span></b><span lang=\"EN-GB\"> to avoid becoming pregnant if you are a woman of child-bearing age\ntaking Hepsera.</span></p>", "ID": "1b96921a-96e1-42b1-b7d1-4ff6aba53566", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "0d2abf95-921d-4833-8a6f-9fbba4575367", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "1b96921a-96e1-42b1-b7d1-4ff6aba53566"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "7847f5cd-0319-4ff8-9d4a-b6cf04c25433", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "0d2abf95-921d-4833-8a6f-9fbba4575367"}, {"Element": "<b><span lang=\"EN-GB\">Use an effective method of contraception</span></b>", "ID": "bd33775f-b605-4189-9499-f6ec43ecef2f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1b96921a-96e1-42b1-b7d1-4ff6aba53566"}, {"Element": "<span lang=\"EN-GB\">Use an effective method of contraception</span>", "ID": "c1b55749-d584-4fa2-a733-2875b942fb5d", "Styles": "None", "Classes": "None", "Text": "Use an effective method of contraception", "ParentId": "bd33775f-b605-4189-9499-f6ec43ecef2f"}, {"Element": "<span lang=\"EN-GB\"> to avoid becoming pregnant if you are a woman of child-bearing age\ntaking Hepsera.</span>", "ID": "8e663535-e807-467a-a3e1-0eba54c9923d", "Styles": "None", "Classes": "None", "Text": " to avoid becoming pregnant if you are a woman of child-bearing age taking Hepsera.", "ParentId": "1b96921a-96e1-42b1-b7d1-4ff6aba53566"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a30ac4ec-123a-4a28-be5b-ae4af70098cf", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8fa772b5-17be-497e-965b-0f635af4d458", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a30ac4ec-123a-4a28-be5b-ae4af70098cf"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Do not breast-feed while taking Hepsera.</span></b><span lang=\"EN-GB\"> \u00a0It is not known whether the active substance in this medicine\npasses into breast milk.</span></p>", "ID": "097be48b-9092-4ac9-bd68-46e32f91fbdd", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "889c61b3-fed4-446b-90c9-53115faaa599", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "097be48b-9092-4ac9-bd68-46e32f91fbdd"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "e4d91088-6011-4871-9de2-a26b7234a50b", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "889c61b3-fed4-446b-90c9-53115faaa599"}, {"Element": "<b><span lang=\"EN-GB\">Do not breast-feed while taking Hepsera.</span></b>", "ID": "67336c98-ba20-44a9-8853-78aaff96aa76", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "097be48b-9092-4ac9-bd68-46e32f91fbdd"}, {"Element": "<span lang=\"EN-GB\">Do not breast-feed while taking Hepsera.</span>", "ID": "ced444d1-b523-4af0-92d3-e4dc96403574", "Styles": "None", "Classes": "None", "Text": "Do not breast-feed while taking Hepsera.", "ParentId": "67336c98-ba20-44a9-8853-78aaff96aa76"}, {"Element": "<span lang=\"EN-GB\"> \u00a0It is not known whether the active substance in this medicine\npasses into breast milk.</span>", "ID": "9f63f7fc-1442-444d-a61d-2e95615bc36c", "Styles": "None", "Classes": "None", "Text": " \u00a0It is not known whether the active substance in this medicine passes into breast milk.", "ParentId": "097be48b-9092-4ac9-bd68-46e32f91fbdd"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><s><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></s></p>", "ID": "03375850-661f-4254-a65c-6ab1d6d524e9", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<s><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></s>", "ID": "6e3c03de-3947-4da4-89a1-3940131a87b7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "03375850-661f-4254-a65c-6ab1d6d524e9"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "1786bd60-4dd9-48a7-9138-57502b7aa089", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6e3c03de-3947-4da4-89a1-3940131a87b7"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "0d3d6343-cc08-4420-9460-457a7f1a77e9", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "1786bd60-4dd9-48a7-9138-57502b7aa089"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Hepsera contains lactose</span></b></p>", "ID": "5d9876dc-3350-49a6-aac9-8b37751d5a53", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">Hepsera contains lactose</span></b>", "ID": "a3551d7e-599b-4db0-9113-f30eb67f5749", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5d9876dc-3350-49a6-aac9-8b37751d5a53"}, {"Element": "<span lang=\"EN-GB\">Hepsera contains lactose</span>", "ID": "78d7d0a2-4b04-4791-a6a3-c08bfa66e4fb", "Styles": "None", "Classes": "None", "Text": "Hepsera contains lactose", "ParentId": "a3551d7e-599b-4db0-9113-f30eb67f5749"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If you are\nlactose-intolerant, or if you have been told that you have an intolerance to\nsome sugars, talk to your doctor before taking Hepsera.</span></p>", "ID": "0569382d-0f15-4bfa-a125-28e3de1828b2", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">If you are\nlactose-intolerant, or if you have been told that you have an intolerance to\nsome sugars, talk to your doctor before taking Hepsera.</span>", "ID": "5fd43008-9922-4fbf-a223-ed74b8360ab6", "Styles": "None", "Classes": "None", "Text": "If you are lactose-intolerant, or if you have been told that you have an intolerance to some sugars, talk to your doctor before taking Hepsera.", "ParentId": "0569382d-0f15-4bfa-a125-28e3de1828b2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "88dd7477-8d80-4181-b947-39abc2196aec", "Styles": "margin-right:-.1pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e45d2119-2afe-40b5-b209-6cea76305454", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "88dd7477-8d80-4181-b947-39abc2196aec"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bc80edf0-c07e-4ce1-9f8f-4b2842f61fb4", "Styles": "margin-right:-.1pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "611733e7-e76d-4516-a187-4c03af671667", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bc80edf0-c07e-4ce1-9f8f-4b2842f61fb4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to take Hepsera</span></b></p>", "ID": "7adf07bc-3c74-4f70-953a-8a275c121c6a", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to take Hepsera</span></b>", "ID": "2d54edd4-3cfb-4842-a0be-901371c72989", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7adf07bc-3c74-4f70-953a-8a275c121c6a"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to take Hepsera</span>", "ID": "a05e2720-286f-43ed-be05-cf19a4786f4f", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to take Hepsera", "ParentId": "2d54edd4-3cfb-4842-a0be-901371c72989"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d5f7ea01-5a42-4cea-ab44-dea315070184", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "83412a82-f07a-4f7b-a4e8-1efbb0774a4e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d5f7ea01-5a42-4cea-ab44-dea315070184"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Always take this\nmedicine exactly as your doctor has told you.</span></b><span lang=\"EN-GB\">\u00a0 This\nis to make sure that your medicine is fully effective and to reduce the\ndevelopment of resistance to the treatment. \u00a0Check with your doctor or pharmacist\nif you are not sure.</span></p>", "ID": "111f8b91-60f6-4503-bc5a-04b573d92b8a", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">Always take this\nmedicine exactly as your doctor has told you.</span></b>", "ID": "a02bf9b7-37dc-4cdc-a9e7-a75c400e49c3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "111f8b91-60f6-4503-bc5a-04b573d92b8a"}, {"Element": "<span lang=\"EN-GB\">Always take this\nmedicine exactly as your doctor has told you.</span>", "ID": "7ee2bfb6-534e-4a52-beb7-b572b2b9df52", "Styles": "None", "Classes": "None", "Text": "Always take this medicine exactly as your doctor has told you.", "ParentId": "a02bf9b7-37dc-4cdc-a9e7-a75c400e49c3"}, {"Element": "<span lang=\"EN-GB\">\u00a0 This\nis to make sure that your medicine is fully effective and to reduce the\ndevelopment of resistance to the treatment. \u00a0Check with your doctor or pharmacist\nif you are not sure.</span>", "ID": "07832606-6105-4085-bbad-f89a0ca4be61", "Styles": "None", "Classes": "None", "Text": "\u00a0 This is to make sure that your medicine is fully effective and to reduce the development of resistance to the treatment. \u00a0Check with your doctor or pharmacist if you are not sure.", "ParentId": "111f8b91-60f6-4503-bc5a-04b573d92b8a"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0164a649-4cfd-4a3d-bf09-477e69b47c49", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d2b34341-a9c0-4750-943a-e6043d33cd0f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0164a649-4cfd-4a3d-bf09-477e69b47c49"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">The recommended dose</span></b><span lang=\"EN-GB\"> is one 10\u00a0mg tablet each day, taken with or without food.</span></p>", "ID": "3cd4b675-ccd9-475d-a168-bb54c5cdeed1", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "9f3c1f16-c473-4ae6-8721-578073532d64", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "3cd4b675-ccd9-475d-a168-bb54c5cdeed1"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "d2203a9b-bd63-4314-a457-54470bf0dd16", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "9f3c1f16-c473-4ae6-8721-578073532d64"}, {"Element": "<b><span lang=\"EN-GB\">The recommended dose</span></b>", "ID": "74689803-97c3-4de2-99b2-5d5279920ada", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3cd4b675-ccd9-475d-a168-bb54c5cdeed1"}, {"Element": "<span lang=\"EN-GB\">The recommended dose</span>", "ID": "e4529e8b-717c-4b76-a97a-c9639fecc78a", "Styles": "None", "Classes": "None", "Text": "The recommended dose", "ParentId": "74689803-97c3-4de2-99b2-5d5279920ada"}, {"Element": "<span lang=\"EN-GB\"> is one 10\u00a0mg tablet each day, taken with or without food.</span>", "ID": "bcf679fe-ccce-4014-9b42-39c67b5534ab", "Styles": "None", "Classes": "None", "Text": " is one 10\u00a0mg tablet each day, taken with or without food.", "ParentId": "3cd4b675-ccd9-475d-a168-bb54c5cdeed1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3a011d9a-174a-4ac0-9d15-66b40ee6d7ce", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5dee7541-a07c-4d86-ba1f-d5d9d68679e2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3a011d9a-174a-4ac0-9d15-66b40ee6d7ce"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">A different dose</span></b><span lang=\"EN-GB\">\nmay be given to patients with <b>kidney problems</b>.</span></p>", "ID": "2905d5b1-0021-468c-99b0-1d9a1f0ea060", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "7b1444b4-df6a-4bef-a5cc-2c15ecd1da8d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "2905d5b1-0021-468c-99b0-1d9a1f0ea060"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "95bc6665-e451-4734-a001-6d7e6da0f8cf", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "7b1444b4-df6a-4bef-a5cc-2c15ecd1da8d"}, {"Element": "<b><span lang=\"EN-GB\">A different dose</span></b>", "ID": "cd5fc391-13b3-4631-ad90-8f1bde714094", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2905d5b1-0021-468c-99b0-1d9a1f0ea060"}, {"Element": "<span lang=\"EN-GB\">A different dose</span>", "ID": "93e88030-0792-49ff-b7db-8c93d17727bb", "Styles": "None", "Classes": "None", "Text": "A different dose", "ParentId": "cd5fc391-13b3-4631-ad90-8f1bde714094"}, {"Element": "<span lang=\"EN-GB\">\nmay be given to patients with <b>kidney problems</b>.</span>", "ID": "7288e4b0-efcd-4c74-a3ad-4707dae04c84", "Styles": "None", "Classes": "None", "Text": " may be given to patients with .", "ParentId": "2905d5b1-0021-468c-99b0-1d9a1f0ea060"}, {"Element": "<b>kidney problems</b>", "ID": "4e2c789c-330f-4156-b065-8c56290b2340", "Styles": "None", "Classes": "None", "Text": "kidney problems", "ParentId": "7288e4b0-efcd-4c74-a3ad-4707dae04c84"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1870e449-8d7e-49d4-a856-c321f2d18840", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "106105c8-6b5a-4190-89e0-a477256387ef", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1870e449-8d7e-49d4-a856-c321f2d18840"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">If you take more Hepsera than you should</span></b></p>", "ID": "9f02c04e-6ab5-48ac-a319-7be88150e9ca", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">If you take more Hepsera than you should</span></b>", "ID": "c254e787-c789-4531-900c-0278055f2053", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9f02c04e-6ab5-48ac-a319-7be88150e9ca"}, {"Element": "<span lang=\"EN-GB\">If you take more Hepsera than you should</span>", "ID": "dfecd2c8-80f6-4de1-ac50-359396833d40", "Styles": "None", "Classes": "None", "Text": "If you take more Hepsera than you should", "ParentId": "c254e787-c789-4531-900c-0278055f2053"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7e92afd3-453a-4304-8b33-1dee397b630d", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "133aaac9-54ea-435c-a1f6-0e32f7e95cca", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7e92afd3-453a-4304-8b33-1dee397b630d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If you\naccidentally take too many Hepsera tablets, contact your doctor or nearest\nhospital immediately.</span></p>", "ID": "4f9d3e7e-4c8a-42a3-8273-40a236a36b92", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">If you\naccidentally take too many Hepsera tablets, contact your doctor or nearest\nhospital immediately.</span>", "ID": "d82cc869-e1ba-4f7a-852b-be131120ccdd", "Styles": "None", "Classes": "None", "Text": "If you accidentally take too many Hepsera tablets, contact your doctor or nearest hospital immediately.", "ParentId": "4f9d3e7e-4c8a-42a3-8273-40a236a36b92"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c6b453d0-1980-4526-ae40-29ddee39681a", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8c94c908-75df-4ce7-b11f-17a092ae3121", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c6b453d0-1980-4526-ae40-29ddee39681a"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">If you forget to take Hepsera or you vomit</span></b></p>", "ID": "18828f68-8225-402d-82dd-37e977cb7d7e", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">If you forget to take Hepsera or you vomit</span></b>", "ID": "bca7ff77-ac7b-4863-993d-a4196bf57111", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "18828f68-8225-402d-82dd-37e977cb7d7e"}, {"Element": "<span lang=\"EN-GB\">If you forget to take Hepsera or you vomit</span>", "ID": "1da73551-b919-490e-9598-a0ce665aeefb", "Styles": "None", "Classes": "None", "Text": "If you forget to take Hepsera or you vomit", "ParentId": "bca7ff77-ac7b-4863-993d-a4196bf57111"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3f6a5d3d-3275-4f09-ad12-e61aa096fa1e", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "23e3df31-1e38-4562-9861-a22ad1cce14c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3f6a5d3d-3275-4f09-ad12-e61aa096fa1e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">It is important\nnot to miss a dose.</span></p>", "ID": "b8c2f475-edbe-4de6-bc5a-e2bf6cc9953c", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">It is important\nnot to miss a dose.</span>", "ID": "1dea1e2f-4235-4aea-8f6d-d99dd10f7ab2", "Styles": "None", "Classes": "None", "Text": "It is important not to miss a dose.", "ParentId": "b8c2f475-edbe-4de6-bc5a-e2bf6cc9953c"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fbd63df5-85a6-4bf1-b5de-085d73be82cf", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6756a828-8644-4a96-9ba0-5c4cded4ee4e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fbd63df5-85a6-4bf1-b5de-085d73be82cf"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">If you do miss a dose</span></b><span lang=\"EN-GB\"> of Hepsera, take it as soon as you can, and then take your next\nscheduled dose at its regular time.</span></p>", "ID": "4f629a56-dca5-4add-b011-0b708ed1252c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "7b83a50f-1823-4a1b-aa37-beb8aa5270a7", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "4f629a56-dca5-4add-b011-0b708ed1252c"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "2e1418eb-3081-48ea-b262-27177b0e3cbd", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "7b83a50f-1823-4a1b-aa37-beb8aa5270a7"}, {"Element": "<b><span lang=\"EN-GB\">If you do miss a dose</span></b>", "ID": "bfbe6598-1f12-4ad0-b774-beb9ef15e47a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4f629a56-dca5-4add-b011-0b708ed1252c"}, {"Element": "<span lang=\"EN-GB\">If you do miss a dose</span>", "ID": "5ef8ff6b-32a9-410e-8da6-225d799fe89b", "Styles": "None", "Classes": "None", "Text": "If you do miss a dose", "ParentId": "bfbe6598-1f12-4ad0-b774-beb9ef15e47a"}, {"Element": "<span lang=\"EN-GB\"> of Hepsera, take it as soon as you can, and then take your next\nscheduled dose at its regular time.</span>", "ID": "a7b6e8f6-42e1-4c44-aca5-f180c07473a8", "Styles": "None", "Classes": "None", "Text": " of Hepsera, take it as soon as you can, and then take your next scheduled dose at its regular time.", "ParentId": "4f629a56-dca5-4add-b011-0b708ed1252c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "28e463b0-5f60-42f2-9d29-90863af32661", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "52b3df8d-31eb-4974-9b48-d94008c829d7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "28e463b0-5f60-42f2-9d29-90863af32661"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">If it is nearly time for your next dose,</span></b><span lang=\"EN-GB\"> skip the missed dose.\u00a0 Wait and take the next dose at the regular\ntime.\u00a0 Do not take a double dose (two doses close together).</span></p>", "ID": "3f6dd80e-e67e-44e2-97f4-0c5e301e7a84", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "9c213dc0-9a69-40a9-87b0-20fb7202c23b", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "3f6dd80e-e67e-44e2-97f4-0c5e301e7a84"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "d7560a90-3b7c-4f9a-b981-d45b67a45400", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "9c213dc0-9a69-40a9-87b0-20fb7202c23b"}, {"Element": "<b><span lang=\"EN-GB\">If it is nearly time for your next dose,</span></b>", "ID": "65cbf4d3-7440-4f2e-b31e-c89f2dde4473", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3f6dd80e-e67e-44e2-97f4-0c5e301e7a84"}, {"Element": "<span lang=\"EN-GB\">If it is nearly time for your next dose,</span>", "ID": "21852c66-2bba-4c42-abdd-6e29fa52ef61", "Styles": "None", "Classes": "None", "Text": "If it is nearly time for your next dose,", "ParentId": "65cbf4d3-7440-4f2e-b31e-c89f2dde4473"}, {"Element": "<span lang=\"EN-GB\"> skip the missed dose.\u00a0 Wait and take the next dose at the regular\ntime.\u00a0 Do not take a double dose (two doses close together).</span>", "ID": "f69f34b7-e1d3-4d59-a40c-bb9a62a104fd", "Styles": "None", "Classes": "None", "Text": " skip the missed dose.\u00a0 Wait and take the next dose at the regular time.\u00a0 Do not take a double dose (two doses close together).", "ParentId": "3f6dd80e-e67e-44e2-97f4-0c5e301e7a84"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e40d43f4-3388-4b5c-9fbb-68775d212d33", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "106670ed-0181-4bdc-8794-fb51fe223d0e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e40d43f4-3388-4b5c-9fbb-68775d212d33"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">If you are sick (vomit) less than 1\u00a0hour\nafter taking Hepsera</span></b><span lang=\"EN-GB\"> take another tablet. \u00a0You do\nnot need to take another tablet if you are sick more than 1\u00a0hour after\ntaking Hepsera.</span></p>", "ID": "59bc0ba4-60c8-43fa-86f6-6deff33eb1d9", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "980a70a8-718b-4cfb-97a9-9925c0a9f974", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "59bc0ba4-60c8-43fa-86f6-6deff33eb1d9"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "6a2685d7-98c3-4ec8-a7dc-92e6d79860d5", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "980a70a8-718b-4cfb-97a9-9925c0a9f974"}, {"Element": "<b><span lang=\"EN-GB\">If you are sick (vomit) less than 1\u00a0hour\nafter taking Hepsera</span></b>", "ID": "3aa74959-fa1d-46be-b398-b41f4ee0f747", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "59bc0ba4-60c8-43fa-86f6-6deff33eb1d9"}, {"Element": "<span lang=\"EN-GB\">If you are sick (vomit) less than 1\u00a0hour\nafter taking Hepsera</span>", "ID": "13a9adf4-4b6f-44d6-8720-b4de7f635818", "Styles": "None", "Classes": "None", "Text": "If you are sick (vomit) less than 1\u00a0hour after taking Hepsera", "ParentId": "3aa74959-fa1d-46be-b398-b41f4ee0f747"}, {"Element": "<span lang=\"EN-GB\"> take another tablet. \u00a0You do\nnot need to take another tablet if you are sick more than 1\u00a0hour after\ntaking Hepsera.</span>", "ID": "81152d41-04d4-4c97-86ff-9e0b512b8d01", "Styles": "None", "Classes": "None", "Text": " take another tablet. \u00a0You do not need to take another tablet if you are sick more than 1\u00a0hour after taking Hepsera.", "ParentId": "59bc0ba4-60c8-43fa-86f6-6deff33eb1d9"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7b498c3a-1b0b-4682-ab51-97f3b8a7cf42", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3c37de65-9b58-4702-9679-2017860ec809", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7b498c3a-1b0b-4682-ab51-97f3b8a7cf42"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">If you stop taking Hepsera</span></b></p>", "ID": "1b7b2a9d-08a4-4ef8-b904-451a1a01e3f0", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">If you stop taking Hepsera</span></b>", "ID": "915fcf42-c549-4d65-83c5-de23ffe9faa5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1b7b2a9d-08a4-4ef8-b904-451a1a01e3f0"}, {"Element": "<span lang=\"EN-GB\">If you stop taking Hepsera</span>", "ID": "ff20dfb0-5ae8-4535-8e85-f56a308737bf", "Styles": "None", "Classes": "None", "Text": "If you stop taking Hepsera", "ParentId": "915fcf42-c549-4d65-83c5-de23ffe9faa5"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "baa01cc3-5f65-4bec-95bb-fc0d15a61a99", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ba095c1d-47e4-4141-a982-2748377c0473", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "baa01cc3-5f65-4bec-95bb-fc0d15a61a99"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Tell your doctor immediately about any new, </span></b><span lang=\"EN-GB\">unusual or worsening symptoms that you notice after stopping\ntreatment. \u00a0See\u00a0section\u00a02 for more details.</span></p>", "ID": "17134ada-63a4-4d8d-846a-44b2dd78e672", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "7a7b9f81-90b1-4bc8-9188-e7b3b6191d3c", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "17134ada-63a4-4d8d-846a-44b2dd78e672"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "cb65abd0-8218-4f1c-8733-08c415b192f3", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "7a7b9f81-90b1-4bc8-9188-e7b3b6191d3c"}, {"Element": "<b><span lang=\"EN-GB\">Tell your doctor immediately about any new, </span></b>", "ID": "cc5da2df-ec89-46b1-a2ad-56aee4675f02", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "17134ada-63a4-4d8d-846a-44b2dd78e672"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor immediately about any new, </span>", "ID": "577a9ddc-4e83-4d29-9405-479c31fef7d2", "Styles": "None", "Classes": "None", "Text": "Tell your doctor immediately about any new, ", "ParentId": "cc5da2df-ec89-46b1-a2ad-56aee4675f02"}, {"Element": "<span lang=\"EN-GB\">unusual or worsening symptoms that you notice after stopping\ntreatment. \u00a0See\u00a0section\u00a02 for more details.</span>", "ID": "090e15b6-6b5f-4ada-83be-d91a8ff9116d", "Styles": "None", "Classes": "None", "Text": "unusual or worsening symptoms that you notice after stopping treatment. \u00a0See\u00a0section\u00a02 for more details.", "ParentId": "17134ada-63a4-4d8d-846a-44b2dd78e672"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cc058ade-dacc-4fa1-9049-c2dd9d24c6c6", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f865d5a5-eb5a-4421-aaed-d2de55efed08", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cc058ade-dacc-4fa1-9049-c2dd9d24c6c6"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Don\u2019t stop taking Hepsera</span></b><span lang=\"EN-GB\"> without your doctor\u2019s advice.</span></p>", "ID": "d95e4a27-82bc-498f-9efb-1f9ee5415ca3", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "9742b4bd-58b3-44ec-9c44-c247c9557c5f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d95e4a27-82bc-498f-9efb-1f9ee5415ca3"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "d39d415e-a70e-4530-8b74-cedead34bd94", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "9742b4bd-58b3-44ec-9c44-c247c9557c5f"}, {"Element": "<b><span lang=\"EN-GB\">Don\u2019t stop taking Hepsera</span></b>", "ID": "bfa85333-2623-43ca-bff5-502c57bfa0d8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d95e4a27-82bc-498f-9efb-1f9ee5415ca3"}, {"Element": "<span lang=\"EN-GB\">Don\u2019t stop taking Hepsera</span>", "ID": "fe641b7f-a300-4571-9b86-7bd61caf15e2", "Styles": "None", "Classes": "None", "Text": "Don\u2019t stop taking Hepsera", "ParentId": "bfa85333-2623-43ca-bff5-502c57bfa0d8"}, {"Element": "<span lang=\"EN-GB\"> without your doctor\u2019s advice.</span>", "ID": "06906c0c-eda8-406c-af98-75f7cc777d8e", "Styles": "None", "Classes": "None", "Text": " without your doctor\u2019s advice.", "ParentId": "d95e4a27-82bc-498f-9efb-1f9ee5415ca3"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e965db09-51e3-4e35-b5b9-af991bad8efb", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "211ec8a2-eb0f-4489-a8af-e138c0eda56f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e965db09-51e3-4e35-b5b9-af991bad8efb"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If you have any further\nquestions on the use of this medicine, ask your doctor or pharmacist.</span></p>", "ID": "eed03c8e-add6-4242-a57d-e71ac4931fb6", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">If you have any further\nquestions on the use of this medicine, ask your doctor or pharmacist.</span>", "ID": "2ba34afd-ffd2-4ec6-96f6-b53b530edf3c", "Styles": "None", "Classes": "None", "Text": "If you have any further questions on the use of this medicine, ask your doctor or pharmacist.", "ParentId": "eed03c8e-add6-4242-a57d-e71ac4931fb6"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6c359031-b726-4d54-bc83-a45e6d88402f", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "89e537ca-f311-4829-9929-a875d9aec0f1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6c359031-b726-4d54-bc83-a45e6d88402f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "81acd7ae-2914-4418-a35f-dd586e463b05", "Styles": "margin-right:-.1pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "922cf997-e69a-4ca6-9d70-2eaa6e287dd1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "81acd7ae-2914-4418-a35f-dd586e463b05"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side effects</span></b></p>", "ID": "bd6f952a-0431-4746-8344-6f4091a6d349", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side effects</span></b>", "ID": "7f3ff2c7-e2a4-4763-8ca7-d0d01acd2a64", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bd6f952a-0431-4746-8344-6f4091a6d349"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side effects</span>", "ID": "1cbf90d4-1758-4d14-b733-2bdde5ff31c2", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side effects", "ParentId": "7f3ff2c7-e2a4-4763-8ca7-d0d01acd2a64"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "55ee4fdc-c97b-40fc-8a8a-16a93d6692f9", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9587515f-4e51-4aa2-a4e3-016209d3110d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "55ee4fdc-c97b-40fc-8a8a-16a93d6692f9"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Like all\nmedicines, this medicine can cause side effects, although not everybody gets\nthem.</span></p>", "ID": "423b74a1-7db6-4e46-9aa9-702969c8f2f8", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Like all\nmedicines, this medicine can cause side effects, although not everybody gets\nthem.</span>", "ID": "f14ed405-6ad5-4564-9ceb-fc4077864a34", "Styles": "None", "Classes": "None", "Text": "Like all medicines, this medicine can cause side effects, although not everybody gets them.", "ParentId": "423b74a1-7db6-4e46-9aa9-702969c8f2f8"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "90c86f04-4351-428b-8209-bad035e169f5", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b06b5db4-548d-4fb6-93d0-221bb01a6896", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "90c86f04-4351-428b-8209-bad035e169f5"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Very rare side effects</span></b></p>", "ID": "e9af8f81-39fb-4fbb-bd48-b3ffccb2113e", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">Very rare side effects</span></b>", "ID": "fac15585-7675-45dc-bc4c-8c094b26ff4b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e9af8f81-39fb-4fbb-bd48-b3ffccb2113e"}, {"Element": "<span lang=\"EN-GB\">Very rare side effects</span>", "ID": "d0d2c134-a741-4195-bde7-a2eba768e328", "Styles": "None", "Classes": "None", "Text": "Very rare side effects", "ParentId": "fac15585-7675-45dc-bc4c-8c094b26ff4b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">(These can affect less than 1 in 10,000\u00a0people taking Hepsera)</span></i></p>", "ID": "929d7aae-dade-4cec-99c0-423b1bbd0e59", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">(These can affect less than 1 in 10,000\u00a0people taking Hepsera)</span></i>", "ID": "945c9edb-3a83-4e03-9262-d6ac62b3d378", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "929d7aae-dade-4cec-99c0-423b1bbd0e59"}, {"Element": "<span lang=\"EN-GB\">(These can affect less than 1 in 10,000\u00a0people taking Hepsera)</span>", "ID": "ace49684-0986-4520-8c55-5d773b95add4", "Styles": "None", "Classes": "None", "Text": "(These can affect less than 1 in 10,000\u00a0people taking Hepsera)", "ParentId": "945c9edb-3a83-4e03-9262-d6ac62b3d378"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "104272ff-6e9a-4ff9-a7c4-61b0f624f55e", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e96c8865-be38-4250-ad81-22f809919681", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "104272ff-6e9a-4ff9-a7c4-61b0f624f55e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Lactic acidosis is a serious but very rare\nside effect of taking Hepsera.</span></b><span lang=\"EN-GB\"> \u00a0It can cause too\nmuch lactic acid in the blood and enlargement of the liver. \u00a0Lactic acidosis\noccurs more often in women, particularly if they are very overweight. \u00a0People\nwith liver disease may also be at risk.</span></p>", "ID": "b1c53bb5-7e42-464b-8132-69fa3ce65e18", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "4512ccb6-82a2-4502-9926-342fac30d75c", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "b1c53bb5-7e42-464b-8132-69fa3ce65e18"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "700b5a01-3676-41f5-80cf-0296a410266a", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "4512ccb6-82a2-4502-9926-342fac30d75c"}, {"Element": "<b><span lang=\"EN-GB\">Lactic acidosis is a serious but very rare\nside effect of taking Hepsera.</span></b>", "ID": "10ba78b5-1d26-46ce-bb66-93133da447ca", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b1c53bb5-7e42-464b-8132-69fa3ce65e18"}, {"Element": "<span lang=\"EN-GB\">Lactic acidosis is a serious but very rare\nside effect of taking Hepsera.</span>", "ID": "f9ec563d-f393-407d-957c-688f90988eb3", "Styles": "None", "Classes": "None", "Text": "Lactic acidosis is a serious but very rare side effect of taking Hepsera.", "ParentId": "10ba78b5-1d26-46ce-bb66-93133da447ca"}, {"Element": "<span lang=\"EN-GB\"> \u00a0It can cause too\nmuch lactic acid in the blood and enlargement of the liver. \u00a0Lactic acidosis\noccurs more often in women, particularly if they are very overweight. \u00a0People\nwith liver disease may also be at risk.</span>", "ID": "36d762c6-2d2a-4158-aac2-a2c3deaa2e50", "Styles": "None", "Classes": "None", "Text": " \u00a0It can cause too much lactic acid in the blood and enlargement of the liver. \u00a0Lactic acidosis occurs more often in women, particularly if they are very overweight. \u00a0People with liver disease may also be at risk.", "ParentId": "b1c53bb5-7e42-464b-8132-69fa3ce65e18"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2fe8ab59-979d-4c79-ac07-bf40d887ed2a", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9043a4da-7508-4d2a-bd83-c11607c5f7ea", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2fe8ab59-979d-4c79-ac07-bf40d887ed2a"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Some of the signs of lactic acidosis are:</span></b></p>", "ID": "1d63771e-2398-492d-a29d-0be8d0967e04", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">Some of the signs of lactic acidosis are:</span></b>", "ID": "4db019c3-8caa-4863-9b0e-16ba8ed6c324", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1d63771e-2398-492d-a29d-0be8d0967e04"}, {"Element": "<span lang=\"EN-GB\">Some of the signs of lactic acidosis are:</span>", "ID": "0cd58f0d-c4c6-45b6-8829-1a3a5e921044", "Styles": "None", "Classes": "None", "Text": "Some of the signs of lactic acidosis are:", "ParentId": "4db019c3-8caa-4863-9b0e-16ba8ed6c324"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bc8c94ac-ecd3-41e6-8154-e7abbc96822b", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ab177b12-e954-4ed5-99e1-0845a541cc17", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bc8c94ac-ecd3-41e6-8154-e7abbc96822b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Feeling sick (nausea) and sickness (vomiting)</span></p>", "ID": "43384793-a038-405d-87b3-50e4989cf0b2", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "f5d32fcc-ffe7-4356-a49f-224c23a4ab14", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "43384793-a038-405d-87b3-50e4989cf0b2"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "6f48de7a-d7f6-4e62-8b70-fd6d5d554894", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "f5d32fcc-ffe7-4356-a49f-224c23a4ab14"}, {"Element": "<span lang=\"EN-GB\">Feeling sick (nausea) and sickness (vomiting)</span>", "ID": "35441567-08f9-430e-8aab-8edb438d9e34", "Styles": "None", "Classes": "None", "Text": "Feeling sick (nausea) and sickness (vomiting)", "ParentId": "43384793-a038-405d-87b3-50e4989cf0b2"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8d729fcf-6a9b-44f9-a061-c9aaefb776a7", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f96c3be5-ac8c-4fa7-8696-4118e916c791", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8d729fcf-6a9b-44f9-a061-c9aaefb776a7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Stomach pain</span></p>", "ID": "76ef5f02-6bad-4e88-9ba6-f3d9fad6d3e3", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "873e2cca-2182-4e20-a4c1-f42e4fca64c2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "76ef5f02-6bad-4e88-9ba6-f3d9fad6d3e3"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "1ba18a99-d202-483e-aa90-1af57aa134e6", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "873e2cca-2182-4e20-a4c1-f42e4fca64c2"}, {"Element": "<span lang=\"EN-GB\">Stomach pain</span>", "ID": "227121da-51e1-43c6-8e70-4fd2e2d0e235", "Styles": "None", "Classes": "None", "Text": "Stomach pain", "ParentId": "76ef5f02-6bad-4e88-9ba6-f3d9fad6d3e3"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fd13afb5-7119-456c-a409-ebbd13e76f07", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "51466f8f-f373-4cd5-b992-f844892ad2cb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fd13afb5-7119-456c-a409-ebbd13e76f07"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><span style=\"font-family:Wingdings\">\u00e0</span><b><span lang=\"EN-GB\">Contact your doctor\nat once</span></b><span lang=\"EN-GB\"> if you get any of these symptoms. \u00a0They are\nthe same as some of the common side effects of Hepsera. \u00a0If you do get any of\nthem, it is unlikely to be serious, but you need to check. \u00a0Your doctor will\nmonitor you regularly while you take Hepsera.</span></p>", "ID": "d48e4b5b-2493-4ba2-8118-87292ab3d455", "Styles": "margin-left:28.35pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span style=\"font-family:Wingdings\">\u00e0</span>", "ID": "8310541f-c0f3-4d24-b937-6baa5dbbce1e", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00e0", "ParentId": "d48e4b5b-2493-4ba2-8118-87292ab3d455"}, {"Element": "<b><span lang=\"EN-GB\">Contact your doctor\nat once</span></b>", "ID": "eae720b8-2bc6-4d01-9662-64078ae57636", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d48e4b5b-2493-4ba2-8118-87292ab3d455"}, {"Element": "<span lang=\"EN-GB\">Contact your doctor\nat once</span>", "ID": "686253c9-47ee-4e36-8ef9-e6ed94b505d5", "Styles": "None", "Classes": "None", "Text": "Contact your doctor at once", "ParentId": "eae720b8-2bc6-4d01-9662-64078ae57636"}, {"Element": "<span lang=\"EN-GB\"> if you get any of these symptoms. \u00a0They are\nthe same as some of the common side effects of Hepsera. \u00a0If you do get any of\nthem, it is unlikely to be serious, but you need to check. \u00a0Your doctor will\nmonitor you regularly while you take Hepsera.</span>", "ID": "23e3e037-8395-4814-84c2-47d1ebd4f62c", "Styles": "None", "Classes": "None", "Text": " if you get any of these symptoms. \u00a0They are the same as some of the common side effects of Hepsera. \u00a0If you do get any of them, it is unlikely to be serious, but you need to check. \u00a0Your doctor will monitor you regularly while you take Hepsera.", "ParentId": "d48e4b5b-2493-4ba2-8118-87292ab3d455"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ae6233b8-3d3b-4473-85bd-30e146543d05", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8f9799ab-c8f5-44cf-8357-6eaa49e0dfa0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ae6233b8-3d3b-4473-85bd-30e146543d05"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Common side effects</span></b></p>", "ID": "afd8afac-104b-48de-80ff-2d27c6b20d53", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">Common side effects</span></b>", "ID": "9957e47f-3bca-4e02-b229-cdba811662a1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "afd8afac-104b-48de-80ff-2d27c6b20d53"}, {"Element": "<span lang=\"EN-GB\">Common side effects</span>", "ID": "2342b8d5-b63a-494d-ad66-266f817cc55f", "Styles": "None", "Classes": "None", "Text": "Common side effects", "ParentId": "9957e47f-3bca-4e02-b229-cdba811662a1"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">(These can affect 1 to 10 in every 100\u00a0people taking Hepsera)</span></i></p>", "ID": "a55146b6-dfbe-4b67-a167-d02a2423248a", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">(These can affect 1 to 10 in every 100\u00a0people taking Hepsera)</span></i>", "ID": "cbfb9965-a0e8-4284-8b5d-0b0688b4680e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a55146b6-dfbe-4b67-a167-d02a2423248a"}, {"Element": "<span lang=\"EN-GB\">(These can affect 1 to 10 in every 100\u00a0people taking Hepsera)</span>", "ID": "664bbc6c-ab7e-4a07-955f-ab4ff2ca86b3", "Styles": "None", "Classes": "None", "Text": "(These can affect 1 to 10 in every 100\u00a0people taking Hepsera)", "ParentId": "cbfb9965-a0e8-4284-8b5d-0b0688b4680e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "41266a37-a92d-4df2-b327-349fe55e9d7f", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dcd0e856-ed7a-4125-8d2f-b29546b4dac1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "41266a37-a92d-4df2-b327-349fe55e9d7f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Headache</span></p>", "ID": "cceec540-8c1d-480b-aae3-85e2fc98dc2c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "5f2c3a3e-45b4-4632-922a-4cad1e079d45", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "cceec540-8c1d-480b-aae3-85e2fc98dc2c"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "0ac2d50c-1151-4ec8-aeff-87f281b7c61d", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "5f2c3a3e-45b4-4632-922a-4cad1e079d45"}, {"Element": "<span lang=\"EN-GB\">Headache</span>", "ID": "8f8cf365-6c9c-4636-8196-3a9864501f04", "Styles": "None", "Classes": "None", "Text": "Headache", "ParentId": "cceec540-8c1d-480b-aae3-85e2fc98dc2c"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "09e5e501-ab31-4cc5-8429-10bfc3fc697f", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4a1b3527-f29f-4dec-a7ee-f3378eb23509", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "09e5e501-ab31-4cc5-8429-10bfc3fc697f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Feeling sick (nausea)</span></p>", "ID": "794743f2-0bf0-4fdb-bb62-d729a45890c6", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "dab7f54e-7ceb-400d-a06f-000ebe2bdb3d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "794743f2-0bf0-4fdb-bb62-d729a45890c6"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "8b8918af-06b2-40ac-a955-d315a715de35", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "dab7f54e-7ceb-400d-a06f-000ebe2bdb3d"}, {"Element": "<span lang=\"EN-GB\">Feeling sick (nausea)</span>", "ID": "7a115531-3f14-4b1d-b473-ba18cdc31d02", "Styles": "None", "Classes": "None", "Text": "Feeling sick (nausea)", "ParentId": "794743f2-0bf0-4fdb-bb62-d729a45890c6"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b9fdb613-1bb9-4700-b47f-758ecbb2f6cf", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "54c76182-2d85-4f16-9297-498ad2414506", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b9fdb613-1bb9-4700-b47f-758ecbb2f6cf"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Diarrhoea</span></p>", "ID": "9d6a9fb2-f9f9-4aa3-aa8a-7fd310de31e9", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "8e1324bd-58de-4ced-9740-36c247d38574", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "9d6a9fb2-f9f9-4aa3-aa8a-7fd310de31e9"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "b9dfb681-b744-439c-b4ac-e9357852bd9c", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "8e1324bd-58de-4ced-9740-36c247d38574"}, {"Element": "<span lang=\"EN-GB\">Diarrhoea</span>", "ID": "558e6544-b9c6-4c4b-b019-05a5dfad3a86", "Styles": "None", "Classes": "None", "Text": "Diarrhoea", "ParentId": "9d6a9fb2-f9f9-4aa3-aa8a-7fd310de31e9"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cf28c79e-ae26-48ff-8968-100e8a73e28f", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "99373335-1c01-411b-b1d5-11e05967f92f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cf28c79e-ae26-48ff-8968-100e8a73e28f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Digestive problems including wind or discomfort\nafter eating meals</span></p>", "ID": "d7e149c3-546b-4058-9c16-5a87697f51ab", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "5d7995dc-a74d-4925-be4a-f852d50f1d23", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d7e149c3-546b-4058-9c16-5a87697f51ab"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "289fd65c-2d6f-4d4b-990f-b884cc271f4b", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "5d7995dc-a74d-4925-be4a-f852d50f1d23"}, {"Element": "<span lang=\"EN-GB\">Digestive problems including wind or discomfort\nafter eating meals</span>", "ID": "f813b7fe-fe62-4173-aa97-25ebd2033e08", "Styles": "None", "Classes": "None", "Text": "Digestive problems including wind or discomfort after eating meals", "ParentId": "d7e149c3-546b-4058-9c16-5a87697f51ab"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d43a4b93-c257-4085-a681-7c23ccd2228f", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f6d7520b-a8d9-41e5-91c3-4f8caafb15e8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d43a4b93-c257-4085-a681-7c23ccd2228f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Stomach pain</span></p>", "ID": "9913dd0f-b842-46fb-9341-d9272ad4494d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "a8aaf597-491a-4624-8133-4058825bc0ba", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "9913dd0f-b842-46fb-9341-d9272ad4494d"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "7c31ce42-44aa-4797-8e54-3043fd294305", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "a8aaf597-491a-4624-8133-4058825bc0ba"}, {"Element": "<span lang=\"EN-GB\">Stomach pain</span>", "ID": "62e19b76-8549-4731-815c-0cf96bc80199", "Styles": "None", "Classes": "None", "Text": "Stomach pain", "ParentId": "9913dd0f-b842-46fb-9341-d9272ad4494d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bc9ef6c2-67a5-4638-9db3-7682c3ce47d8", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "29c54038-3a24-4697-8687-87da5f676205", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bc9ef6c2-67a5-4638-9db3-7682c3ce47d8"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Kidney problems, as shown by blood tests</span></p>", "ID": "7d2f0cf0-e9ef-43da-9cf0-60b5ba4e4144", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "44150eee-1370-485d-a560-bfeca4ba658d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "7d2f0cf0-e9ef-43da-9cf0-60b5ba4e4144"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "9b995b83-4c1e-466c-a883-75fec35085d0", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "44150eee-1370-485d-a560-bfeca4ba658d"}, {"Element": "<span lang=\"EN-GB\">Kidney problems, as shown by blood tests</span>", "ID": "d285f3ba-2a86-4703-a9ba-d5f35d102d58", "Styles": "None", "Classes": "None", "Text": "Kidney problems, as shown by blood tests", "ParentId": "7d2f0cf0-e9ef-43da-9cf0-60b5ba4e4144"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c97a4821-47bf-4255-90b1-67f73fcb3826", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8654e875-7716-4760-a5f5-0d326f03a727", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c97a4821-47bf-4255-90b1-67f73fcb3826"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><span style=\"font-family:Wingdings\">\u00e0</span><span lang=\"EN-GB\">Tell a doctor or\npharmacist if you are worried about any of these.</span></p>", "ID": "a8905b01-cabf-4020-8162-f9ee7e7a7080", "Styles": "margin-left:28.35pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span style=\"font-family:Wingdings\">\u00e0</span>", "ID": "23cd201f-98e2-42f3-933e-bc3242591c85", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00e0", "ParentId": "a8905b01-cabf-4020-8162-f9ee7e7a7080"}, {"Element": "<span lang=\"EN-GB\">Tell a doctor or\npharmacist if you are worried about any of these.</span>", "ID": "1af615f9-b494-4e74-bfd3-4fa7fcf4b4e4", "Styles": "None", "Classes": "None", "Text": "Tell a doctor or pharmacist if you are worried about any of these.", "ParentId": "a8905b01-cabf-4020-8162-f9ee7e7a7080"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "abe1b8ac-52dc-46b5-a6f5-1db0b74d0535", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "123c00f8-bd8f-4904-ba41-7cec70afab18", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "abe1b8ac-52dc-46b5-a6f5-1db0b74d0535"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Very common side effects</span></b></p>", "ID": "ac354197-5abc-4999-8118-89a807d18f84", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">Very common side effects</span></b>", "ID": "ce2190f8-7f4c-4995-b4d2-5d7824107393", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ac354197-5abc-4999-8118-89a807d18f84"}, {"Element": "<span lang=\"EN-GB\">Very common side effects</span>", "ID": "73cf7099-3faf-4e69-ad16-d04ab441d5a3", "Styles": "None", "Classes": "None", "Text": "Very common side effects", "ParentId": "ce2190f8-7f4c-4995-b4d2-5d7824107393"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">(These can affect more than 10 in every 100\u00a0people taking\nHepsera)</span></i></p>", "ID": "e7956780-7788-421f-8b7e-454edda37fd6", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<i><span lang=\"EN-GB\">(These can affect more than 10 in every 100\u00a0people taking\nHepsera)</span></i>", "ID": "0b76a79b-c22e-4a61-8ea0-206d1b270736", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e7956780-7788-421f-8b7e-454edda37fd6"}, {"Element": "<span lang=\"EN-GB\">(These can affect more than 10 in every 100\u00a0people taking\nHepsera)</span>", "ID": "5381e06c-548d-443d-95ac-af3578cd22fe", "Styles": "None", "Classes": "None", "Text": "(These can affect more than 10 in every 100\u00a0people taking Hepsera)", "ParentId": "0b76a79b-c22e-4a61-8ea0-206d1b270736"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c9b98501-2319-42de-bcac-e6454d6203dc", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ac01460c-7cec-4e30-8fe3-65b6f6e284d0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c9b98501-2319-42de-bcac-e6454d6203dc"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Weakness</span></p>", "ID": "476d5f3c-643b-4c0c-815b-3f1f9d991e6a", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "e5c0c130-f9fa-465f-ab8c-f4b770d27efc", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "476d5f3c-643b-4c0c-815b-3f1f9d991e6a"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "d13b0cfd-5aea-4bac-9295-4f682a6e609d", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "e5c0c130-f9fa-465f-ab8c-f4b770d27efc"}, {"Element": "<span lang=\"EN-GB\">Weakness</span>", "ID": "05bc0c93-bbff-4fc9-aa7b-1c0db0f99c10", "Styles": "None", "Classes": "None", "Text": "Weakness", "ParentId": "476d5f3c-643b-4c0c-815b-3f1f9d991e6a"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6320eb12-6773-45ab-8545-6e6ab454208e", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1f4f5b11-27c8-4019-a3c2-ffb7a133edab", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6320eb12-6773-45ab-8545-6e6ab454208e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><span style=\"font-family:Wingdings\">\u00e0</span><span lang=\"EN-GB\">Tell a doctor or\npharmacist if you are worried about this.</span></p>", "ID": "7b154322-f1a8-4c57-bd92-f89630bc78bf", "Styles": "margin-left:28.35pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span style=\"font-family:Wingdings\">\u00e0</span>", "ID": "bcc012bc-0907-4e11-b98b-e6b8cbce759f", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00e0", "ParentId": "7b154322-f1a8-4c57-bd92-f89630bc78bf"}, {"Element": "<span lang=\"EN-GB\">Tell a doctor or\npharmacist if you are worried about this.</span>", "ID": "83ed4358-18e9-44d2-b6fa-1557cfb1b5ca", "Styles": "None", "Classes": "None", "Text": "Tell a doctor or pharmacist if you are worried about this.", "ParentId": "7b154322-f1a8-4c57-bd92-f89630bc78bf"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1b5cc64e-db88-468f-95c8-65819180b834", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8eaf8f36-1907-46d8-bbb0-8eba9606fabb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1b5cc64e-db88-468f-95c8-65819180b834"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Side effects before or after having a liver transplant</span></b></p>", "ID": "8fd0ba2c-edf4-4c2c-80cc-9d86bce6cf01", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">Side effects before or after having a liver transplant</span></b>", "ID": "75515bf7-52c0-465f-a431-8f7431997dc8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8fd0ba2c-edf4-4c2c-80cc-9d86bce6cf01"}, {"Element": "<span lang=\"EN-GB\">Side effects before or after having a liver transplant</span>", "ID": "bcb948cc-b993-4a28-8e73-1ab6daf3777d", "Styles": "None", "Classes": "None", "Text": "Side effects before or after having a liver transplant", "ParentId": "75515bf7-52c0-465f-a431-8f7431997dc8"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3be572d6-dad9-43af-a9ec-4407dfcaad93", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3d15d73f-902d-46c3-af25-c4f7dd44f36f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3be572d6-dad9-43af-a9ec-4407dfcaad93"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Some patients have experienced:</span></p>", "ID": "0306dba0-17ed-4b38-8e8b-4e4860c2ee85", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Some patients have experienced:</span>", "ID": "0bf49cd8-3812-46a5-b07b-e6fa14affcfb", "Styles": "None", "Classes": "None", "Text": "Some patients have experienced:", "ParentId": "0306dba0-17ed-4b38-8e8b-4e4860c2ee85"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Rash and itching \u2013 common</span></p>", "ID": "af1652bd-107b-49ac-b465-b54db4e2e4b6", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "6a9d067c-36e8-4f64-a32a-8d8b97cae13c", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "af1652bd-107b-49ac-b465-b54db4e2e4b6"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "652cc794-49dd-46df-be0d-6d9d5628e285", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "6a9d067c-36e8-4f64-a32a-8d8b97cae13c"}, {"Element": "<span lang=\"EN-GB\">Rash and itching \u2013 common</span>", "ID": "6212e4d3-cddf-4efc-ac47-178c15f97e5b", "Styles": "None", "Classes": "None", "Text": "Rash and itching \u2013 common", "ParentId": "af1652bd-107b-49ac-b465-b54db4e2e4b6"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9b85610c-3888-4192-af76-9af053cdb667", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a7457453-8a51-4a38-95d3-fa02ae900eec", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9b85610c-3888-4192-af76-9af053cdb667"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Feeling sick (nausea) or being sick (vomiting) \u2013\ncommon</span></p>", "ID": "936abdfb-c42c-42ce-851e-0dc523ed6897", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "050457af-2872-4ad5-9e6f-fabd7b7f66e7", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "936abdfb-c42c-42ce-851e-0dc523ed6897"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "54389d7f-138b-4783-acb0-f228b658b552", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "050457af-2872-4ad5-9e6f-fabd7b7f66e7"}, {"Element": "<span lang=\"EN-GB\">Feeling sick (nausea) or being sick (vomiting) \u2013\ncommon</span>", "ID": "2ae1c5a7-3953-40cb-b42e-0328e9c0c7c4", "Styles": "None", "Classes": "None", "Text": "Feeling sick (nausea) or being sick (vomiting) \u2013 common", "ParentId": "936abdfb-c42c-42ce-851e-0dc523ed6897"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "58cb7ec7-b733-40cf-922d-4597fa7e01fb", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d281e1cc-dcb7-480d-bf8f-fd6ab6d03236", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "58cb7ec7-b733-40cf-922d-4597fa7e01fb"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Kidney failure \u2013 common</span></p>", "ID": "dda4f0d2-ee8d-4629-8070-df7c850ae3c4", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "76769b0d-e1ef-4b33-9002-9685766992f2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "dda4f0d2-ee8d-4629-8070-df7c850ae3c4"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "c49aee19-e652-4d1c-a2e1-b40f9468382b", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "76769b0d-e1ef-4b33-9002-9685766992f2"}, {"Element": "<span lang=\"EN-GB\">Kidney failure \u2013 common</span>", "ID": "6e44c31d-24ee-410c-b086-b079f2a6d8a7", "Styles": "None", "Classes": "None", "Text": "Kidney failure \u2013 common", "ParentId": "dda4f0d2-ee8d-4629-8070-df7c850ae3c4"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2b5d8e0f-e733-4e0d-9782-7afaedefeb63", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0be206b0-ccd1-4347-9054-5f1112b25c68", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2b5d8e0f-e733-4e0d-9782-7afaedefeb63"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Kidney problems \u2013 very common</span></p>", "ID": "0d71ebff-055f-44df-93b6-a58bc4d1b7b6", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "72067aaa-d80f-4ce0-9669-4ea115aff8e6", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "0d71ebff-055f-44df-93b6-a58bc4d1b7b6"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "9818db62-eeb3-4ba7-ac74-188b4d8c72cb", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "72067aaa-d80f-4ce0-9669-4ea115aff8e6"}, {"Element": "<span lang=\"EN-GB\">Kidney problems \u2013 very common</span>", "ID": "cb678cfd-be27-4d61-9660-c22adc6c53d9", "Styles": "None", "Classes": "None", "Text": "Kidney problems \u2013 very common", "ParentId": "0d71ebff-055f-44df-93b6-a58bc4d1b7b6"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cb0459c0-f625-416d-bda1-43bcfcdc69d3", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a35752f3-52b7-4069-8b47-7c6f51620928", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cb0459c0-f625-416d-bda1-43bcfcdc69d3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal\"><span style=\"font-family:Wingdings\">\u00e0</span><span lang=\"EN-GB\">Tell a doctor or pharmacist\nif you are worried about any of these.</span></p>", "ID": "e6615b9e-7418-4001-8d0f-b3d4db99cbf7", "Styles": "margin-left:28.35pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span style=\"font-family:Wingdings\">\u00e0</span>", "ID": "94dbf017-3c69-4bdf-a4c5-e86788c56891", "Styles": "font-family:Wingdings", "Classes": "None", "Text": "\u00e0", "ParentId": "e6615b9e-7418-4001-8d0f-b3d4db99cbf7"}, {"Element": "<span lang=\"EN-GB\">Tell a doctor or pharmacist\nif you are worried about any of these.</span>", "ID": "40502957-eccd-4f21-81bc-0ff5122c54a7", "Styles": "None", "Classes": "None", "Text": "Tell a doctor or pharmacist if you are worried about any of these.", "ParentId": "e6615b9e-7418-4001-8d0f-b3d4db99cbf7"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a9a274ad-b2d6-4839-937b-79c7701f4aa8", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "515eaf9a-4cb3-4cf0-962e-fc05888a4fda", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a9a274ad-b2d6-4839-937b-79c7701f4aa8"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Also tests may show decreases in phosphate\n(common) or increases in creatinine (very common) in the blood.</span></p>", "ID": "bb624e2f-93de-4f78-b7f9-7bf139adaad3", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "b0fd85c4-dca0-4af4-a180-b0dd80fc5948", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "bb624e2f-93de-4f78-b7f9-7bf139adaad3"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "6e036ef5-0c15-4fe2-a89a-2eb6ef45d9b9", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "b0fd85c4-dca0-4af4-a180-b0dd80fc5948"}, {"Element": "<span lang=\"EN-GB\">Also tests may show decreases in phosphate\n(common) or increases in creatinine (very common) in the blood.</span>", "ID": "b44ebb5a-b2a4-44a2-b18c-2ef78041d6e3", "Styles": "None", "Classes": "None", "Text": "Also tests may show decreases in phosphate (common) or increases in creatinine (very common) in the blood.", "ParentId": "bb624e2f-93de-4f78-b7f9-7bf139adaad3"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9a3c1f76-335a-4bc7-bf79-e7cbc9580221", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "927c761c-0f86-40e8-943a-92a66c378571", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9a3c1f76-335a-4bc7-bf79-e7cbc9580221"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Other possible side effects</span></b></p>", "ID": "b58bc539-e544-41c9-ae1e-d2271e52d238", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">Other possible side effects</span></b>", "ID": "b2f50f76-d097-49d9-9816-d6dff402a033", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b58bc539-e544-41c9-ae1e-d2271e52d238"}, {"Element": "<span lang=\"EN-GB\">Other possible side effects</span>", "ID": "c01f3772-0dbd-4823-8957-5b1d82cc951e", "Styles": "None", "Classes": "None", "Text": "Other possible side effects", "ParentId": "b2f50f76-d097-49d9-9816-d6dff402a033"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "849aaf1e-06e8-47b7-b6d3-4c799b831125", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0266a9b9-9987-4dd5-8c5f-0db680f255c6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "849aaf1e-06e8-47b7-b6d3-4c799b831125"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Some patients may also experience:</span></p>", "ID": "b0f63978-eb8a-4186-b672-896e05031c89", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Some patients may also experience:</span>", "ID": "3a5c35dc-2ff1-42b3-a8d9-ebb3ab153717", "Styles": "None", "Classes": "None", "Text": "Some patients may also experience:", "ParentId": "b0f63978-eb8a-4186-b672-896e05031c89"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Kidney failure</span></p>", "ID": "c9902963-3917-4c47-b2de-2f578edc2491", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "ee2d53a2-5bbe-456e-a12c-678d5d3a2003", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "c9902963-3917-4c47-b2de-2f578edc2491"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "01b19d62-fd88-44c0-a9cd-aad0494e0c96", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "ee2d53a2-5bbe-456e-a12c-678d5d3a2003"}, {"Element": "<span lang=\"EN-GB\">Kidney failure</span>", "ID": "3a5117fe-17b0-4e0f-80c1-112aba6a6806", "Styles": "None", "Classes": "None", "Text": "Kidney failure", "ParentId": "c9902963-3917-4c47-b2de-2f578edc2491"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "98a0fb2a-2dc3-4897-8376-5e9775427a80", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "383eb795-1577-44bd-98d0-fb6bd51be022", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "98a0fb2a-2dc3-4897-8376-5e9775427a80"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Damage to kidney tubule cells</span></p>", "ID": "da622b7d-2fca-4e2a-ab45-cffae681f63a", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "8f383dc5-675c-4789-b378-c1c603f60309", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "da622b7d-2fca-4e2a-ab45-cffae681f63a"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "4a0a234d-ecbf-4b37-8bcc-33de5661baa2", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "8f383dc5-675c-4789-b378-c1c603f60309"}, {"Element": "<span lang=\"EN-GB\">Damage to kidney tubule cells</span>", "ID": "391815fa-f933-4896-b647-9835252fd7ef", "Styles": "None", "Classes": "None", "Text": "Damage to kidney tubule cells", "ParentId": "da622b7d-2fca-4e2a-ab45-cffae681f63a"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8a3b1560-4fe4-4f0c-bc10-01768b61e1a8", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3f990e04-460a-47b3-b5e5-f23309a4af48", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8a3b1560-4fe4-4f0c-bc10-01768b61e1a8"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Kidney problems may lead to softening of the\nbones (which causes bone pain and sometimes leads to fractures) and muscle pain\nor weakness.</span></p>", "ID": "d32e3036-b01c-4ab2-80c7-8f3d5b9e8a1f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "4c3f841e-60b7-4b18-89cb-b09570f90e0d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d32e3036-b01c-4ab2-80c7-8f3d5b9e8a1f"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "3602fadf-7f0e-4407-b677-531807b61cc7", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "4c3f841e-60b7-4b18-89cb-b09570f90e0d"}, {"Element": "<span lang=\"EN-GB\">Kidney problems may lead to softening of the\nbones (which causes bone pain and sometimes leads to fractures) and muscle pain\nor weakness.</span>", "ID": "c207243c-61b7-44c9-84f8-dfbbc1a98133", "Styles": "None", "Classes": "None", "Text": "Kidney problems may lead to softening of the bones (which causes bone pain and sometimes leads to fractures) and muscle pain or weakness.", "ParentId": "d32e3036-b01c-4ab2-80c7-8f3d5b9e8a1f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e28c1107-2141-4ddd-92dc-3064341b2451", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "aad7dcdc-3736-498f-917d-e38228e89ae0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e28c1107-2141-4ddd-92dc-3064341b2451"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Inflammation of the pancreas (pancreatitis)</span></p>", "ID": "6c2a945d-9a14-47d9-9ef9-0ab1b09f1808", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "5dd7aa01-baa2-4456-b0c2-dd51f348f637", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "6c2a945d-9a14-47d9-9ef9-0ab1b09f1808"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "a93ebfae-5b64-4190-b9de-6e281d657450", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "5dd7aa01-baa2-4456-b0c2-dd51f348f637"}, {"Element": "<span lang=\"EN-GB\">Inflammation of the pancreas (pancreatitis)</span>", "ID": "3fff357e-1d8a-4b05-84f0-cbfeb7341593", "Styles": "None", "Classes": "None", "Text": "Inflammation of the pancreas (pancreatitis)", "ParentId": "6c2a945d-9a14-47d9-9ef9-0ab1b09f1808"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "80b48158-6e83-4f5c-8e16-b4b696687d44", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a79c3f5d-2d03-447d-948b-8b26d2de8eb1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "80b48158-6e83-4f5c-8e16-b4b696687d44"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Reporting of side effects</span></b></p>", "ID": "6eafba91-b352-4e2b-a21e-ef5addc31295", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">Reporting of side effects</span></b>", "ID": "3fbe6e9e-238d-44d3-8d64-5b54dacb7e39", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6eafba91-b352-4e2b-a21e-ef5addc31295"}, {"Element": "<span lang=\"EN-GB\">Reporting of side effects</span>", "ID": "efc32e1a-852e-40f4-b2b8-ede76aa14a54", "Styles": "None", "Classes": "None", "Text": "Reporting of side effects", "ParentId": "3fbe6e9e-238d-44d3-8d64-5b54dacb7e39"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">If you get any side effects, talk to your doctor or pharmacist.</span><span lang=\"EN-GB\">\u00a0 This includes any possible side effects not listed in this\nleaflet.\u00a0 You can also report side effects directly via <span style=\"color:\nblack;background:#D9D9D9\">the national reporting system listed in <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"color:black;text-decoration:none\">Appendix\u00a0V</span></a></span>.\u00a0 By\nreporting side effects you can help provide more information on the safety of\nthis medicine.</span></p>", "ID": "a21dd0f6-eeeb-42db-94bb-bacd7fbc2587", "Styles": "margin-right:-.1pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">If you get any side effects, talk to your doctor or pharmacist.</span>", "ID": "27dec0cb-c52e-4132-ac16-24d269945aa7", "Styles": "None", "Classes": "None", "Text": "If you get any side effects, talk to your doctor or pharmacist.", "ParentId": "a21dd0f6-eeeb-42db-94bb-bacd7fbc2587"}, {"Element": "<span lang=\"EN-GB\">\u00a0 This includes any possible side effects not listed in this\nleaflet.\u00a0 You can also report side effects directly via <span style=\"color:\nblack;background:#D9D9D9\">the national reporting system listed in <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"color:black;text-decoration:none\">Appendix\u00a0V</span></a></span>.\u00a0 By\nreporting side effects you can help provide more information on the safety of\nthis medicine.</span>", "ID": "e4602e67-56f8-45d2-844a-ce83067153aa", "Styles": "None", "Classes": "None", "Text": "\u00a0 This includes any possible side effects not listed in this leaflet.\u00a0 You can also report side effects directly via .\u00a0 By reporting side effects you can help provide more information on the safety of this medicine.", "ParentId": "a21dd0f6-eeeb-42db-94bb-bacd7fbc2587"}, {"Element": "<span style=\"color:\nblack;background:#D9D9D9\">the national reporting system listed in <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"color:black;text-decoration:none\">Appendix\u00a0V</span></a></span>", "ID": "f867e60e-d73e-4913-a108-2fd7ca862109", "Styles": "color:\nblack;background:#D9D9D9", "Classes": "None", "Text": "the national reporting system listed in ", "ParentId": "e4602e67-56f8-45d2-844a-ce83067153aa"}, {"Element": "<a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\"><span style=\"color:black;text-decoration:none\">Appendix\u00a0V</span></a>", "ID": "3f5439b0-8acc-488d-a9db-964d153fbef6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f867e60e-d73e-4913-a108-2fd7ca862109"}, {"Element": "<span style=\"color:black;text-decoration:none\">Appendix\u00a0V</span>", "ID": "3746e24f-9898-4936-a141-fb5b4bff105d", "Styles": "color:black;text-decoration:none", "Classes": "None", "Text": "Appendix\u00a0V", "ParentId": "3f5439b0-8acc-488d-a9db-964d153fbef6"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "76a18278-5b5b-4ba8-b3f4-3bcc9c8ffd52", "Styles": "margin-right:-.1pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4f8b7031-dcd3-4b45-871a-00a1845768f5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "76a18278-5b5b-4ba8-b3f4-3bcc9c8ffd52"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0a4cc8f7-3bf1-45aa-ae60-dac4276a67bf", "Styles": "margin-right:-.1pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e19a9281-40bc-4fda-83d0-10beb3b2d33e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0a4cc8f7-3bf1-45aa-ae60-dac4276a67bf"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store Hepsera</span></b></p>", "ID": "f8b0eda4-97a8-4620-8039-6bc5a1008592", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store Hepsera</span></b>", "ID": "ab70411a-9644-40b6-b215-d97bf6f7b33f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f8b0eda4-97a8-4620-8039-6bc5a1008592"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store Hepsera</span>", "ID": "925a81dd-70de-44e2-9346-f3ed6b96f4f2", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store Hepsera", "ParentId": "ab70411a-9644-40b6-b215-d97bf6f7b33f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5d74ebb4-a9b4-48fb-8aa6-bf684760f59e", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3b089037-eee1-4a51-9622-3604ee955dab", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5d74ebb4-a9b4-48fb-8aa6-bf684760f59e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Keep this\nmedicine out of the sight and reach of children.</span></p>", "ID": "b76da9e7-1c84-4462-9815-9ddae96c03f4", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Keep this\nmedicine out of the sight and reach of children.</span>", "ID": "891c8ef1-e948-4185-82ed-cc41574bf3bb", "Styles": "None", "Classes": "None", "Text": "Keep this medicine out of the sight and reach of children.", "ParentId": "b76da9e7-1c84-4462-9815-9ddae96c03f4"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "27391642-01ec-4592-9480-2eb283664188", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "83f0cd6b-bd37-4fbe-be25-f172033c1429", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "27391642-01ec-4592-9480-2eb283664188"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Do not use this\nmedicine after the expiry date which is stated on the bottle and carton after {EXP}.\u00a0\nThe expiry date refers to the last day of that month.</span></p>", "ID": "566f14ae-896e-452f-a4da-623b504aa2d2", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Do not use this\nmedicine after the expiry date which is stated on the bottle and carton after {EXP}.\u00a0\nThe expiry date refers to the last day of that month.</span>", "ID": "d785a59f-4b26-48cb-b254-cd089da1dc9d", "Styles": "None", "Classes": "None", "Text": "Do not use this medicine after the expiry date which is stated on the bottle and carton after {EXP}.\u00a0 The expiry date refers to the last day of that month.", "ParentId": "566f14ae-896e-452f-a4da-623b504aa2d2"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "94fe7f2e-24fd-423d-ac27-5d30ba5f0725", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9e47ffa0-4b75-4c94-8a1a-b12cbdd4ec47", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "94fe7f2e-24fd-423d-ac27-5d30ba5f0725"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Do not store\nabove 30\u00baC (86\u00baF). \u00a0Store in the original package in order to protect from\nmoisture. \u00a0Keep the bottle tightly closed.</span></p>", "ID": "4a3f5786-47c8-4150-aa1d-5bc7dc7da637", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Do not store\nabove 30\u00baC (86\u00baF). \u00a0Store in the original package in order to protect from\nmoisture. \u00a0Keep the bottle tightly closed.</span>", "ID": "ca4e871f-0990-4528-8cf1-aaba62149b0e", "Styles": "None", "Classes": "None", "Text": "Do not store above 30\u00baC (86\u00baF). \u00a0Store in the original package in order to protect from moisture. \u00a0Keep the bottle tightly closed.", "ParentId": "4a3f5786-47c8-4150-aa1d-5bc7dc7da637"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a8e99417-45fc-4730-8f66-cca33cbb824f", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b185e02b-d100-4601-8c71-c9f5c2788196", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a8e99417-45fc-4730-8f66-cca33cbb824f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Return any left\nover tablets to your pharmacist. \u00a0Only keep them if your doctor tells you to. \u00a0Do\nnot throw away any medicines via wastewater or household waste. \u00a0Ask your\npharmacist how to throw away medicines you no longer use. \u00a0These measures will\nhelp protect the environment.</span></p>", "ID": "ff21c36c-8b35-448c-bb98-290220b1ebf4", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Return any left\nover tablets to your pharmacist. \u00a0Only keep them if your doctor tells you to. \u00a0Do\nnot throw away any medicines via wastewater or household waste. \u00a0Ask your\npharmacist how to throw away medicines you no longer use. \u00a0These measures will\nhelp protect the environment.</span>", "ID": "f6c6fb51-2425-4804-892b-2bc914db5f73", "Styles": "None", "Classes": "None", "Text": "Return any left over tablets to your pharmacist. \u00a0Only keep them if your doctor tells you to. \u00a0Do not throw away any medicines via wastewater or household waste. \u00a0Ask your pharmacist how to throw away medicines you no longer use. \u00a0These measures will help protect the environment.", "ParentId": "ff21c36c-8b35-448c-bb98-290220b1ebf4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b1e6d640-cec8-4266-869a-639fcf46ad0d", "Styles": "margin-right:-.1pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b78788b4-192f-49a8-8cbe-75a37b60fa23", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b1e6d640-cec8-4266-869a-639fcf46ad0d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6e4e6404-4395-47cb-8eb1-649d9ae8bd06", "Styles": "margin-right:-.1pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a8584369-d69e-47d9-bb38-726ba4c07885", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6e4e6404-4395-47cb-8eb1-649d9ae8bd06"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the pack and other information</span></b></p>", "ID": "16b6ccae-761e-4abe-80d0-2294b0c35dc8", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the pack and other information</span></b>", "ID": "0b62583a-81d7-4965-9b64-a78c79643971", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "16b6ccae-761e-4abe-80d0-2294b0c35dc8"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the pack and other information</span>", "ID": "3788c97d-b931-4196-9b01-0569e0f011fb", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the pack and other information", "ParentId": "0b62583a-81d7-4965-9b64-a78c79643971"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "93fc7a6e-4481-4060-9c4e-ca67137be5a1", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e827f457-b2d8-44d2-aa68-c1d714e63435", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "93fc7a6e-4481-4060-9c4e-ca67137be5a1"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">What Hepsera contains</span></b></p>", "ID": "6817f1c0-53c6-4d8b-9af7-bdd05ccc3816", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">What Hepsera contains</span></b>", "ID": "6746759f-fd9f-4170-a2fb-359ecb6c4db9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6817f1c0-53c6-4d8b-9af7-bdd05ccc3816"}, {"Element": "<span lang=\"EN-GB\">What Hepsera contains</span>", "ID": "6a29bc40-bdd5-420b-9de5-debacb311485", "Styles": "None", "Classes": "None", "Text": "What Hepsera contains", "ParentId": "6746759f-fd9f-4170-a2fb-359ecb6c4db9"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "8d4ce083-1d5d-4bad-9e8e-20a5f00fbaaa", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "d2de7b19-aa61-474d-aa0a-d4b56d59c1ef", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8d4ce083-1d5d-4bad-9e8e-20a5f00fbaaa"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "b02c24aa-4045-4ef0-9ec5-db55bf222ffd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d2de7b19-aa61-474d-aa0a-d4b56d59c1ef"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "3985f5e9-f136-4957-bae1-250f62225ce7", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "b02c24aa-4045-4ef0-9ec5-db55bf222ffd"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">The active substance</span></b><span lang=\"EN-GB\"> in Hepsera is adefovir dipivoxil.\u00a0 Each tablet contains 10\u00a0mg\nadefovir dipivoxil.</span></p>", "ID": "1cd85bde-83f3-4e07-b8c3-3a678b9627a0", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "8153a7de-608d-46ff-9dc1-b16b35517d49", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "1cd85bde-83f3-4e07-b8c3-3a678b9627a0"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "ee2954fb-22be-4bd8-bc70-a612ddb9bc76", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "8153a7de-608d-46ff-9dc1-b16b35517d49"}, {"Element": "<b><span lang=\"EN-GB\">The active substance</span></b>", "ID": "ecb82f73-8645-470d-bbf2-5bbcf89aa1a1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1cd85bde-83f3-4e07-b8c3-3a678b9627a0"}, {"Element": "<span lang=\"EN-GB\">The active substance</span>", "ID": "62f62374-f637-4763-ab23-a57f191703cd", "Styles": "None", "Classes": "None", "Text": "The active substance", "ParentId": "ecb82f73-8645-470d-bbf2-5bbcf89aa1a1"}, {"Element": "<span lang=\"EN-GB\"> in Hepsera is adefovir dipivoxil.\u00a0 Each tablet contains 10\u00a0mg\nadefovir dipivoxil.</span>", "ID": "86fb4ddb-e13f-414f-bb81-aa3f31406e60", "Styles": "None", "Classes": "None", "Text": " in Hepsera is adefovir dipivoxil.\u00a0 Each tablet contains 10\u00a0mg adefovir dipivoxil.", "ParentId": "1cd85bde-83f3-4e07-b8c3-3a678b9627a0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "58f0232e-be79-4481-b3a6-269c69abc1c1", "Styles": "margin-left:27.0pt;text-indent:-27.0pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "43fde791-1121-4309-97d1-e95e07bceec2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "58f0232e-be79-4481-b3a6-269c69abc1c1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">The other ingredients are: pregelatinised\nstarch, croscarmellose sodium, lactose monohydrate, talc and magnesium\nstearate.</span></p>", "ID": "8a7dfb5d-724f-4ea9-b5be-dc60aafefa04", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;line-height:\nnormal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "e37326c1-4616-49c3-a56a-b3f6bb605fb6", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "8a7dfb5d-724f-4ea9-b5be-dc60aafefa04"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "9ff05e1c-a620-42aa-876b-1db5d276b608", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "e37326c1-4616-49c3-a56a-b3f6bb605fb6"}, {"Element": "<span lang=\"EN-GB\">The other ingredients are: pregelatinised\nstarch, croscarmellose sodium, lactose monohydrate, talc and magnesium\nstearate.</span>", "ID": "041987bf-c3bc-4fdd-85c4-51b68964cf4c", "Styles": "None", "Classes": "None", "Text": "The other ingredients are: pregelatinised starch, croscarmellose sodium, lactose monohydrate, talc and magnesium stearate.", "ParentId": "8a7dfb5d-724f-4ea9-b5be-dc60aafefa04"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1c9d4632-bf01-49c7-a064-ed2e92e13d9d", "Styles": "margin-right:-.1pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3e853c97-3a24-4b1c-97e6-539154374371", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1c9d4632-bf01-49c7-a064-ed2e92e13d9d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">What Hepsera looks like and contents of the pack</span></b></p>", "ID": "4354a6f9-a017-4059-b600-e9af2b703b81", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">What Hepsera looks like and contents of the pack</span></b>", "ID": "b91f79c5-4058-4c75-8a4c-94b24575d334", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4354a6f9-a017-4059-b600-e9af2b703b81"}, {"Element": "<span lang=\"EN-GB\">What Hepsera looks like and contents of the pack</span>", "ID": "b64b2262-eb18-4ea9-a081-7bf245c8d37d", "Styles": "None", "Classes": "None", "Text": "What Hepsera looks like and contents of the pack", "ParentId": "b91f79c5-4058-4c75-8a4c-94b24575d334"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4382ae07-56bb-43f8-9a59-98598b0d3fe0", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "276bf590-87dd-4dc7-8ad7-bc01d799abe3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4382ae07-56bb-43f8-9a59-98598b0d3fe0"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Hepsera\n10\u00a0mg tablets are round, white to off\u2011white tablets.\u00a0 The tablets\nare marked with \u201cGILEAD\u201d and \u201c10\u201d on one side and a stylised shape of a liver\non the other side.\u00a0 Hepsera 10\u00a0mg tablets are supplied in bottles of\n30\u00a0tablets with silica gel desiccant.\u00a0 The silica gel desiccant is\ncontained in either a separate sachet or a small canister and should not be\nswallowed.</span></p>", "ID": "7db2a9cd-d44c-47a9-ad80-cf1c593bd606", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Hepsera\n10\u00a0mg tablets are round, white to off\u2011white tablets.\u00a0 The tablets\nare marked with \u201cGILEAD\u201d and \u201c10\u201d on one side and a stylised shape of a liver\non the other side.\u00a0 Hepsera 10\u00a0mg tablets are supplied in bottles of\n30\u00a0tablets with silica gel desiccant.\u00a0 The silica gel desiccant is\ncontained in either a separate sachet or a small canister and should not be\nswallowed.</span>", "ID": "5a5a2437-c284-4767-b1b8-8a4a5cffa8f1", "Styles": "None", "Classes": "None", "Text": "Hepsera 10\u00a0mg tablets are round, white to off\u2011white tablets.\u00a0 The tablets are marked with \u201cGILEAD\u201d and \u201c10\u201d on one side and a stylised shape of a liver on the other side.\u00a0 Hepsera 10\u00a0mg tablets are supplied in bottles of 30\u00a0tablets with silica gel desiccant.\u00a0 The silica gel desiccant is contained in either a separate sachet or a small canister and should not be swallowed.", "ParentId": "7db2a9cd-d44c-47a9-ad80-cf1c593bd606"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4efaa001-c8b8-49f2-936f-58bd627ad929", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ddf88409-4475-4750-83af-50de34e1d757", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4efaa001-c8b8-49f2-936f-58bd627ad929"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The following\npack sizes are available: outer cartons containing 1\u00a0bottle of\n30\u00a0tablets and outer cartons containing 90 (3\u00a0bottles of\n30)\u00a0tablets. \u00a0Not all pack sizes may be marketed.</span></p>", "ID": "92a45fd4-bdc0-4671-8688-7486d4118f93", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">The following\npack sizes are available: outer cartons containing 1\u00a0bottle of\n30\u00a0tablets and outer cartons containing 90 (3\u00a0bottles of\n30)\u00a0tablets. \u00a0Not all pack sizes may be marketed.</span>", "ID": "984c0e06-3e92-4fce-a9c7-50946f2e5e76", "Styles": "None", "Classes": "None", "Text": "The following pack sizes are available: outer cartons containing 1\u00a0bottle of 30\u00a0tablets and outer cartons containing 90 (3\u00a0bottles of 30)\u00a0tablets. \u00a0Not all pack sizes may be marketed.", "ParentId": "92a45fd4-bdc0-4671-8688-7486d4118f93"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a9090e3b-16c3-4e13-980c-fd97d01c0884", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4db75956-dc11-4bb0-a038-cf8828347ac6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a9090e3b-16c3-4e13-980c-fd97d01c0884"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Marketing Authorisation Holder and Manufacturer</span></b></p>", "ID": "dc2ab278-c6d3-4c30-a60d-3968b3117244", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">Marketing Authorisation Holder and Manufacturer</span></b>", "ID": "eb919da0-64c9-401f-a7a1-0c938af6771c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dc2ab278-c6d3-4c30-a60d-3968b3117244"}, {"Element": "<span lang=\"EN-GB\">Marketing Authorisation Holder and Manufacturer</span>", "ID": "004c6d76-c17f-4212-a4ec-ee7bc3a09314", "Styles": "None", "Classes": "None", "Text": "Marketing Authorisation Holder and Manufacturer", "ParentId": "eb919da0-64c9-401f-a7a1-0c938af6771c"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8f66469a-1dd7-497b-bedf-c9d346be6cc0", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c48234d8-3be3-44b6-85be-2e34b52c88c6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8f66469a-1dd7-497b-bedf-c9d346be6cc0"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Marketing Authorisation Holder:</span></b></p>", "ID": "1e917f3f-9de5-4acf-b213-d23760d49ad9", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">Marketing Authorisation Holder:</span></b>", "ID": "ffa006c5-67ba-4b1f-b9d0-a7c809217f41", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1e917f3f-9de5-4acf-b213-d23760d49ad9"}, {"Element": "<span lang=\"EN-GB\">Marketing Authorisation Holder:</span>", "ID": "8b867855-86fc-4999-af64-e22743a58391", "Styles": "None", "Classes": "None", "Text": "Marketing Authorisation Holder:", "ParentId": "ffa006c5-67ba-4b1f-b9d0-a7c809217f41"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "be96713a-aaa0-477e-b0ca-d58158c988ac", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "49f204e2-2329-457f-897f-01a7507b477e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "be96713a-aaa0-477e-b0ca-d58158c988ac"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Gilead Sciences Ireland UC</span></p>", "ID": "c77511f2-19d8-4f60-87b6-35473a56d768", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Gilead Sciences Ireland UC</span>", "ID": "be510357-c369-4b19-b1c6-1e22702b3791", "Styles": "None", "Classes": "None", "Text": "Gilead Sciences Ireland UC", "ParentId": "c77511f2-19d8-4f60-87b6-35473a56d768"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Carrigtohill</span></p>", "ID": "5ccbef7a-d446-48d9-9643-7e8f7fece0a7", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Carrigtohill</span>", "ID": "5388752a-6102-491c-9e85-e894f3aab08c", "Styles": "None", "Classes": "None", "Text": "Carrigtohill", "ParentId": "5ccbef7a-d446-48d9-9643-7e8f7fece0a7"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">County Cork, T45 DP77</span></p>", "ID": "8f61cc47-1a94-4df7-8320-243ad6946dab", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">County Cork, T45 DP77</span>", "ID": "f470e360-f844-4bdc-9630-4d86412b4d79", "Styles": "None", "Classes": "None", "Text": "County Cork, T45 DP77", "ParentId": "8f61cc47-1a94-4df7-8320-243ad6946dab"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Ireland</span></p>", "ID": "4c84ec11-564e-4615-96a0-0b7794d43968", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Ireland</span>", "ID": "7e44f05e-e152-4c1a-b641-30ef883df456", "Styles": "None", "Classes": "None", "Text": "Ireland", "ParentId": "4c84ec11-564e-4615-96a0-0b7794d43968"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fec0aef1-a90d-4fe9-a2db-321bb6c35088", "Styles": "margin-right:-.1pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a361ece2-80c7-4e87-a10e-86f33487fbfb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fec0aef1-a90d-4fe9-a2db-321bb6c35088"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Manufacturer:</span></b></p>", "ID": "2671d0ed-d264-4c4c-9846-d73d9ce30a01", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">Manufacturer:</span></b>", "ID": "55c9f502-1037-45f7-bbb8-c1a08c8cf6d2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2671d0ed-d264-4c4c-9846-d73d9ce30a01"}, {"Element": "<span lang=\"EN-GB\">Manufacturer:</span>", "ID": "7a82df2b-cef1-4612-98b2-eeb8cadcda4c", "Styles": "None", "Classes": "None", "Text": "Manufacturer:", "ParentId": "55c9f502-1037-45f7-bbb8-c1a08c8cf6d2"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9182fd1c-ad70-45af-811b-27a9c8f10e54", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b75f99e2-f855-40c9-9dc9-8591c5339fa8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9182fd1c-ad70-45af-811b-27a9c8f10e54"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Gilead Sciences Ireland UC</span></p>", "ID": "75b6a6c2-db96-46aa-9c1a-91350ec28932", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Gilead Sciences Ireland UC</span>", "ID": "5d830218-de45-4474-8b12-598d82a749f4", "Styles": "None", "Classes": "None", "Text": "Gilead Sciences Ireland UC", "ParentId": "75b6a6c2-db96-46aa-9c1a-91350ec28932"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">IDA Business &amp; Technology Park</span></p>", "ID": "a98a56f1-d63b-4f51-9d17-d1754b753bd2", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">IDA Business &amp; Technology Park</span>", "ID": "82dc187e-0802-44a8-8729-70eeb7e41533", "Styles": "None", "Classes": "None", "Text": "IDA Business & Technology Park", "ParentId": "a98a56f1-d63b-4f51-9d17-d1754b753bd2"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Carrigtohill</span></p>", "ID": "9cd129f2-07ac-4f92-bf06-02d06d847150", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Carrigtohill</span>", "ID": "8e70323a-240c-4b6d-95f5-095f3f990297", "Styles": "None", "Classes": "None", "Text": "Carrigtohill", "ParentId": "9cd129f2-07ac-4f92-bf06-02d06d847150"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">County Cork</span></p>", "ID": "da87cb79-d0a1-4d62-874a-2d2a08b7ee12", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">County Cork</span>", "ID": "a8e2fc7c-ec80-4d4e-b8c7-eac5562b40a4", "Styles": "None", "Classes": "None", "Text": "County Cork", "ParentId": "da87cb79-d0a1-4d62-874a-2d2a08b7ee12"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Ireland</span></p>", "ID": "117c3513-981b-49be-a1e7-e103542ca583", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Ireland</span>", "ID": "865bac9e-197b-4576-9e6c-b77b29dfbed5", "Styles": "None", "Classes": "None", "Text": "Ireland", "ParentId": "117c3513-981b-49be-a1e7-e103542ca583"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cf83b6e6-5649-4d08-a981-98ac3b5dce92", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5db3711b-b7ed-4995-8234-aaee31bee849", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cf83b6e6-5649-4d08-a981-98ac3b5dce92"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">For any information about this medicine, please contact the local\nrepresentative of the Marketing Authorisation Holder:</span></p>", "ID": "3d4d1f94-2f10-44db-b86b-6c5f4158ee06", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">For any information about this medicine, please contact the local\nrepresentative of the Marketing Authorisation Holder:</span>", "ID": "e3acbfa2-6cfd-4494-be5b-e512913f0548", "Styles": "None", "Classes": "None", "Text": "For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:", "ParentId": "3d4d1f94-2f10-44db-b86b-6c5f4158ee06"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6ddd888d-2b6c-4991-b6ab-02dbd1f1a1a4", "Styles": "line-height:normal;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "64031677-a0c1-448e-a7b0-49d7670fa0b1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6ddd888d-2b6c-4991-b6ab-02dbd1f1a1a4"}, {"Element": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:-1.7pt;border-collapse:collapse\" width=\"624\">\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Belgi\u00eb/Belgique/Belgien</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Belgium SPRL-BVBA</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">T\u00e9l/Tel: + 32\n  (0) 24 01 35 50</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:1.7pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Lietuva</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Poland Sp. z o.o.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 48 22\n  262 8702</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u0422\u0435\u043b.:\n  + 353 (0) 1 686 1888</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Belgium SPRL-BVBA</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">T\u00e9l/Tel: + 32\n  (0) 24 01 35 50</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u010cesk\u00e1\n  republika</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences s.r.o.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: </span><span lang=\"EN-GB\">+ 420 (0) 910 871 986</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Magyarorsz\u00e1g</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences </span><span lang=\"EN-GB\">Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Danmark</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tlf: + 46 (0)\n  8 5057 1849</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Malta</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences </span><span lang=\"EN-GB\">Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Deutschland</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences GmbH</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 49 (0)\n  89 899890-0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Nederland</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Netherlands B.V.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 31 (0)\n  20 718 36 98</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Eesti</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Poland Sp. z o.o.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 48 22\n  262 8702</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Norge</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tlf: + 46 (0)\n  8 5057 1849</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences \u0395\u03bb\u03bb\u03ac\u03c2 \u039c.\u0395\u03a0\u0395.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb:\n  + 30 210 8930 100</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00d6sterreich</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences GesmbH</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 43 1\n  260 830</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Espa\u00f1a</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences, S.L.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 34 91\n  378 98 30</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Polska</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead Sciences\n  Poland Sp. z o.o.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 48 22\n  262 8702</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">France</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">T\u00e9l: + 33 (0)\n  1 46 09 41 00</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Portugal</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences, Lda.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 351 21\n  7928790</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">Hrvatska</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Gilead Sciences </span><span lang=\"EN-GB\">Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Rom\u00e2nia</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences </span><span lang=\"EN-GB\">Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Ireland</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  214 825 999</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Slovenija</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences </span><span lang=\"EN-GB\">Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00cdsland</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">S\u00edmi: + 46 (0)\n  8 5057 1849</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Slovensk\u00e1\n  republika</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Slovakia s.r.o.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 421 (0)\n  232 121 210</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Italia</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences S.r.l.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 39 02\n  439201</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Suomi/Finland</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Puh/Tel: + 46\n  (0) 8 5057 1849</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences \u0395\u03bb\u03bb\u03ac\u03c2 \u039c.\u0395\u03a0\u0395.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb:\n  + 30 210 8930 100</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Sverige</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 46 (0)\n  8 5057 1849</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Latvija</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><a name=\"OLE_LINK1\"></a><a name=\"OLE_LINK2\"><span lang=\"EN-GB\">Gilead Sciences Poland Sp. z o.o.</span></a></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 48 22\n  262 8702</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">United\n  Kingdom</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Ltd</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 44 (0) 8000\n  113 700</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n</table>", "ID": "889fa6ce-8598-4b30-8317-4511fba377fe", "Styles": "margin-left:-1.7pt;border-collapse:collapse", "Classes": "['MsoNormalTable']", "Text": "                ", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Belgi\u00eb/Belgique/Belgien</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Belgium SPRL-BVBA</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">T\u00e9l/Tel: + 32\n  (0) 24 01 35 50</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:1.7pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Lietuva</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Poland Sp. z o.o.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 48 22\n  262 8702</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "be4d740b-1355-467a-bc66-1a6444269e86", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "889fa6ce-8598-4b30-8317-4511fba377fe"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Belgi\u00eb/Belgique/Belgien</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Belgium SPRL-BVBA</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">T\u00e9l/Tel: + 32\n  (0) 24 01 35 50</span></p>\n<p class=\"MsoNormal\" style=\"margin-right:1.7pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "e44b5fa7-e652-4eb7-b2a0-ffeec61ff5ff", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "be4d740b-1355-467a-bc66-1a6444269e86"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Belgi\u00eb/Belgique/Belgien</span></b></p>", "ID": "16b295a9-22b2-425e-8761-5854bd7aaf8e", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e44b5fa7-e652-4eb7-b2a0-ffeec61ff5ff"}, {"Element": "<b><span lang=\"EN-GB\">Belgi\u00eb/Belgique/Belgien</span></b>", "ID": "0544c31e-496d-4ec8-b567-a8eee99c94c5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "16b295a9-22b2-425e-8761-5854bd7aaf8e"}, {"Element": "<span lang=\"EN-GB\">Belgi\u00eb/Belgique/Belgien</span>", "ID": "1f48660e-89fa-49d2-9681-c53705779657", "Styles": "None", "Classes": "None", "Text": "Belgi\u00eb/Belgique/Belgien", "ParentId": "0544c31e-496d-4ec8-b567-a8eee99c94c5"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Belgium SPRL-BVBA</span></p>", "ID": "10f66f9e-222d-4a5b-8eb9-b0459e568c24", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e44b5fa7-e652-4eb7-b2a0-ffeec61ff5ff"}, {"Element": "<span lang=\"EN-GB\">Gilead\n  Sciences Belgium SPRL-BVBA</span>", "ID": "cfdc2953-4d3c-4ce4-9ad7-6c85dfc89c6c", "Styles": "None", "Classes": "None", "Text": "Gilead   Sciences Belgium SPRL-BVBA", "ParentId": "10f66f9e-222d-4a5b-8eb9-b0459e568c24"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">T\u00e9l/Tel: + 32\n  (0) 24 01 35 50</span></p>", "ID": "7ac5f9ad-6fc3-499c-a677-5ced892345dd", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e44b5fa7-e652-4eb7-b2a0-ffeec61ff5ff"}, {"Element": "<span lang=\"EN-GB\">T\u00e9l/Tel: + 32\n  (0) 24 01 35 50</span>", "ID": "afe68125-b60f-4d95-9404-de49a3f200db", "Styles": "None", "Classes": "None", "Text": "T\u00e9l/Tel: + 32   (0) 24 01 35 50", "ParentId": "7ac5f9ad-6fc3-499c-a677-5ced892345dd"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:1.7pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "182e816e-7f41-48d7-9c2a-44fc34747d59", "Styles": "margin-right:1.7pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e44b5fa7-e652-4eb7-b2a0-ffeec61ff5ff"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "234e7552-aa74-4c74-a650-850e2f055306", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "182e816e-7f41-48d7-9c2a-44fc34747d59"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Lietuva</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Poland Sp. z o.o.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 48 22\n  262 8702</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "4cc98ad4-dd3a-4d74-90df-104d0b741cc6", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "be4d740b-1355-467a-bc66-1a6444269e86"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Lietuva</span></b></p>", "ID": "41d0241b-403c-442c-8d87-6bffe52baabf", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4cc98ad4-dd3a-4d74-90df-104d0b741cc6"}, {"Element": "<b><span lang=\"EN-GB\">Lietuva</span></b>", "ID": "c6c7f300-74c0-480b-a053-ee92cd06f166", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "41d0241b-403c-442c-8d87-6bffe52baabf"}, {"Element": "<span lang=\"EN-GB\">Lietuva</span>", "ID": "eaec74f3-6a7c-4a64-8915-69c2b14b227d", "Styles": "None", "Classes": "None", "Text": "Lietuva", "ParentId": "c6c7f300-74c0-480b-a053-ee92cd06f166"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Poland Sp. z o.o.</span></p>", "ID": "8fc09a17-448b-4f58-bd73-912238e94e0b", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4cc98ad4-dd3a-4d74-90df-104d0b741cc6"}, {"Element": "<span lang=\"EN-GB\">Gilead\n  Sciences Poland Sp. z o.o.</span>", "ID": "62dedd93-d06d-4d4e-8bbe-66f4d54122e9", "Styles": "None", "Classes": "None", "Text": "Gilead   Sciences Poland Sp. z o.o.", "ParentId": "8fc09a17-448b-4f58-bd73-912238e94e0b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 48 22\n  262 8702</span></p>", "ID": "9bfd09eb-c8ca-4aca-bcf1-31aa06aba033", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4cc98ad4-dd3a-4d74-90df-104d0b741cc6"}, {"Element": "<span lang=\"EN-GB\">Tel: + 48 22\n  262 8702</span>", "ID": "7dc8b7df-86b6-4244-8607-734be29283bf", "Styles": "None", "Classes": "None", "Text": "Tel: + 48 22   262 8702", "ParentId": "9bfd09eb-c8ca-4aca-bcf1-31aa06aba033"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ee1938a7-3f11-43f5-97a4-6c3f69337328", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4cc98ad4-dd3a-4d74-90df-104d0b741cc6"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8218ba0c-5e2e-485d-90d2-8e7744f612fb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ee1938a7-3f11-43f5-97a4-6c3f69337328"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u0422\u0435\u043b.:\n  + 353 (0) 1 686 1888</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Belgium SPRL-BVBA</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">T\u00e9l/Tel: + 32\n  (0) 24 01 35 50</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "45595a73-560e-40c9-8a6c-c58c5d1b569d", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "889fa6ce-8598-4b30-8317-4511fba377fe"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u0422\u0435\u043b.:\n  + 353 (0) 1 686 1888</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "daa61ef5-e02d-41ba-ac04-4fd6abedfdb3", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "45595a73-560e-40c9-8a6c-c58c5d1b569d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>", "ID": "52b11429-6ff5-47b3-a3b0-19db8839e890", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "daa61ef5-e02d-41ba-ac04-4fd6abedfdb3"}, {"Element": "<b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b>", "ID": "e3c9ff9f-56aa-4f8f-b09e-6906448af5df", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "52b11429-6ff5-47b3-a3b0-19db8839e890"}, {"Element": "<span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span>", "ID": "055755cc-1972-43a5-9d9e-32c913fe9009", "Styles": "None", "Classes": "None", "Text": "\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f", "ParentId": "e3c9ff9f-56aa-4f8f-b09e-6906448af5df"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Ireland UC</span></p>", "ID": "f08f09e8-ad1e-44f4-8d3b-986aedd5bb60", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "daa61ef5-e02d-41ba-ac04-4fd6abedfdb3"}, {"Element": "<span lang=\"EN-GB\">Gilead\n  Sciences Ireland UC</span>", "ID": "8a5661a0-930a-4a3d-b218-59c1e43a2091", "Styles": "None", "Classes": "None", "Text": "Gilead   Sciences Ireland UC", "ParentId": "f08f09e8-ad1e-44f4-8d3b-986aedd5bb60"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u0422\u0435\u043b.:\n  + 353 (0) 1 686 1888</span></p>", "ID": "64e72724-0fed-46c1-9845-d407145c0110", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "daa61ef5-e02d-41ba-ac04-4fd6abedfdb3"}, {"Element": "<span lang=\"EN-GB\">\u0422\u0435\u043b.:\n  + 353 (0) 1 686 1888</span>", "ID": "764579c7-a84d-423f-8e7e-fac4035e0be9", "Styles": "None", "Classes": "None", "Text": "\u0422\u0435\u043b.:   + 353 (0) 1 686 1888", "ParentId": "64e72724-0fed-46c1-9845-d407145c0110"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0957ffd4-69ab-4be4-8a2c-5ae0ab00a42a", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "daa61ef5-e02d-41ba-ac04-4fd6abedfdb3"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fa008a37-387d-4244-9248-af0a3132a579", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0957ffd4-69ab-4be4-8a2c-5ae0ab00a42a"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Belgium SPRL-BVBA</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">T\u00e9l/Tel: + 32\n  (0) 24 01 35 50</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "67b36c40-de24-4e9a-a1f8-047bcc271931", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "45595a73-560e-40c9-8a6c-c58c5d1b569d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Luxembourg/Luxemburg</span></b></p>", "ID": "22111989-3d30-472e-b16c-e352745ad5e2", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "67b36c40-de24-4e9a-a1f8-047bcc271931"}, {"Element": "<b><span lang=\"EN-GB\">Luxembourg/Luxemburg</span></b>", "ID": "22f24598-405d-4da0-92a8-9c8709ed2e54", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "22111989-3d30-472e-b16c-e352745ad5e2"}, {"Element": "<span lang=\"EN-GB\">Luxembourg/Luxemburg</span>", "ID": "9d6ea943-119b-4037-91fc-f9682efb5dba", "Styles": "None", "Classes": "None", "Text": "Luxembourg/Luxemburg", "ParentId": "22f24598-405d-4da0-92a8-9c8709ed2e54"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Belgium SPRL-BVBA</span></p>", "ID": "86793d1b-9d92-4c4a-8953-963562b58a15", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "67b36c40-de24-4e9a-a1f8-047bcc271931"}, {"Element": "<span lang=\"EN-GB\">Gilead\n  Sciences Belgium SPRL-BVBA</span>", "ID": "178256e0-477d-4640-a9b7-3534e33913d6", "Styles": "None", "Classes": "None", "Text": "Gilead   Sciences Belgium SPRL-BVBA", "ParentId": "86793d1b-9d92-4c4a-8953-963562b58a15"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">T\u00e9l/Tel: + 32\n  (0) 24 01 35 50</span></p>", "ID": "5acd59b9-780e-43a5-bd7d-13f71855d200", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "67b36c40-de24-4e9a-a1f8-047bcc271931"}, {"Element": "<span lang=\"EN-GB\">T\u00e9l/Tel: + 32\n  (0) 24 01 35 50</span>", "ID": "58904c61-80e7-4092-9669-49d17bd144e8", "Styles": "None", "Classes": "None", "Text": "T\u00e9l/Tel: + 32   (0) 24 01 35 50", "ParentId": "5acd59b9-780e-43a5-bd7d-13f71855d200"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e9cf39cc-4c84-4530-93ff-73b99fdc0906", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "67b36c40-de24-4e9a-a1f8-047bcc271931"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "284f5b94-5679-4e34-919e-d6b65d1a21dd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e9cf39cc-4c84-4530-93ff-73b99fdc0906"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u010cesk\u00e1\n  republika</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences s.r.o.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: </span><span lang=\"EN-GB\">+ 420 (0) 910 871 986</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Magyarorsz\u00e1g</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences </span><span lang=\"EN-GB\">Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "60af33bc-141f-4b34-939c-a7c18286b833", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "889fa6ce-8598-4b30-8317-4511fba377fe"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u010cesk\u00e1\n  republika</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences s.r.o.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: </span><span lang=\"EN-GB\">+ 420 (0) 910 871 986</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "3bfb8c0f-607d-4042-83d6-93824d683c16", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "60af33bc-141f-4b34-939c-a7c18286b833"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u010cesk\u00e1\n  republika</span></b></p>", "ID": "fc039cbc-22ed-40fa-b5fd-339b68ab76c1", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3bfb8c0f-607d-4042-83d6-93824d683c16"}, {"Element": "<b><span lang=\"EN-GB\">\u010cesk\u00e1\n  republika</span></b>", "ID": "48d966e4-79ac-4840-977f-dadca23a1803", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fc039cbc-22ed-40fa-b5fd-339b68ab76c1"}, {"Element": "<span lang=\"EN-GB\">\u010cesk\u00e1\n  republika</span>", "ID": "ce567ab4-c6c3-41bf-b784-7a248017dd7f", "Styles": "None", "Classes": "None", "Text": "\u010cesk\u00e1   republika", "ParentId": "48d966e4-79ac-4840-977f-dadca23a1803"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences s.r.o.</span></p>", "ID": "82019b03-b40d-4a09-ad96-4cae95f47bcf", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3bfb8c0f-607d-4042-83d6-93824d683c16"}, {"Element": "<span lang=\"EN-GB\">Gilead\n  Sciences s.r.o.</span>", "ID": "fd4ff115-8049-463d-a239-b310d9985af6", "Styles": "None", "Classes": "None", "Text": "Gilead   Sciences s.r.o.", "ParentId": "82019b03-b40d-4a09-ad96-4cae95f47bcf"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: </span><span lang=\"EN-GB\">+ 420 (0) 910 871 986</span></p>", "ID": "3297c8ba-15a6-484a-bd36-2471dca6fae8", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3bfb8c0f-607d-4042-83d6-93824d683c16"}, {"Element": "<span lang=\"EN-GB\">Tel: </span>", "ID": "ed7ab14a-d269-4eb6-b910-302bf5bd4620", "Styles": "None", "Classes": "None", "Text": "Tel: ", "ParentId": "3297c8ba-15a6-484a-bd36-2471dca6fae8"}, {"Element": "<span lang=\"EN-GB\">+ 420 (0) 910 871 986</span>", "ID": "3770d8df-2795-40ca-8241-0fb2c853bcd7", "Styles": "None", "Classes": "None", "Text": "+ 420 (0) 910 871 986", "ParentId": "3297c8ba-15a6-484a-bd36-2471dca6fae8"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f6bc2c10-a54a-4315-a9d8-d5071e58aefa", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3bfb8c0f-607d-4042-83d6-93824d683c16"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "60a9b67e-cf3a-4576-81c2-de23262103b5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f6bc2c10-a54a-4315-a9d8-d5071e58aefa"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Magyarorsz\u00e1g</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences </span><span lang=\"EN-GB\">Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "e9d52e17-1bb0-455e-8ed1-45cd4bbfd05c", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "60af33bc-141f-4b34-939c-a7c18286b833"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Magyarorsz\u00e1g</span></b></p>", "ID": "f5b8fcbd-88bc-4253-99e0-420d3dd24299", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e9d52e17-1bb0-455e-8ed1-45cd4bbfd05c"}, {"Element": "<b><span lang=\"EN-GB\">Magyarorsz\u00e1g</span></b>", "ID": "92338f5f-da05-4f7c-b409-6006ead90554", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f5b8fcbd-88bc-4253-99e0-420d3dd24299"}, {"Element": "<span lang=\"EN-GB\">Magyarorsz\u00e1g</span>", "ID": "2be07dab-9b12-4843-b7b0-e35add293551", "Styles": "None", "Classes": "None", "Text": "Magyarorsz\u00e1g", "ParentId": "92338f5f-da05-4f7c-b409-6006ead90554"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences </span><span lang=\"EN-GB\">Ireland UC</span></p>", "ID": "824fc685-c3f1-4c0f-bcbc-15d9c3541d6f", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e9d52e17-1bb0-455e-8ed1-45cd4bbfd05c"}, {"Element": "<span lang=\"EN-GB\">Gilead\n  Sciences </span>", "ID": "5ca2d192-66b8-4235-a619-36fb2cfc53a3", "Styles": "None", "Classes": "None", "Text": "Gilead   Sciences ", "ParentId": "824fc685-c3f1-4c0f-bcbc-15d9c3541d6f"}, {"Element": "<span lang=\"EN-GB\">Ireland UC</span>", "ID": "9025c447-1f01-4eb0-af5a-c3bdfb1eb2cd", "Styles": "None", "Classes": "None", "Text": "Ireland UC", "ParentId": "824fc685-c3f1-4c0f-bcbc-15d9c3541d6f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span></p>", "ID": "a2e0e9a5-9310-4900-b42b-81d909c91472", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e9d52e17-1bb0-455e-8ed1-45cd4bbfd05c"}, {"Element": "<span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span>", "ID": "260dbbf1-24a8-4f57-ac52-921a2ae2f614", "Styles": "None", "Classes": "None", "Text": "Tel: + 353 (0)   1 686 1888", "ParentId": "a2e0e9a5-9310-4900-b42b-81d909c91472"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "08454f24-8cea-4dc4-b584-5a421c11f00d", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e9d52e17-1bb0-455e-8ed1-45cd4bbfd05c"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "38c45156-f20f-4e99-adee-979010794875", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "08454f24-8cea-4dc4-b584-5a421c11f00d"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Danmark</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tlf: + 46 (0)\n  8 5057 1849</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Malta</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences </span><span lang=\"EN-GB\">Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "2eaea5b1-6452-4c83-a94c-9804564e6dc5", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "889fa6ce-8598-4b30-8317-4511fba377fe"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Danmark</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tlf: + 46 (0)\n  8 5057 1849</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "8b3d8c7a-ef3b-406f-88fe-bad5ede50db2", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "2eaea5b1-6452-4c83-a94c-9804564e6dc5"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Danmark</span></b></p>", "ID": "dea19841-66c4-4cda-b32e-2e1697ca3f38", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8b3d8c7a-ef3b-406f-88fe-bad5ede50db2"}, {"Element": "<b><span lang=\"EN-GB\">Danmark</span></b>", "ID": "b8f8eb90-6775-4f7e-8de1-7224cec68948", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dea19841-66c4-4cda-b32e-2e1697ca3f38"}, {"Element": "<span lang=\"EN-GB\">Danmark</span>", "ID": "bbcf4ad7-9849-47e2-aef2-a3a0fc713d51", "Styles": "None", "Classes": "None", "Text": "Danmark", "ParentId": "b8f8eb90-6775-4f7e-8de1-7224cec68948"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span></p>", "ID": "6550b306-7d49-4947-8c81-91c8f57699c3", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8b3d8c7a-ef3b-406f-88fe-bad5ede50db2"}, {"Element": "<span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span>", "ID": "f29d08a9-b2a3-4d03-9fbe-1999391880f5", "Styles": "None", "Classes": "None", "Text": "Gilead   Sciences Sweden AB", "ParentId": "6550b306-7d49-4947-8c81-91c8f57699c3"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tlf: + 46 (0)\n  8 5057 1849</span></p>", "ID": "0a5f2d95-563e-4590-8bbe-3b53d3ff1d6f", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8b3d8c7a-ef3b-406f-88fe-bad5ede50db2"}, {"Element": "<span lang=\"EN-GB\">Tlf: + 46 (0)\n  8 5057 1849</span>", "ID": "bab79f70-b991-41a0-949e-f55da3a64667", "Styles": "None", "Classes": "None", "Text": "Tlf: + 46 (0)   8 5057 1849", "ParentId": "0a5f2d95-563e-4590-8bbe-3b53d3ff1d6f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "76539a4e-c38c-4608-a4cc-e4f5b7a9821a", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8b3d8c7a-ef3b-406f-88fe-bad5ede50db2"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "41f0ff95-62a2-46c8-a304-0e2079fd4231", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "76539a4e-c38c-4608-a4cc-e4f5b7a9821a"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Malta</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences </span><span lang=\"EN-GB\">Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "d2002967-ac20-43e6-aecf-41a4dafd5b4b", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "2eaea5b1-6452-4c83-a94c-9804564e6dc5"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Malta</span></b></p>", "ID": "db5d6136-5c76-492a-9469-d179d5243057", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d2002967-ac20-43e6-aecf-41a4dafd5b4b"}, {"Element": "<b><span lang=\"EN-GB\">Malta</span></b>", "ID": "332198af-3940-4a80-9013-a8de863d0530", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "db5d6136-5c76-492a-9469-d179d5243057"}, {"Element": "<span lang=\"EN-GB\">Malta</span>", "ID": "3e6b1993-ad01-420c-a57c-9f6c5fdac050", "Styles": "None", "Classes": "None", "Text": "Malta", "ParentId": "332198af-3940-4a80-9013-a8de863d0530"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences </span><span lang=\"EN-GB\">Ireland UC</span></p>", "ID": "c9a6bc7c-b6b2-4ff1-b369-3dd4d621a142", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d2002967-ac20-43e6-aecf-41a4dafd5b4b"}, {"Element": "<span lang=\"EN-GB\">Gilead\n  Sciences </span>", "ID": "b41ecaea-cbc1-4df1-9805-be7cbfbc3e09", "Styles": "None", "Classes": "None", "Text": "Gilead   Sciences ", "ParentId": "c9a6bc7c-b6b2-4ff1-b369-3dd4d621a142"}, {"Element": "<span lang=\"EN-GB\">Ireland UC</span>", "ID": "9158422f-62e7-4ddf-9b02-0ac43825d7fb", "Styles": "None", "Classes": "None", "Text": "Ireland UC", "ParentId": "c9a6bc7c-b6b2-4ff1-b369-3dd4d621a142"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span></p>", "ID": "e3d204d6-294c-4326-8371-19f61dac60d2", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d2002967-ac20-43e6-aecf-41a4dafd5b4b"}, {"Element": "<span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span>", "ID": "a1960a28-f8b8-4394-aa2e-95c2a19ea2c2", "Styles": "None", "Classes": "None", "Text": "Tel: + 353 (0)   1 686 1888", "ParentId": "e3d204d6-294c-4326-8371-19f61dac60d2"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d0236ed1-098c-4fa0-abe5-5f97919b0f37", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d2002967-ac20-43e6-aecf-41a4dafd5b4b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2769a086-b33f-4dd5-a486-b2392469464b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d0236ed1-098c-4fa0-abe5-5f97919b0f37"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Deutschland</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences GmbH</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 49 (0)\n  89 899890-0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Nederland</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Netherlands B.V.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 31 (0)\n  20 718 36 98</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "56bb6913-f1c4-4596-a23e-4e9a9400b426", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "889fa6ce-8598-4b30-8317-4511fba377fe"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Deutschland</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences GmbH</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 49 (0)\n  89 899890-0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "1a30b906-30ce-4395-b511-9b1999f33663", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "56bb6913-f1c4-4596-a23e-4e9a9400b426"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Deutschland</span></b></p>", "ID": "2803d555-d0b2-494a-90a0-442ddfc16785", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1a30b906-30ce-4395-b511-9b1999f33663"}, {"Element": "<b><span lang=\"EN-GB\">Deutschland</span></b>", "ID": "7b16da90-be75-4501-8bfb-3282ee407b5d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2803d555-d0b2-494a-90a0-442ddfc16785"}, {"Element": "<span lang=\"EN-GB\">Deutschland</span>", "ID": "58734e0e-9b08-43bc-a6e5-ef4f23334423", "Styles": "None", "Classes": "None", "Text": "Deutschland", "ParentId": "7b16da90-be75-4501-8bfb-3282ee407b5d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences GmbH</span></p>", "ID": "d5214948-d08e-4127-9d6b-44f10da39dee", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1a30b906-30ce-4395-b511-9b1999f33663"}, {"Element": "<span lang=\"EN-GB\">Gilead\n  Sciences GmbH</span>", "ID": "e7b5e16c-790a-47ff-84fb-048d8d789a0b", "Styles": "None", "Classes": "None", "Text": "Gilead   Sciences GmbH", "ParentId": "d5214948-d08e-4127-9d6b-44f10da39dee"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 49 (0)\n  89 899890-0</span></p>", "ID": "3a5001d6-a212-498a-8713-72b528b19d59", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1a30b906-30ce-4395-b511-9b1999f33663"}, {"Element": "<span lang=\"EN-GB\">Tel: + 49 (0)\n  89 899890-0</span>", "ID": "82c045e0-5fe6-435d-b253-0281d1955226", "Styles": "None", "Classes": "None", "Text": "Tel: + 49 (0)   89 899890-0", "ParentId": "3a5001d6-a212-498a-8713-72b528b19d59"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "20f6f15a-7060-48e3-8a6f-613654e72bbf", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1a30b906-30ce-4395-b511-9b1999f33663"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c30e64a4-c995-483e-8d67-e231a943ef98", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "20f6f15a-7060-48e3-8a6f-613654e72bbf"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Nederland</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Netherlands B.V.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 31 (0)\n  20 718 36 98</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "655c89d2-c1b6-4472-bec2-fe9304b20b4c", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "56bb6913-f1c4-4596-a23e-4e9a9400b426"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Nederland</span></b></p>", "ID": "470b1c24-66c0-43ad-8b0a-05749179f279", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "655c89d2-c1b6-4472-bec2-fe9304b20b4c"}, {"Element": "<b><span lang=\"EN-GB\">Nederland</span></b>", "ID": "b08e2a88-b020-4ad5-9a5d-0423d2f227d2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "470b1c24-66c0-43ad-8b0a-05749179f279"}, {"Element": "<span lang=\"EN-GB\">Nederland</span>", "ID": "e6abee8c-a988-4c38-9659-c338ac9652a3", "Styles": "None", "Classes": "None", "Text": "Nederland", "ParentId": "b08e2a88-b020-4ad5-9a5d-0423d2f227d2"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Netherlands B.V.</span></p>", "ID": "982bc0fe-d596-4e37-b8c7-5e395971a2a0", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "655c89d2-c1b6-4472-bec2-fe9304b20b4c"}, {"Element": "<span lang=\"EN-GB\">Gilead\n  Sciences Netherlands B.V.</span>", "ID": "2854d9e8-ae05-4db4-96b8-3f8c5d64301a", "Styles": "None", "Classes": "None", "Text": "Gilead   Sciences Netherlands B.V.", "ParentId": "982bc0fe-d596-4e37-b8c7-5e395971a2a0"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 31 (0)\n  20 718 36 98</span></p>", "ID": "a4dad6b1-2967-4d52-86b3-c52a548120a0", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "655c89d2-c1b6-4472-bec2-fe9304b20b4c"}, {"Element": "<span lang=\"EN-GB\">Tel: + 31 (0)\n  20 718 36 98</span>", "ID": "ca5ba19a-22f9-4fca-ae19-0baf9a74b87f", "Styles": "None", "Classes": "None", "Text": "Tel: + 31 (0)   20 718 36 98", "ParentId": "a4dad6b1-2967-4d52-86b3-c52a548120a0"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "759b207c-eca5-4904-9e7e-fd404666de74", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "655c89d2-c1b6-4472-bec2-fe9304b20b4c"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e18e053d-0b19-4fdc-becb-a225bec7ac51", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "759b207c-eca5-4904-9e7e-fd404666de74"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Eesti</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Poland Sp. z o.o.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 48 22\n  262 8702</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Norge</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tlf: + 46 (0)\n  8 5057 1849</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "7764a639-4518-466c-806f-5815467d379e", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "889fa6ce-8598-4b30-8317-4511fba377fe"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Eesti</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Poland Sp. z o.o.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 48 22\n  262 8702</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "23aba58f-7257-4d0e-8742-2cd63691c85e", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "7764a639-4518-466c-806f-5815467d379e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Eesti</span></b></p>", "ID": "4566d0b8-83ef-4f8c-8df4-229c3871e589", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "23aba58f-7257-4d0e-8742-2cd63691c85e"}, {"Element": "<b><span lang=\"EN-GB\">Eesti</span></b>", "ID": "9843d956-5e4a-466f-b6cf-1a1e38158381", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4566d0b8-83ef-4f8c-8df4-229c3871e589"}, {"Element": "<span lang=\"EN-GB\">Eesti</span>", "ID": "38255fc7-a91d-413f-96c6-95131be55b92", "Styles": "None", "Classes": "None", "Text": "Eesti", "ParentId": "9843d956-5e4a-466f-b6cf-1a1e38158381"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Poland Sp. z o.o.</span></p>", "ID": "369377f5-42f3-476f-bb77-b602a578d03f", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "23aba58f-7257-4d0e-8742-2cd63691c85e"}, {"Element": "<span lang=\"EN-GB\">Gilead\n  Sciences Poland Sp. z o.o.</span>", "ID": "b0a1234d-80a9-4689-b9aa-e8ee642c7c16", "Styles": "None", "Classes": "None", "Text": "Gilead   Sciences Poland Sp. z o.o.", "ParentId": "369377f5-42f3-476f-bb77-b602a578d03f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 48 22\n  262 8702</span></p>", "ID": "743641c8-e59e-4565-b4d6-b20955140cf7", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "23aba58f-7257-4d0e-8742-2cd63691c85e"}, {"Element": "<span lang=\"EN-GB\">Tel: + 48 22\n  262 8702</span>", "ID": "8fa657e9-c4aa-4006-910e-724f6be04e47", "Styles": "None", "Classes": "None", "Text": "Tel: + 48 22   262 8702", "ParentId": "743641c8-e59e-4565-b4d6-b20955140cf7"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e99db09b-5ab7-407b-810f-5f7a13c8eeeb", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "23aba58f-7257-4d0e-8742-2cd63691c85e"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "221a44b2-f516-434f-a71a-43a21c7b02da", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e99db09b-5ab7-407b-810f-5f7a13c8eeeb"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Norge</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tlf: + 46 (0)\n  8 5057 1849</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "50f49468-0271-446e-a043-3d807affe390", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "7764a639-4518-466c-806f-5815467d379e"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Norge</span></b></p>", "ID": "577d9773-7ff7-49d9-b563-f5904521cdd1", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "50f49468-0271-446e-a043-3d807affe390"}, {"Element": "<b><span lang=\"EN-GB\">Norge</span></b>", "ID": "81909220-0286-4004-b10f-cb5e8700718f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "577d9773-7ff7-49d9-b563-f5904521cdd1"}, {"Element": "<span lang=\"EN-GB\">Norge</span>", "ID": "b286ca0e-72b1-4e90-9c8e-3d1d01257694", "Styles": "None", "Classes": "None", "Text": "Norge", "ParentId": "81909220-0286-4004-b10f-cb5e8700718f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span></p>", "ID": "d10362c8-70a8-4db0-ac06-ec13e5ec768d", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "50f49468-0271-446e-a043-3d807affe390"}, {"Element": "<span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span>", "ID": "d556e001-dcf0-4f75-94ae-ed6600523f48", "Styles": "None", "Classes": "None", "Text": "Gilead   Sciences Sweden AB", "ParentId": "d10362c8-70a8-4db0-ac06-ec13e5ec768d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tlf: + 46 (0)\n  8 5057 1849</span></p>", "ID": "0a928671-3651-475e-a4d4-b330086a504c", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "50f49468-0271-446e-a043-3d807affe390"}, {"Element": "<span lang=\"EN-GB\">Tlf: + 46 (0)\n  8 5057 1849</span>", "ID": "3e877c2b-9137-4aff-b3fb-a01c5c773340", "Styles": "None", "Classes": "None", "Text": "Tlf: + 46 (0)   8 5057 1849", "ParentId": "0a928671-3651-475e-a4d4-b330086a504c"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9c07397c-2b5e-4d00-8922-150fc6794e66", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "50f49468-0271-446e-a043-3d807affe390"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d6340cdf-4b18-4cc4-8e7e-dee731e532cd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9c07397c-2b5e-4d00-8922-150fc6794e66"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences \u0395\u03bb\u03bb\u03ac\u03c2 \u039c.\u0395\u03a0\u0395.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb:\n  + 30 210 8930 100</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00d6sterreich</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences GesmbH</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 43 1\n  260 830</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>", "ID": "d3a8bce4-d598-4a83-a642-f80863509fd0", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "889fa6ce-8598-4b30-8317-4511fba377fe"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences \u0395\u03bb\u03bb\u03ac\u03c2 \u039c.\u0395\u03a0\u0395.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb:\n  + 30 210 8930 100</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "5ad490e5-c2fb-4781-bb11-ab4610ad61cb", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "d3a8bce4-d598-4a83-a642-f80863509fd0"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>", "ID": "11990bdc-cf7f-4445-a7f7-68215bd96110", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5ad490e5-c2fb-4781-bb11-ab4610ad61cb"}, {"Element": "<b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b>", "ID": "18d69602-1162-4dd4-8ea9-4cb2e8a40b75", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "11990bdc-cf7f-4445-a7f7-68215bd96110"}, {"Element": "<span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span>", "ID": "03512af1-d79d-419a-ae5f-d2543158341f", "Styles": "None", "Classes": "None", "Text": "\u0395\u03bb\u03bb\u03ac\u03b4\u03b1", "ParentId": "18d69602-1162-4dd4-8ea9-4cb2e8a40b75"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences \u0395\u03bb\u03bb\u03ac\u03c2 \u039c.\u0395\u03a0\u0395.</span></p>", "ID": "97ec0051-77fa-44ff-9194-5514db6ba90c", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5ad490e5-c2fb-4781-bb11-ab4610ad61cb"}, {"Element": "<span lang=\"EN-GB\">Gilead\n  Sciences \u0395\u03bb\u03bb\u03ac\u03c2 \u039c.\u0395\u03a0\u0395.</span>", "ID": "d318aced-2e94-4bc8-9159-40d2d1436bf3", "Styles": "None", "Classes": "None", "Text": "Gilead   Sciences \u0395\u03bb\u03bb\u03ac\u03c2 \u039c.\u0395\u03a0\u0395.", "ParentId": "97ec0051-77fa-44ff-9194-5514db6ba90c"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb:\n  + 30 210 8930 100</span></p>", "ID": "6a03e83e-1724-40d3-a012-54e769770f1d", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5ad490e5-c2fb-4781-bb11-ab4610ad61cb"}, {"Element": "<span lang=\"EN-GB\">\u03a4\u03b7\u03bb:\n  + 30 210 8930 100</span>", "ID": "19969aa4-cd74-44b3-8e1a-945d290f752a", "Styles": "None", "Classes": "None", "Text": "\u03a4\u03b7\u03bb:   + 30 210 8930 100", "ParentId": "6a03e83e-1724-40d3-a012-54e769770f1d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c132f3d5-aec4-484c-940e-c9de520d44bb", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5ad490e5-c2fb-4781-bb11-ab4610ad61cb"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "41172c6b-1f46-4cf7-8e1c-60af89566512", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c132f3d5-aec4-484c-940e-c9de520d44bb"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00d6sterreich</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences GesmbH</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 43 1\n  260 830</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "804a49c8-4c1f-4d09-80c8-9b41fe02783d", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "d3a8bce4-d598-4a83-a642-f80863509fd0"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00d6sterreich</span></b></p>", "ID": "e25feab9-ec95-4173-93e3-11961c9f3b94", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "804a49c8-4c1f-4d09-80c8-9b41fe02783d"}, {"Element": "<b><span lang=\"EN-GB\">\u00d6sterreich</span></b>", "ID": "f49b4478-c1f0-4f1c-8760-999d3e7d7d93", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e25feab9-ec95-4173-93e3-11961c9f3b94"}, {"Element": "<span lang=\"EN-GB\">\u00d6sterreich</span>", "ID": "7d07310d-3449-43b9-8731-903ec502ce69", "Styles": "None", "Classes": "None", "Text": "\u00d6sterreich", "ParentId": "f49b4478-c1f0-4f1c-8760-999d3e7d7d93"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences GesmbH</span></p>", "ID": "e4c7fa00-5e73-441b-98e7-7ae0da1630d8", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "804a49c8-4c1f-4d09-80c8-9b41fe02783d"}, {"Element": "<span lang=\"EN-GB\">Gilead\n  Sciences GesmbH</span>", "ID": "5102f37f-0fcf-4d6f-8e9a-69eae05de383", "Styles": "None", "Classes": "None", "Text": "Gilead   Sciences GesmbH", "ParentId": "e4c7fa00-5e73-441b-98e7-7ae0da1630d8"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 43 1\n  260 830</span></p>", "ID": "cffdab31-1333-44ca-ac62-768ac4a853f0", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "804a49c8-4c1f-4d09-80c8-9b41fe02783d"}, {"Element": "<span lang=\"EN-GB\">Tel: + 43 1\n  260 830</span>", "ID": "f7ccf722-16ea-43cb-9d57-014d3ccbc7d3", "Styles": "None", "Classes": "None", "Text": "Tel: + 43 1   260 830", "ParentId": "cffdab31-1333-44ca-ac62-768ac4a853f0"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "c8032e3e-10a8-4767-99f3-eb246a2a72c8", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "804a49c8-4c1f-4d09-80c8-9b41fe02783d"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "7cc4cf6a-ea93-4590-be41-5227b61be356", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c8032e3e-10a8-4767-99f3-eb246a2a72c8"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0f7f4e22-7e41-465b-8268-28f8df234fdc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7cc4cf6a-ea93-4590-be41-5227b61be356"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Espa\u00f1a</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences, S.L.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 34 91\n  378 98 30</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Polska</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead Sciences\n  Poland Sp. z o.o.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 48 22\n  262 8702</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "0183266c-81cb-4e24-b5db-f5548fe42faa", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "889fa6ce-8598-4b30-8317-4511fba377fe"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Espa\u00f1a</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences, S.L.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 34 91\n  378 98 30</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "51f15ad9-0fce-42d4-95a6-e0c81175a5b5", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "0183266c-81cb-4e24-b5db-f5548fe42faa"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Espa\u00f1a</span></b></p>", "ID": "9acfc3af-4f87-4ea1-8e3c-997a6a7171d4", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "51f15ad9-0fce-42d4-95a6-e0c81175a5b5"}, {"Element": "<b><span lang=\"EN-GB\">Espa\u00f1a</span></b>", "ID": "38037039-93bc-4340-8dc2-a0deb037057b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9acfc3af-4f87-4ea1-8e3c-997a6a7171d4"}, {"Element": "<span lang=\"EN-GB\">Espa\u00f1a</span>", "ID": "cab7b517-a517-4668-9ffa-59e872802016", "Styles": "None", "Classes": "None", "Text": "Espa\u00f1a", "ParentId": "38037039-93bc-4340-8dc2-a0deb037057b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences, S.L.</span></p>", "ID": "b43755d1-f7ab-405d-8b73-c7e709a654ec", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "51f15ad9-0fce-42d4-95a6-e0c81175a5b5"}, {"Element": "<span lang=\"EN-GB\">Gilead\n  Sciences, S.L.</span>", "ID": "d181d072-9747-423e-b177-3eaafa8ed2ba", "Styles": "None", "Classes": "None", "Text": "Gilead   Sciences, S.L.", "ParentId": "b43755d1-f7ab-405d-8b73-c7e709a654ec"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 34 91\n  378 98 30</span></p>", "ID": "1d1ed29c-3808-42e9-a085-446b9de84091", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "51f15ad9-0fce-42d4-95a6-e0c81175a5b5"}, {"Element": "<span lang=\"EN-GB\">Tel: + 34 91\n  378 98 30</span>", "ID": "497f2e3a-4b68-4f69-bb54-99391b2320a5", "Styles": "None", "Classes": "None", "Text": "Tel: + 34 91   378 98 30", "ParentId": "1d1ed29c-3808-42e9-a085-446b9de84091"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "afb94c2a-3f89-47e4-a66e-a863388008ef", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "51f15ad9-0fce-42d4-95a6-e0c81175a5b5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "442a348c-0869-4497-a251-4ee3c8a00745", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "afb94c2a-3f89-47e4-a66e-a863388008ef"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Polska</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead Sciences\n  Poland Sp. z o.o.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 48 22\n  262 8702</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "baef8030-6335-4d80-8ea1-5fdd697dc6ba", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "0183266c-81cb-4e24-b5db-f5548fe42faa"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Polska</span></b></p>", "ID": "56ce4b54-1c04-4420-8c9d-09c688b64a9f", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "baef8030-6335-4d80-8ea1-5fdd697dc6ba"}, {"Element": "<b><span lang=\"EN-GB\">Polska</span></b>", "ID": "e429f71c-fa6f-4d0b-83e7-12fd084225d9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "56ce4b54-1c04-4420-8c9d-09c688b64a9f"}, {"Element": "<span lang=\"EN-GB\">Polska</span>", "ID": "82edb6de-f7c0-49d1-8265-821819b4381a", "Styles": "None", "Classes": "None", "Text": "Polska", "ParentId": "e429f71c-fa6f-4d0b-83e7-12fd084225d9"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead Sciences\n  Poland Sp. z o.o.</span></p>", "ID": "16ad9037-572f-4a79-8bb6-03eedb9886c4", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "baef8030-6335-4d80-8ea1-5fdd697dc6ba"}, {"Element": "<span lang=\"EN-GB\">Gilead Sciences\n  Poland Sp. z o.o.</span>", "ID": "2e35fbd1-66cd-4856-ac73-32d095c4fadf", "Styles": "None", "Classes": "None", "Text": "Gilead Sciences   Poland Sp. z o.o.", "ParentId": "16ad9037-572f-4a79-8bb6-03eedb9886c4"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 48 22\n  262 8702</span></p>", "ID": "5fad98ac-7ffa-4466-919c-3b53af8c1730", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "baef8030-6335-4d80-8ea1-5fdd697dc6ba"}, {"Element": "<span lang=\"EN-GB\">Tel: + 48 22\n  262 8702</span>", "ID": "57e2eb0d-84f6-4dc9-aa5c-37b635fc7628", "Styles": "None", "Classes": "None", "Text": "Tel: + 48 22   262 8702", "ParentId": "5fad98ac-7ffa-4466-919c-3b53af8c1730"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fea62aee-eaa1-417b-b58c-b0aa3c6a20b5", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "baef8030-6335-4d80-8ea1-5fdd697dc6ba"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ae2ec8cc-401b-4a52-a060-da9e85ca3a85", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fea62aee-eaa1-417b-b58c-b0aa3c6a20b5"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">France</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">T\u00e9l: + 33 (0)\n  1 46 09 41 00</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Portugal</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences, Lda.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 351 21\n  7928790</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "6644a1ad-8178-4ad2-abda-1f6fec2f76e2", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "889fa6ce-8598-4b30-8317-4511fba377fe"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">France</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">T\u00e9l: + 33 (0)\n  1 46 09 41 00</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "5cc91990-433c-4a45-9fd8-2e82cb1f46cf", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "6644a1ad-8178-4ad2-abda-1f6fec2f76e2"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">France</span></b></p>", "ID": "03222998-1523-4490-a82d-1882617698f8", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5cc91990-433c-4a45-9fd8-2e82cb1f46cf"}, {"Element": "<b><span lang=\"EN-GB\">France</span></b>", "ID": "69147d75-9737-4bc0-a862-e73a026c945f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "03222998-1523-4490-a82d-1882617698f8"}, {"Element": "<span lang=\"EN-GB\">France</span>", "ID": "9d51553e-baca-48da-9475-ffb9179fb9e7", "Styles": "None", "Classes": "None", "Text": "France", "ParentId": "69147d75-9737-4bc0-a862-e73a026c945f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences</span></p>", "ID": "577afab2-397b-4c2c-82f0-fec6df28027b", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5cc91990-433c-4a45-9fd8-2e82cb1f46cf"}, {"Element": "<span lang=\"EN-GB\">Gilead\n  Sciences</span>", "ID": "80f5b935-209b-4f92-bfc6-16edaf88a225", "Styles": "None", "Classes": "None", "Text": "Gilead   Sciences", "ParentId": "577afab2-397b-4c2c-82f0-fec6df28027b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">T\u00e9l: + 33 (0)\n  1 46 09 41 00</span></p>", "ID": "b9874198-8780-464f-a538-10f63be18ae6", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5cc91990-433c-4a45-9fd8-2e82cb1f46cf"}, {"Element": "<span lang=\"EN-GB\">T\u00e9l: + 33 (0)\n  1 46 09 41 00</span>", "ID": "beff7d80-ba81-4199-a73c-33eb19379041", "Styles": "None", "Classes": "None", "Text": "T\u00e9l: + 33 (0)   1 46 09 41 00", "ParentId": "b9874198-8780-464f-a538-10f63be18ae6"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "930fe8fa-37a3-4cff-8fa7-927aff689b41", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5cc91990-433c-4a45-9fd8-2e82cb1f46cf"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "15f73869-f3fc-473c-9091-644b66230714", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "930fe8fa-37a3-4cff-8fa7-927aff689b41"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7b561358-8056-4c4f-9157-edc04a781a14", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "15f73869-f3fc-473c-9091-644b66230714"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Portugal</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences, Lda.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 351 21\n  7928790</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "46b0d3fe-21b5-4e4e-a792-f062aa1444ce", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "6644a1ad-8178-4ad2-abda-1f6fec2f76e2"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Portugal</span></b></p>", "ID": "545079b0-4006-4160-acc0-19f00804db27", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "46b0d3fe-21b5-4e4e-a792-f062aa1444ce"}, {"Element": "<b><span lang=\"EN-GB\">Portugal</span></b>", "ID": "1602e5dc-a260-4d1a-8d7d-34c9c053d2e2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "545079b0-4006-4160-acc0-19f00804db27"}, {"Element": "<span lang=\"EN-GB\">Portugal</span>", "ID": "01836cd2-f28f-484c-a88f-ff4d924c20ad", "Styles": "None", "Classes": "None", "Text": "Portugal", "ParentId": "1602e5dc-a260-4d1a-8d7d-34c9c053d2e2"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences, Lda.</span></p>", "ID": "880fbe24-b026-44f2-b1fe-390b32516310", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "46b0d3fe-21b5-4e4e-a792-f062aa1444ce"}, {"Element": "<span lang=\"EN-GB\">Gilead\n  Sciences, Lda.</span>", "ID": "c053059a-625c-4f19-8f3d-d9ba41e33d8e", "Styles": "None", "Classes": "None", "Text": "Gilead   Sciences, Lda.", "ParentId": "880fbe24-b026-44f2-b1fe-390b32516310"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 351 21\n  7928790</span></p>", "ID": "5817f722-ac81-4549-9ce7-317c37ce17bc", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "46b0d3fe-21b5-4e4e-a792-f062aa1444ce"}, {"Element": "<span lang=\"EN-GB\">Tel: + 351 21\n  7928790</span>", "ID": "b1d116ee-c648-4f9c-bee8-a2700e722ca8", "Styles": "None", "Classes": "None", "Text": "Tel: + 351 21   7928790", "ParentId": "5817f722-ac81-4549-9ce7-317c37ce17bc"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "33eadfbe-b6fb-4f3d-ab35-a1590368c4cd", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "46b0d3fe-21b5-4e4e-a792-f062aa1444ce"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "63be9f3a-6bc9-44e4-8b69-f7aca94a0a6a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "33eadfbe-b6fb-4f3d-ab35-a1590368c4cd"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">Hrvatska</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Gilead Sciences </span><span lang=\"EN-GB\">Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Rom\u00e2nia</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences </span><span lang=\"EN-GB\">Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span></p>\n</td>\n</tr>", "ID": "c64e767f-ad6f-46ae-bbf3-659da396c520", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "889fa6ce-8598-4b30-8317-4511fba377fe"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">Hrvatska</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Gilead Sciences </span><span lang=\"EN-GB\">Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "cf57416e-6950-43c1-86b4-30cbe56ec7f2", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "c64e767f-ad6f-46ae-bbf3-659da396c520"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">Hrvatska</span></b></p>", "ID": "4cfad45a-f20c-4733-b09e-34cd90a7d81b", "Styles": "line-height:normal;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cf57416e-6950-43c1-86b4-30cbe56ec7f2"}, {"Element": "<b><span lang=\"EN-GB\">Hrvatska</span></b>", "ID": "30b72a75-b63a-499b-b6a1-214c29d50724", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4cfad45a-f20c-4733-b09e-34cd90a7d81b"}, {"Element": "<span lang=\"EN-GB\">Hrvatska</span>", "ID": "e7e6a3fa-a1e2-49cb-a380-28f231e1d288", "Styles": "None", "Classes": "None", "Text": "Hrvatska", "ParentId": "30b72a75-b63a-499b-b6a1-214c29d50724"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Gilead Sciences </span><span lang=\"EN-GB\">Ireland UC</span></p>", "ID": "691aff48-7398-4796-9e9c-da2096fa72fb", "Styles": "line-height:normal;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cf57416e-6950-43c1-86b4-30cbe56ec7f2"}, {"Element": "<span lang=\"EN-GB\">Gilead Sciences </span>", "ID": "550a459c-e468-4357-9aea-92020ba243ee", "Styles": "None", "Classes": "None", "Text": "Gilead Sciences ", "ParentId": "691aff48-7398-4796-9e9c-da2096fa72fb"}, {"Element": "<span lang=\"EN-GB\">Ireland UC</span>", "ID": "0b1181a7-04db-4e4f-8426-9031148fbd22", "Styles": "None", "Classes": "None", "Text": "Ireland UC", "ParentId": "691aff48-7398-4796-9e9c-da2096fa72fb"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span></p>", "ID": "0d52e327-4532-48ee-953e-edf6f65992b4", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cf57416e-6950-43c1-86b4-30cbe56ec7f2"}, {"Element": "<span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span>", "ID": "e988bdc3-fa03-412a-89b3-357708982883", "Styles": "None", "Classes": "None", "Text": "Tel: + 353 (0)   1 686 1888", "ParentId": "0d52e327-4532-48ee-953e-edf6f65992b4"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "7d23cdef-0311-4dfc-91b9-74f87ac2e150", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cf57416e-6950-43c1-86b4-30cbe56ec7f2"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "2ea5e189-8e19-481e-8b58-352feb100c4d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7d23cdef-0311-4dfc-91b9-74f87ac2e150"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "587de1a8-5240-48ef-9823-8c12bc164882", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2ea5e189-8e19-481e-8b58-352feb100c4d"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Rom\u00e2nia</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences </span><span lang=\"EN-GB\">Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span></p>\n</td>", "ID": "1e1b4b2c-7bc0-444b-898b-8369efc70fa0", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "c64e767f-ad6f-46ae-bbf3-659da396c520"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Rom\u00e2nia</span></b></p>", "ID": "f104eaee-cdc7-4ddb-93c4-01600ea54f94", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1e1b4b2c-7bc0-444b-898b-8369efc70fa0"}, {"Element": "<b><span lang=\"EN-GB\">Rom\u00e2nia</span></b>", "ID": "f60cb2ce-e920-4996-a2fa-1b7733ddfcf0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f104eaee-cdc7-4ddb-93c4-01600ea54f94"}, {"Element": "<span lang=\"EN-GB\">Rom\u00e2nia</span>", "ID": "442cf973-0ad0-4f03-842a-7abe9191416d", "Styles": "None", "Classes": "None", "Text": "Rom\u00e2nia", "ParentId": "f60cb2ce-e920-4996-a2fa-1b7733ddfcf0"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences </span><span lang=\"EN-GB\">Ireland UC</span></p>", "ID": "a6d9418d-ebdf-4f3c-b3f0-fb9f9dff1e8b", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1e1b4b2c-7bc0-444b-898b-8369efc70fa0"}, {"Element": "<span lang=\"EN-GB\">Gilead\n  Sciences </span>", "ID": "acb690d0-4f58-4b66-b74a-be7a315b4d34", "Styles": "None", "Classes": "None", "Text": "Gilead   Sciences ", "ParentId": "a6d9418d-ebdf-4f3c-b3f0-fb9f9dff1e8b"}, {"Element": "<span lang=\"EN-GB\">Ireland UC</span>", "ID": "ea468783-49d7-4bf3-aaba-8c5bd83a7803", "Styles": "None", "Classes": "None", "Text": "Ireland UC", "ParentId": "a6d9418d-ebdf-4f3c-b3f0-fb9f9dff1e8b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span></p>", "ID": "67f03694-b4fa-4a4e-a64b-c9eee9b35c9b", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1e1b4b2c-7bc0-444b-898b-8369efc70fa0"}, {"Element": "<span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span>", "ID": "f5eb2cb6-f444-4175-862f-b6e65c487db0", "Styles": "None", "Classes": "None", "Text": "Tel: + 353 (0)   1 686 1888", "ParentId": "67f03694-b4fa-4a4e-a64b-c9eee9b35c9b"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Ireland</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  214 825 999</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Slovenija</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences </span><span lang=\"EN-GB\">Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "17f7ce1a-14da-437b-bf06-b1bb9e7e0062", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "889fa6ce-8598-4b30-8317-4511fba377fe"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Ireland</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  214 825 999</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "91ab5b6d-9c7b-404d-9abf-c11e4969bf6d", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "17f7ce1a-14da-437b-bf06-b1bb9e7e0062"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Ireland</span></b></p>", "ID": "0f5f5eb5-7cff-4bee-ac99-b13da1d797bd", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "91ab5b6d-9c7b-404d-9abf-c11e4969bf6d"}, {"Element": "<b><span lang=\"EN-GB\">Ireland</span></b>", "ID": "cdf2c061-def8-49f1-bd00-b1fe6483cfec", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0f5f5eb5-7cff-4bee-ac99-b13da1d797bd"}, {"Element": "<span lang=\"EN-GB\">Ireland</span>", "ID": "66ebe825-d798-4a1d-b0d3-316f8ed13f5d", "Styles": "None", "Classes": "None", "Text": "Ireland", "ParentId": "cdf2c061-def8-49f1-bd00-b1fe6483cfec"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Ireland UC</span></p>", "ID": "901dd2a1-12c5-4034-a3f6-55ba8a4ab672", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "91ab5b6d-9c7b-404d-9abf-c11e4969bf6d"}, {"Element": "<span lang=\"EN-GB\">Gilead\n  Sciences Ireland UC</span>", "ID": "f610a02e-6063-47fb-a4a8-76057ed1d88b", "Styles": "None", "Classes": "None", "Text": "Gilead   Sciences Ireland UC", "ParentId": "901dd2a1-12c5-4034-a3f6-55ba8a4ab672"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  214 825 999</span></p>", "ID": "0e532665-209a-4639-a828-1d86b51e7f5a", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "91ab5b6d-9c7b-404d-9abf-c11e4969bf6d"}, {"Element": "<span lang=\"EN-GB\">Tel: + 353 (0)\n  214 825 999</span>", "ID": "7d729ebd-2447-4c80-b329-3b8ac31400c2", "Styles": "None", "Classes": "None", "Text": "Tel: + 353 (0)   214 825 999", "ParentId": "0e532665-209a-4639-a828-1d86b51e7f5a"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f7e44777-af91-49a2-999a-3c86c0c498b3", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "91ab5b6d-9c7b-404d-9abf-c11e4969bf6d"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e08f1f6b-d280-473c-ba8d-028f08e58953", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f7e44777-af91-49a2-999a-3c86c0c498b3"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Slovenija</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences </span><span lang=\"EN-GB\">Ireland UC</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "fd71bad1-27d2-4f19-87b5-a3da0ad28379", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "17f7ce1a-14da-437b-bf06-b1bb9e7e0062"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Slovenija</span></b></p>", "ID": "b320aecb-6732-44e3-ba9c-77054b6b66dc", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fd71bad1-27d2-4f19-87b5-a3da0ad28379"}, {"Element": "<b><span lang=\"EN-GB\">Slovenija</span></b>", "ID": "13d2d720-435a-4a0f-b2a3-0fb2d22c63a4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b320aecb-6732-44e3-ba9c-77054b6b66dc"}, {"Element": "<span lang=\"EN-GB\">Slovenija</span>", "ID": "4594be43-fd0e-47e9-a4fe-d644fbac71e3", "Styles": "None", "Classes": "None", "Text": "Slovenija", "ParentId": "13d2d720-435a-4a0f-b2a3-0fb2d22c63a4"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences </span><span lang=\"EN-GB\">Ireland UC</span></p>", "ID": "aae4cbdd-9696-45c4-b53a-df0dbb1c68ed", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fd71bad1-27d2-4f19-87b5-a3da0ad28379"}, {"Element": "<span lang=\"EN-GB\">Gilead\n  Sciences </span>", "ID": "95d8af0b-e840-4ecd-9fa2-92df8f7f4e31", "Styles": "None", "Classes": "None", "Text": "Gilead   Sciences ", "ParentId": "aae4cbdd-9696-45c4-b53a-df0dbb1c68ed"}, {"Element": "<span lang=\"EN-GB\">Ireland UC</span>", "ID": "29eb2320-54d3-4eb0-b9cb-913d5690925a", "Styles": "None", "Classes": "None", "Text": "Ireland UC", "ParentId": "aae4cbdd-9696-45c4-b53a-df0dbb1c68ed"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span></p>", "ID": "fa6a3d9b-8fcf-4f90-98e9-c260fd1f5bdf", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fd71bad1-27d2-4f19-87b5-a3da0ad28379"}, {"Element": "<span lang=\"EN-GB\">Tel: + 353 (0)\n  1 686 1888</span>", "ID": "aebb0024-99a3-4af0-a5c4-11593491760d", "Styles": "None", "Classes": "None", "Text": "Tel: + 353 (0)   1 686 1888", "ParentId": "fa6a3d9b-8fcf-4f90-98e9-c260fd1f5bdf"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0ed8f228-d5cb-470e-9901-ab58817a742a", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fd71bad1-27d2-4f19-87b5-a3da0ad28379"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "aee3949e-babb-478b-96eb-1a637690ef7f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0ed8f228-d5cb-470e-9901-ab58817a742a"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00cdsland</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">S\u00edmi: + 46 (0)\n  8 5057 1849</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Slovensk\u00e1\n  republika</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Slovakia s.r.o.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 421 (0)\n  232 121 210</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>", "ID": "9ef7b131-bd9d-4349-9d36-ac39e67a9835", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "889fa6ce-8598-4b30-8317-4511fba377fe"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00cdsland</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">S\u00edmi: + 46 (0)\n  8 5057 1849</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "d1bce2b7-869d-496a-b521-7ba49740128c", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "9ef7b131-bd9d-4349-9d36-ac39e67a9835"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00cdsland</span></b></p>", "ID": "3fec6273-cda8-4319-b807-84fadf5155c2", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d1bce2b7-869d-496a-b521-7ba49740128c"}, {"Element": "<b><span lang=\"EN-GB\">\u00cdsland</span></b>", "ID": "53f37458-e4a4-450c-af08-3cfcb7e89b86", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3fec6273-cda8-4319-b807-84fadf5155c2"}, {"Element": "<span lang=\"EN-GB\">\u00cdsland</span>", "ID": "7ef2e3f1-a2a3-435c-bde6-fb5afb3334e5", "Styles": "None", "Classes": "None", "Text": "\u00cdsland", "ParentId": "53f37458-e4a4-450c-af08-3cfcb7e89b86"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span></p>", "ID": "672f3ff0-3cbc-489d-83b5-6b31f01dac58", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d1bce2b7-869d-496a-b521-7ba49740128c"}, {"Element": "<span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span>", "ID": "01d18d29-5290-4b5b-bec9-ad0b6e15fa53", "Styles": "None", "Classes": "None", "Text": "Gilead   Sciences Sweden AB", "ParentId": "672f3ff0-3cbc-489d-83b5-6b31f01dac58"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">S\u00edmi: + 46 (0)\n  8 5057 1849</span></p>", "ID": "bd67f817-a182-4f2b-b11f-15e35675cce1", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d1bce2b7-869d-496a-b521-7ba49740128c"}, {"Element": "<span lang=\"EN-GB\">S\u00edmi: + 46 (0)\n  8 5057 1849</span>", "ID": "e5032756-7789-4e51-9d50-717c9992ec80", "Styles": "None", "Classes": "None", "Text": "S\u00edmi: + 46 (0)   8 5057 1849", "ParentId": "bd67f817-a182-4f2b-b11f-15e35675cce1"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "2054738a-ba9e-4fc6-bcea-29c68fedaa59", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d1bce2b7-869d-496a-b521-7ba49740128c"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "d947abfb-fb50-4960-be2a-7576a1777b68", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2054738a-ba9e-4fc6-bcea-29c68fedaa59"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "984807d8-0133-4d6f-835b-df474ad7bb4c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d947abfb-fb50-4960-be2a-7576a1777b68"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Slovensk\u00e1\n  republika</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Slovakia s.r.o.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 421 (0)\n  232 121 210</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "09527fb7-0fba-400e-8f2b-e7bd6ee20c38", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "9ef7b131-bd9d-4349-9d36-ac39e67a9835"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Slovensk\u00e1\n  republika</span></b></p>", "ID": "634a5c39-1c83-4952-ab53-f8dc095d261b", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "09527fb7-0fba-400e-8f2b-e7bd6ee20c38"}, {"Element": "<b><span lang=\"EN-GB\">Slovensk\u00e1\n  republika</span></b>", "ID": "2c8bc12f-a9c3-44af-b9b7-5a14b79baca0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "634a5c39-1c83-4952-ab53-f8dc095d261b"}, {"Element": "<span lang=\"EN-GB\">Slovensk\u00e1\n  republika</span>", "ID": "bf189ed3-c380-4731-af5b-97588ffb4e50", "Styles": "None", "Classes": "None", "Text": "Slovensk\u00e1   republika", "ParentId": "2c8bc12f-a9c3-44af-b9b7-5a14b79baca0"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Slovakia s.r.o.</span></p>", "ID": "7acfe30c-be1c-4526-a976-d6937020fba1", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "09527fb7-0fba-400e-8f2b-e7bd6ee20c38"}, {"Element": "<span lang=\"EN-GB\">Gilead\n  Sciences Slovakia s.r.o.</span>", "ID": "8bc6c302-9bc1-4acd-ac1c-333e589acac6", "Styles": "None", "Classes": "None", "Text": "Gilead   Sciences Slovakia s.r.o.", "ParentId": "7acfe30c-be1c-4526-a976-d6937020fba1"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 421 (0)\n  232 121 210</span></p>", "ID": "1319c8e6-9cbb-41c2-b003-b478526f1dbd", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "09527fb7-0fba-400e-8f2b-e7bd6ee20c38"}, {"Element": "<span lang=\"EN-GB\">Tel: + 421 (0)\n  232 121 210</span>", "ID": "59d7bfa2-4e8e-4e50-8010-f9892d779803", "Styles": "None", "Classes": "None", "Text": "Tel: + 421 (0)   232 121 210", "ParentId": "1319c8e6-9cbb-41c2-b003-b478526f1dbd"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "69f5d595-fdaf-48d9-b41a-9aabf41934d9", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "09527fb7-0fba-400e-8f2b-e7bd6ee20c38"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "eef12259-8665-4629-b5b3-5fc0ce26fe57", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "69f5d595-fdaf-48d9-b41a-9aabf41934d9"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "84dd0ee5-af93-42de-b73b-62ead6471c26", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "eef12259-8665-4629-b5b3-5fc0ce26fe57"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Italia</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences S.r.l.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 39 02\n  439201</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Suomi/Finland</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Puh/Tel: + 46\n  (0) 8 5057 1849</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>", "ID": "0ff78f7e-171d-4af5-8f7d-54d8c8492cea", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "889fa6ce-8598-4b30-8317-4511fba377fe"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Italia</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences S.r.l.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 39 02\n  439201</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "f313f756-20c9-42be-9a30-0eb8de59bc30", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "0ff78f7e-171d-4af5-8f7d-54d8c8492cea"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Italia</span></b></p>", "ID": "a449b195-646c-4662-80b5-86762b78ae1f", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f313f756-20c9-42be-9a30-0eb8de59bc30"}, {"Element": "<b><span lang=\"EN-GB\">Italia</span></b>", "ID": "da97924f-1e3d-4023-939a-dc1f8b68aa35", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a449b195-646c-4662-80b5-86762b78ae1f"}, {"Element": "<span lang=\"EN-GB\">Italia</span>", "ID": "4acaf394-6645-4d17-a986-0539c57a3852", "Styles": "None", "Classes": "None", "Text": "Italia", "ParentId": "da97924f-1e3d-4023-939a-dc1f8b68aa35"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences S.r.l.</span></p>", "ID": "9d6ef016-eed3-436b-95bd-6f935541124c", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f313f756-20c9-42be-9a30-0eb8de59bc30"}, {"Element": "<span lang=\"EN-GB\">Gilead\n  Sciences S.r.l.</span>", "ID": "94bcef81-00c4-4a6a-ba60-485c99487392", "Styles": "None", "Classes": "None", "Text": "Gilead   Sciences S.r.l.", "ParentId": "9d6ef016-eed3-436b-95bd-6f935541124c"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 39 02\n  439201</span></p>", "ID": "6279de84-7419-4368-8fc4-d490e7589fa7", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f313f756-20c9-42be-9a30-0eb8de59bc30"}, {"Element": "<span lang=\"EN-GB\">Tel: + 39 02\n  439201</span>", "ID": "cc8997e8-ed35-4ad1-a4eb-ef06d9b18959", "Styles": "None", "Classes": "None", "Text": "Tel: + 39 02   439201", "ParentId": "6279de84-7419-4368-8fc4-d490e7589fa7"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "d6dd3486-f9e6-4e9a-9c34-2e2713882207", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f313f756-20c9-42be-9a30-0eb8de59bc30"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "9ec72f10-fd43-4e3d-be25-f13bf1efd2c3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d6dd3486-f9e6-4e9a-9c34-2e2713882207"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b04e706c-6822-480c-aa3f-d6d0bc55d0ff", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9ec72f10-fd43-4e3d-be25-f13bf1efd2c3"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Suomi/Finland</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Puh/Tel: + 46\n  (0) 8 5057 1849</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "c69ed44a-7732-4e63-91a6-3e9998f00db6", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "0ff78f7e-171d-4af5-8f7d-54d8c8492cea"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Suomi/Finland</span></b></p>", "ID": "c1393f44-d01b-4aef-9703-2b7204e7ae77", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c69ed44a-7732-4e63-91a6-3e9998f00db6"}, {"Element": "<b><span lang=\"EN-GB\">Suomi/Finland</span></b>", "ID": "8ba0e23a-7090-4184-8d19-91b8301362af", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c1393f44-d01b-4aef-9703-2b7204e7ae77"}, {"Element": "<span lang=\"EN-GB\">Suomi/Finland</span>", "ID": "f9b44df9-ba77-491c-9f3e-944307e66c32", "Styles": "None", "Classes": "None", "Text": "Suomi/Finland", "ParentId": "8ba0e23a-7090-4184-8d19-91b8301362af"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span></p>", "ID": "609f13b4-cd2a-464e-beab-a4d57c8040a2", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c69ed44a-7732-4e63-91a6-3e9998f00db6"}, {"Element": "<span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span>", "ID": "834b1f1e-c982-4f41-aca0-92568a624342", "Styles": "None", "Classes": "None", "Text": "Gilead   Sciences Sweden AB", "ParentId": "609f13b4-cd2a-464e-beab-a4d57c8040a2"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Puh/Tel: + 46\n  (0) 8 5057 1849</span></p>", "ID": "089f388d-901f-4818-b634-4a04ee917537", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c69ed44a-7732-4e63-91a6-3e9998f00db6"}, {"Element": "<span lang=\"EN-GB\">Puh/Tel: + 46\n  (0) 8 5057 1849</span>", "ID": "41bf2387-581c-401d-8181-1a3f5d7633d5", "Styles": "None", "Classes": "None", "Text": "Puh/Tel: + 46   (0) 8 5057 1849", "ParentId": "089f388d-901f-4818-b634-4a04ee917537"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "425c56a9-1537-4c41-a386-62fb65dae59a", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c69ed44a-7732-4e63-91a6-3e9998f00db6"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "1abf48f8-f82b-4956-8952-92cc4b2e8fb9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "425c56a9-1537-4c41-a386-62fb65dae59a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1fbf6c56-0084-496a-b23e-e83809aeba52", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1abf48f8-f82b-4956-8952-92cc4b2e8fb9"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences \u0395\u03bb\u03bb\u03ac\u03c2 \u039c.\u0395\u03a0\u0395.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb:\n  + 30 210 8930 100</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Sverige</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 46 (0)\n  8 5057 1849</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>", "ID": "804bdea2-ac73-438a-84bd-b9475fbcf361", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "889fa6ce-8598-4b30-8317-4511fba377fe"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences \u0395\u03bb\u03bb\u03ac\u03c2 \u039c.\u0395\u03a0\u0395.</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb:\n  + 30 210 8930 100</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "9935b920-c1ec-49eb-94af-2e2a7c689a4e", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "804bdea2-ac73-438a-84bd-b9475fbcf361"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span></b></p>", "ID": "f46695c3-9f53-4002-901c-e70d0e27fc3f", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9935b920-c1ec-49eb-94af-2e2a7c689a4e"}, {"Element": "<b><span lang=\"EN-GB\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span></b>", "ID": "7944d8fb-43eb-4812-b7ca-a1561d518740", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f46695c3-9f53-4002-901c-e70d0e27fc3f"}, {"Element": "<span lang=\"EN-GB\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span>", "ID": "08a23b3f-467f-469f-a3c9-a952c9f15e3a", "Styles": "None", "Classes": "None", "Text": "\u039a\u03cd\u03c0\u03c1\u03bf\u03c2", "ParentId": "7944d8fb-43eb-4812-b7ca-a1561d518740"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences \u0395\u03bb\u03bb\u03ac\u03c2 \u039c.\u0395\u03a0\u0395.</span></p>", "ID": "57000b80-a7e8-40d3-88b7-abb60c234bc5", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9935b920-c1ec-49eb-94af-2e2a7c689a4e"}, {"Element": "<span lang=\"EN-GB\">Gilead\n  Sciences \u0395\u03bb\u03bb\u03ac\u03c2 \u039c.\u0395\u03a0\u0395.</span>", "ID": "e1066c62-85d1-40c4-a17a-697e78b88173", "Styles": "None", "Classes": "None", "Text": "Gilead   Sciences \u0395\u03bb\u03bb\u03ac\u03c2 \u039c.\u0395\u03a0\u0395.", "ParentId": "57000b80-a7e8-40d3-88b7-abb60c234bc5"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb:\n  + 30 210 8930 100</span></p>", "ID": "8031e9c8-08ca-4361-a1cc-d5cf1624c415", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9935b920-c1ec-49eb-94af-2e2a7c689a4e"}, {"Element": "<span lang=\"EN-GB\">\u03a4\u03b7\u03bb:\n  + 30 210 8930 100</span>", "ID": "3450c728-ff7a-4f53-970b-7ce2cd0b518d", "Styles": "None", "Classes": "None", "Text": "\u03a4\u03b7\u03bb:   + 30 210 8930 100", "ParentId": "8031e9c8-08ca-4361-a1cc-d5cf1624c415"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "6c1cb66e-17ce-4b78-91de-9ff9d3dd6086", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9935b920-c1ec-49eb-94af-2e2a7c689a4e"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "1b578cd5-f6de-47c8-9ded-d3df5731e884", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6c1cb66e-17ce-4b78-91de-9ff9d3dd6086"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ed141e8a-08f5-4a28-ad6a-f91dd5457a38", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1b578cd5-f6de-47c8-9ded-d3df5731e884"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Sverige</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 46 (0)\n  8 5057 1849</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "cea02af7-c66a-430a-bd7d-7b92e1d80a65", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "804bdea2-ac73-438a-84bd-b9475fbcf361"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Sverige</span></b></p>", "ID": "63044322-99b1-4361-9f88-aafa0736acb2", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cea02af7-c66a-430a-bd7d-7b92e1d80a65"}, {"Element": "<b><span lang=\"EN-GB\">Sverige</span></b>", "ID": "c04a88b3-ee69-4014-bf30-fd1a637afdbd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "63044322-99b1-4361-9f88-aafa0736acb2"}, {"Element": "<span lang=\"EN-GB\">Sverige</span>", "ID": "fd0d46b8-9d0b-4821-9147-23ec55cef28f", "Styles": "None", "Classes": "None", "Text": "Sverige", "ParentId": "c04a88b3-ee69-4014-bf30-fd1a637afdbd"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span></p>", "ID": "1f5592b7-353b-419d-90b2-c623077cab0b", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cea02af7-c66a-430a-bd7d-7b92e1d80a65"}, {"Element": "<span lang=\"EN-GB\">Gilead\n  Sciences Sweden AB</span>", "ID": "1ac4b884-e90a-45e3-8d58-f98b4191343f", "Styles": "None", "Classes": "None", "Text": "Gilead   Sciences Sweden AB", "ParentId": "1f5592b7-353b-419d-90b2-c623077cab0b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 46 (0)\n  8 5057 1849</span></p>", "ID": "53ed564d-ae5b-47f9-a451-7c3e60ae7b0d", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cea02af7-c66a-430a-bd7d-7b92e1d80a65"}, {"Element": "<span lang=\"EN-GB\">Tel: + 46 (0)\n  8 5057 1849</span>", "ID": "9bb1829d-1c22-441f-a73b-f07ba2a9ed79", "Styles": "None", "Classes": "None", "Text": "Tel: + 46 (0)   8 5057 1849", "ParentId": "53ed564d-ae5b-47f9-a451-7c3e60ae7b0d"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "0288c1ec-a592-40f7-9904-84b5739fcc03", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cea02af7-c66a-430a-bd7d-7b92e1d80a65"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "3db8bff9-04ac-47cf-8d8a-dff7b711f6d8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0288c1ec-a592-40f7-9904-84b5739fcc03"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "068f5824-065d-4e0d-820c-03ea083f4ab0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3db8bff9-04ac-47cf-8d8a-dff7b711f6d8"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Latvija</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><a name=\"OLE_LINK1\"></a><a name=\"OLE_LINK2\"><span lang=\"EN-GB\">Gilead Sciences Poland Sp. z o.o.</span></a></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 48 22\n  262 8702</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">United\n  Kingdom</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Ltd</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 44 (0) 8000\n  113 700</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "86a59927-645b-42b3-8b71-6d039a4c8096", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "889fa6ce-8598-4b30-8317-4511fba377fe"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Latvija</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><a name=\"OLE_LINK1\"></a><a name=\"OLE_LINK2\"><span lang=\"EN-GB\">Gilead Sciences Poland Sp. z o.o.</span></a></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 48 22\n  262 8702</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "eb4f529f-50ca-48e9-8d20-573beb391e6b", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "86a59927-645b-42b3-8b71-6d039a4c8096"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Latvija</span></b></p>", "ID": "e64436ab-c9e6-4240-b5b0-ab82d14a8cf4", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "eb4f529f-50ca-48e9-8d20-573beb391e6b"}, {"Element": "<b><span lang=\"EN-GB\">Latvija</span></b>", "ID": "b5963d77-e6f1-4f2e-a200-d18f1bb23cb1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e64436ab-c9e6-4240-b5b0-ab82d14a8cf4"}, {"Element": "<span lang=\"EN-GB\">Latvija</span>", "ID": "e173c152-422e-4e47-b16c-b4ddd02e4608", "Styles": "None", "Classes": "None", "Text": "Latvija", "ParentId": "b5963d77-e6f1-4f2e-a200-d18f1bb23cb1"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><a name=\"OLE_LINK1\"></a><a name=\"OLE_LINK2\"><span lang=\"EN-GB\">Gilead Sciences Poland Sp. z o.o.</span></a></p>", "ID": "19dc7827-9d43-4fff-95ad-556dff594b3e", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "eb4f529f-50ca-48e9-8d20-573beb391e6b"}, {"Element": "<a name=\"OLE_LINK1\"></a>", "ID": "aed75629-319f-4d84-b435-979f4fb39af7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "19dc7827-9d43-4fff-95ad-556dff594b3e"}, {"Element": "<a name=\"OLE_LINK2\"><span lang=\"EN-GB\">Gilead Sciences Poland Sp. z o.o.</span></a>", "ID": "03d9e06d-5ca9-4fa8-9987-dbea6ba366a8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "19dc7827-9d43-4fff-95ad-556dff594b3e"}, {"Element": "<span lang=\"EN-GB\">Gilead Sciences Poland Sp. z o.o.</span>", "ID": "dadf70e0-ea83-4634-af8f-63802c1162e4", "Styles": "None", "Classes": "None", "Text": "Gilead Sciences Poland Sp. z o.o.", "ParentId": "03d9e06d-5ca9-4fa8-9987-dbea6ba366a8"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 48 22\n  262 8702</span></p>", "ID": "2e629fff-8bf7-464f-b9fb-023d1fe226f4", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "eb4f529f-50ca-48e9-8d20-573beb391e6b"}, {"Element": "<span lang=\"EN-GB\">Tel: + 48 22\n  262 8702</span>", "ID": "a0ab3116-79f0-468e-a5a3-109ae2974f87", "Styles": "None", "Classes": "None", "Text": "Tel: + 48 22   262 8702", "ParentId": "2e629fff-8bf7-464f-b9fb-023d1fe226f4"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fafc4935-654f-4f5a-92c9-b53d9786ba74", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "eb4f529f-50ca-48e9-8d20-573beb391e6b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6e35fe22-c2d9-49fd-bce8-b4b4446b7aca", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fafc4935-654f-4f5a-92c9-b53d9786ba74"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b2f3061a-f1c7-45d6-b205-123d690f23c7", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "eb4f529f-50ca-48e9-8d20-573beb391e6b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "aa8c5be8-34ef-4f5a-9d83-21fb31ccf5b7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b2f3061a-f1c7-45d6-b205-123d690f23c7"}, {"Element": "<td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\">\n<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">United\n  Kingdom</span></b></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Ltd</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 44 (0) 8000\n  113 700</span></p>\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "88c14406-3497-4fd2-85ed-8c83742ab7fa", "Styles": "width:233.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "86a59927-645b-42b3-8b71-6d039a4c8096"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">United\n  Kingdom</span></b></p>", "ID": "b4e8a7a1-2762-4a44-bf9b-6e08717bc185", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "88c14406-3497-4fd2-85ed-8c83742ab7fa"}, {"Element": "<b><span lang=\"EN-GB\">United\n  Kingdom</span></b>", "ID": "1aa75788-fff2-4edc-88e2-f32aa6eb269b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b4e8a7a1-2762-4a44-bf9b-6e08717bc185"}, {"Element": "<span lang=\"EN-GB\">United\n  Kingdom</span>", "ID": "cf13988e-0f8e-4adf-bcb5-63b9da072572", "Styles": "None", "Classes": "None", "Text": "United   Kingdom", "ParentId": "1aa75788-fff2-4edc-88e2-f32aa6eb269b"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Gilead\n  Sciences Ltd</span></p>", "ID": "36ea9474-1115-4820-8159-bf9ae5b20b3f", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "88c14406-3497-4fd2-85ed-8c83742ab7fa"}, {"Element": "<span lang=\"EN-GB\">Gilead\n  Sciences Ltd</span>", "ID": "d8c3a010-7559-493d-a224-22a686f69cac", "Styles": "None", "Classes": "None", "Text": "Gilead   Sciences Ltd", "ParentId": "36ea9474-1115-4820-8159-bf9ae5b20b3f"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: + 44 (0) 8000\n  113 700</span></p>", "ID": "f3587aef-4af7-4960-8286-921e1f552c51", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "88c14406-3497-4fd2-85ed-8c83742ab7fa"}, {"Element": "<span lang=\"EN-GB\">Tel: + 44 (0) 8000\n  113 700</span>", "ID": "3ad3b2d5-1b47-4961-9912-a51f7c89eda6", "Styles": "None", "Classes": "None", "Text": "Tel: + 44 (0) 8000   113 700", "ParentId": "f3587aef-4af7-4960-8286-921e1f552c51"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a5cd7037-ef74-4370-8842-1cd15eeb13dd", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "88c14406-3497-4fd2-85ed-8c83742ab7fa"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ac42fe4a-7853-4f71-ae42-7f280d61054f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a5cd7037-ef74-4370-8842-1cd15eeb13dd"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-22.45pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9b02a15b-18bc-4a65-838c-06e0811b5a92", "Styles": "margin-right:-22.45pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9c300a11-752f-4aa8-9fc8-bdc8321e8896", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9b02a15b-18bc-4a65-838c-06e0811b5a92"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e0711631-5ec0-4940-af93-dd3ed13560d6", "Styles": "margin-right:-.1pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bd7d48aa-ea2d-45bd-be49-1e22a380740a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e0711631-5ec0-4940-af93-dd3ed13560d6"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">This leaflet was last revised in {MM/YYYY}.</span></b></p>", "ID": "ed218390-81bc-45a5-ae8c-989bb41e8e95", "Styles": "margin-right:-.1pt;line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<b><span lang=\"EN-GB\">This leaflet was last revised in {MM/YYYY}.</span></b>", "ID": "a93023c4-1eab-4be1-8831-ac2593bf9454", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ed218390-81bc-45a5-ae8c-989bb41e8e95"}, {"Element": "<span lang=\"EN-GB\">This leaflet was last revised in {MM/YYYY}.</span>", "ID": "9c1bf13f-48ec-45b6-8c78-678259c8bd99", "Styles": "None", "Classes": "None", "Text": "This leaflet was last revised in {MM/YYYY}.", "ParentId": "a93023c4-1eab-4be1-8831-ac2593bf9454"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "50f1b56c-2633-40a1-88d6-84bb20577b34", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0cae6c81-486e-4b41-b46c-036eaea0d362", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "50f1b56c-2633-40a1-88d6-84bb20577b34"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Detailed\ninformation on this medicine is available on the European Medicines Agency web\nsite: </span><span lang=\"EN-GB\">http://www.ema.europa.eu</span></p>", "ID": "64200b7d-edd9-4078-b8d8-f06d1a587ded", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">Detailed\ninformation on this medicine is available on the European Medicines Agency web\nsite: </span>", "ID": "fd3cd2dd-6586-4c36-bce2-85d028e38f6e", "Styles": "None", "Classes": "None", "Text": "Detailed information on this medicine is available on the European Medicines Agency web site: ", "ParentId": "64200b7d-edd9-4078-b8d8-f06d1a587ded"}, {"Element": "<span lang=\"EN-GB\">http://www.ema.europa.eu</span>", "ID": "f2201153-0ee6-4b0a-9b1c-9408051e940b", "Styles": "None", "Classes": "None", "Text": "http://www.ema.europa.eu", "ParentId": "64200b7d-edd9-4078-b8d8-f06d1a587ded"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "aff13fc3-b9dd-41cc-bffa-9283fc583eed", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "25f3c199-30aa-46c9-bb81-9ffeac59fe3c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "aff13fc3-b9dd-41cc-bffa-9283fc583eed"}, {"Element": "<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">This leaflet is\navailable in all EU/EEA languages on the European Medicines Agency website.</span></p>", "ID": "5db94b50-676e-441c-9f61-2cdea7415cdc", "Styles": "line-height:normal", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e7d42d-d2a5-4b11-8ccb-2f4b9db07af5"}, {"Element": "<span lang=\"EN-GB\">This leaflet is\navailable in all EU/EEA languages on the European Medicines Agency website.</span>", "ID": "b5239fc9-7277-4454-95be-eba75c2790c7", "Styles": "None", "Classes": "None", "Text": "This leaflet is available in all EU/EEA languages on the European Medicines Agency website.", "ParentId": "5db94b50-676e-441c-9f61-2cdea7415cdc"}]}